{
    "Tamarind": {
        "sections": {
            "Overview": "Tamarind is a tree that is found in tropical Africa and southern Asia. It is also grown as an ornamental plant. The fruit pulp is widely used in Asian cuisine (97768, 107381).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Tamarind has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when tamarind seed polysaccharides 1% are used as eye drops 4-5 times daily for up to 3 months (97766, 97767).\n\nThere is insufficient reliable information available about the safety of tamarind when used orally in amounts greater than those found in food.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using in amounts greater than those found in foods.",
            "Adverse Effects": "General\nTamarind is generally well tolerated when used orally in food amounts. When used orally in medicinal amounts, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDry eye. Tamarind seed polysaccharide extract, alone or in combination with other ingredients, seems to be helpful in the management of dry eye.\nClinical research shows that a tamarind seed polysaccharide extract might improve symptoms of dry eye (16301, 97766, 97767). Application of tamarind seed polysaccharide 1% eye drops (Visine Intensive 1% EDO, Johnson and Johnson) 5 times daily for 3 months improves symptoms of dry eye, such as blurred vision, ocular burning, and the feeling of gritty eyes, by approximately 32% when compared with baseline. However, it is not as effective as hydroxypropyl-guar eye drops (Systane UD, Alcon Labs, Inc.), which also help to protect the eye surface from further evaporation (97767). Other clinical research in patients with moderate dry eye shows that the application of drops containing a combination of tamarind seed polysaccharide 0.2% and hyaluronic acid 0.2% (Xiloial monodose, Farmigea S.p.A.) 4 times daily for 3 months reduces symptoms of dry eye by almost twice as much as drops containing carmellose sodium (Optive monodose, Allegan Inc.) (97766).\nless\nFluorosis. Tamarind increases urinary fluoride excretion in people with fluorosis, but it is unclear if this improves symptoms of fluorosis.\nClinical research in adolescent males who have dental fluorosis associated with living in areas of India with high levels of fluoride in drinking water shows that taking 10 grams of tamarind daily for 18 days with a standard diet increases urinary excretion of fluoride when compared with the standard diet alone (76982). Similarly, males who use defluorinated drinking water, starting 2 weeks before taking tamarind 10 grams daily for 3 weeks, have increased urinary fluoride excretion when compared with using defluorinated water alone (76989). The studies did not report the effects of tamarind on clinical symptoms of fluorosis.\nless\nPOSSIBLY INEFFECTIVE\nPremature ejaculation. Tamarind seed powder does not seem to improve premature ejaculation.\nClinical research in patients with premature ejaculation shows that treatment with tamarind seed powder 130 mg daily for 4 weeks does not change measures of erectile function, ejaculatory latency, or sexual satisfaction when compared with placebo (103852).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCommon cold. Although there has been interest in using oral tamarind for the common cold, there is insufficient reliable information about the clinical effects of tamarind for this condition.\nConstipation. Although there has been interest in using oral tamarind for constipation, there is insufficient reliable information about the clinical effects of tamarind for this condition.\nIntestinal parasite infection. Although there has been interest in using oral tamarind for intestinal parasite infection, there is insufficient reliable information about the clinical effects of tamarind for this condition.\nKnee pain. Oral tamarind has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical trial in adults with mild to moderate non-arthritic knee pain shows that twice daily use of a specific tamarind seed and turmeric rhizome extract combination (TamaFlex, GNC) reduces knee pain and improves exercise capacity when compared with placebo. After 90 days of treatment, patients taking 125 mg or 200 mg of the combination twice daily for 90 days have greater improvements in pain, 6-minute walking distance, and 9-step stair climb time when compared with placebo (103853). It is unclear if these effects are due to tamarind, turmeric, mangosteen,or the combination.\nless\nLiver disease. Although there has been interest in using oral tamarind for liver disease, there is insufficient reliable information about the clinical effects of tamarind for this condition.\nOsteoarthritis. Oral tamarind has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study of patients with mild-to-moderate knee osteoarthritis shows that taking a specific product containing tamarind and turmeric rhizome extracts (TamaFlex, GNC) 250 mg daily for 8 weeks improves pain, stiffness, and function of the arthritic knee when compared with placebo. This product also appears to improve walking speed, stair climbing ability, and range of knee motion. Similar results were found with a combination product containing extracts of tamarind, turmeric rhizome, and mangosteen (TamaFlex plus, GNC) 300 mg taken daily for 8 weeks (110718). It is unclear if these findings are due to tamarind, other ingredients, or the combination.\nless\nPregnancy-induced nausea and vomiting. Although there has been interest in using oral tamarind for pregnancy-induced nausea and vomiting, there is insufficient reliable information about the clinical effects of tamarind for this condition.\nMore evidence is needed to rate tamarind for these uses.",
            "Dosing & Administration": "Adult\nAll routes:Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tamarind.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, tamarind seed extract might have additive effects when used with antidiabetes drugs.\nAnimal research suggests that an extract of tamarind seed can reduce fasting blood glucose levels (76988). Monitor blood glucose levels closely. Dose adjustments might be necessary.\nless\nASPIRIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, tamarind fruit extract might increase the effects and side effects of aspirin.\nTaking tamarind fruit extract as a component of millet porridge concurrently with aspirin seems to increase aspirin absorption and blood levels (12187).\nless\nIBUPROFEN (Advil, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, tamarind fruit extract might increase the effects and side effects of ibuprofen.\nTaking tamarind fruit extract as a component of millet porridge concurrently with ibuprofen seems to increase ibuprofen absorption and blood levels (12093).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, tamarind might have additive effects with other supplements with hypoglycemic effects.\nAnimal research suggests that an extract of tamarind seed can reduce fasting blood glucose levels (76988). Monitor blood glucose levels closely. See other herbs and supplements with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTamarind seed extract might lower blood glucose levels (76988). Theoretically, it might interfere with blood glucose control during and after procedures. Tell patients to discontinue using medicinal amounts of tamarind at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tamarind.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tamarind.",
            "Mechanism of Action": "General\nThe applicable parts of tamarind are the seeds and partially dried fruit or pod. Major constituents include alkaloids, glycosides, and anthraquinones (107381). It also contains phenolic compounds, malic and tartaric acids, pectin, proteins, vitamins, minerals, sugars (arabinose, xylose, galactose, and glucose), and volatile oil. The oil contains over 60 compounds, including methyl salicylate and safrole (11). The fruit pulp contains 30% to 40% sugars, and the seeds contain a mucilage, consisting mainly of a branched polysaccharide containing xylose and galactoxylose (97766, 97767, 107381).\nAnalgesic effects\nTheoretically, anti-inflammatory activity of tamarind could reduce musculoskeletal pain, such as knee pain, but these mechanisms are not well established (103853). Some researchers theorize that the polyphenolic proanthocyanidins in tamarind have anti-inflammatory properties and defend against oxidative stress (110718).\nAnthelmintic effects\nIn laboratory research, aqueous and alcoholic extracts of tamarind bark show activity against the annelids, Pheretima posthuma and Tubifex tubifex (107383). Tamarind extracts also have activity against Onchocerca ocheng, which is responsible for the bovine form of onchocerciasis (river blindness) (107384).\nAnti-inflammatory effects\nAnimal research shows that a trypsin inhibitor isolated from tamarind seed (TTI) can reduce plasma concentrations of total leukocytes and inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6 . In vitro studies suggest that TTI strongly inhibits human neutrophil elastase, which is implicated in macrophage infiltration and the recruitment, influx, and infiltration of neutrophils in the gut. Researchers hypothesize that an increase in neutrophils contributes to inflammation. Histologically, the study also suggests that TTI reduces mononuclear inflammatory infiltrates, prevents chronic enteritis, and preserves intestinal thickness of the submucosal layer of the intestine (110719).\nAnti-obesity effects\nAnimal research shows inconsistent effects of tamarind seed extracts on weight gain. In mice fed high-fat diets, giving a tamarind seed extract for 10 weeks attenuates blood glucose increases when compared with no intervention (103814). Although giving a trypsin inhibitor extracted from tamarind seeds for 10 days does not produce weight loss, it does reduce food consumption and induces satiety by stimulating cholecystokinin and leptin secretion (107382).\nAntidiabetic effects\nIn vitro, an aqueous extract of tamarind fruit pulp has strong alpha-amylase inhibitory activity, and moderate alpha-glucosidase inhibitory activity. These carbohydrate-digesting enzymes normally increase glucose absorption from the intestine; inhibition therefore helps to reduce postprandial hyperglycemia. The tamarind extract also increases glucose uptake from cultured L6 myotubes, indicating that it may increase glucose uptake in muscles in vivo (107381). Additionally, some animal research shows that a trypsin inhibitor isolated from tamarind seeds (TTI) may reduce fasting blood glucose levels (110719).\nAntilipidemic effects\nAnimal research suggests that a trypsin inhibitor isolated from tamarind seeds (TTI) may lower total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol (110719).\nAntimicrobial effects\nLaboratory research suggests that the tamarind constituent, tamarindienal, has antifungal activity against Aspergillus niger and Candida albicans, and antibacterial activity against Bacillus subtilis, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa (11).\nFluoride lowering effects\nSmall clinical studies show that tamarind increases urinary excretion of fluoride. This is thought to be due to acidification of the urine (76982, 76989).\nHormonal effects\nLaboratory research suggests that tamarind seed extract increases cellular production of insulin-like growth factor 1, improves mitochondrial oxygen respiration, and increases Leydig cell production of testosterone by approximately 17%. Animal research shows that tamarind seed extract increases testicular steroidogenesis gene expression, but that the related increase in testosterone production may be transient (103814).\nLaxative effects\nTamarind fruit pulp has mild laxative properties, but heating causes loss of this effect (11).\nOphthalmic effects\nTamarind seeds contain a polysaccharide with a branched chain structure, similar to the mucin found in the eye which helps protect and wet the corneal surface. Eye drops containing this polysaccharide have shown benefit for dry eye syndromes in clinical research (16301, 97766, 97767)."
        }
    },
    "Tamarix Dioica": {
        "sections": {
            "Overview": "Tamarix dioica is an evergreen shrub or small tree that grows up to 6 meters in height. It is native to tropical and temperate regions of Asia (104102). Tamarix dioica is listed as an invasive noxious weed by the United States Department of Agriculture (104105).",
            "Safety": "There is insufficient reliable information available about the safety of Tamarix dioica.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Tamarix dioica.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Tamarix dioica.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Tamarix dioica.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Tamarix dioica.",
            "Mechanism of Action": "General\nThe applicable part of Tamarix dioica is the whole plant. Tamarix dioica contains flavonoids, phenols, steroids, saponins, terpenoids, tannins, and phlobatannins. The leaves also contain D-mannitol, kaempferide, and tamarixetin (104102).\nAnalgesic effects\nA methanolic extract of Tamarix dioica dried stem bark has dose-dependent analgesic effects in mice (104102).\nAnti-inflammatory effects\nA methanolic extract of Tamarix dioica dried stem bark has dose- and time-dependent anti-inflammatory effects in mice. These effects may be due to inhibition of phospholipase A2 (104102).\nAntipyretic effects\nA methanolic extract of Tamarix dioica dried stem bark has dose-dependent antipyretic activity in mice. This effect may be due to aspirin-like central and peripheral activity, including prostaglandin inhibition (104102)."
        }
    },
    "Tangerine": {
        "sections": {
            "Overview": "The tangerine is a type of citrus fruit native to tropical areas of Asia (54757). It is now widely cultivated across the world, including in the United States and southern Europe.",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Tangerine has Generally Recognized as Safe (GRAS) status in the US (4912).\nThere is insufficient reliable information available about the safety of tangerine when used orally or topically as a medicine.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, very few adverse effects have been reported with the medicinal use of tangerine. However, a thorough evaluation of safety outcomes has not been conducted.\n\nTopically, contact dermatitis has been associated with tangerine essential oil (28610).\nDermatologic\nAccording to one case report, the essential oil of tangerine in a fragrance has been associated with contact dermatitis (28610).\nless\nGastrointestinal\nIn a case report, a 5 year-old patient had a phytobezoar that included tangerine residues (28611). In another case report, orange and tangerine caused obstruction of the small intestine (28612).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCancer. Observational research has found that daily intake of oranges and/or tangerines is associated with a reduced odds of developing nasopharyngeal carcinoma when compared with consuming oranges and/or tangerines less than once a week (28608).\nMore evidence is needed to rate tangerine for this use.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tangerine.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Case-control study)\nIn vitro, tangeretin, a constituent of tangerine, induces a 52% increase in the metabolism of midazolam by cytochrome P450 3A4 (CYP3A4) (28609). This suggests that tangeretin may stimulate CYP3A4 activity. However, in humans, drinking tangerine juice 200 mL slightly delayed the absorption, but did not affect the metabolism, of midazolam, a CYP3A4 substrate (28609). Theoretically, tangerine juice might increase CYP3A4 activity and decrease levels of drugs metabolized by this enzyme. However, this effect is unlikely.\nSome drugs metabolized by CYP3A4 include amitriptyline (Elavil), amiodarone (Cordarone), citalopram (Celexa), felodipine (Plendil), lansoprazole (Prevacid), ondansetron (Zofran), prednisone (Deltasone, Orasone), sertraline (Zoloft), sibutramine (Meridia), and many others.\nless\nMIDAZOLAM (Versed)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Case-control study)\nIn vitro, tangeretin, a constituent of tangerine, appears to increase the metabolism of midazolam in human liver microsomes by up to 52% (28609). However, in humans, drinking tangerine juice 200 mL slightly delayed the absorption, but did not affect the metabolism, of midazolam (28609). Theoretically, tangerine juice might increase the metabolism and reduce the effects of midazolam. However, this effect is unlikely.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of tangerine.",
            "Pharmacokinetics": "Absorption\nIn human research, consumption of tangerine juice concentrate increases serum levels of free beta-cryptoxanthin, zeaxanthin, and lutein (28613).",
            "Mechanism of Action": "General\nTangerine peel contains fat, protein, ash, magnesium, carotenoids, dietary fiber, and polyphenols (53350), as well as hesperidin, tangeretin, and nobiletin (28614), and other highly methoxylated flavones (28603). Tangerine juice contains esters of beta-cryptoxanthin, zeaxanthin, lutein, and vitamin C (28613, 54757). Tangerine seeds contain limonoids (28607, 28615).\nAnti-inflammatory effects\nIn animal research, nobiletin, a polymethoxyflavonoid constituent of tangerine, shows higher anti-inflammatory activity than indomethacin (28601). In vitro, the tangerine constituents hesperidin, nobiletin, and tangeretin, individually or in combination, reduce pro-inflammatory cytokine expression and have anti-neuroinflammatory effects (28614).\nAntibacterial effects\nIn vitro, a tangerine extract inhibits five clinical strains of Helicobacter pylori, with a minimum inhibitory concentration (MIC) of 60 mcg/mL (43416).\nAnticancer effects\nIn vitro, tangerine peel extract increases apoptosis of cancer cells; the caspase-3 pathway may be involved (28604, 28605). In vitro, highly methoxylated flavones, which are constituents of tangerine peel, induce differentiation and phagocytic activity of leukemia cells (28603). In vitro, limonoid constituents of tangerine induce apoptosis and inhibit the growth of some, but not all, cancer cell lines (28607).\nAntioxidant effects\nIn vitro evidence suggests that tangerine peel has antioxidant activity. This effect is attributed to the high polyphenol content (7.6 grams/100 grams) of the peel (53350). However, other in vitro evidence shows that hesperidin, a polyphenol found in tangerine juice, may not protect low-density lipoprotein (LDL) or very low-density lipoprotein (VLDL) cholesterol from oxidation (54757).\nCardiovascular effects\nIn a hamster model of atherosclerosis, tangerine juice inhibits development of atherosclerosis and lowers levels of cholesterol and triglycerides (54757)."
        }
    },
    "Tannic acid": {
        "sections": {
            "Overview": "Tannic acid is a specific form of tannin. It is extracted from the nutgalls formed on the twigs of certain oak trees by insects (11).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Tannic acid has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY UNSAFE when used topically on damaged or broken skin. Tannic acid has been reported to cause liver damage when applied to burns. However, it is possible that this toxicity was due to digallic acid, an impurity that is sometimes found in tannic acid (11).\nThere is insufficient reliable information available about the safety of tannic acid when applied to intact skin or when taken by mouth as a medicine.\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used topically on damaged or broken skin (2). There is insufficient reliable information available about the safety of tannic acid when used orally during pregnancy and lactation; avoid using amounts greater than those found in foods.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, large amounts of tannic acid can cause gastric irritation, nausea, and vomiting (11). Extensive use of tannins on burns or in enemas has been associated with fatal liver damage (11). However, this toxicity may be due to digallic acid, an impurity that is sometimes found in tannic acid (11).\nGastrointestinal\nOrally, large amounts of tannic acid can cause gastric irritation, nausea, and vomiting (11).\nless\nHepatic\nExtensive use of tannins on burns or in enemas has been associated with fatal liver damage (11). However, this toxicity may be due to digallic acid, an impurity that is sometimes found in tannic acid (11).\nless",
            "Effectiveness": "POSSIBLY INEFFECTIVE\nBurns. Applying tannic acid doesn't seem to be effective for treating minor burn or sunburn (272).\nDiaper rash. Applying tannic acid doesn't seem to be effective for treating diaper rash (272).\nHerpes labialis (cold sores). Applying tannic acid doesn't seem to be effective for treating cold sores and fever blisters (272).\nPrickly heat. Applying tannic acid doesn't seem to be effective for treating prickly heat (272).\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiarrhea. Research on the use of gelatin tannate (tannic acid suspended in a gelatin solution) for the treatment of diarrhea due to acute gastroenteritis is conflicting. A small clinical study in children 3 months to 6 years of age with acute gastroenteritis shows that taking gelatin tannate 250-500 mg four times daily for 5 days in combination with oral rehydration solution (ORS), starting within 3 days of symptom presentation, reduces the number of bowel movements at 72 hours and reduces the duration of diarrhea by about 31 hours when compared with ORS alone (101433). However, another small clinical study in children younger than 5 years old with acute gastroenteritis shows that taking this same dose of gelatin tannate along with ORS, starting within 5 days of symptom presentation, does not affect the number of daily watery stools or duration of diarrhea when compared with placebo and ORS (101267). The difference in these findings might be due to the duration of symptoms at the time of treatment initiation, severity of diarrhea, or the use of a placebo control.\nHyperhidrosis. A small preliminary clinical study in patients with palmar-plantar hyperhidrosis shows that applying tannic acid 20% lotion to one palm nightly is less effective for reducing symptoms of hyperhidrosis than once weekly iontophoresis with a glycopyrronium bromide 1% medium (101266).\nOsteoarthritis. Some clinical research in patients with knee osteoarthritis shows that applying a specific cream containing tannic acid, comfrey extract, aloe vera gel, eucalyptus oil, and frankincense oil (4Jointz, Arthritis Relief Plus Ltd) about 3.5 grams three times daily for 6-12 weeks decreases pain and stiffness and improves physical function when compared with placebo (44919, 92571). It is not clear if this effect is due to tannic acid, the other ingredients, or the combination.\nMore evidence is needed to rate tannic acid for these uses.",
            "Dosing & Administration": "Adult\nGeneral: Tannic acid, a specific form of tannin, can alter the absorption of foods and nutrients by binding with digestive enzymes, alkaloid substances, minerals, and nitrogen-rich compounds. However, tannic acid is neutralized during processing and dietary consumption, making it difficult to determine the extent, if any, to which it might alter absorption (11, 103714, 103715). Until more is known, separate the oral use of tannic acid from other products by at least 1 hour.\nTopical:\nOsteoarthritis: About 3.5 grams of a specific cream containing tannic acid 100 mg/gram, comfrey extract 200 mg/gram, aloe vera gel 300 mg/gram, eucalyptus oil 40 mg/gram, and frankincense oil 1 mg/gram (4Jointz, Arthritis Relief Plus Ltd) has been applied to the knee three times daily for 6-12 weeks (44919, 92570).\nChildren\nOral:\nDiarrhea: Gelatin tannate (Gelenterum sachet by Novintethical Pharma Sagl) 250-500 mg four times daily for 5 days in combination with oral rehydration solution has been used in children under 5 years of age (101433).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tannic acid.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "IRON\nTaking tannic acid in conjunction with non-heme iron supplements might reduce the absorption of iron. Clinical research in healthy patients shows that taking tannic acid 100 mg along with ferrous sulfate 5 mg decreases the fasting bioavailability of iron from 25% to 16.8% (92475).",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of tannic acid.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tannic acid.",
            "Mechanism of Action": "General\nTannic acid, a specific form of tannin, is a polymer of gallic molecules and glucose (11). Pharmaceutical-grade tannic acid is generally considered to be pentadigalloylglucose. However, the molecular weight and structure of pharmaceutical-grade and food-grade tannic acid varies (11).\nAnti-cancer effects\nSome evidence suggests that tannins might cause cancer, but other evidence suggests that tannins might prevent cancer (12). Regular consumption of herbs with high tannin concentrations correlates with increased incidence of esophageal or nasal cancer (12).\nAnti-diabetic effects\nThere is interest in tannic acid to improve glycemic control in diabetes. In vitro research shows that tannic acid inhibited alpha-amylase to a greater degree when compared with a specific supplement starch blocker (Phase 2 Starch Blocker), and also when compared with quercetin, rutin, polyphenon, and other flavonoids and polyphenols from green tea. However, there is concern that tannic acid will complex with protein present in the stomach, inactivating it after oral administration. Additional in vitro research shows that tannic acid encapsulated in calcium-alginate microspheres might avoid inactivation in the stomach, allowing it to travel intact to the small intestine to inactivate alpha-amylase activity (101269).\nAnti-inflammatory effects\nIn a mouse model, tannic acid attenuates gastric ulcer-induced changes in levels of tumor necrosis factor (TNF)-alpha and interleukins 1-beta, 6, and 10, in part due to mechanisms involving nitric oxide and prostaglandin E2 (106548).\nAntimicrobial effects\nTannins show some evidence of antiviral and antimicrobial effects (11).\nAntioxidant effects\nIn a mouse model, tannic acid attenuates gastric ulcer-induced changes in levels of myeloperoxidase, superoxide dismutase, catalase, malondialdehyde, and glutathione, in part due to mechanisms involving sulfhydryl compounds (106548).\nDental effects\nTannins show some evidence of antimicrobial and cariostatic effects (11).\nDermatologic effects\nTannic acid has astringent effects (11, 12). It dehydrates tissue, internally reducing secretions, and externally forming a protective layer of harder, constricted cells (12).\nGastrointestinal effects\nIn a mouse model, tannic acid acts as a physical barrier and demonstrates dose-dependent gastroprotective effects against ethanol- and acidified ethanol-induced gastric ulcers, in part due to mechanisms involving ATP-dependent potassium channels (106548).\nHepatic effects\nAnimal research in an acetaminophen-induced hepatotoxicity mice model shows that administering tannic acid seems to prevent morphological changes in the liver and also attenuate increases in liver enzymes and markers of inflammation (101268).\nNeurologic effects\nTannins show some evidence of CNS depressant effects (11)."
        }
    },
    "Tansy": {
        "sections": {
            "Overview": "Tansy is a perennial herb that is native to Europe. It has a long history of medicinal use and was first introduced to North America for use in folk remedies and as an ornamental plant (77009).",
            "Safety": "LIKELY SAFE when used orally in food amounts. Thujone-free tansy is approved by the US Food and Drug Administration (FDA) for use as an additive in alcoholic beverages (4912).\nPOSSIBLY UNSAFE when used topically. Tansy can cause severe contact dermatitis (6, 18, 19).\nLIKELY UNSAFE when tansy is used orally in medicinal amounts. Tansy contains the toxic constituent thujone (2, 6, 515). Fatalities have been associated with ingestion of as little as 10 drops of tansy oil (6). Fatalities have also been reported from prepared teas or powdered forms of tansy (4, 6). However, thujone concentration varies widely amongst tansy chemotypes (4, 6, 515).\nPREGNANCY: LIKELY UNSAFE when used orally or topically due to potential abortifacient, menstrual flow, and uterine stimulant effects (12, 19).\nLACTATION: LIKELY UNSAFE when used orally due to thujone content (2, 6).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is limited reliable information available about the adverse effects of tansy. Orally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity. Symptoms of thujone toxicity include rapid pulse, irregular heartbeat, tachypnea, severe gastroenteritis, vomiting, dilated pupils, hepatotoxicity, nephrotoxicity, and death (4, 6, 77012, 77014, 77015). Fatalities have been associated with ingestion of as little as 10 drops of tansy oil (6), occurring within 1-3.5 hours after ingestion (18). Fatalities have also been reported from prepared teas or powdered forms of tansy (4, 6).\n\nTopically, the Compositae family, of which tansy is a member, has been reported to cause contact dermatitis and photosensitivity (46978).\nCardiovascular\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity. Cardiovascular symptoms include rapid, feeble pulse and irregular heartbeat (4, 77014).\nless\nDermatologic\nTopically, atopic dermatitis has been reported from members of the Compositae family, of which tansy is a member (46978, 77007, 77011). Photosensitivity, typically presenting as eczema, has also been reported from contact with members of the Compositae family (42856).\nless\nGastrointestinal\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity. Gastrointestinal symptoms include severe gastroenteritis, vomiting, and abdominal pain (77012).\nless\nGenitourinary\nOrally, large doses of tansy have been reported to induce abortion and uterine bleeding (77015).\nless\nHepatic\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity, which can result in hepatotoxicity (77015).\nless\nNeurologic/CNS\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity. Neurologic symptoms include loss of consciousness, tremors, seizures, and vertigo (2, 18, 77012).\nless\nOcular/Otic\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity. Ocular symptoms include dilated pupils and pupillary rigidity (2, 18).\nless\nPulmonary/Respiratory\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity. Respiratory symptoms include tachypnea (77015).\nless\nRenal\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity, which can result in nephrotoxicity (77015).\nless\nOther\nOrally, varieties of tansy that contain the toxic constituent thujone have been reported to cause thujone toxicity, which has resulted in death after the ingestion of as little as 10 drops of tansy oil (6), occurring within 1-3.5 hours after ingestion (18). Fatalities have also been reported from prepared teas or powdered forms of tansy (4, 6).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of tansy.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tansy.",
            "Interactions with Drugs": "ALCOHOL (Ethanol)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nThujone, a constituent of tansy, can increase and alter the effects of alcohol (7).",
            "Interactions with Supplements": "THUJONE-CONTAINING HERBS\nConcomitant use of herbs containing thujone can increase the risk of thujone toxicity. Thujone-containing herbs include oak moss, oriental arborvitae, sage, wormwood, thuja (cedar), and tree moss (12); avoid using.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCROSS-ALLERGENICITY\nTansy can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nPORPHYRIA\nTheoretically, tansy can exacerbate porphyria in people with underlying defects in hepatic heme synthesis (12).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of tansy.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tansy.",
            "Mechanism of Action": "General\nThe applicable parts of tansy are the above ground parts. The activity and toxicity of the above ground parts of tansy vary greatly according to the subspecies (515). Thujone, one of the major active constituents of tansy, comprises 0% to 95% of tansy oil (515, 77006). Tansy contains beta-sitosterol as the major sterol and alpha-amyrin as the major triterpene. Tansy also contains the sterols stigmasterol, campesterol and cholesterol, and the triterpenes beta-amyrin and taraxasterol (77009). Other constituents include caffeic acid, volatile compounds, surface flavonoids, vacuolar flavonoids, and glycosides (77008, 6946).\nAcarical activity\nThujone, the major constituent of tansy, is believed to be responsible for the acaricidal activity of tansy oil (77006).\nAllergenic activity\nThe Compositae family, of which tansy is a member, has been reported to cause contact dermatitis and photosensitivity (46978).The sesquiterpene lactones (42876, 42856) and the oleoresins found in Compositae plants are hypothesized to be the main allergenic constituents (46978).\nAnti-inflammatory activity\nTansy has demonstrated anti-inflammatory activity in vitro (77010).\nAntimicrobial activity\nTansy oil has demonstrated antifungal, antibacterial, and anthelmintic activity in vitro (4, 12666).\nNeurologic activity\nIt is theorized that thujone oil, the primary constituent of tansy, has mind-altering effects similar to tetrahydrocannabinol (THC), the psychoactive principle of marijuana (515)."
        }
    },
    "Tansy Ragwort": {
        "sections": {
            "Overview": "Tansy ragwort is a plant that is sometimes used as medicine.",
            "Warnings": "Tansy ragwort contains hepatotoxic pyrrolizidine alkaloid (PA) constituents, which are likely unsafe when used orally or topically on broken skin (12841, 12842).",
            "Safety": "LIKELY UNSAFE when products containing hepatotoxic pyrrolizidine alkaloid (PA) constituents are used orally. Repeated exposure to low concentrations of hepatotoxic PAs can cause severe veno-occlusive disease. Hepatotoxic PAs might also be carcinogenic and mutagenic (12841, 12842). Tell patients not to use tansy ragwort preparations that are not certified and labeled as hepatotoxic PA-free. ...when products containing hepatotoxic PAs are used topically on abraded or broken skin. Absorption of hepatotoxic PAs through broken skin can lead to systemic toxicities (12841). Tell patients not to use topical tansy ragwort preparations that are not certified and labeled as hepatotoxic PA-free. There is insufficient reliable information available about the safety of using topical PA-free tansy ragwort on unbroken skin.\nPREGNANCY: LIKELY UNSAFE when used orally. Tansy ragwort preparations containing hepatotoxic pyrrolizidine alkaloid (PA) constituents might be teratogenic and hepatotoxic (12841, 12842). There is insufficient reliable information available about the safety of using tansy ragwort products that do not contain hepatotoxic PAs during pregnancy.\nLACTATION: LIKELY UNSAFE when used orally. Hepatotoxic pyrrolizidine alkaloid (PA) constituents in tansy ragwort are excreted in milk (12841, 12842). There is insufficient reliable information available about the safety of using tansy ragwort products that do not contain hepatotoxic PAs during lactation.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nWhen used orally or topically on broken skin, tansy ragwort may be unsafe. When used topically on intact skin, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\nHepatic\nOrally, the major concern with tansy ragwort use is its pyrrolizidine alkaloid (PA) content. These constituents can cause liver and lung injury (12841, 12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021). Sub-acute veno-occlusive disease can cause vague symptoms, including colicky pains, vomiting, diarrhea, and ascites within several days; persistent liver enlargement occurs within a few weeks (4021, 12842).\nless\nPulmonary/Respiratory\nOrally, the major concern with tansy ragwort use is its pyrrolizidine alkaloid (PA) content. These constituents can cause lung damage with pulmonary-arterial hypertension (12841, 12842).\nless\nOther\nOrally, the major concern with tansy ragwort use is its pyrrolizidine alkaloid (PA) content. These constituents are carcinogenic and mutagenic (12841, 12842).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of tansy ragwort.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tansy ragwort.",
            "Interactions with Drugs": "CYTOCHROME P450 3A4 (CYP3A4) INDUCERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, CYP3A4 inducers might increase the risk of adverse effects from the pyrrolizidine alkaloid (PA) constituents in tansy ragwort.\nTansy ragwort contains PAs. PAs are substrates of CYP3A4 (12841, 12860). Theoretically, drugs that induce CYP3A4 might increase the conversion of PAs to toxic metabolites.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS THAT INDUCE CYTOCHROME P450 3A4 (CYP3A4)\nThe pyrrolizidine alkaloid (PA) constituents of tansy ragwort are converted to toxic metabolites via CYP3A4.\nTheoretically, taking CYP3A4 inducers might increase the risk of adverse effects from the PA constituents of tansy ragwort (12841, 12860). See natural ingredients that induce CYP3A4 here.\nless\nPYRROLIZIDINE ALKALOID (PA)-CONTAINING HERBS AND SUPPLEMENTS\nTansy ragwort contains pyrrolizidine alkaloids (PA), which are hepatotoxic.\nTheoretically, tansy ragwort might have additive hepatotoxic effects when used with other herbs that contain PAs. PA-containing herbs can cause ascites, cirrhosis, hepatic fibrosis, hepatomegaly, and sinusoidal obstruction syndrome (12841). See other PA-containing natural ingredients here.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information regarding the presentation or treatment of overdose with tansy ragwort.",
            "Pharmacokinetics": "There is insufficient reliable information regarding the pharmacokinetics of tansy ragwort.",
            "Mechanism of Action": "General\nThe applicable parts of tansy ragwort are the above ground flowering parts. Tansy ragwort contains various pyrrolizidine alkaloids (PA), some of which are toxic. PAs are most concentrated in the plant roots, but may be found in all plant parts.\nHepatotoxic effects\nPyrrolizidine alkaloids (PA), particularly unsaturated PAs, can cause hepatotoxicity. Cyclic diesters such as retrorsine and senecionine are the most hepatotoxic. Liver toxicity may result from PA-enhanced oxidative stress, but the exact mechanism of toxicity is unknown. Single doses of 10-20 mg PAs or chronic ingestion of amounts less than 10 mcg can cause veno-occlusive disease (12841, 12860).\nPulmonary effects\nPyrrolizidine alkaloids (PA) are also toxic to the lungs. In animals, pneumotoxicity occurs as pulmonary hypertension and right ventricular hypertrophy (12841, 12842)."
        }
    },
    "Tapioca": {
        "sections": {
            "Overview": "Tapioca is a common starch derived from the cassava plant. It is used as a thickening agent and as a source of starch in noodles, puddings, bread, and other food products (92950).",
            "Safety": "LIKELY SAFE when used orally in the amounts commonly found in food (92944, 92946). Tapioca has generally recognized as safe (GRAS) status in the US (92949).\nPOSSIBLY SAFE when used orally in medicinal amounts, short-term. Specific forms of tapioca, including tapioca maltodextrin and tapioca resistant maltodextrin, have been used with apparent safety at doses up to 25 grams daily and 7.7 grams daily, respectively, for up to 12 weeks (108895). Single doses of up to 50 grams have also been used with apparent safety (108894).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in the amounts commonly found in food (92944, 92946). There is insufficient reliable information available about the safety of tapioca when used in larger amounts as medicine during pregnancy or lactation; avoid use.",
            "Adverse Effects": "General\nOrally, tapioca seem to be well tolerated.\nMost Common Adverse Effects\nOrally: Abdominal pain, bloating, flatulence, vomiting.\nGastrointestinal\nOrally, tapioca resistant maltodextrin may cause abdominal pain, bloating, flatulence, and vomiting (108894, 108895). Additionally, there is some concern that consuming tapioca pearls could result in bowel obstruction in predisposed patients. In one case, a 13-year-old female with superior mesenteric artery syndrome presented with bilious vomiting and epigastric pain due to duodenal impaction and small bowel obstruction after consuming \"bubble tea\" containing tapioca pearls, requiring hospitalization and conservative treatment (115953).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nImpaired glucose tolerance (prediabetes). It is unclear if oral tapioca starch is beneficial in patients with prediabetes.\nA small clinical study in patients with prediabetes shows that eating bread containing tapioca starch 6 grams as a single dose lowers postprandial blood glucose levels by approximately 20 mg/dL when compared with placebo bread (92946). Another small clinical study in patients with prediabetes shows that taking an oral nutritional supplement providing tapioca maltodextrin 17.9 grams and tapioca resistant maltodextrin 7.7 grams daily for 12 weeks reduces glycated hemoglobin (HbA1c) by 0.29%, but does not reduce fasting blood glucose, when compared to baseline (108895). The validity of these findings is limited by the lack of a control group.\nless\nMore evidence is needed to rate tapioca for this use.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available regarding the standardization of tapioca.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tapioca.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tapioca.",
            "Mechanism of Action": "General\nTapioca is prepared by cooking cassava root, drying it, grinding and sieving it, and then cooking it again (92947). Tapioca is a starch. It also contains fiber, as well as some minerals such as calcium and potassium (92950). Highly cross-linked tapioca starch is more difficult to digest and ferment.\nAntidiabetic activity\nThere is interest in using tapioca to reduce postprandial blood glucose levels. In preliminary clinical studies, single doses of bread containing tapioca starch, tapioca maltodextrin, or tapioca resistant maltodextrin reduced postprandial blood glucose levels when compared with control foods or supplements (92946, 108894, 108895). Also, highly cross-linked starch from tapioca reduced postprandial blood glucose levels in healthy males when compared to unmodified tapioca starch (92945). In general, raw starches have lower glucose peaks compared to cooked starches (92947)."
        }
    },
    "Tarragon": {
        "sections": {
            "Overview": "Tarragon is a perennial herb. The leaves of the plant are traditionally used as medicine (12). Do not confuse tarragon with mugwort (Artemisia vulgaris).",
            "Safety": "LIKELY SAFE when the leaf or essential oil is used orally in amounts commonly found in foods. Tarragon has Generally Recognized as Safe (GRAS) status in the US (4912).\nThere is insufficient reliable information available about the safety of tarragon when used orally or topically in medicinal amounts, or when used by inhalation for aromatherapy.\nPREGNANCY AND LACTATION: LIKELY UNSAFE Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted. There is concern that long-term consumption of estragole, a constituent of tarragon, increases the risk for cancer. However, this risk has only been shown in animals (77046, 77029, 77042).",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nPostoperative nausea and vomiting (PONV). Preliminary clinical research shows that applying a mixture of essential oils from ginger, cardamom, and tarragon to the neck at the first sign of PONV and inhaling as aromatherapy can inhibit nausea and/or vomiting for 30 minutes in 50% to 88% of postoperative patients. The treatment effect appears to vary depending on the number of emetic drugs administered and whether the drugs were given during or after the operation (77054). It is not clear if this effect is due to tarragon, the other ingredients, or the combination. Also, the validity of this finding is limited by the lack of a comparator group.\nMore evidence is needed to rate tarragon for this use.",
            "Dosing & Administration": "Adult\nTopical:\nPostoperative nausea and vomiting (PONV): 1-2 drops of 1:1:1 ratio mixture of essential oils of ginger rhizome, cardamom fruit, and tarragon aerial parts, applied to the neck of patients postoperatively at the first sign of nausea and vomiting, has been used (77054).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tarragon. Tarragon oil is commonly found to be adulterated (11). Depending on the metal composition of the soil, tarragon may contain varying levels of metals (59401).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nEvidence from in vitro research suggests that tarragon extract inhibits platelet aggregation and adhesion (49445, 76932, 77038). Theoretically, tarragon might increase the risk of bleeding when used with antiplatelet or anticoagulant drugs. Some anticoagulant or antiplatelet drugs include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), and others.\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nEvidence from animal research suggests that tarragon essential oil can cause sedation and motor impairment when administered intraperitoneally at a dose of 1 mL/kg (77024). Theoretically, concomitant use of tarragon with CNS depressants, including antihistamines, barbiturates, benzodiazepines, and tricyclic antidepressants, may increase sedative and other adverse effects.\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro research suggests that tarragon extract inhibits monoamine oxidase (MAO)-A and MAO-B enzymes (106774). Theoretically, concomitant use with MAOIs might increase the effects and adverse effects associated with MAOIs.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nIn vitro research suggests that tarragon extract inhibits platelet aggregation and adhesion (49445, 76932, 77038). Theoretically, concomitant use with herbs that affect platelet aggregation could increase the risk of bleeding in some people. These herbs include angelica, danshen, garlic, ginger, ginkgo, red clover, turmeric, willow, Panax ginseng, and others.\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nAnimal research suggests that tarragon essential oil can cause sedation and motor impairment when administered intraperitoneally at a dose of 1 mL/kg (77024). Theoretically, concomitant use of tarragon essential oil with herbs and supplements with sedative properties may increase sedative effects. Some of these include 5-HTP, calamus, California poppy, catnip, hops, Jamaican dogwood, kava, St. John's wort, skullcap, valerian, yerba mansa, and others.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Tarragon contains estragole, a chemical that has demonstrated carcinogenic activity in animals (30635, 77020). Animal studies suggest that very high dosages of estragole may increase the risk of liver cancer (77046, 77029). In mice, estragole and its metabolite, 1'-hydroxyestragole, caused significant increases in the incidence of hepatocellular carcinoma (77042). Other studies have shown that metabolites of estragole form hepatic DNA adducts (49405). The amount of estragole needed for rodents to be in danger of developing cancer is in the range of 1-10 mg/kg, or about 100-1000 times the amount that humans would typically use in teas and as flavoring (77020). The essential oil of tarragon contains 172-7000 ppm of estragole.\n\nTarralin, a decoction of tarragon, has demonstrated no toxicity in rats at oral doses of 1000 mg/kg daily for 90 days (77023).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tarragon.",
            "Mechanism of Action": "General\nThe applicable parts of tarragon are the above ground parts. Tarragon essential oil contains approximately 81% estragole (12). Tarragon is considered a rich plant source of potassium (19). It also contains many other constituents, including alpha-pinene, alpha-trans-ocimene, volatile oils, alkylamides, and various coumarin derivatives, such as herniarin and skimmin (49405, 77017, 77021, 77022, 77024, 77026, 77027, 77030, 77034, 77037)(77050, 77051, 106774).\nAnti-inflammatory effects\nIn vitro research shows that tarragon is able to suppress, but not scavenge, nitric oxide. Overproduction of nitric oxide has been implicated in the development of a number of diseases (30640).\nAnticoagulant effects\nIn vitro research shows that methanol extracts and chloroform fraction of tarragon inhibit platelet adhesion to laminin-coated wells and change cell adhesive properties, self-aggregation, and protein secretion (77038, 76932). In vivo research shows that tarragon essential oil has high antiplatelet activity and can destabilize clot retraction (49445).\nAntidiabetic effects\nThere is interest in using tarragon for the treatment of diabetes. In mice, oral administration of tarragon for 9 days reduced hyperphagia and polydipsia, without affecting glycemic control (62110). In other animal research, tarralin, an ethanolic extract of tarragon, lowered elevated blood glucose levels by 20% to 24% (77031). Furthermore, tarralin reduced blood insulin concentrations in diabetic mice by 33%. Tarralin significantly decreased phosphoenolpyruvate carboxykinase (PEPCK) mRNA expression in diabetic rats; however, in nondiabetic animals, tarralin did not alter PEPCK expression, blood glucose, or insulin concentrations (77043). An ethanolic extract of tarragon inhibited the activity of aldose reductase (ALR2) inhibitor, an enzyme involved in diabetic complications, by 40% (77030).\nAntimicrobial effects\nTarragon essential oils demonstrate antimicrobial activity in vitro, although these effects are weaker than that of many other spice essential oils (39809, 77028). In vitro, tarragon essential oil has demonstrated at least partial inhibition of Helicobacter pylori, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Shigella, Listeria monocytogenes, and Pseudomonas aeruginosa (36131, 77032, 77040). Tarragon essential oils have also demonstrated antifungal activity against Aspergillus niger, Candida albicans, Cryptococcus neoformans, Colletrotichum species, and dermatophytes (77021, 77022, 77028, 77032, 77040).\nAntioxidant effects\nAnimal research in mice with chemically-induced encephalomyelitis shows that taking tarragon extract 500 mg/kg orally daily for 33 days increases serum antioxidant activity (106775).\nHepatotoxic effects\nEstragole, a constituent of tarragon, has demonstrated hepatic carcinogenicity in animal research. In mice, estragole and its metabolite, 1'-hydroxyestragole, caused significant increases in the incidence of hepatocellular carcinoma (77042). Other studies have shown that metabolites of estragole form hepatic DNA adducts (49405). Estragole also produced necrotic changes in hepatocytes in female mice (77029). Estragole inhibited the glucocorticoid induction of liver-specific enzyme, tyrosine aminotransferase, and tryptophan oxygenase in female rats, but not in male rats or mice (77046).\nInsecticidal effects\nConstituents of tarragon, including pellitorine, neopellitorine A, neopellitorine B, and herniarine, demonstrate insecticidal activity against Sitophilus oryzae and Rhyzopertha dominica (77019).\nNeurologic effects\nThere is interest in using tarragon for neurological conditions, such as epilepsy, multiple sclerosis, Alzheimer disease, and Parkinson disease. Tarragon essential oil has demonstrated dose- and time-dependent antiseizure activity in animal models of experimental seizures (77024). At the doses needed for antiseizure activity, tarragon has also demonstrated sedative effects (77024).\n\nAnimal research in mice with chemically-induced encephalomyelitis shows that taking tarragon extract 500 mg/kg orally for 33 days ameliorates neural demyelination when compared with control. In addition, taking tarragon reduced serum levels of the proinflammatory cytokines, interleukin (IL)-23 and IL-17A (106775).\n\nIn vitro, tarragon oil obtained from France has demonstrated potent inhibitory activity against acetylcholinesterase (AChE); however, tarragon oil obtained from Hungary did not demonstrate AChE inhibitory activity (77045). Inhalation of tarragon oil might increase sympathetic activity, as evidenced by low-frequency amplitude of systolic blood pressure in humans (49420).\n\nIn vitro, tarragon extract also inhibits monoamine oxidase (MAO)-A and MAO-B enzymes. In vitro research suggests that the constituents herniarin and skimmin are responsible for the MAO inhibitory activity of tarragon (106774).\nWeight loss effects\nAnimal research in obese mice fed a high-fat diet shows that taking tarragon extract for 4 weeks improves markers of fat oxidation, but not body weight, body fat composition, or glucose tolerance, when compared with control (106776)."
        }
    },
    "Tart Cherry": {
        "sections": {
            "Overview": "Tart cherry refers to the fruit of the Prunus avium tree. There are more than 270 varieties of tart cherry, but only a few are important commercially (6). The most popular tart cherry variety grown in the US is the Montmorency cherry. While up to 97% of tart cherries grown are used for cooking and baking, some tart cherry products are marketed for specific health benefits (93197).",
            "Safety": "LIKELY SAFE when the fruit is used in amounts commonly found in foods. ...when tart cherry fruit, fruit juice, or fruit juice concentrate is used orally in supplemental amounts for up to 3 months (17403, 93149, 93151, 93152, 93153, 93154, 93156, 93157, 93158, 93160)(93161, 93168, 93179, 105633).\nPOSSIBLY SAFE when tart cherry fruit extract or powder is used orally, short term. Cherry fruit extract or freeze-dried cherry powder up to 500 mg daily for up 7 days has been used with apparent safety (93157, 93158, 105631).\nThere is insufficient reliable information available about the safety of tart cherry stem when used orally.\nPREGNANCY AND LACTATION: LIKELY SAFE when the fruit is consumed in typical food amounts. There is insufficient reliable information available about the safety of tart cherry fruit or stem when used in medicinal amounts; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nTart cherry is generally well tolerated when consumed as whole fruit, juice concentrate, or seed extracts.\nMost Common Adverse Effects\nOrally: Abdominal pain, asthenia, gastrointestinal upset, loose stools.\nEndocrine\nOne case of hyperglycemia after drinking a specific blend of tart cherry and apple juices (Sour cherry juice, Cherrypharm Inc.) has been reported (93160).\nless\nGastrointestinal\nIn a clinical study, 29% of children who consumed 75 mL of tart cherry juice concentrate twice daily for 2 weeks reported abdominal pain (112815). Two cases of loose stools after consumption of 90 whole tart cherries, and one case of gastrointestinal disturbance after drinking 10.5 ounces of tart cherry concentrate (Cherrish, Cherrish Corp.) twice daily for 14 days have been reported (93186, 93192). One case of gastrointestinal symptoms after drinking a specific blend of tart cherry and apple juice (Sour cherry juice, Cherrypharm Inc.) has been reported (93160).\nless\nImmunologic\nOne case of a skin reaction possibly due to cherry allergy after drinking a specific blend of tart cherry and apple juice (Sour cherry juice, Cherrypharm Inc.) has been reported (93160).\nless\nMusculoskeletal\nIn a clinical study, 31% of children who consumed tart cherry juice concentrate 75 mLl twice daily for 2 weeks reported asthenia (112815).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAthletic performance. Most available research suggests that oral tart cherry modestly improves muscular strength and endurance when compared with control. However, most studies are limited by a high risk of selection bias.\nA meta-analysis of 14 small studies involving a total of 303 trained athletes and untrained healthy adults shows that tart cherry might modestly improve recovery of muscular strength and power when compared with control. Also, some subgroup analyses show that tart cherry may improve recovery of jump height and sprint time when compared with control (105629). Another meta-analysis, along with a more recent clinical study, involving marathon runners, cyclists, or triathletes at various levels of training, shows that taking tart cherry juice concentrate or powder 1.5 hours before exercise, or for up to 7 days prior to exercise, improves exercise endurance, as measured by the time to complete an exercise time trial, when compared with control (102340, 116151). Both meta-analyses have a high risk of selection bias and some have high heterogeneity. Additionally, not all data agree. A small clinical study does not find that tart cherry juice improves exercise performance or recovery in adults (116142).\n\nSpecific products assessed in the meta-analyses above include tart cherry juice (CherryActive, Active Edge Nutrition) 60 mL, 90 minutes prior exercise (98699); a specific tart cherry concentrate (CherryActive, Active Edge Nutrition) 30 mL twice daily for 8 days (93149); and a specific freeze-dried tart cherry supplement (CherryPURE, Shoreline Fruit LLC) 480 mg daily 7 days before, on the day of, and 2 days after exercise (93158).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAromatase inhibitor-induced arthralgia. It is unclear if oral tart cherry is beneficial in patients with aromatase inhibitor-induced arthralgia (AIIA).\nPreliminary clinical research in a small group of females with non-metastatic, hormone-receptor positive breast cancer and AIIA after taking aromatase inhibitors for at least 4 weeks shows that taking tart cherry juice concentrate 30 mL daily for 6 weeks reduces pain scores on a visual analog scale by about 35%, compared with 1% in those taking placebo (109657).\nless\nAttention deficit-hyperactivity disorder (ADHD). It is unclear if oral tart cherry juice is beneficial in children with ADHD.\nA small clinical study in children and adolescents aged 6 to 18 years with ADHD shows that consuming tart cherry juice concentrate 75 mL twice daily for 2 weeks with standard treatment does not improve ADHD symptoms including cognitive impairment, hyperactivity, impulsivity, or oppositional behavior when compared with placebo (112815).\nless\nCognitive function. It is unclear if oral tart cherry improves cognitive function.\nPreliminary clinical research in healthy, middle-aged adults shows that taking tart cherry juice concentrate 30 mL orally twice daily for 3 months reduces mental fatigue and improves performance on tests evaluating sustained attention, psychomotor speed, and alertness when compared with placebo. However, it does not affect sleep quality or cerebral blood flow (109655).\nless\nExercise-induced muscle soreness. Research on the use of oral tart cherry juice or supplements for the reduction of exercise-induced muscle soreness is conflicting.\nA meta-analysis of 12 small studies in trained athletes and untrained healthy adults shows that tart cherry might modestly attenuate delayed muscle soreness after exercise involving maximal muscle contractions or maximal effort sprints when compared with control. However, tart cherry juice seems to be no better than placebo for improving delayed muscle soreness after prolonged aerobic exercise (105629). These findings are limited by a high risk of selection bias, high heterogeneity, and imprecision. Some products assessed in the meta-analysis include a specific Montmorency tart cherry concentrate (Holland & Barrett Ltd.) 30 mL twice daily for 5 days before, on the day of, and for 2 days after intermittent sprint exercises (102341); a specific freeze-dried tart cherry supplement (CherryPURE, Shoreline Fruit LLC) 480 mg daily for 7 days before, on the day of, and 2 days after running a half-marathon or doing back squats (93157, 93158); a specific Montmorency tart cherry juice concentrate (CherryActive, Active Edge Nutrition) 30 mL diluted in water and taken twice daily for 8 days (93149, 93151, 101880, 102344); and a specific juice (Sour cherry juice, Cherrypharm Inc.) containing 90% tart cherry juice and 10% apple juice as a sweetener, twice daily (93152, 93154).\n\nSome individual clinical studies have yielded mixed findings. One clinical study in professional rugby players shows that taking a Montmorency tart cherry juice concentrate gel, 30 mL (equivalent to 100 cherries) twice daily for 2 days before, on the day of, and for 2 days after a match does not improve muscle soreness when compared with placebo (102339). Similarly, in male professional soccer players, taking tart cherry juice, 60 mL before and after a 90-minute match and then 12 and 36 hours later, does not improve subjective muscle soreness when compared with placebo (102342). Also, a small study in healthy males shows that taking a specific tart cherry supplement (Tart Cherry Extract Powder NordicCherry, Specnova, LLC.) 500 mg daily for 7 days prior to performing resistance exercise does not reduce muscle soreness when compared with placebo (105631). In contrast, a small clinical study in recreational long-distance runners shows that drinking a specific tart cherry juice (Cherrish, Cherrish Corp.) 10.5 ounces twice daily for 7 days prior to a long-distance race decreases post-race muscle pain by around 65% when compared with placebo (93156).\n\nReasons for the discrepancies may include differences in tart cherry products, the small number of subjects, and heterogeneity in study populations and evaluated endpoints. In some studies, the subjects' normal diets were continued during the study, whereas in others, a reduced polyphenol diet was consumed for the duration of the study (102342, 105629).\nless\nExercise-induced respiratory infections. It is unclear if oral tart cherry juice reduces the risk of exercise-induced respiratory infections.\nA small clinical study in recreational athletes shows that drinking a specific juice blend (Sour cherry juice, Cherrypharm Inc.), containing 90% tart cherry juice and 10% apple juice as a sweetener, 8 ounces twice daily for 5 days before, on the day of, and 2 days after running a marathon, decreases the risk for upper respiratory tract symptoms such as cough, sore throat, congestion, and sneezing when compared with placebo (93168).\nless\nFibromyalgia. It is unclear if oral tart cherry improves symptoms in patients with fibromyalgia.\nA very small clinical study in females with fibromyalgia participating in an eccentric exercise program shows that taking a specific tart cherry concentrate (Cherrish, Cherrish Corp.) 10.5 ounces twice daily for 14 days does not improve pain or muscle strength when compared with placebo (93192).\nless\nGout. It is unclear if oral tart cherry juice reduces symptoms of gout; research is conflicting.\nPreliminary clinical research shows that tart cherry juice lowers serum urate and increases urinary urate excretion in healthy people, as well as people with hyperuricemia that has not progressed to gout (93166, 102338). However, in patients with gout, taking Montmorency tart cherry juice concentrate (Cherryvite) in doses of 7.5-30 mL twice daily for 28 days does not affect urate excretion or the frequency of gout flares (102343).\n\nTart cherry has also been evaluated in combination with other ingredients. A small, unblinded clinical study in adults with chronic gout shows that taking a combination product (GoutFighter, MaxBiocare Pty Ltd.) containing tart cherry fruit extract 100 mg, celery seed extract 300 mg, devil's claw tuber extract 150 mg, folic acid 90 mcg, potassium citrate 50 mg, and ascorbic acid 50 mg orally, as 2 tablets twice daily for 45 days, modestly reduces mean serum uric acid levels and reduces perceived pain and frequency of joint swelling when compared to baseline (106488). The validity of these findings is limited by the lack of a comparator group. A moderate-sized, open-label clinical study in adult males with gout shows that adding an oral 25% tart cherry and citrate mixture twice daily to febuxostat for 12 weeks reduces serum urate levels from baseline but not when compared with sodium bicarbonate or a citrate mixture. The average number of gout flares is reduced when compared with sodium bicarbonate but is comparable to the citrate mixture group (116150). The validity of these results is limited by the lack of statistical adjustment for multiple comparisons. It is unclear if any of the effects are due to tart cherry, other ingredients, or the combination.\nless\nHypertension. It is unclear if oral tart cherry juice reduces blood pressure; research is conflicting.\nA very small clinical study in males with mild hypertension shows that taking 60 mL of a specific tart cherry concentrate (CherryActive, Active Edge Nutrition) modestly decreases systolic, but not diastolic, blood pressure 1-3 hours after consumption when compared with placebo (93155). This finding is limited by the small study size and the use of a single dose. Another small study in healthy adults without hypertension shows that drinking 30 mL of Montmorency tart cherry concentrate (Cherry Marketing Institute) diluted in 240 mL of water daily for 3 months does not reduce blood pressure when compared with baseline or placebo (105633).\nless\nInsomnia. Some small clinical studies suggest that oral tart cherry juice may modestly improve sleep and reduce insomnia. This effect might be due to the melatonin content in tart cherry juice. However, the evidence is conflicting.\nA small clinical study in healthy adults less than 40 years of age shows that consuming a specific tart cherry juice concentrate (CherryActive, Active Edge Nutrition) 30 mL standardized to contain 1.42 mcg/mL of melatonin twice daily for 7 days modestly increases total sleep time and efficiency when compared with placebo (17199). Another small clinical study in adults aged 65 years and older with chronic insomnia shows that drinking a specific juice blend (Sour cherry juice, Cherrypharm Inc.), containing 90% tart cherry juice and 10% apple juice as a sweetener, 8 ounces twice daily for 14 days, modestly improves insomnia severity, but not sleep latency, when compared with placebo (17403). However, another very small clinical study in healthy adults shows that taking Montmorency tart cherry juice 240 mL twice daily or powdered Montmorency tart cherry capsules 1000 mg daily for 30 days does not improve sleep quality, sleep time, or serum melatonin concentration when compared with placebo (112813). Furthermore, a small crossover clinical study in adults with overweight or obesity and self-reported poor sleep quality or insomnia shows that taking Montmorency tart cherry powder capsules (CherryPURE Tart Cherry Powder, Shoreline Fruit) 500 mg one hour before bed for 14 days does not improve objective sleep outcomes or subjective sleep scores when compared with placebo (116145).\n\nThe effects of tart cherry on sleep measures have also been evaluated in combination with other ingredients. A very small crossover study in healthy adults without a sleep disorder shows that taking a combination product containing tart cherry powder 220 mg, tryptophan, glycine, magnesium, and L-theanine 2 hours before bedtime for 3 nights decreases the time to fall asleep by about 24 minutes, increases total sleep duration by about 22 minutes, improves sleep efficiency, and reduces morning sleepiness, but does not improve the total time in bed or wakefulness after falling asleep when compared with placebo (111184). It is unclear if these effects are due to tart cherry, other ingredients, or the combination.\nless\nMetabolic syndrome. Oral tart cherry juice does not seem to improve cardiovascular or metabolic biomarkers in patients at risk for or with metabolic syndrome.\nThree meta-analyses of small, moderate-quality clinical studies in healthy adults, patients with metabolic syndrome, or those with risk factors for metabolic syndrome, that include many of the same studies, show that drinking tart cherry juice 30-480 mL daily for 1-12 weeks does not improve fasting blood glucose, insulin levels, lipid profiles, blood pressure, body weight, body mass index, fat mass, percentage body fat, or waist circumference when compared with placebo (112812, 112814, 116147).\nless\nOsteoarthritis. It is unclear if oral tart cherry juice is beneficial in patients with osteoarthritis.\nA small clinical study in patients with osteoarthritis shows that drinking a specific juice blend (Sour cherry juice, Cherrypharm Inc.) containing 90% tart cherry juice and 10% apple juice as a sweetener, 8 ounces twice daily for 6 weeks, does not improve pain, stiffness, function, walking speed, or acetaminophen use when compared with placebo (93160). The validity of this finding is limited because the trial was not adequately powered to detect small differences between groups.\nless\nRange of motion. It is unclear if oral tart cherry is beneficial for range of motion.\nA small clinical study in healthy, recreationally active adults shows that taking tart cherry extract capsules containing about 132 mg anthocyanins and 612 mg polyphenols twice daily for 4 days does not improve range of motion following a maximal eccentric exercise protocol when compared with placebo (116149).\nless\nUlcerative colitis. It is unclear if oral tart cherry is beneficial in patients with ulcerative colitis (UC).\nA small clinical study in adults with mild-to-moderate UC shows that consuming Montmorency tart cherry concentrate (Montmorency Tart Cherry Juice Concentrate, King Orchards) 30 mL twice daily diluted in 100 mL water for 6 weeks modestly improves patient-reported quality of life and symptom scores and reduces fecal calprotectin when compared with placebo (116146). The validity of these results is limited by heterogenous methods, including the use of differing baseline treatment medications among participants.\nless\nMore evidence is needed to rate tart cherry for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTart cherry juice is commonly consumed in doses of 240-480 mL daily. Tart cherry juice concentrate, 30-60 mL diluted in water, is taken daily for up 3 months. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information about the standardization of tart cherry. However, the anthocyanin content of certain commercially available tart cherry products has been quantified (93149, 93151, 93152, 93154, 93156, 93157, 93158, 93160, 93168, 93192).\n\nA specific tart cherry and apple juice proprietary blend (Sour cherry juice, Cherrypharm Inc.) is reported to contain 450-600 mg of phenolic compounds and 30-40 mg of anthocyanins per 8 or 12 ounce serving. This is equivalent to 50-60 tart cherries (93152, 93154, 93160, 93168).\n\nA specific tart cherry concentrate (CherryActive, Active Edge Nutrition) contains the equivalent of about 90-100 tart cherries per 30 mL serving (17199, 93155, 93173, 93179). The amount of phenolic compounds in this product is 178.8 gallic acid equivalents per liter, and the anthocyanin content ranges from 2.2 mg per serving up to 273.5 mg per serving (93149, 93151). The reason for the wide range is unclear. This product is also reported to contain 42.6 mcg of melatonin per 30 mL serving (17199).\n\nAnother specific tart cherry concentrate (Cherrish, Cherrish Corp.) contains 600 mg of phenolic compounds and 40 mg of anthocyanins per 10.5 ounce bottle, equivalent to 45-60 tart cherries (93156, 93192).\n\nA specific freeze-dried tart cherry supplement (CherryPURE, Shoreline Fruit LLC) contains phenolic compounds and anthocyanins equivalent to approximately 17.4 ounces of tart cherry juice per capsule (93157, 93158).\n\nSome research suggests that the anthocyanin and phenolic content is higher in tart cherry juice concentrate and frozen tart cherries than in canned and dried tart cherries (93182). Processing of tart cherries may decrease their anthocyanin content by up to 90% (93189). Some research also shows that the anthocyanin content in pasteurized tart cherry juice declines significantly during storage, with up to 75% of the original anthocyanin concentration lost after 6 months of storage at room temperature (93178).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tart cherry.",
            "Pharmacokinetics": "Absorption\nAfter tart cherry ingestion, key phenolic compounds and anthocyanins (vanillic acid, cyanidin 3-O-glucoside, cyanidin 3-O-rutinoside) are detectable in plasma (116148). Some pharmacokinetic research shows that protocatechuic acid and vanillic acid reach peak levels in the plasma 1-2 hours after ingestion of tart cherries, with trace amounts detectable 8 hours after ingestion. Another phenolic acid, chlorogenic acid, was not detectable in plasma following tart cherry consumption, suggesting that it is not bioavailable (93173). The time to maximum serum concentration for cyanidin metabolites is between 2 and 4 hours (93186).\nMetabolism\nSome preliminary pharmacokinetic research suggests that anthocyanins from tart cherry undergo enterohepatic metabolism (93186).\nExcretion\nSome preliminary pharmacokinetic research shows that both unmodified anthocyanins and anthocyanin metabolites are found in the urine after consumption of whole tart cherries (93186).",
            "Mechanism of Action": "General\nThe applicable parts of tart cherry are the fruit, seed, and stem. Tart cherry fruit contains carbohydrates, proteins, vitamin C, vitamin A, alpha-linolenic acid, vitamin E, beta-carotene, folic acid, thiamine, potassium, phosphorus, calcium, tannins, anthocyanins, and other phenolic compounds (chlorogenic acid, protocatechuic acid, and vanillic acid) (4282, 17199, 93159, 93173, 93175, 116148). While Balaton and Montmorency tart cherries contain the same anthocyanins, their concentration is approximately 6-times higher in the Balaton compared to the Montmorency variety (93159). Tart cherry also contains antioxidants including kaempferol, quercetin, melatonin, and hydroxycinnamic acids (4282, 4283, 16409, 93174). Compared to sweet cherries, tart cherries contain larger amounts of vitamin A, beta-carotene, anthocyanins, and phenolics (93169, 93174). Most of the anthocyanins and phenolic compounds are found in the skin of tart cherries (93176). The melatonin content seems to vary between different varieties of tart cherry. Montmorency tart cherries contain about 13 ng of melatonin per gram of fruit, and Balaton tart cherries contain about 2 ng of melatonin per gram of fruit (16409). The stem of the tart cherry contains an isoflavone constituent, prunetin 5-O-beta-D-glycopyranoside (4284). Around one-third of the content of tart cherry seeds is oils such as oleic acid, triglycerides, tocopherols, and tocotrienols. The remaining two-thirds of the content is flavonoids, anthocyanins, and catechins (93163).\nAnalgesic effects\nEvidence from animal research shows that anthocyanins from tart cherry decrease pain, with similar efficacy to indomethacin. The analgesic effect is thought to be due to anti-inflammatory activity (93188).\nAnti-gout effects\nResearch in rats shows that tart cherry juice inhibits hepatic xanthine oxidase activity, reducing uric acid production (102343). Preliminary clinical research shows that taking a specific tart cherry product (CherryActive, Active Edge Nutrition) 30-60 mL decreases serum urate and increases urinary urate excretion in healthy people (93166). In overweight and obese people with or without hyperuricemia who have not progressed to gout, drinking tart cherry juice 240 mL daily for 4 weeks reduces serum uric acid by about 19% when compared with placebo. However, in people with gout, taking Montmorency tart cherry juice concentrate (Cherryvite), 7.5-30 mL twice daily for 28 days, does not affect urinary urate excretion or the area under the concentration-time curve (AUC) for serum urate levels (102343). In healthy adults, consuming tart cherry juice (Cheribundi) 480 mL, or a specific supplement (CherryPURE, Shoreline Fruit) containing 480-960 mg freeze-dried tart cherries, as a single dose seems to reduce uric acid by an average of 8% for up to 8 hours post-ingestion (105630).\n\nIt is possible that the uricosuric effect of start cherry may be sufficient to reduce serum urate levels in people with normal kidney function, but not in those with gout or reduced kidney function (102343). Other mechanisms by which tart cherry may reduce gout symptoms include reducing levels of the proinflammatory cytokines C-reactive protein and monocyte chemoattractant protein-1, and exerting anti-inflammatory effects by inhibiting cyclooxygenase activity and scavenging nitric oxide radicals (102338, 102343).\nAnti-inflammatory effects\nAlthough one clinical study found no anti-inflammatory effects after a single dose of tart cherry (105630), other clinical studies (93164, 93165) and animal studies (93170, 93183, 93194) show that tart cherry given in multiple doses for at least 7 days does have anti-inflammatory effects. In vitro research confirms these findings (93182, 93184, 93191, 93193). One laboratory study shows that compounds found in tart cherry may have anti-inflammatory activity ten times stronger than that of aspirin (6). Some in vitro research shows that tart cherries inhibit cyclooxygenase (COX) II to a similar degree as naproxen and ibuprofen (93184) and that Balaton tart cherries have higher COX II inhibitory activity compared with Montmorency tart cherries (93193). Additionally, tart cherries inhibit around 25% to 30% of COX I activity in vitro, compared with 45% to 55% with naproxen and ibuprofen (93184). Other in vitro research shows that Balaton tart cherries inhibit up to 50% of COX I activity (93193). Tart cherry juice concentrate appears to inhibit COX-1 activity to a higher degree than frozen, canned, or dried tart cherries (93182).\n\nIn vitro studies also show that tart cherry seed extract (SCSE) suppresses tumor necrosis factor-alpha and interleukin-8 from CD3+ T-lymphocytes in patients with diabetes and rheumatoid arthritis compared to control cells, suggesting that SCSE may have therapeutic potential in these and other chronic inflammatory disorders. These effects are thought to be related to increased heme oxygenase -1 (HO-1) expression induced by SCSE (93180, 93181). HO-1 is an enzyme believed to protect tissue from oxidative and cellular stressors (93167, 93187). A meta-analysis of 10 studies in healthy and/or overweight adults shows that oral tart cherry decreases C-reactive protein levels in healthy adults under 51 years of age, but does not affect interleukin-6 or tumor necrosis factor alpha (TNF-alpha) levels (109656). Conversely, a clinical study in healthy adults shows that tart cherry juice reduces TNF-alpha levels, but does not affect other inflammatory markers (109654).\nAntibacterial effects\nTart cherry is of interest as an ingredient in chewing gum to prevent dental caries. In vitro, tart cherry juice inhibits the growth of various oral pathogenic bacteria. In human research, chewing gum containing tart cherry has bactericidal activity against Streptococcus mutans (98698). In other human research in healthy adults, taking tart cherry daily for 30 days has no effect on the composition of the gut microbiome (109654).\nAntidiabetes effects\nTart cherry has a low glycemic index and might be a good dietary choice in diabetes. Preliminary research in healthy females shows that eating muffins enriched with 20% or 30% tart cherry pulp modestly decreases postprandial glucose when compared with eating regular muffins (93148). Animal research shows that tart cherry may decrease blood glucose levels by enhancing peroxisome proliferator-activated receptor (PPAR)-gamma activity, which is the mechanism by which thiazolidinedione drugs work (93185). However, clinical research in healthy adults and patients with metabolic syndrome shows that drinking tart cherry juice daily for up to 3 months does not reduce fasting blood glucose when compared with placebo (105632, 105633). Other clinical research in healthy adults shows that taking tart cherry daily for 30 days does not affect insulin or glycated hemoglobin levels (109654).\nAntihypertensive effects\nA meta-analysis of 6 clinical trials evaluating healthy adults, as well as those with metabolic syndrome, shows that oral tart cherry juice, taken in doses ranging from 130 mL to 480 mL daily, does not affect systolic or diastolic blood pressure when compared with placebo (109658). It is unclear whether tart cherry may have an effect in adults with high blood pressure.\nAntioxidant effects\nClinical research (93161, 93164, 93165, 93179, 93186), animal studies (93170, 93183, 93185), and in vitro research (93150, 93159, 93176, 93177, 93182, 93184, 93191, 93193, 93195) show that tart cherry has antioxidant effects. Cyanidin and its derivatives are thought to be significant contributors to the antioxidant capacity of tart cherry (93177). In humans, the antioxidant effects of tart cherries peak 1 hour after consumption and again 8-12 hours after consumption. The enterohepatic metabolism of tart cherry anthocyanins is thought to explain this biphasic antioxidant response (93186). Some in vitro research shows that tart cherry juice concentrate and dried tart cherries have increased antioxidant capacity compared with canned or frozen tart cherries (93182).\nBone effects\nA small clinical study in healthy females aged 65-85 years suggests that drinking Montmorency tart cherry juice 240 mL twice daily for 90 days does not affect bone-specific alkaline phosphatase or osteocalcin levels, but reduces tartrate resistant acid phosphatase type 5b levels when compared with baseline, suggesting a reduction in bone resorption (105628).\nCardiovascular effects\nAnimal research shows that tart cherry might have cardioprotective effects (93162, 93167, 93171, 93187). Some animal research shows that tart cherry seed extract (SCSE) might improve cardiac function post-myocardial infarction via upregulation of heme oxygenase-1 (HO-1). This HO-1 enzyme is believed to protect tissue, including cardiac tissue, from oxidative and cellular stressors (93167, 93187). Other animal research shows that SCSE improves cardiac function, decreases plaque formation, and decreases infarct size in hypercholesterolemic rabbits. The mechanism of action is believed to be increased HO-1 and cyclooxygenase activity (93171).\nCytotoxic effects\nSome in vitro and animal research shows that tart cherry might have chemopreventive and cytotoxic effects (93172, 93196). In mice, tart cherry and its constituent anthocyanins and cyanidins decrease cecal adenoma compared to control. However, the growth and numbers of colonic tumors are not affected. In vitro, anthocyanins and cyanidins from tart cherry are not cytotoxic but decrease the growth of human colon cancer cells. These effects are thought to be due to inhibition of epidermal growth factor receptor kinase by tart cherry (93172).\nErgogenic effects\nResearch on the effects of tart cherry juice for improving exercise endurance has produced conflicting results. However, various mechanisms of action have been suggested. The anti-inflammatory and antioxidant activity of tart cherry may reduce inflammation and oxidative stress associated with exercise. Also, tart cherry has a lower glycemic index than other carbohydrate sources, producing a slower rate of increase in postprandial glucose levels and extending the duration of carbohydrate availability during exercise (102340).\nLipid effects\nAnimal research shows that tart cherry might improve lipid levels. Feeding tart cherry to rats with hyperlipidemia and insulin resistance for 90 days decreases fasting plasma glucose, lipid, and insulin levels and reduces fatty liver. These effects may be due to enhancement of hepatic peroxisome proliferator-activated receptor (PPAR)-alpha activity by tart cherry (93185).\nMemory effects\nClinical research in healthy adults over 65 years of age with normal cognitive function shows that taking 1 cup of Montmorency tartcherry juice twice daily for 12 weeks increases subjective contentment with memory scores, and increases scores on a paired associates learning task, when compared with placebo (102140).\nMetabolic effects\nAnimal research shows that tart cherry might slow the development of metabolic syndrome through anti-inflammatory effects. In a rat model of obesity and metabolic syndrome, supplementing the diet with tart cherry powder containing 1% anthocyanins decreased lipids, fat mass, abdominal fat, and inflammatory mediators compared to a calorie-matched control (93194).\nPhotoprotective effects\nAnimal research shows that tart cherry seed extract might have photoprotective effects, possibly due to inhibition of UV-B mediated skin damage by oils in the seeds (93163).\nSleep effects\nTart cherry fruit contains melatonin, which might improve insomnia. Also, anti-inflammatory properties of tart cherry could influence pro-inflammatory cytokines involved in sleep regulation (17199).\nWeight loss effects\nPreliminary clinical research shows that consuming muffins enriched with 20% to 30% tart cherry pulp improves satiety and reduces energy intake when compared to control in healthy females (93148). However, the long-term effects of tart cherry on body weight and hunger in overweight or obese people is unknown."
        }
    },
    "Tartaric Acid": {
        "sections": {
            "Overview": "Tartaric acid is a type of alpha hydroxy acid. Alpha hydroxy acids are natural acids found in foods, including, but not limited to, citrus fruits, sugarcane, sour milk, apples, and grapes (6064, 10104, 95601). Tartaric acid is the main organic acid in grapes, raisins, and wine. It is also found in tamarind (108163, 108164, 108167). Potassium bitartrate, the potassium salt of tartaric acid, is sometimes found as an active ingredient in US Food and Drug Administration (FDA)-approved prescription products; these products are not within the scope of this topic.",
            "Safety": "LIKELY SAFE when tartaric acid is used orally in the amounts commonly found in foods.\nThere is insufficient reliable information available about the safety of tartaric acid when applied topically or used orally as a supplement.\nPREGNANCY AND LACTATION: LIKELY SAFE when tartaric acid is used orally in the amounts commonly found in foods. There is insufficient reliable information available about the safety of tartaric acid when used as a supplement during pregnancy or lactation; avoid amounts greater than those found in foods.",
            "Adverse Effects": "General\nOrally, topically, or when inhaled, no adverse effects have been reported. However, thorough evaluations of safety outcomes have not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. It is unclear if inhaled tartaric acid is beneficial for asthma.\nPreliminary clinical research in asymptomatic and medicated patients with asthma shows that using two inhalations of tartaric acid 20% in sodium chloride to stimulate cough modestly improves pulmonary function five minutes later, based on the peak expiration, when compared with baseline. There were no changes in other pulmonary function tests (108166).\nless\nSwallowing dysfunction. It is unclear if inhaled tartaric acid is beneficial for preventing silent aspiration in patients with swallowing dysfunction.\nAn observational study in patients susceptible to silent aspiration related to dysphagia suggests that the stimulation of cough using inhalation of tartaric acid 10% was able to induce reflexive cough in about 90% of patients and the expectoration of aspirated food in approximately 71% of patients (108165). The validity of this finding is limited by the observational nature of the study and the lack of a comparator group.\nless\nMore evidence is needed to rate tartaric acid for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tartaric acid.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tartaric acid.",
            "Pharmacokinetics": "Absorption\nFollowing consumption of wine and grape juice, tartaric acid undergoes intestinal absorption (108163, 108164).\nExcretion\nTartaric acid is excreted in the urine. Urinary concentrations increase with increased intake from wine (108163, 108164).",
            "Mechanism of Action": "General\nTartaric acid is an alpha hydroxy acid. Alpha hydroxy acids are a group of natural acids found in foods (6064, 10104). Tartaric acid is found in levels of 1.5 to 4 grams/L in wine. Tartaric acid constitutes up to 1% of whole fresh grapes and is also found in tamarind (108163, 108164, 108167). Tartaric acid is also found in low levels in other fruits, such as bananas (108164).\nCholesterol effects\nUrinary tartaric acid levels, a marker of recent tartaric acid intake, are inversely associated with levels of total and low-density lipoprotein (LDL) cholesterol (108163).\nGastrointestinal effects\nTartaric acid may be used as a fuel source by colonic bacteria in the production of short chain fatty acids. In human research, use of cream of tartar as a source of tartaric acid decreases intestinal transit time but does not seem to affect the production of short chain fatty acids or levels of fecal bile acids (108167).\nHepatic effects\nIn an animal model of metabolic dysfunction-associated steatotic liver disease (MASLD), tartaric acid reduces hepatic steatosis and fibrosis, partly by inhibiting pathways associated with fatty acid synthesis, inflammation, and lipid metabolism (116949).\nHormonal effects\nIn an animal model of polycystic ovarian syndrome (PCOS), tartaric acid improves serum levels of reproductive hormones (e.g., estradiol, luteinizing hormone, progesterone, testosterone) and the number of ovarian follicles (116948).\nRespiratory effects\nWhen inhaled, tartaric acid induces coughing. This is thought to be beneficial in patients with swallowing dysfunction and asthma (108165, 108166)."
        }
    },
    "Taurine": {
        "sections": {
            "Overview": "Taurine is often referred to as a non-essential amino acid, but it is actually an amino sulfonic acid. It is present in normal diets, with the highest levels found in meat, seafood, and eggs (3467, 77089, 77210, 101473, 101474). Taurine can also be synthesized through oxidation and decarboxylation of cysteine in the liver. Amounts supplied by a typical Western diet range from 40-400 mg daily (5280, 101471, 101473). Taurine is also a common ingredient in energy drinks (101471).",
            "Safety": "LIKELY SAFE when used in amounts found in foods. Typical daily intakes for adults range from 40-400 mg (101471).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts. Taurine 2-4 grams daily in two or three divided doses has been used safely in studies lasting up to 3 months (5248, 5271, 8217, 8221, 10454, 77147, 95612, 98337, 104165, 104167). Higher doses of taurine 6 grams daily have been used safely in studies lasting up to 4 weeks (98336, 98337). A risk assessment of orally administered taurine has identified an Observed Safe Level (OSL) of up to 3 grams daily for healthy adults (31996).\nCHILDREN: LIKELY SAFE when used in amounts found in foods.\nCHILDREN: POSSIBLY SAFE when used orally and appropriately in medicinal amounts. Taurine 2.4-4.8 grams daily in three divided doses has been safely used in children 6-16 years of age for up to 12 weeks (103210).\nPREGNANCY AND LACTATION: LIKELY SAFE when used in amounts found in foods. There is insufficient reliable information available about the safety of taurine when used in medicinal amounts during pregnancy and lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, taurine is generally well-tolerated when used in typical doses for up to one year.\nMost Common Adverse Effects\nOrally: Constipation, diarrhea, and dyspepsia.\nSerious Adverse Effects (Rare)\nOrally: Hypersensitivity reactions in sensitive individuals. Case reports raise concerns for serious cardiovascular adverse effects, but these reports have involved energy drinks containing taurine and other ingredients. It is unclear if these adverse effects are due to taurine, other ingredients, or the combination.\nCardiovascular\nChanges in heart rate and increased blood pressure have been reported following the co-administration of taurine and caffeine, although the effects of taurine alone are unclear (77088). In healthy individuals, consumption of energy drinks containing taurine increased platelet aggregation and decreased endothelial function (77151, 112268, 112741). A case of cardiac arrest following strenuous exercise and an excessive intake of energy drinks containing caffeine and taurine has been reported (77136). In another case report, a 28-year-old male without cardiovascular risk factors presented to the hospital with radiating chest pain, shortness of breath, and diaphoresis after excessive intake of an energy drink containing taurine, caffeine, sugar, and glucuronolactone. Electrocardiogram findings confirmed myocardial infarction, and subsequent catheterization confirmed thrombotic occlusion (112741).\nless\nEndocrine\nOrally, taurine has been reported to cause hypoglycemia (77153).\nless\nGastrointestinal\nOrally, constipation has been reported following the administration of taurine (77231). Dyspepsia has also been reported after oral taurine use (104165).\nless\nHematologic\nIn clinical research, taurine reduced platelet aggregation (77245). A case of massive intravascular hemolysis, presenting with confusion, dark urine, dyspnea, emesis, and fever, has been reported following the administration of a naturopathic vitamin infusion containing taurine, free amino acids, magnesium, and a vitamin B and D complex (77177). However, the effects of taurine alone are unclear.\nless\nImmunologic\nA case report describes a hypersensitivity reaction in a female patient with a history of allergies to sulfonamides, sulfites, and various foods, after ingestion of taurine and other sulfur-containing supplements. The amount of taurine in the products ranged from 50-500 mg per dose. The allergic reaction recurred upon rechallenge with taurine 250-300 mg (91514).\nless\nNeurologic/CNS\nIn a case study, encephalopathy occurred in a body-builder who took approximately 14 grams of taurine in combination with insulin and anabolic steroids. It is not known if this was due to the taurine or the other drugs taken (15536).\n\nCases of seizures following the consumption of energy drinks containing taurine have been reported (77105, 77196). In clinical research, taurine has been reported to cause drowsiness and ataxia in epileptic children (77241).\nless\nPsychiatric\nIn a case report, a 36-year-old male with adequately controlled bipolar disorder was hospitalized with symptoms of mania after consuming several cans of an energy drink containing taurine, caffeine, glucuronolactone, B vitamins, and other ingredients (Red Bull Energy Drink) over a period of four days (14302). It is unknown if this effect was related to taurine.\nless\nPulmonary/Respiratory\nIn human research, an exacerbation of pulmonary symptoms of cystic fibrosis has been associated with taurine supplementation, although this could also be caused by progression of the disease (77231).\nless\nRenal\nA case of acute kidney failure has been reported following the concomitant intake of 1 liter of vodka and 3 liters of an energy drink providing taurine 4.6 grams, caffeine 780 mg, and alcohol 380 grams (77185).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCongestive heart failure (CHF). Oral taurine may improve left ventricular function, heart failure-related symptoms, and exercise capacity in patients with CHF.\nA meta-analysis of clinical trials in patients with heart failure shows that taking taurine 0.5-6 grams daily for up to 1 year modestly improves heart failure severity when compared with placebo (114794, 114796). However, the validity of this study limited by high heterogeneity. In individual studies, taking taurine 2-6 grams in two or three divided doses daily for 6-8 weeks seems to improve left ventricular function (5248, 5271, 8221) and symptoms of heart failure (5271, 5306, 8221) when compared with placebo or coenzyme Q10 in patients with New York Heart Association (NYHA) functional class II to IV. Also, taking taurine 500 mg three times daily for 2 weeks seems to improve exercise capacity when compared with placebo in patients with heart failure (77176). Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year (5306, 8217, 8218, 8221).\nless\nHepatitis. Oral taurine may improve liver function in patients with acute or chronic hepatitis.\nSeveral small clinical trials show that taking taurine 1.5-4 grams daily for up to 3 months improves liver function in patients with acute and chronic hepatitis when compared with placebo (10454, 77114, 77147).\nless\nPOSSIBLY INEFFECTIVE\nObesity. Oral taurine does not appear to improve body weight in adults who are obese or overweight.\nA meta-analysis of 12 small clinical trials shows that taurine supplementation does not reduce body weight or body mass index (BMI) when compared with placebo. The studies included in this analysis evaluated taurine doses of 0.5-6 grams daily for 15 days to 6 months. Most of the patient populations evaluated in the included studies had liver or metabolic disorders; three studies specifically evaluated overweight or obese adults (104166). Additionally, a more recent clinical trial in a small group of females with obesity shows that taking taurine 1 gram three times daily along with a calorie-restricted diet for 8 weeks does not reduce body weight, BMI, or waist circumference when compared with calorie restriction alone (104167). In contrast, a very small study in adults with type 2 diabetes on antidiabetes medication shows that taking taurine 500 mg twice daily for 8 weeks reduces body mass, BMI, and body fat percentage when compared with control (112271). The validity of these effects is limited by the small sample size.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcademic performance. It is unclear if oral taurine is beneficial to improve academic performance.\nA very small clinical study in college entrance examinees over age 19 shows that taking a jelly containing taurine 3 grams daily for 14 days does not improve academic achievement when compared with baseline or placebo (110579). Due to its small size, this study may have been inadequately powered to detect a difference between groups.\nless\nAge-related macular degeneration (AMD). Although there has been interest in using oral taurine for AMD, there is insufficient reliable information about the clinical effects of taurine for this purpose.\nAndrogenic alopecia. Oral taurine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized clinical study in adults with androgenic alopecia or telogen effluvium shows that taking a combination product containing taurine, cysteine, methionine, iron, selenium, and hydrolyzed collagen (GFM Oral, Cantabria Labs) along with conventional therapy, consisting primarily of finasteride or minoxidil, daily for 12 weeks improves hair loss when compared with conventional therapy alone (111636). It is unclear if this effect is due to taurine, other ingredients, or the combination.\nless\nAthletic performance. Research on the use of taurine for improving endurance or power output is limited and conflicting; however, it may improve performance by a small amount in some athletes.\nResearch is conflicting on the effects of taurine on athletic performance. Several clinical studies in trained and untrained athletes show that taking taurine 1-6 grams as a single dose before endurance exercise, or 3 grams daily for 8 weeks after endurance exercise, does not improve endurance or aerobic capacity when compared with placebo (77159, 77203, 95613, 98334).\n\nHowever, a meta-analysis of 7 small clinical trials shows that taking taurine 1-6 grams daily for up to 2 weeks slightly improves endurance when compared with control. Also, preliminary studies in male cyclists, recreationally active males, Olympic-level athletes, and female athletes habituated to caffeine show that taking taurine 50 mg/kg or 1-6 grams one time 1.5-2 hours prior to a cycling test increases the time to exhaustion and peak, mean, and minimum power output but does not improve perceived exertion, fatigue index, heart rate, or anaerobic capacity when compared with placebo (101475, 103211, 112265, 112269). The reasons for these discrepancies are unclear; the meta-analysis did not identify a dose or duration-related benefit. One small clinical trial shows that taking taurine 40 mg/kg improves muscle power in caffeine-deprived athletes who regularly use caffeine, but actually seems to worsen muscle power in athletes who do not regularly use caffeine (98335). Overall, it is not clear which population is most likely to benefit from taurine use (98337, 98338).\n\nStudy results are mixed when taurine has been evaluated in combination with other ingredients. One small study shows that taking a specific product containing taurine and caffeine (AdvoCare Spark) does not improve sprint performance in college athletes when compared with placebo (77195). However, other small studies of cyclists and boxers suggest that taking taurine in combination with a variety of other ingredients including B vitamins, caffeine, and glucuronolactone (Red Bull Energy Drink) or ginseng, kudzu, and soybean, may improve measures such as endurance, power, balance, or agility (37815, 57945, 110577, 112269). It is unclear if the benefits seen in these studies are due to taurine, other ingredients, or the combinations.\nless\nAttention deficit-hyperactivity disorder (ADHD). Although there has been interest in using oral taurine for ADHD, there is insufficient reliable information about the clinical effects of taurine for this purpose.\nAutism spectrum disorder. Although there has been interest in using oral taurine for autism spectrum disorder, there is insufficient reliable information about the clinical effects of taurine for this purpose.\nChemotherapy-induced nausea and vomiting (CINV). It is unclear if oral taurine is beneficial in patients with CINV.\nOne small clinical trial in patients with acute lymphoblastic leukemia receiving 6 months of chemotherapy shows that taking taurine (pure powder, Aviforme) 1000 mg twice daily, starting 6 hours after receiving chemotherapeutic agents, significantly improves CINV in 87.5% of patients. Other symptoms, such as reduced appetite and smell and taste impairment, are also improved in some patients (91512).\nless\nChemotherapy-induced nephrotoxicity. It is unclear if oral taurine is beneficial for preventing or treating chemotherapy-induced nephrotoxicity.\nOne small clinical trial in patients with acute lymphoblastic leukemia receiving 6 months of chemotherapy shows that taking taurine (pure powder, Aviforme) 1000 mg twice daily reduces plasma creatinine, urea, bilirubin, and liver enzymes after 4 months when compared with placebo. This suggests a protective effect against chemotherapy-induced nephrotoxicity and hepatotoxicity. A reduction in overall fatigue is also observed (95616).\nless\nCirrhosis. It is unclear if oral taurine is beneficial in patients with cirrhosis.\nOne small, uncontrolled clinical study in patients with cirrhosis shows that taking taurine 1 gram three times daily for 4 weeks reduces the severity and frequency of muscle cramps when compared to baseline (104165). Another small clinical trial in patients with cirrhosis shows that taking taurine 6 grams daily for 4 weeks reduces portal hypertension by 12%, compared with a 2% increase in the placebo group (98336). However, it is unclear if this is associated with a reduced risk for complications such as variceal bleeding and ascites.\nless\nCognitive function. It is unclear if oral taurine is beneficial for improving cognitive function; however, taking an energy drink (Red Bull Energy Drink) containing taurine and other ingredients may modestly improve some measures of cognitive function.\nLevels of taurine decrease with age, but supplementation does not seem to have neuroprotective effects or cognitive benefits in the elderly (101471, 110574, 110578). In one small crossover study, taurine alone did not reduce errors in sleep-deprived individuals when compared with placebo (38154). However, taurine taken as part of an energy drink formulation containing taurine, caffeine, glucuronolactone, and B vitamins (Red Bull Energy Drink) improves focused and sustained attention, wakefulness, verbal reasoning, driving ability and quality, and reaction speed when compared with placebo (9899, 38117, 77088, 77202). Preliminary clinical research in young adults also shows that consuming the Red Bull Energy Drink might improve attention and verbal reasoning, but does not seem to improve memory, when compared with placebo (9899, 77088).\nless\nCritical illness (trauma). It is unclear if oral taurine is beneficial in patients with critical illness.\nA meta-analysis of small clinical trials including adults in the intensive care unit (ICU) shows that receiving enteral nutrition enhanced with taurine for 5-14 days does not reduce mortality or shorten ICU length of stay when compared with control. Taurine was added to enteral nutrition at doses of 30-50 mg/kg or 10 mg total daily (114795). However, the study may have been inadequately powered to detect a difference between groups.\nless\nCystic fibrosis. Oral taurine may reduce steatorrhea in children with cystic fibrosis, but it does not seem to improve other measures of nutritional status.\nSome small clinical studies in children with cystic fibrosis show that taking taurine 30-40 mg/kg daily for 7 days to 6 months might be useful as adjunctive therapy to reduce steatorrhea when compared with baseline or placebo (10455, 77227, 77231). However, it does not seem to improve growth, lung function, muscle protein breakdown, or other symptoms of cystic fibrosis (77224 ,77228). Also, adding taurine 500-1500 mg daily to treatment with ursodeoxycholic acid for up to one year does not improve liver function tests, fat absorption, or nutritional status in patients with cystic fibrosis and associated liver disease when compared with ursodeoxycholic acid alone (77246, 77256).\nless\nDelirium. It is unclear if oral taurine prevents delirium in patients in the intensive care unit.\nA large clinical study of hospitalized adults in Iran who underwent liver transplantation shows that taking a specific taurine powder product (100% Taurine Amino Acid, MyProtein) 2 grams daily for 30 days post-transplant reduces the risk of delirium by 73% when compared with placebo. These results also suggest that for every four patients treated with taurine over placebo, one additional case of delirium is prevented. Patients who took taurine also had less time on the ventilator and shorter intensive care and hospital stays (110575). However, it is unclear if these effects are due to taurine or other factors since ventilator time and intensive care length of stay are risk factors for delirium.\nless\nDiabetes. It is unclear if oral taurine is beneficial in patients with diabetes.\nPlasma levels of taurine are reported to be lower in patients with diabetes than in healthy controls (101473). However, clinical research evaluating taurine for glycemic control is mixed (77074, 103212). One small clinical trial in patients with type 2 diabetes shows that taking taurine 1 gram three times daily for 8 weeks reduces blood glucose, insulin resistance, total cholesterol, and low-density lipoprotein (LDL) cholesterol when compared with placebo (103212). Although there was no improvement in glycated hemoglobin (HbA1c), the study duration was not long enough to detect a meaningful reduction in HbA1c. Other preliminary clinical research shows that taking taurine 1-1.5 grams twice daily for 2-4 months does not affect fasting blood glucose, HbA1c, or insulin but may improve measures of insulin resistance in patients with type 2 diabetes when compared with placebo (77074, 112271). However, taking taurine while following an exercise program 3 times weekly does appear to reduce fasting blood sugar and HbA1c when compared with exercise plus placebo (112271). The reasons for these discrepant findings are unclear; however, all the included studies were small and potentially inadequately powered to detect a difference in outcomes.\n\nA meta-analysis of clinical trials in patients with diabetes and other metabolic disorders shows that taking taurine 0.5-6 grams orally daily for up to 1 year reduces fasting blood glucose by approximately 6 mg/mL, when compared with placebo (114796). However, many of the studies included patients who did not have diabetes. The validity of this study is also limited by high heterogeneity.\nless\nEpilepsy. Although there has been interest in using oral taurine for epilepsy, there is insufficient reliable information about the clinical effects of taurine for this condition.\nErectile dysfunction (ED). It is unclear if oral taurine is beneficial in patients with erectile dysfunction.\nAn open-label clinical study in adults with mild-to-moderate ED shows that taking a specific combination supplement (Icarifil, Anvest Health S.p.A) containing taurine 50 mg, panax ginseng , L-carnitine, L-citrulline, tribulus, and other ingredients orally daily for 3 months improves patient-reported erectile function when compared to baseline. Additionally, taking the supplement with tadalafil improves some, but not all, patient-reported assessments of erectile function when compared with taking tadalafil alone (114989). It is unclear if this effect is due to taurine, other ingredients, or the combination.\nless\nExercise-induced muscle soreness. Small clinical studies suggest that oral taurine may modestly improve exercise-induced muscle soreness.\nOne small clinical trial in healthy, untrained adults shows that taking taurine 2 grams in combination with branched chain amino acids (BCAAs) three times daily for 2 weeks reduces subjective muscle soreness by 37% when compared with placebo (77212). Another small clinical trial in young, untrained males shows that taking taurine (Taisho Pharmaceutical Co., LTD.) 2 grams three times daily after meals before exercise, and continuing for three days after exercise, reduces delayed onset muscle soreness (DOMS), but not creatine kinase levels, when compared with placebo (91513).\nless\nFatigue. It is unclear if oral taurine is beneficial for improving fatigue.\nOne small clinical trial shows that taurine seems to reduce fatigue when taken alone, but increases fatigue when taken in combination with caffeine (77202). However, an observational study in young adults has found that subjective scores for physical and mental fatigue do not seem to correlate with dietary taurine intake (101472). One small clinical trial shows that drinking 500 mL of an energy drink providing taurine 1 gram plus other ingredients including caffeine and B vitamins decreases measures of driving-related fatigue in a driving simulation when compared with placebo (91075).\nless\nHelicobacter pylori. It is unclear if oral taurine can aid in the eradication of helicobacter pylori (H. pylori).\nOne clinical trial shows that taking taurine 500 mg twice daily in combination with conventional treatment for 6 weeks increases H. pylori eradication and shortens duodenal ulcer scarring time in patients with confirmed H. pylori infection when compared with conventional treatment alone (77145).\nless\nHyperlipidemia. It is unclear if oral taurine is beneficial for lowering lipid levels.\nA meta-analysis of 12 small clinical trials in adults with various liver or metabolic disorders, but without a specific diagnosis of hyperlipidemia, shows that taurine supplementation reduces total cholesterol by 11 mg/dL and triglycerides by 13 mg/dL, but does not seem to improve low-density lipoprotein (LDL) cholesterol or high-density lipoprotein (HDL) cholesterol levels, when compared with placebo. The studies included in this analysis evaluated doses of 0.5-6 grams daily for 15 days to 6 months (104166). Another meta-analysis of clinical trials in patients with various cardiovascular and metabolic disorders shows that taking taurine 0.5-6 grams orally daily for up to 1 year reduces triglyceride and low-density lipoprotein cholesterol levels by approximately 18 mg/dL and 6 mg/dL, respectively, when compared with placebo. Taking taurine did not affect high density lipoprotein cholesterol levels (114796). However, many of the studies included patients who did not have hyperlipidemia. The validity of this study is also limited by high heterogeneity. The benefits of taurine in adults with hyperlipidemia are unclear.\n\nThe effect of taurine has also been investigated in combination with exercise. A very small study in adults with type 2 diabetes on antidiabetes medication shows that taking taurine 500 mg twice daily while participating in an exercise program 3 times weekly for 8 weeks reduces triglycerides, total cholesterol, and LDL cholesterol and increases HDL cholesterol when compared with exercise plus placebo (112271).\nless\nHypertension. Oral taurine may modestly reduce blood pressure in patients with hypertension; however, the long-term antihypertensive effects of taurine are unclear.\nOne clinical study in patients with elevated blood pressure or stage 1 hypertension shows that taking taurine 1.6 grams daily for 12 weeks reduces systolic blood pressure (SBP) by 5 mmHg and diastolic blood pressure (DBP) by 3 mmHg when compared with placebo. The benefit is seen after 8 weeks of continued supplementation (95614). A small clinical trial in patients with stage 2 hypertension (previously classified as borderline hypertension) shows that taking taurine 6 grams daily for 7 days reduces both SBP and DBP when compared to baseline (77229). The long-term effects of taurine on blood pressure are unclear.\n\nA meta-analysis of 12 small clinical trials in adults with various liver or metabolic disorders, but without a specific hypertension diagnosis, shows that taurine supplementation reduces SBP by 5 mmHg and DBP by 3 mmHg when compared with placebo. The studies included in this analysis evaluated doses of 0.5-6 grams daily for 15 days to 6 months (104166). Two meta-analyses of clinical trials in patients with cardiovascular and other metabolic disorders show that taking taurine 0.5-6 grams orally daily for up to 1 year reduces systolic and diastolic blood pressure by approximately 4 mmHg and 2 mmHg, respectively, when compared with placebo (114794, 114796). However, many of the studies included patients who did not have hypertension. The validity of this study is also limited by high heterogeneity.\n\nTaurine is commonly found in energy drinks, and its effect on blood pressure when used in combination with other ingredients in the form of an energy drink has been evaluated. A small observational study in young adults suggests that drinking a specific combination product containing taurine 100 mg, caffeine, and group B vitamins (Redbull Energy Drink) reduces heart rate but does not change SBP or DBP when compared to baseline (112266). However, another small observational study in young healthy adults suggests that drinking a specific combination product containing taurine 2000 mg, caffeine, ginseng, glucuronolactone, inositol, guarana, L-carnitine, and B vitamins (Monster Energy Drink) increases both SBP and DBP by about 16 mmHg and raises heart rate by 17 beats per minute 15 minutes after consumption when compared to baseline. However, 90 minutes after consumption only DBP and heart rate remain elevated (112268). In both studies, the validity of the effects is limited by a lack of a comparator group. Additionally, it is unclear if the effects are due to taurine, other ingredients, or the combination.\nless\nInfant development. Higher maternal intake of taurine from the diet may be linked to increased newborn length and weight; however, feeding taurine-containing formula to newborns does not appear to improve infant development.\nOne observational study has found a positive correlation between maternal dietary taurine intake and newborn length. In pregnant patients with high taurine intake (>120 mg/day), neonatal birth weight and length were significantly higher when compared with groups with lower taurine intake (101474). However, clinical research shows that administering infant formula containing taurine 45 mg/L for up to 12 weeks does not affect weight, length, head circumference, or behavior in preterm and full-term infants when compared with formula without taurine (77119, 77216, 77218, 77239, 77260).\nless\nIron deficiency anemia. It is unclear if oral taurine is beneficial in patients with iron deficiency anemia.\nOne small clinical trial in females with iron deficiency anemia shows that taking taurine 1000 mg plus ferrous sulfate 325 mg daily for 20 weeks improves hemoglobin concentrations, red blood cell counts, and serum ferritin levels when compared with ferrous sulfate plus placebo (77070).\nless\nMuscular dystrophy. It is unclear if oral taurine is beneficial in patients with muscular dystrophy.\nOne very small crossover trial in patients with muscular dystrophy shows that taking taurine 100-150 mg/kg for 6 months improves the ability to relax muscles after voluntary use when compared with placebo (77235).\nless\nPhysical performance. It is unclear if oral taurine improves physical performance in older adults.\nA small study in elderly females living in a care facility shows that taking taurine powder 1.5 grams daily for 14 weeks in addition to standardized exercise training may modestly improve some measures of physical fitness (i.e. agility, endurance) when compared to baseline. These measures were not improved in patients who took taurine but did not participate in exercise training or who participated in exercise training but did not take taurine (110574). The validity of these findings is limited by lack of randomization, blinding, and statistical comparison between groups.\nless\nPostoperative recovery. It is unclear if oral taurine is beneficial for improving postoperative recovery.\nOne small clinical trial in patients recovering from surgery after a hip fracture shows that taking taurine 6 grams daily for 7 days after surgery does not improve morbidity and mortality outcomes after 1 year when compared with placebo (95615).\nless\nPsychosis. It is unclear if oral taurine is beneficial in patients with psychosis.\nOne small clinical trial in adults up to 25 years of age with first-episode psychosis shows that taking taurine 4 grams daily for 12 weeks in combination with prescribed antipsychotics reduces positive psychotic symptoms, but not negative or cognitive symptoms, when compared with placebo (95612).\nless\nSleep deprivation. Oral taurine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking a combination product containing taurine, caffeine, glucuronolactone, and B vitamins (Red Bull Energy Drink) reduces lane drifting and sleepiness and improves driving quality and reaction time during a car-driving simulator exercise in sleep-deprived individuals when compared with placebo (38117, 77066). Other preliminary clinical research in sleep-deprived surgical trainees shows that taking taurine 2 grams in addition to caffeine 150 mg improves reaction time during performance of simulated laparoscopic surgery when compared with placebo, although error-making is not reduced (38154).\nless\nTourette syndrome. Oral taurine may improve tic severity in children with Tourette syndrome who are taking tiapride at a dose of 300 mg or less. Taurine may not be effective in children taking higher doses of tiapride.\nOne clinical trial in children 6-16 years of age with Tourette syndrome or other tic disorders shows that taking taurine along with tiapride reduces the severity of tics when compared with tiapride alone. For every 6 children taking taurine, one additional child saw a 60% or greater reduction in tic severity as measured on the Yale Global Tic Severity Scale when compared with placebo. However, taurine did not improve tic severity in children taking tiapride at a dose greater than 300 mg daily (103210). Taurine was taken in age-dependent doses of 2.4 grams daily in those 6-8 years, 3.6 grams daily in those 9-13 years, and 4.8 grams daily in those 14-16 years.\nless\nTraumatic brain injury (TBI). It is unclear if oral taurine is beneficial in patients with a TBI.\nA small clinical study of adults in Iran receiving treatment in the intensive care unit (ICU) following TBI shows that adding a specific taurine powder product (Nutricost) 30 mg/kg/day up to 3 grams daily to enteral nutrition for 14 days may modestly improve disease severity scores, but does not reduce days on the ventilator, ICU length of stay, or mortality at 30 days when compared with usual enteral nutrition (110573). Due to its small size, this study may have been underpowered to detect differences between groups.\nless\nMore evidence is needed to rate taurine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTaurine has most often been used in doses of 1.5-6 grams daily, taken in divided doses. The duration of therapy depends on the condition being treated. Doses of up to 6 grams daily have been used for up to one year. See Effectiveness section for condition-specific information.\n\nConcomitant use of taurine supplements or taurine-containing energy drinks with alcohol should be avoided if possible. Some research suggests that consuming taurine might increase alcohol consumption, potentially increasing the risk for alcohol poisoning (101471).\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nEnergy drinks typically contain taurine 750-1000 mg per serving (101471).\n\nPediatric amino acid formulations such as Aminosyn-PF and Trophamine contain taurine 70 mg/100mL and 25 mg/100mL respectively (77083).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taurine might increase the risk of hypotension when taken with antihypertensive drugs.\nSome clinical evidence suggests that taurine can reduce both systolic and diastolic blood pressure (77229, 95614, 104166).\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taurine might reduce excretion and increase plasma levels of lithium.\nTaurine is thought to have diuretic properties (3647), which might reduce the excretion of lithium.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTaurine might have hypotensive effects.\nTaking taurine with other products with hypotensive effects might increase the risk of hypotension. Taurine has shown hypotensive effects in clinical research (77229, 95614, 104166).\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with taurine.",
            "Pharmacokinetics": "Absorption\nIn vitro research suggests that taurine uptake is mediated by both PAT1 (SLC36A1) and TauT (SLC6A6) transport mechanisms. TauT uptake may predominate during periods of low taurine concentrations (such as seen between meals), and PAT1 uptake seems to predominate during periods of high taurine concentrations (such as during meals) (77135).\nDistribution\nAnimal research suggests that taurine distributes rapidly into the liver and kidneys, but only in low amounts to the brain and muscle (77059). Taurine is found in human platelets (8219, 77075).\nExcretion\nTaurine is conjugated to bile acids (77230, 77246). It is also excreted in the urine, with higher urinary levels found after red meat consumption (77181). Urinary taurine excretion is decreased in people with calcium oxalate or phosphate-containing renal calculi (77149).",
            "Mechanism of Action": "General\nTaurine is a non-essential amino acid also known as 2-aminoethanesulfonic acid. It is found in high levels in protein-rich foods, such as meat, fish, and eggs, as well as in breast milk. Taurine is normally synthesized in the human body in adequate amounts by oxidation and decarboxylation of cysteine (5280, 101473). Taurine is important in several metabolic processes in the body, including stabilizing cell membranes in electrically active tissues, such as the brain and heart, and supporting proliferation of neural progenitor cells and synapse formation in the brain. It is found in high concentrations in the developing brain, and also in the adult hippocampus, cerebellum, and hypothalamus (101471). Taurine also has functions in the gallbladder, eyes, and blood vessels, and may have some antioxidant and detoxifying properties. Taurine is also a vasorelaxant in the retina (77106).\nAnti-inflammatory effects\nTaurine has been shown to ameliorate inflammation in vitro and in vivo (77090, 103213). In cellular research, taurine inhibited the production of pro-inflammatory interleukin (IL)-1 and IL-6 (77155). A similar reduction in IL-6 has been seen clinically (77187), although conflicting research exists (103209, 110576). In humans, taurine down-regulates inflammatory mediators, such as C-reactive protein (CRP) and malondialdehyde (MDA), protecting and regenerating damaged tissue (77099, 103209, 110576). However, research related to the effect of taurine on tumor necrosis factor (TNF)-alpha has mixed results (103209, 110576).\nAntiallergy effects\nIn a mouse model of allergic rhinitis, taurine ameliorated the signs and symptoms of allergic rhinitis, likely through antioxidant and anti-inflammatory effects (103213).\nAntidiabetic effects\nIn animal research, intraperitoneal administration of taurine dose-dependently attenuated streptozotocin-induced elevations in blood glucose (77162). In humans, plasma taurine levels have been found to be lower in people with type 2 diabetes than in controls, and they are lowest in those with type 2 diabetes who also have neuropathy (101473). Taurine is thought to act on beta cell secretion and to interfere with insulin signaling pathways. In animals it improves glucose tolerance, insulin sensitivity, insulin resistance, hyperinsulinemia, and hyperglycemia (101473).\nAntiemetic effects\nThe inhibitory effect of taurine on nausea and vomiting may result from its neuroprotective or inhibitory neurotransmitter actions. At the presynaptic site, taurine may inhibit voltage gated calcium channels and/or open the chloride channels and suppress the release of excitatory neurotransmitters like glutamate. It may also increase K+ efflux to decrease the postsynaptic depolarization. Taurine may also act as an inhibitory neurotransmitter to lead to a reduction of nausea and vomiting (91512). Taurine displays inhibitory activity in the olfactory bulb by decreasing excitability and modulating release of GABA. GABA acts as an inhibitory neurotransmitter in taste buds, and taurine acts as an agonist for GABA receptors. Therefore, taurine may play a role in decreasing taste sensation and improving hypergeusia. Taurine may also help reduce bitter tastes (91512).\nAntiepileptic effects\nPossible mechanisms for an antiepileptic effect of taurine include modulation of calcium homeostasis (77060, 77261), prevention of glutamate-induced neuronal excitotoxicity (77171), establishing equilibrium between inhibitory and excitatory brain processes (77144), or activating GABA-A receptors (77063, 77072, 77219). The results of preliminary studies using taurine in humans with epilepsy are mixed, which could be due to variable penetration of taurine into the brain (77059, 77232, 77240, 77243, 77252).\nAntihypertensive effects\nAn inverse correlation between plasma taurine levels and systolic blood pressure has been reported (101473). Taurine inhibits sympathetic nervous system activity, dilates blood vessels, and suppresses the renin-angiotensin-aldosterone system (77229, 101473). In laboratory studies, taurine significantly upregulates expression of cystathionine beta-synthase and cystathionine gamma-lyase in human mesenteric arteries. This increases production of hydrogen sulfide, resulting in vascular relaxation via inhibition of calcium influx (95614).\nAntineoplastic effect\nIn cellular research, taurine inhibited doxorubicin efflux from M5076 tumor cells and decreased the weight of tumors by 40% compared to doxorubicin alone (77148).\nAntioxidant effects\nIn preliminary research in vitro, taurine has demonstrated both direct and indirect antioxidant activity, via the scavenging of reactive oxygen species and the stabilization of membrane permeability, respectively (77112, 77118). In cancer cells, taurine has been shown to scavenge oxidant and cytotoxic agents, thus protecting against carcinogenesis (77191). Various clinical studies also suggest that taurine has antioxidant effects (77107, 77192, 103209). In one observational study, plasma taurine levels have been linked to improvements in oxidative stress makers in people taking hypolipidemic agents, possibly due to reduced superoxide anion production at the respiratory chain level (77192). In another human study, lipoperoxidation following coronary artery bypass grafting was reduced by taurine, indicating that it may be a free-radical scavenger (77107). In patients with type 2 diabetes, taurine 1000 mg three times daily for 8 weeks increased the activity of the antioxidant enzymes superoxide dismutase and catalase when compared with placebo (103209).\nAntitoxin effects\nIn preclinical research, taurine prevents methamphetamine-induced developmental angiogenesis defects, possibly due to its antioxidant effects (77198). Anti-inflammatory, antioxidant, cytoprotective, osmoregulatory, and membrane stabilizing effects of taurine may contribute to its protective effects against toxicity of drugs and other compounds (77205).\nAntiulcer effects\nIn individuals with Helicobacter pylori-induced duodenal ulcers, adjunct taurine (Dibicor) contributes to eradication of H. pylori, shortening of duodenal scarring time, improvement in KI-67, BCL-2 expression, and stimulation of apoptotic activity of epitheliocytes compared with conventional omeprazole and antibiotic treatment alone (77145).\nAthletic performance enhancement effects\nSome evidence from animal research suggests that the quantity of taurine in the muscle tissue may impact exercise performance. The mechanism for this activity may involve reduction of oxidative stress, increased calcium release from the sarcoplasmic reticulum into the muscle interstitial space, and the stabilization and hyperexcitement of the cell membrane. Additional research suggests that taurine may influence the amount of energy provided by the glycolytic pathway during high-intensity exercise, reducing blood lactate accumulation during exercise and improving anaerobic capacity (95613).\nBiliary effects\nTaurine seems to stimulate bile acid synthesis (3467).\nCardiovascular effects\nTaurine has been explored as a potential preventative factor for various cardiovascular conditions (3467), including coronary heart disease (77146, 77169), cardiac remodeling (77150), and ischemic disease (77111, 77128), due in part to its anti-inflammatory, antioxidant, bile acid-conjugating, blood pressure-regulating, and intracellular calcium-modulating activities. Taurine might also lower blood pressure and might normalize excessive sympathetic nervous system activity that often occurs in people with hypertension and heart failure (3467, 8219, 8221, 8222). It also has an inotropic effect on cardiac myocytes and increases stroke volume (101475). Additionally, taurine seems to modestly lower the heart rate in patients with cardiovascular or other metabolic disorders (114794). Decreased and increased heart rate and increased blood pressure have been reported following the co-administration of taurine and caffeine in human research (77088, 112268).\n\nThe concentration of taurine increases in the left ventricle of patients with CHF (9900). Preliminary studies also suggest taurine might have natriuretic and diuretic activity (3467). Despite evidence of taurine's possible cardioprotective effects, some conflicting evidence exists. One observational study in patients suffering from cardiac arrest has found that patients with serum taurine levels in the upper quartile have around 4-fold higher odds of in-hospital mortality when compared with patients with taurine levels in the lower three quartiles (103208). Another study in young healthy adults suggests that taurine taken as part of an energy drink impairs endothelial cell function, decreases velocities of carotid arteries, and reduces cardiac output but does not seem to impact electrocardiogram parameters (112268).\n\nIn an animal model, heart perfusion with higher doses of taurine shortens cardiac repolarization, QT interval, and ventricular effective refractory periods, facilitating re-entry and leading to an increased incidence of ventricular arrhythmias. Researchers theorize that this mechanism may give insight into fatal outcomes secondary to intoxication with energy drinks reported in humans (112267).\nEffects in traumatic brain injury (TBI)\nTaurine levels increase in the brain in response to stress and it is released from swollen cells as normal volumes are re-established in people with TBI. Taurine levels in the cerebrospinal fluid (CSF) of patients with TBI almost double, then return to baseline within 3 days (101471).\nGABA modulating effects\nTaurine stimulates action potentials in GABAergic neurons, specifically targeting GABA-A receptors (101471). It has been suggested that effects of taurine on GABA receptors may contribute to seizures occurring after consumption of taurine-containing energy drinks. Taurine may decrease expression of beta 2/3 subunits of GABA receptors, lowering the seizure threshold (77196).\nHormonal effects\nIn preliminary human research, a supplement containing taurine and other ingredients taken before exercise increased the post-exercise serum concentration of growth hormone (46700, 77122).\nHypersensitivity\nTaurine can be metabolized to sulfites, acetaldehyde, and aminoacetaldehyde which may cause hypersensitivity-type reactions (91514).\nLipid metabolism effects\nIn healthy people, taurine seems to reduce total cholesterol and low-density lipoprotein, but increases very low density lipoprotein (VLDL) cholesterol (77061, 77114, 77258). Studies have shown both increases and decreases in serum triglycerides (77076, 77114, 77258). These effects may be mediated by an effect of taurine on lipoprotein lipase. In people with liver injury, taurine decreases total cholesterol and triglycerides (77114).\nMuscle effects\nTaurine has been reported to decrease oxidative stress. It is possible that it prevents increases in carbonyl protein and lipoperoxide levels which contribute to muscle soreness (91513).\nThermoregulatory effects\nIn tests where cycling in a hot environment (35C, 40% relative humidity) is continued to exhaustion, taurine slows the rise in core temperature and increases sweating rate at the end of the test by about 13%. Its vasodilatory effects may be contributing to heat dissipation, and it also seems to have central effects. It acts as an agonist at GABA-A receptors in the hypothalamus, affecting thermoregulation (101475)."
        }
    },
    "Tea Tree Oil": {
        "sections": {
            "Overview": "Tea tree is a tree that grows in the swampy, southeast coast of Australia. The oil from tea tree leaves has been used medicinally for centuries. Tea tree oil became commercially available in the 1930s, primarily for topical use for skin conditions (77280, 109947). Tea tree oil is obtained by steam distillation of tea tree leaves. Tea tree oil has the aroma of nutmeg (515).",
            "Safety": "POSSIBLY SAFE when used topically and appropriately for up to 12 weeks (1538, 4028, 4031, 4445, 7032, 8573, 19157, 19158, 19159, 19163)(19318, 109944, 109945, 113000).\nLIKELY UNSAFE when used orally. Tea tree oil has been reported to cause significant toxicity when used orally (4028, 10011, 19166, 19168, 19170, 109947).\nCHILDREN: POSSIBLY SAFE when used topically and appropriately. Tea tree oil 5% preparations have been used with apparent safety in children (8573).\nCHILDREN: LIKELY UNSAFE when used orally. Ingestion of tea tree oil can be toxic (4030, 10010, 10013, 11799).\nPREGNANCY AND LACTATION: POSSIBLY SAFE when used topically and appropriately (512).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally. Ingestion of tea tree oil can be toxic (515).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tea tree oil can cause significant toxicity and should not be used. Topically, tea tree oil is generally well tolerated.\nMost Common Adverse Effects\nTopically: Allergic reactions, burning, dryness, irritation, pruritus, redness, and stinging.\nDermatologic\nIngestion of as little as 2.5 mL of tea tree oil can cause petechial body rash. It can take up to a week for symptoms to resolve (10011).\n\nTopically, tea tree oil is usually well tolerated. However, it can cause local irritation and inflammation in some patients. Treatment with topical corticosteroids may be needed in some cases (10033, 13713, 19176, 91442, 91443, 109946, 109947). Severe allergic contact dermatitis has also been reported (109947, 109948, 112999). Tea tree oil can cause skin dryness, and less frequently pruritus, stinging, burning, and redness in patients with acne (8573, 91447, 109947). It may also cause mild oral mucosal burning (4445).\nless\nEndocrine\nIn one case, a prepubertal male who used a hair styling gel and shampoo product containing both tea tree oil and lavender oil developed gynecomastia. The gynecomastia resolved when the products were discontinued. It is possible that this effect was due to lavender oil, which has been associated with other cases of gynecomastia in prepubertal males (15254).\nless\nGastrointestinal\nOrally, tea tree oil can cause eucalyptus-like odor on the breath. In young children, ingestion of 10 mL or less of tea tree oil can cause this effect (4030, 10010, 11799).\nless\nHematologic\nOrally, as little as 2.5 mL of tea tree oil can cause neutrophil leukocytosis. It can take up to a week for symptoms to resolve (10011).\nless\nImmunologic\nOrally, tea tree oil can cause or worsen systemic contact dermatitis (4028, 19168). Topically, tea tree oil is usually well tolerated. However, it can cause allergic contact eczema and allergic contact dermatitis in some children and adults. Corticosteroids may be needed in some cases (658, 4027, 4028, 4029, 10015, 10029, 10030, 10031, 10032, 91443)(105242, 105244, 109947, 109948, 112999).\n\nIn young children, ingestion of 10 mL or less of tea tree oil can cause significant ataxia, drowsiness, disorientation, and coma (4030, 10010, 11799).\nless\nNeurologic/CNS\nOrally, tea tree oil can cause ataxia and CNS depression (109947).\nless\nOcular/Otic\nThere is some concern that topical use of tea tree oil in the middle ear for treatment of ear infections might cause ototoxicity. There is preliminary evidence from animal research that preparations of pure tea tree oil can cause ototoxicity and impaired hearing. However, so far there are no reports of ototoxicity in humans. Until more is known, tell patients to avoid pure or highly concentrated tea tree oil preparations. Concentrations of 2% seem less likely to have this effect (7025).\nless\nPulmonary/Respiratory\nOrally, tea tree oil can cause dyspnea and pneumonitis (109947).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAcne. Some clinical research shows that topical tea tree oil seems to improve symptoms of acne in adults and adolescents.\nSome preliminary clinical research shows that applying a tea tree oil 5% gel is as effective as benzoyl peroxide 5% (Oxy-5, Benzac AC, and others) and more effective than placebo for treating acne. Tea tree oil might work more slowly than benzoyl peroxide, but it seems to be less irritating to facial skin (8573). Other clinical research shows that applying a tea tree oil 5% gel for 20 minutes twice daily for 45 days decreases acne lesions 3.6-fold, acne severity 5.7-fold, and comedone numbers, pustules, and papules when compared with placebo in patients with mild to moderate acne (19176). Another small clinical study in patients with mild to moderate acne shows that applying a topical tea tree oil nanoemulsion with adapalene gel 0.1% once daily for 12 weeks reduces acne lesions and improves acne severity scores when compared with adapelene gel alone. However, the tea tree oil product was associated with an increased occurrence of mild adverse effects (109945). Conversely, a small clinical trial shows that applying tea tree oil 5% cream twice daily for 8 weeks reduces inflammatory acne lesions by 38%, compared with a 65% reduction in patients using a product based on Lactobacillus-fermented Chamaecyparis obtuse 5% cream. Additionally, the time of onset was slower with tea tree oil (91447).\nless\nOnychomycosis. Some clinical research suggests that topical pure tea tree oil seems to be beneficial for onychomycosis. It is unclear if the diluted oil is beneficial.\nTopical application of pure tea tree oil twice daily for 6 months can produce a mycological cure in about 18% of patients with toenail infections. It can also improve nail appearance and symptoms in about 56% of patients after three months and 60% of patients after 6 months of treatment. It seems to be comparable to twice daily application of clotrimazole 1% solution (1538). However, preliminary clinical research shows that lower concentrations of tea tree oil do not seem to be as effective. For example, there is some evidence that a tea tree oil 5% cream applied three times daily for 2 months has no beneficial effect (7032).\nless\nTinea pedis. Some clinical research suggests that topical tea tree oil 25% or 50% seems to be beneficial for tinea pedis, although it does not seem to work as well as standard treatments.\nTopical application of tea tree oil 25% or 50% solution twice daily appears to produce both clinical improvement and a mycological cure in 48% to 50% of patients after 4 weeks of treatment, compared with 13% of those using placebo (10033). However, tea tree oil 25% or 50% concentrations don't appear to be as effective for mycological cure as clotrimazole or terbinafine (13713). Also, although topical application of a tea tree oil 10% cream seems comparable to tolnaftate 1% cream for relieving symptoms of tinea pedis, including scaling, inflammation, itching, and burning, the tea tree oil cream appears no more effective than placebo in producing a mycological cure (4031).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBacterial vaginosis. Although there is interest in using intravaginal tea tree oil for bacterial vaginosis, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nBlepharitis. Topical tea tree oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with seborrheic blepharitis shows that using a specific topical swab (TTO Thermal Swab, Jeomed Medicine and Health Production Company) containing tea tree oil and chamomile twice daily for 8 weeks improves blepharitis symptom scores, such as burning, itching, and dry eyes, when compared with using baby shampoo. Symptom improvements were maintained 4 weeks after treatment discontinuation (109944). A small open-label clinical trial in adults with mild-to-moderate anterior blepharitis shows that applying an eye gel containing tea tree oil 2%, hyaluronic acid, and other ingredients (Blephamed eye gel, Saya Teb Mana Co, Tehran, Iran) to the eyelid and roots of the eyelashes twice daily for 2 weeks improves symptoms of eyelid debris, but not eyelid erythema or edema, when compared with standard treatment including topical erythromycin ointment and fluorometholone eye drops(113000). It is unclear if this effect is due to tea tree oil, hyaluronic acid, or the combination.\nless\nCheilitis. Although there is interest in using topical tea tree oil for cheilitis, there is insufficient reliable information about the clinical effects of tea tree oil for this purpose.\nContact dermatitis. Preliminary clinical research suggests that topical tea tree oil is beneficial for nickel-induced contact dermatitis.\nPreliminary clinical research shows that undiluted or diluted tea tree oil for 3-5 days may reduce the area and redness of acute contact dermatitis reactions in people with nickel hypersensitivity (16337, 19191). Other preliminary clinical research in individuals with nickel allergy shows that applying 60-120 mcL of tea tree oil 20% or 50% (Australian bodycare tea tree oil, Maxmedica AB) once, immediately prior to nickel exposure, reduces nickel-induced contact dermatitis by 41% when compared with no treatment (19191).\nless\nDandruff. It is unclear if topical tea tree oil is beneficial for dandruff in adults and adolescents.\nPreliminary clinical research shows that a tea tree oil 5% shampoo, used for three minutes daily prior to rinsing for 4 weeks, reduces the total area and severity of scalp lesions, as well as the severity of dandruff, itchiness, and greasiness, by 23% to 28% in patients aged 14 years and older. However, it does not improve scalp scaliness (19178).\nless\nDental plaque. It is unclear if brushing or rinsing with tea tree oil is beneficial for dental plaque; the available evidence is conflicting.\nPreliminary clinical research shows that brushing with a tea tree oil 2.5% gel twice daily for 8 weeks reduces papillary bleeding, but does not improve gingival health or plaque, in patients with plaque-induced gingivitis (19179). Other preliminary clinical research also shows that using tea tree oil mouthwash does not reduce plaque formation following a professional tooth cleaning (19180). However, a small preliminary clinical trial shows that using a mouthwash made from 3-4 drops of pure tea tree oil in water 2-3 times daily after brushing for 14 days is as effective as using a mouthwash containing chlorhexidine 0.12% twice daily for reducing plaque (105241).\n\nSome preliminary clinical research has also evaluated tea tree oil in combination with other ingredients. A combination of tea tree oil 1.5% and xylitol 10% (Tebodont) for 3 months reduces plaque formation on tooth surfaces when compared with pretreatment (19181). Other research shows that rinsing with 10 mL of a solution containing tea tree oil, clove, and holy basil 0.2% to 0.3% each, for 30 seconds twice daily for 21 days, reduces plaque formation by 64% when compared to baseline (91446). It is not clear if the effects in these studies are due to tea tree oil, other ingredients, or the combinations.\nless\nDry eye. It is unclear if topical tea tree oil is beneficial for improving symptoms of dry eye due to cataract surgery or meibomian gland dysfunction.\nClinical research in patients with dry eye due to cataract surgery also using artificial tears and topical steroid drops shows that eyelid scrubbing with eye shampoo containing an undisclosed amount of tea tree oil for one month improves symptoms of dry eye, such as sensitivity, pain, and blurred vision, and reduces demodex counts, when compared with using shampoo without tea tree oil. There was no benefit of the tea tree oil on visual acuity (101998).\n\nClinical research in patients with meibomian gland dysfunction shows that applying a tea tree oil 1% shampoo around the eye once daily for 3 months improves gland function scores and dry eye symptom scores when compared with Johnson's baby shampoo (109943).\nless\nFuruncles (boils). Although there is interest in using topical tea tree oil for boils, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nGingivitis. It is unclear if brushing or rinsing with tea tree oil is beneficial for gingivitis; the available evidence is conflicting.\nA small preliminary clinical trial shows that using a mouthwash comprised of 3-4 drops of pure tea tree oil in water 2-3 times daily after brushing for 14 days is as effective as using a mouthwash containing chlorhexidine 0.12% twice daily for reducing plaque and bleeding and improving gum health (105241). Other preliminary clinical research in patients with severe gingivitis shows that brushing with a tea tree oil 2.5% gel twice daily for 8 weeks reduces papillary bleeding when compared with baseline. However, the gel does not appear to improve plaque or the severity of plaque-induced gingivitis (19179).\n\nCombination products containing tea tree oil have also been investigated. Preliminary clinical research shows that rinsing with a specific product containing a combination of tea tree oil 1.5% and xylitol 10% (Tebodont) for 3 months reduces gum inflammation by 26% to 32% when compared with pretreatment (19181). Also, clinical research shows that rinsing with 10 mL of a solution containing tea tree oil, clove, and holy basil 0.2% to 0.3% each, for 30 seconds twice daily for 21 days, reduces gum inflammation by 76% when compared to baseline (91446). It is not clear if the effects in these studies are due to tea tree oil, other ingredients, or the combinations.\nless\nHalitosis. It is unclear if tea tree oil mouth rinses are beneficial for halitosis.\nPreliminary clinical research in adults with halitosis shows that using a specific tea tree oil mouth rinse (100% Organic Tea Tree Oil, Dessert Essence) 10 mL twice daily for 7 days moderately improves halitosis severity scores and reduces salivary levels of Solobacterium moorei when compared with placebo. The improvements were similar to using chlorhexidine gluconate 0.2% mouth rinse (109941).\n\nTea tree oil has also been studied as a combination treatment. One small clinical study suggests that applying an essential oil solution containing tea tree, peppermint, and lemon oils 0.125% as part of a single three-minute oral cleaning reduces the level of bad breath in patients from an intensive care unit when compared with baseline or benzydamine hydrochloride. 15 mL of the solution was applied to cotton sponges used to clean the teeth, tongue, and oral cavity (19177). Similarly, a small clinical trial in adults shows that cleaning the teeth, oral mucosa and tongue with gauze soaked in solution containing a tea tree oil, lemon and peppermint essential oil blend in a 1:1:0.2 ratio diluted with distilled water to 0.5% twice daily for 7 days improves halitosis when compared with gauze soaked with saline solution (112957). It is unclear if this effect is due to the tea tree oil, other ingredients, or the combination.\nless\nHemorrhoids. Topical tea tree oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne small clinical study in children with hemorrhoids shows that application of a specific gel (Proctoial, BSD Pharma) containing tea tree oil, hyaluronic acid, and methylsulfonylmethane (MSM) daily for 14 days decreases symptoms of hemorrhoids, such as anal pain, defecation pain, irritation, inflammation, visible bleeding, and itching, when compared with placebo (19318).\nless\nHerpes labialis (cold sores). It is unclear if topical tea tree oil is beneficial for herpes labialis.\nOne small clinical study in adults with cold sores shows that applying a tea tree oil 6% gel five times daily does not improve the rate of cold sore resolution when compared with a placebo gel (2035). However, this study may have been inadequately powered to detect a difference between groups.\nless\nHirsutism. Topical tea tree oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with mild idiopathic hirsutism shows that using a spray containing lavender and tea tree oils twice daily for 3 months on specific hirsutism-affected areas decreases hair diameter by 8% to 9% and total hirsutism score by 11% when compared with baseline. The spray provides lavender oil 48 mcg and tea tree oil 2 mcg per square cm of skin. These improvements were not observed in a placebo group (91448).\nless\nInsect bite. Although there is interest in using topical tea tree oil for insect bites, there is insufficient reliable information about the clinical effects of tea tree oil for this purpose.\nLice. Topical tea tree oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nThere is preliminary evidence that tea tree oil repels lice and reduces blood feeding (19187). When used in combination with lavender oil, tea tree oil has ovicidal effects on head lice and reduces the number of live lice. A pediculicide containing tea tree oil 10% weight per volume and lavender oil 1% weight per volume (NeutraLice Natural Lotion, Key Pharmaceuticals Pty Ltd) has been applied to the hair for 10 minutes, either as a single application or three times over 2 weeks, in children aged 4-12 years (19188, 19189). It is unclear if any effects are due to tea tree oil, lavender, or the combination.\nless\nMethicillin-resistant Staphylococcus aureus (MRSA). It is unclear if topical tea tree oil is beneficial for the prevention of MRSA colonization or the treatment of MRSA infection.\nPreliminary clinical research shows that tea tree oil is not effective for preventing MRSA colonization. Using tea tree oil 5% body wash (Novabac 5% skin wash, Novasel Australia Pty Ltd.) is no more effective than a standard wash (Johnson's baby softwash, Johnson & Johnson) for preventing MRSA colonization in critically ill patients (91441).\n\nThere is contradictory evidence on the effects of tea tree oil for the treatment of MRSA infection. In patients with MRSA-colonized wounds, use of a 3% water-miscible solution of tea tree oil during the wound cleansing routine for each dressing change does not improve MRSA clearance (19190). Also, in patients with MRSA colonization, tea tree oil given in various preparations along with standard treatment for 5 days does not appear to increase overall MRSA clearance when compared with standard treatment alone. These various preparations, which contain tea tree oil 5% or 10%, include a cream applied to the nostrils three times daily, a body wash used at least once daily, or a cream applied to lesions, ulcers, wounds, and axillae or groin areas once daily. Although these various preparations do not improve overall clearance, it seems that using a tea tree cream and body wash may be more effective for eradicating MRSA from specific sites such as wounds and superficial skin infections when compared with standard treatments alone (19163). Also, preliminary clinical research suggests that using tea tree oil 4% nasal ointment plus tea tree oil 5% body wash increases MRSA clearance when compared with a triclosan body wash and mupirocin 2% nasal ointment (19158, 19159). Larger, high-quality studies are needed to confirm these results.\nless\nNipple fissures. It is unclear if topical tea tree oil improves nipple-related complications of breastfeeding, such as nipple fissures and pain.\nA small clinical study in breastfeeding adults in Turkey shows that applying either tea tree oil or coconut oil to the nipples immediately after breastfeeding on the 3rd, 7th and 10th day postpartum reduces the incidence of nipple fissures when compared with a control group receiving no treatment (113002).\nless\nOcular demodicosis. It is unclear if topical tea tree oil is beneficial for ocular demodicosis; available evidence is conflicting.\nSmall clinical studies suggest that tea tree oil can eradicate Demodex infestation in the eyelids and reduce associated symptoms such as corneal and conjunctival inflammation, ocular irritation, and vision loss. In adults, treatments have included weekly scrubs of the eyelid using tea tree oil 50% and daily scrubs of the eyelid with tea tree shampoo, as well as eyelid massages with tea tree ointment 5% to 10%, for up to 12 weeks (19182, 19183, 19184, 19185, 91445, 105243). In children aged 2.5-11 years, weekly scrubs of the eyelid using tea tree oil 50% and daily eyelid massages with tea tree oil 5% ointment for 4-6 weeks has been used (19184). However, conflicting evidence exists. One meta-analysis of two randomized controlled trials shows that although patients using tea tree oil for 4-6 weeks were 68% more likely to have an eradication of mites, while another meta-analysis of three randomized controlled trials shows that the use of tea tree oil products does not reduce the number of Demodex mites or reported symptoms. Also, a single study shows that receiving intense pulsed light over 12 weeks is more effective than tea tree oil. The certainty of evidence for these endpoints is very low and the majority of available research has an unclear or high risk of bias (105243).\nless\nOropharyngeal candidiasis. It is unclear if rinsing the mouth with tea tree oil is beneficial for the prevention of oropharyngeal candidiasis in various populations.\nOne very small clinical study in adults with HIV/AIDS who are refractory to fluconazole shows that swishing and expelling tea tree oil solution 15 mL four times daily for 2-4 weeks seems to improve oral candidiasis when compared to baseline (4445). Another small clinical study in adults with terminal cancer shows that using tea tree oil, as part of an essential oil mixture containing geranium, peppermint, and lavender twice daily for one week improves subjective measures of oral comfort and objective measures of oral health status and reduces Candida albicans count when compared with saline solution (19192). However, in patients with dentures, adding 1 mL of tea tree oil to a standard 5 mL dose of Coe-Comfort tissue conditioner treatment for 12 days does not reduce inflammation or Candida albicans growth when compared with Coe-Comfort alone (19193).\nless\nOtitis externa. Although there is interest in using tea tree oil in the ear for otitis externa, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nOtitis media. Although there is interest in using tea tree oil in the ear for otitis media, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nPharyngitis. Although there is interest in gargling with tea tree oil for pharyngitis, there is insufficient reliable information about the clinical effects of tea tree oil for this purpose.\nRosacea. Topical tea tree oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with mild to moderate rosacea shows that applying permethrin 2.5% gel containing an undisclosed amount of tea tree oil to the affected area for one hour twice daily for 12 weeks reduces demodex mite counts by about 13% more than placebo. Furthermore, symptoms such as papules, burning, and redness were improved by moderate amounts when compared with placebo (101999). The effect of tea tree oil alone is unknown.\nless\nScabies. Although there is interest in using topical tea tree oil for scabies, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nSeborrheic dermatitis. Although there is interest in using topical tea tree oil for seborrheic dermatitis, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nTinea corporis. Although there is interest in using topical tea tree oil for tinea corporis, there is insufficient reliable information about the clinical effects of tea tree oil for this condition.\nToothache. Although there is interest in rinsing the mouth with tea tree oil for toothache, there is insufficient reliable information about the clinical effects of tea tree oil for this purpose.\nVaccine reaction. Topical tea tree oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical trial in adults shows that applying tea tree oil, in combination with inhaling aromatherapy with eucalyptus oil, immediately after a COVID-19 vaccination and every 2 waking hours over the next 48 hours reduces self-reported pain, swelling, and lump at the injection site, but not erythema, in the first 24 hours when compared with control. However, after 48 hours, only lump at the injection site was reduced compared to control (113141). It is unclear if these effects are due to tea tree oil, eucalyptus oil, or the combination. Additionally, the interpretation of these results is limited by the lack of a placebo in the control group.\nless\nVaginal candidiasis. Although there is interest in using intravaginal tea tree oil for vaginal candidiasis, there is insufficient reliable information about the clinical effects of tea tree oil for this purpose.\nWater warts. It is unclear if topical tea tree oil is beneficial for water warts in children.\nPreliminary clinical research in children with a mean age of 6.3 years with water warts shows that a 4 mcL drop of an oil containing iodine plus Australian tea tree oil 75%, standardized to 40.1% terpinene-4-ol, applied twice daily for up to 30 days, increases lesion resolution when compared with tea tree oil or iodine alone (19194).\nless\nWound healing. Although there is interest in topical tea tree oil for wound healing, there is insufficient reliable information about the clinical effects of tea tree oil for this purpose.\nMore evidence is needed to rate tea tree oil for these uses.",
            "Dosing & Administration": "Adult\nTopical:\nTea tree oil has been used undiluted or in a gel, shampoo, body wash, mouth rinse, spray, or cream at concentrations of 5% to 50%, usually for up to 8 weeks. See Effectiveness section for condition-specific information.\nChildren\nTopical:\nTypical dosing is unavailable. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nGel containing tea tree oil 5%, cream or ointment containing tea tree oil 10% to 50%, solution containing tea tree oil 25% to 50%, and body wash or shampoo containing tea tree oil 5% to 10% have been applied to the skin (4031, 8573, 10033, 19163, 19176, 19158, 19159, 19178, 19182, 19183)(19185, 19188, 19189, 19191, 91445, 91447). Undiluted tea tree oil has also been used (1538, 16337).\n\nSolutions containing tea tree oil 1.5% or tea tree oil 0.125% to 0.3% in combination with other ingredients have been used as mouth rinses in clinical research (19181, 19177, 91446).\n\nThe primary constituent of tea tree oil is terpinen-4-ol, and some products are standardized to this compound. A tea tree oil product used in one clinical study was standardized to contain 40.1% terpinene-4-ol (19194).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-REACTIVITY\nSome people with allergies to other plant oils and resins might be allergic to tea tree oil. Use tea tree oil cautiously in these patients. There are at least two case reports of positive reactions to both tea tree oil and resin (105242).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nOral intake of undiluted tea tree oil is not recommended. In adults, it can cause confusion, inability to walk, disorientation, and ataxia (4028, 10011, 10016). As little as 2.5 mL of tea tree oil can cause neutrophil leukocytosis. It can take up to a week for symptoms to resolve (10011). There is at least one case of coma following ingestion of 120 mL of tea tree oil (4028). In young children, ingestion of 10 mL or less of tea tree oil can cause significant ataxia, drowsiness, disorientation, coma, and respiratory failure (4030, 10010, 11799).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with tea tree oil.",
            "Pharmacokinetics": "There is insufficient reliable information available regarding the pharmacokinetics of tea tree oil.",
            "Mechanism of Action": "General\nTea tree oil is obtained by the distillation of the leaves of the tea tree. The oil contains more than 100 monoterpenoid, sesquiterpenoid, and alcohol compounds. Up to 90% consists of terpinen-4-ol, 1,8-cineole, alpha-terpineol, terpinolene, and alpha- and gamma-terpinene (4027, 7111).\nAnti-inflammatory effects\nEvidence suggests tea tree oil may reduce histamine-induced skin inflammation caused by invading organisms. Tea tree oil applied to histamine-induced inflammation of the skin can decreases mean weal volume (10009). In vitro data suggest terpinen-4-ol and tea tree oil can suppress production of superoxide, inflammatory mediators, including tumor necrosis factor alpha, interleukins 1, 8 and 10, and prostaglandin E2 (16337, 77267, 77271). However, the tea tree oil constituents eucalyptol and limonene may be responsible for the adverse effect of contact eczema (10015, 10029).\nAnti-lice effects\nTea tree oil has been shown to be effective against lice in human research (19188, 19189). In animal research, topical tea tree oil 1% to 2% also acts as a lousicide against Bovicola ovis (91444).\nAnti-mite effects\nTea tree oil is thought to help stimulate embedded Demodex mites to migrate out of the skin for easier removal and may have direct antiparasitic properties. In addition, the antibacterial effects of tea tree oil might inhibit the bacterial activity of Demodex-associated bacteria (19182, 105243, 113000).\nAntibacterial effects\nThe primary constituent terpinen-4-ol is active against numerous pathogenic bacteria and fungi but seems to spare normal skin flora. The constituents, alpha-terpineol and linalool, may contribute to its antimicrobial activity (10012, 10026, 77296, 77302). Tea tree oil appears to disrupt the permeability barrier of microbial cell membrane structures, causing loss of chemiosmotic control (10028). Tea tree oil has in vitro activity against Enterococcus faecium and Enterococcus faecalis, including vancomycin-resistant strains, Klebsiella pneumoniae, including gentamicin-resistant strains, and Stenotrophomonas maltophilia (4448, 4451, 7111, 10012, 10026).\n\nTea tree oil also has in vitro activity against both methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) (4448, 4451, 7111, 10014, 10027, 77285). The oil seems to have limited activity against Pseudomonas aeruginosa (7111, 10012, 10026). Oils produced with increased concentrations of terpinen-4-ol seem to have greater activity against these organisms (7111).\n\nTea tree oil has also been found to be active against Propionibacterium acnes and Escherichia coli (8573) and Porphyromonas gingivalis and other oral microorganisms (48954, 77270).\nAntifungal effects\nTea tree oil is active against various pathogenic fungi in vitro. Tea tree oil has been found to inhibit growth of the yeast Candida albicans (4445, 4446, 10012, 19193). Tea tree oil has also been found to inhibit in vitro growth of the yeast species malassezia, which is commonly found on human skin (4450). It is also active against Aspergillus flavus, Trichophyton mentagrophytes, Trichophyton rubrum, and Pityrosporum ovale (8573, 19178, 43472). Tea tree oil and its constituents terpinen-4-ol, gamma-terpinene, and 1,8-cineole, have antifungal effects against Fusarium graminearum, Fusarium culmorum, and Pyrenophora graminea (77291).\nAntiviral effects\nTea tree oil seems to have in vitro activity against herpes simplex virus (2035, 14389).\nDermatological effects\nThere is interest in using tea tree oil for aging skin. Preliminary clinical research in healthy young adults shows that application of tea tree essential oil 2% or tea tree essential oil nanoemulsion 2%, as 1 mL daily for 90 days, improves skin elasticity, but not hydration, when compared with placebo (109942).\nHormonal effects\nTea tree oil has modest estrogenic and antiandrogenic effects in vitro (15254)."
        }
    },
    "Teazle": {
        "sections": {
            "Overview": "Teazle is a biennial flowering plant. It grows up to 2.5 meters tall and has prickly stems (104150).",
            "Safety": "There is insufficient reliable information available about the safety of teazle.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of teazle.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of teazle.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro research suggests that teazle extract can inhibit acetylcholinesterase activity (104150). Theoretically, concurrent use of anticholinergic drugs and teazle might decrease the effectiveness of teazle or the anticholinergic agent.\nCHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro research suggests that teazle extract can inhibit acetylcholinesterase activity (104150). Theoretically, concurrent use of teazle with other cholinergic drugs might have additive effects and increase the risk of cholinergic side effects.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of teazle.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of teazle.",
            "Mechanism of Action": "General\nThe applicable parts of teazle are the leaves and roots. The leaves and roots contain monoterpene iridoids and polyphenols. Cantleyoside is the predominant iridoid found in teazle roots while sylvestroside III is the predominant iridoid found in the leaves. The roots contain more iridoid constituents than the leaves. Chlorogenic acid is the most abundant polyphenol constituent in both the roots and leaves (104150).\nAntimicrobial effects\nIn vitro research shows that teazle root extracts have antibacterial activity against Escherichia coli and Staphylococcus aureus (104150).\nAntioxidant effects\nIn vitro research shows that teazle extracts have antioxidant effects, with leaf extracts having stronger effects than root extracts (104150).\nCholinergic effects\nIn vitro research shows that teazle extracts have anti-acetylcholinesterase effects, with root extracts having stronger effects than leaf extracts (104150)."
        }
    },
    "Terminalia arjuna": {
        "sections": {
            "Overview": "Terminalia arjuna is a type of tree. Its bark is traditionally used in Ayurvedic medicine (6, 33).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Several small studies have used Terminalia arjuna powdered bark or bark extract with apparent safely in doses up to 2000 mg or 400 mg daily, respectively, for 2 weeks to 3 months (2502, 2503, 2504, 111012, 111093); however, patients should avoid self-treatment with this product due to potentially significant cardiovascular effects. Further study is needed to determine the safety of Terminalia arjuna for long-term use.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information available on the adverse effects of oral Terminalia arjuna. A thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAngina. It is unclear if oral Terminalia arjuna is beneficial in patients with angina.\nLow-quality clinical research in patients with angina shows that taking Terminalia arjuna extract 500-2000 mg orally daily for 3 months reduces the frequency of angina symptoms by 50% to 71% when compared with baseline. These results were similar to taking conventional therapy (2502, 2503). Other preliminary research in adults with chronic stable angina shows that taking Terminalia arjuna 500 mg orally three times daily for 7 days reduces the need for rescue treatment and improves exercise tolerance when compared with placebo. Improvements were similar to taking isosorbide mononitrate 20 mg twice daily (92833).\nless\nAsthma. Although there has been interest in using oral Terminalia arjuna for asthma, there is insufficient reliable information about the clinical effects of Terminalia arjuna for this purpose.\nAthletic performance. It is unclear if oral Terminalia arjuna is beneficial for athletic performance.\nA small clinical study in young regular exercising males shows that taking Terminalia arjuna extract (Oxyjun, Enovate Biolife Pvt Ltd, India) 400 mg daily for 8 weeks increases the time to exhaustion by approximately 117 seconds when compared with placebo. There were also modest improvements in feelings of perceived exertion and the left ventricular ejection fraction, a measure of blood pumped from the heart with each heartbeat (111093). It is unclear if oral Terminalia arjuna is beneficial other populations such as athletes and females.\nless\nCoronary heart disease (CHD). It is unclear if oral Terminalia arjuna is beneficial in patients with CHD.\nPreliminary clinical research in patients with CHD shows that taking Terminalia arjuna bark powder 500 mg orally daily for 30 days decreases levels of total cholesterol by about 10% and low-density lipoprotein (LDL) cholesterol by about 16% when compared with baseline. Taking Terminalia arjuna bark powder did not improve high-density lipoprotein (HDL) cholesterol levels (92832).\nless\nHeart failure. The effects of Terminalia arjuna in patients with heart failure is unclear; evidence to date comes from small, short-term clinical studies, and results are conflicting.\nPreliminary, low-quality clinical research in patients with severe, refractory congestive heart failure shows that taking Terminalia arjuna bark extract 500 mg orally three times daily for 2 weeks, as an adjunct to conventional therapy, improves left ventricular ejection fraction (LVEF) by 17% when compared with placebo (2504). However, other preliminary clinical research in adults with stage II heart failure shows that taking an extract of Terminalia arjuna bark 750 mg orally twice daily as an adjunct to conventional therapy for 12 weeks does not improve LVEF, functional class, or functional capacity when compared with placebo (96726). However, the validity of these trials is limited by short-term treatment and variation in the conventional therapies used to manage heart failure.\nless\nHyperlipidemia. It is unclear if oral Terminalia arjuna is beneficial for improving lipid levels.\nPreliminary clinical research in patients with elevated cardiovascular risk factors, such as hypertension, dyslipidemia, or obesity, shows that taking Terminalia arjuna 5 grams orally twice daily for 60 days decreases levels of low-density lipoprotein (LDL) cholesterol and triglycerides by 17% and 35%, respectively, and increases high-density lipoprotein (HDL) cholesterol levels by 9%, when compared with baseline. Improvements in lipid parameters were similar to taking amlodipine 5 mg and atorvastatin 10 mg daily (109677). However, this study may have been inadequately powered to detect a difference between groups.\nless\nHypertension. It is unclear if oral Terminalia arjuna is beneficial for reducing blood pressure.\nPreliminary clinical research in patients with elevated cardiovascular risk factors such as hypertension, dyslipidemia, or obesity, shows that taking Terminalia arjuna 5 grams orally twice daily for 60 days reduces systolic and diastolic blood pressure by 11% and 14%, respectively, when compared with baseline. Improvements in blood pressure were similar to taking amlodipine 5 mg and atorvastatin 10 mg daily (109677). However, this study may have been inadequately powered to detect a difference between groups.\nless\nObesity. It is unclear if oral Terminalia arjuna is beneficial for weight loss.\nPreliminary clinical research in patients with elevated cardiovascular risk factors, such as hypertension, dyslipidemia, or obesity, shows that taking Terminalia arjuna 5 grams orally twice daily for 60 days reduces body mass index (BMI) by 6% when compared with baseline. Improvements in BMI were similar to taking amlodipine 5 mg and atorvastatin 10 mg daily (109677). This study may have been inadequately powered to detect a difference between groups.\nless\nMore evidence is needed to rate Terminalia arjuna for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTerminalia arjuna is commonly used in doses of 500 mg three times daily for up to 3 months. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Terminalia arjuna.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of Terminalia arjuna with anticoagulant or antiplatelet drugs may increase the risk of bleeding in some patients.\nIn vitro, Terminalia arjuna bark extract inhibits platelet aggregation, decreases platelet activation, and shows antithrombotic properties (92831).\nless\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, use of Terminalia arjuna may increase the levels and clinical effects of CYP2C9 substrates.\nIn vitro research shows that Terminalia arjuna extract inhibits CYP2C9 enzymes and reduces CYP2C9 substrate metabolism (96729).\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, use of Terminalia arjuna may increase the levels and clinical effects of CYP2D6 substrates.\nIn vitro research shows that Terminalia arjuna extract inhibits CYP2D6 enzymes and reduces CYP2D6 substrate metabolism (96729).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, use of Terminalia arjuna may increase the levels and clinical effects of CYP3A4 substrates.\nIn vitro research shows that Terminalia arjuna extract inhibits CYP3A4 enzymes and reduces CYP3A4 substrate metabolism (96729).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, Terminalia arjuna may increase the risk of bleeding in some patients.\nIn vitro, Terminalia arjuna bark extract inhibits platelet aggregation, decreases platelet activation, and shows antithrombotic properties (92831). See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nTheoretically, use of Terminalia arjuna may increase the risk of bleeding in patients with bleeding disorders. In vitro, Terminalia arjuna bark extract inhibits platelet aggregation, decreases platelet activation, and shows antithrombotic properties (92831).\nless\nPERIOPERATIVE\nTheoretically, Terminalia arjuna might increase the risk of bleeding during and after surgical procedures. In vitro research shows that use of Terminalia arjuna bark might inhibit platelet aggregation (92831). Tell patients to discontinue Terminalia arjuna at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Terminalia arjuna.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Terminalia arjuna.",
            "Mechanism of Action": "General\nThe applicable part of Terminalia arjuna is the bark. The bark contains several active constituents, including gallic acid, ethyl gallate, and the flavone luteolin (6).\nAnticancer effects\nTerminalia arjuna contains luteolin, which may have anticancer properties (2506).\nCardiovascular effects\nThe bark of Terminalia arjuna is reported to be beneficial in cardiovascular conditions; however, the exact mechanism is not known. Terminalia arjuna is reported to lower serum cholesterol and low-density lipoprotein (LDL) levels (2505, 2517, 2519). It is also thought to have an antihypertensive effect and act as a cardiac stimulant. However, studies have been conflicting, with some indicating that it may actually increase blood pressure (33). In one study of patients with heart failure, Terminalia arjuna bark extract given daily for 12 weeks led to a larger reduction in red blood cell catalase activity than those receiving placebo; however, there was no change in red blood cell glutathione, red blood cell superoxide dismutase, brain natriuretic peptide (BNP), other markers of oxidative stress, or clinical function (96726). Terminalia arjuna has also been investigated in healthy overweight adults. In this population, Terminalia arjuna extract modestly improves left ventricular ejection fraction, indicative of improved heart activity (111012).\nDrug metabolism effects\nIn vitro research shows that Terminalia arjuna extract potently inhibits CYP3A4, CYP2D6, and CYP2C9 in human liver microsomes (96729). The exact mechanism of this effect is unclear. The constituents arjunic acid, arjunetin, and arjungenin did not exhibit inhibitory activity on any liver microsomes in vitro (96729).\nMusculoskeletal effects\nThere is interest in using Terminalia arjuna for osteoporosis. Animal research in ovariectomized rats shows that taking Terminalia arjuna bark methanolic extract 250-500 mg/kg daily for 40 days attenuates changes in serum calcium and phosphorous levels and bone mineral density when compared with control. An aqueous extract of Terminalia arjuna bark did not consistently improve these parameters (109678)."
        }
    },
    "Terminalia bellirica": {
        "sections": {
            "Overview": "Terminalia bellirica is a type of tree. The fruit of Terminalia bellirica is used in traditional Ayurvedic medicine in combination with Terminalia chebula and Indian gooseberry (6, 33, 105741, 111099).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. A specific Terminalia bellirica extract has been used with apparent safely in doses up to 2000 mg daily for 24 weeks (111762).\nPREGNANCY: POSSIBLY UNSAFE when used orally. One source warns against using Terminalia chebula and Terminalia bellirica during pregnancy; however, the reason for this warning is not described (33). Until more is known, avoid use.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nTerminalia bellirica seems to be well tolerated. However, a thorough evaluation of safety outcomes has not been conducted.\nGastrointestinal\nOrally, mild gastrointestinal intolerance has been reported rarely in clinical research (111762).\nless\nImmunologic\nIn a small clinical study, two adults with hyperlipidemia developed a hypersensitivity rash, one with facial edema, within minutes of oral administration of Triphala (containing an aqueous extract of Terminalia chebula, Terminalia bellirica, and Indian gooseberry), together with guggul extract (105741). It is unclear if this reaction was due to Triphala, guggul, or other factors.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nChronic kidney disease (CKD). It is unclear if oral Terminalia bellirica is beneficial in patients with CKD.\nA small clinical study in patients with chronic kidney disease shows that taking Terminalia bellirica (Ayuric, Natreon, Inc) 1000 mg twice daily for 24 weeks reduces creatinine levels and increases eGFR levels as effectively as febuxostat 40 mg daily. Taking either 500 mg twice daily or 1000 mg twice daily modestly reduces serum uric acid levels when compared to baseline; however, febuxostat was more effective (111762).\nless\nConstipation. Although there has been interest in using oral Terminalia bellirica for constipation, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nCough. Although there has been interest in using oral Terminalia bellirica for cough, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nDiabetes. Although there has been interest in using oral Terminalia bellirica for diabetes, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nDiarrhea. Although there has been interest in using oral Terminalia bellirica for diarrhea, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nGastroesophageal reflux disease (GERD). Although there has been interest in using oral Terminalia bellirica for GERD, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nGingivitis. Although there has been interest in using topical Terminalia bellirica for gingivitis there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nHIV/AIDS. Although there has been interest in using oral Terminalia bellirica for HIV/AIDS, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nHyperlipidemia. Oral Terminalia bellirica has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in adults 35-69 years of age with hyperlipidemia and low to moderate cardiovascular risk shows that taking a capsule of Triphala, containing an aqueous extract of Terminalia chebula, Terminalia bellirica, and Indian gooseberry, 450 mg with a capsule of guggul extract 200 mg, three times daily for 3 months, does not improve levels of total, low-density lipoprotein, or high-density lipoprotein cholesterol or triglycerides when compared with placebo (105741).\nless\nObesity. Although there has been interest in using oral Terminalia bellirica for weight loss, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nRespiratory tract infections. Although there has been interest in using oral Terminalia bellirica for respiratory tract infections, there is insufficient reliable information about the clinical effects of Terminalia bellirica for this purpose.\nMore evidence is needed to rate Terminalia bellirica for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch on the use of Terminalia bellirica is limited; typical dosing is unavailable. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nA specific extract used in clinical research (Ayuric) contains at least 1% of chebulinic acid and chebulagic acid, and at least 15% of other low molecular weight hydrolysable tannins (111762).",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of Terminalia bellirica with antidiabetes drugs could affect blood sugar control and increase the risk of hypoglycemia.\nAnimal research suggests that Terminalia bellirica fruit extract, alone or in combination with Terminalia chebula and Indian gooseberry, has hypoglycemic effects (31025, 109680). This activity has not been shown in humans.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, Terminalia bellirica may increase the risk of hypoglycemia in some patients.\nAnimal research suggests that Terminalia bellirica fruit extract, alone or in combination with Terminalia chebula and Indian gooseberry, has hypoglycemic effects (31025, 109680). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, Terminalia bellirica might interfere with blood glucose control during and after surgical procedures. Animal research shows that use of Terminalia bellirica extract might reduce blood glucose levels (31025, 109680). Tell patients to discontinue Terminalia at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Terminalia bellirica.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Terminalia bellirica.",
            "Mechanism of Action": "General\nThe applicable part of Terminalia bellirica is the fruit (6).\nAnti-diabetic effects\nResearch in rats with chemically-induced diabetes shows that consuming a barley and/or wheat mixture with Terminalia bellirica fruit, Terminalia chebula fruit, and Indian gooseberry fruit extract for 60 days inhibits activity of intestinal alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase-4 (DPP-4) when compared with control (109680).\nCardiovascular effects\nTerminalia bellirica has been reported to improve lipid profiles, but to a lesser degree than other Terminalia species, including Terminalia arjuna or Terminalia chebula (2517, 2519).\nGastrointestinal effects\nTerminalia bellirica is reported to have beneficial effects in bowel irregularity and indigestion; these benefits are attributed to astringent properties (33).\nHepatoprotective effects\nTerminalia bellirica contains gallic acid, and is thought to have hepatoprotective properties (2507)."
        }
    },
    "Terminalia chebula": {
        "sections": {
            "Overview": "Terminalia chebula is a deciduous tree which grows throughout India, Burma, Sri Lanka, and Mauritius (6, 33, 92834, 105739). The fruit of this tree, called Haritaki, is used extensively in Ayurvedic medicine, often in combination with Terminalia bellirica and Indian gooseberry (54631, 105741, 111099).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. A specific extract of Terminalia chebula (Synastol TC) has been used with apparent safely in doses of 250 mg twice daily for 8 weeks (111759). ...when used topically and appropriately, short-term. Terminalia chebula fruit powder has been used topically with apparent safely for up to 40 days (111761).\nPREGNANCY: POSSIBLY UNSAFE when used orally. One source warns against using Terminalia bellirica and Terminalia chebula during pregnancy; however, the reason for this warning is not described (33). Until more is known, avoid use.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information available on the adverse effects of oral Terminalia chebula. A thorough evaluation of safety outcomes has not been conducted.\nImmunologic\nIn a small clinical study, two adults with hyperlipidemia developed a hypersensitivity rash, one with facial edema, within minutes of oral administration of Triphala (containing an aqueous extract of Terminalia chebula, Terminalia bellirica, and Indian gooseberry), together with guggul extract (105741). It is unclear if this reaction was due to Triphala, guggul, or other factors.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. It is unclear if oral Terminalia chebula is beneficial in patients with aging skin.\nA small clinical trial in females ages 25 to 65 years shows that taking Terminalia chebula extract (Synastol TC, Sytheon, Parsippany, NJ, USA) 250 mg twice daily for 8 weeks modestly reduces wrinkle severity, as well as redness and sebum levels, when compared with taking placebo (111759). However, it is unclear if any changes are clinically relevant.\nless\nConstipation. Although there has been interest in using oral Terminalia chebula for constipation, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nCough. Although there has been interest in using oral Terminalia chebula for cough, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nDiabetes. It is unclear if oral Terminalia chebula is beneficial in patients with diabetes.\nPreliminary clinical research in adults with type 2 diabetes and endothelial dysfunction shows that taking a specific aqueous extract of Terminalia chebula (AyuFlex, Natreon Inc) 500 mg orally twice daily for 12 weeks lowers glycated hemoglobin (HbA1c) by 0.07% more than placebo. Taking this same product 250-500 mg orally twice daily also modestly improved lipid parameters (105740). However, these improvements are unlikely to be clinically relevant.\n\nTerminalia chebula has also been studied in combination with other ingredients. Preliminary clinical research in females with diabetes and hyperlipidemia shows that taking a capsule containing Terminalia chebula extract 200 mg, guggul 200 mg, and myrrh 200 mg three times daily for 3 months reduces fasting blood glucose by an additional 21% when compared with placebo. However, there was no improvement in HbA1c. Taking this combination product also moderately improved lipid parameters when compared with placebo (96727).\nless\nDiarrhea. Although there has been interest in using oral Terminalia chebula for diarrhea, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nGastroesophageal reflux disease (GERD). Although there has been interest in using oral Terminalia chebula for GERD, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nHIV/AIDS. Although there has been interest in using oral Terminalia chebula for HIV/AIDS, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nHyperlipidemia. Oral Terminalia chebula has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in females with hyperlipidemia and diabetes shows that taking a capsule containing Terminalia chebula extract 200 mg, guggul 200 mg, and myrrh 200 mg three times daily for 3 months reduces total cholesterol by an additional 15% and LDL cholesterol by an additional 18% when compared with placebo. Taking this combination also increases HDL cholesterol levels by 17%, but does not affect triglyceride levels (96727). It is unclear if this effect is due to Terminalia chebula, other ingredients, or the combination. However, another small clinical study in adults 35-69 years of age with hyperlipidemia and low to moderate cardiovascular risk shows that taking a capsule of Triphala, containing an aqueous extract of Terminalia chebula, Terminalia bellirica, and Indian gooseberry, 450 mg with a capsule of guggul extract 200 mg, three times daily for 3 months, does not improve levels of total, LDL, or HDL cholesterol or triglycerides when compared with placebo (105741).\nless\nOsteoarthritis. Oral Terminalia chebula has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with osteoarthritis shows that taking a specific product (LI73014F2, Laila Nutraceuticals) containing extracts of turmeric rhizome, boswellia, and Terminalia chebula fruit in a 1:2:2 ratio at a dose of 200-400 mg daily for 90 days improves pain, stiffness, and functionality scores by 24% to 37% when compared with placebo (97428).\nless\nRespiratory tract infections. Although there has been interest in using oral Terminalia chebula for respiratory tract infections, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nSchizophrenia. Oral Terminalia chebula has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults hospitalized with schizophrenia shows that taking a product containing Terminalia chebula fruit extract 1.5 grams and sweet almond oil 10% orally twice daily for 4 weeks modestly improves anxiety scores, but not positive or negative symptom scores, when compared with placebo (109679).\nless\nTinea corporis. Topical Terminalia chebula has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical trial in patients with tinea corporis shows that topical application to the lesion twice daily with Terminalia chebula powder mixed with sugar cane vinegar for 40 days was as effective as terbinafine hydrochloride 1% cream for hyphae clearance, pruritus severity, and physician's assessment (111761). This study may have been inadequately powered to detect a difference between groups.\nless\nVaginitis. Although there has been interest in using intravaginal Terminalia chebula for vaginitis, there is insufficient reliable information about the clinical effects of Terminalia chebula for this purpose.\nMore evidence is needed to rate Terminalia chebula for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTerminalia chebula extract is commonly uses in doses of 400-600 mg daily for up to 3 months. See Effectiveness section for condition-specific information.\nTopical:\nResearch on the use of Terminalia chebula is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is limited information available about the standardization of Terminalia chebula. One specific product (LI73014F2, Laila Nutraceuticals) containing extracts of Terminalia chebula fruit, turmeric rhizome, and boswellia in a 2:1:2 ratio has been used in clinical research. The Terminalia chebula fruit extract was standardized to 1% gallic acid and 0.5% ellagic acid (97428). Another study used a specific Terminalia chebula extract (Synastol TC) providing 70% hydrolyzable tannins, including at least 20% chebulinic acid and 15% chebulagic acid (111759).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of Terminalia chebula with antidiabetes drugs could affect blood sugar control and increase the risk of hypoglycemia.\nAnimal research suggests that Terminalia chebula fruit extract has hypoglycemic effects (31025, 54623, 54633, 109680, 109681, 111758).\nless\nCHLORZOXAZONE (Parafon Forte, Paraflex)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, use of Terminalia chebula may increase the risk of adverse effects from chlorzoxazone.\nAnimal research shows that enteral administration of Terminalia chebula for 15 days prior to administration of chlorzoxazone increases blood levels of chlorzoxazone and decreases chlorzoxazone clearance. It is speculated that Terminalia chebula reduces the metabolism of chlorzoxazone by inhibiting cytochrome P450 2E1 (105739).\nless\nOMEPRAZOLE (Prilosec)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, use of Terminalia chebula may increase the risk of adverse effects from omeprazole.\nAnimal research shows that enteral administration of Terminalia chebula for 15 days prior to administration of omeprazole increases blood levels of omeprazole and decreases omeprazole clearance. It is speculated that Terminalia chebula reduces the metabolism of omeprazole by inhibiting cytochrome P450 2C19 (105739).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, Terminalia bellirica or Terminalia chebula may increase the risk of hypoglycemia in some patients.\nAnimal and in vitro research shows that Terminalia bellirica and Terminalia chebula fruit and seed extract have hypoglycemic effects (31025, 54623, 54633, 109680, 109681, 111758). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, Terminalia chebula might interfere with blood glucose control or increase the risk of bleeding during and after surgical procedures. Animal research shows that use of Terminalia chebula might reduce blood glucose levels (31025, 54623, 54633, 109680, 109681, 111758). Tell patients to discontinue Terminalia chebula at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Pharmacokinetics": "Absorption\nIn animal research, constituents of Terminalia chebula, including chebulic acid, gallic acid, protocatechuic acid, corilagin, chebulagic acid, chebulinic acid, 1,2,3,4,6-O-pentagalloylglucose, ellagic acid, and ethyl gallate were found in plasma following intake of the extract. Maximal levels of individual constituents occurred between 20 minutes and 5.5 hours after intake. Chebulagic acid was found in the greatest amounts in plasma (111760).\nExcretion\nIn animals, following intake of Terminalia chebula extract the elimination half-lives of individual constituents ranged from 1.5 to 43.3 hours. Chebulagic acid, corilagin, and chebulinic acid had the longest half-lives of at least 20 hours (111760).",
            "Mechanism of Action": "General\nThe applicable part of Terminalia chebula is the fruit (6, 97428). Terminalia fruit contains chebulinic acid, chebulagic acid, chebulic acid, protocatechuic acid, corilagin, gallic acid, and ellagic acid (111759, 111760).\nAnalgesic effects\nTerminalia chebula is traditionally used for its analgesic effects. Although the mechanism of action is not clear, research in an animal neuropathic pain model suggests that benefits may be related to reductions in brain oxidative stress and/or expression of nerve growth factor and nuclear factor-kappa B (111100).\nAnti-diabetic effects\nAnimal research in rats with chemically-induced diabetes shows that taking Terminalia chebula fruit extract 200-1000 mg/kg orally daily for 4-6 weeks improves fasting blood glucose by 22% to 47% when compared with control (109681, 111758). Terminalia chebula also moderately improved serum lipid parameters, but not body weight (109681, 111758). Research in an animal diabetic model suggests that Terminalia chebula also protects against pancreatic and liver damage and has modest antioxidant effects (111758). Other research in rats with chemically-induced diabetes shows that consuming a barley and/or wheat mixture with Terminalia chebula fruit, Terminalia bellirica fruit, and Indian gooseberry fruit extract for 60 days inhibits activity of intestinal alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase-4 (DPP-4) when compared with control (109680).\nAnti-inflammatory effects\nTerminalia chebula fruit is used for osteoarthritis based on its potential anti-inflammatory effects. In vitro, the fruit extract inhibits the enzyme 5-lipoxygenase. This enzyme is involved in the biosynthesis of pro-inflammatory mediators associated with pain and inflammation in osteoarthritis (97428). Preliminary clinical research in patients with type 2 diabetes and endothelial dysfunction shows that an aqueous extract of Terminalia chebula reduces concentrations of high sensitivity C-reactive protein (105740).\nAntimicrobial effects\nAn ethanolic extract of Terminalia chebula containing gallic acid and its ethyl ester may have activity against methicillin-resistant Staphylococcus aureus (2508). Terminalia chebula may also have activity against cytomegalovirus (CMV), herpes simplex I, HIV, Streptococcus mutans, Salmonella sp., Shigella, and retroviral reverse transcriptase (2509, 2511, 2512, 2513, 2514, 2518).\nAntioxidant effects\nA small clinical study in adults with type 2 diabetes and endothelial dysfunction shows that an aqueous extract of Terminalia chebula improves serum nitric oxide levels and reduces some markers of oxidative stress (malondialdehyde, glutathione) (105740). Antioxidant effects of Terminalia chebula extract have also been shown in some animal research (111758).\nCardiovascular effects\nTerminalia chebula has been reported to improve lipid profiles, but to a lesser degree than Terminalia arjuna (2517, 2519, 105740). Additionally, a small clinical study in adults with type 2 diabetes and endothelial dysfunction shows that an aqueous extract of Terminalia chebula 250 mg or 500 mg twice daily for 12 weeks improves endothelial function when compared with placebo (105740).\nGastrointestinal effects\nTerminalia chebula is reported to have beneficial effects in bowel irregularity and indigestion; these benefits are attributed to astringent properties (33).\nImmunosuppressive effects\nThe gallic acid and chebulagic acid in Terminalia chebula may have immunosuppressive effects against cytotoxic T lymphocytes (2515).\nNeurologic/CNS effects\nAnimal research in mice with depression shows that taking Terminalia chebula fruit extract 100-200 mg/kg orally daily for 15 days decreases brain monoamine oxidase-A enzyme levels and improves depression and anxiety behavioral scores when compared with control (109519)."
        }
    },
    "Testolone": {
        "sections": {
            "Overview": "Testolone is a selective androgen receptor modulator (SARM), a compound which binds to the androgen receptor in select tissues, avoiding or minimizing sex tissue proliferation or hypertrophy (108162). Although SARMs are not legally allowed to be included in dietary supplements in the US, they are sometimes sold on the internet (108160).",
            "Warnings": "SARMs are not legally allowed to be included in dietary supplements. The U.S. Food and Drug Administration (FDA) warned that supplements containing SARMs have been associated with liver toxicity, myocardial infarction, and stroke (94879, 94880, 94881). SARMs are on the list of banned drugs for the National Collegiate Athletic Association (NCAA) and World Anti-Doping Agency (WADA) (94829, 94833, 94834).",
            "Safety": "POSSIBLY UNSAFE when used orally. There are case reports of acute myocarditis and liver injury associated with use of testolone (108160, 108161). Dietary supplements containing selective androgen receptor modulators (SARMs), such as testolone, have been associated with reports of liver toxicity and increased risk of myocardial infarction and stroke (94879, 94880, 94881). The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing SARMs are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing selective androgen receptor modulators (SARMs) are dangerous (91094). Avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nTestolone is possibly unsafe.\nMost Common Adverse Effects\nDecreased appetite, dehydration, elevated liver enzymes, vomiting, and weight loss.\nSerious Adverse Effects (Rare)\nAcute myocarditis, hypophosphatemia, and liver injury.\nCardiovascular\nAcute myocarditis presumably associated with testolone has been reported in a 32-year-old male who used the product for athletic performance enhancement. The patient presented with shortness of breath and a mild fever, with elevations in troponin I, B-type natriuretic peptide, erythrocyte sedimentation rate, C-reactive protein, and D-dimer and received treatment with aspirin, atorvastatin, carvedilol, and furosemide, with a heparin drip (108161).\n\nThe US Food and Drug Administration (FDA) has warned that supplements containing SARMs, such as testolone, have been associated with myocardial infarction and stroke (94879, 94880, 94881).\n\nOne patient in a small study experienced mild palpitations that were thought to be possibly related to the use of oral testolone 100 mg daily for about 8 weeks (108159).\nless\nDermatologic\nOrally, abnormal hair growth and acne occurred in one patient each and were related or possibly related to the use of oral testolone 50 mg or 100 mg daily for about 8 weeks (108159).\nless\nGastrointestinal\nOrally, vomiting and decreased appetite were reported to be some of the most common adverse effects in a dose escalation study of testolone 50-150 mg daily for about 8 weeks (108159).\nless\nHematologic\nOrally, hypophosphatemia occurred in about 23% of patients in a dose escalation study of testolone 50-150 mg daily for about 8 weeks (108159).\nless\nHepatic\nA dose escalation study of testolone 50-150 mg daily for about 8 weeks found that the most common treatment-emergent adverse events included moderate elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin (108159). In one case report, a 52-year-old male was diagnosed with liver injury thought to be related to the use of testolone 20 mg daily (Alpha Bolic) for 4 weeks and then testolone 15 mg daily with ligandrol 10 mg daily (Alpha Elite) for 3 weeks. The patient presented with elevated liver enzymes, jaundice, pruritus, diarrhea, and upper right quadrant pain; liver enzymes were significantly improved 3 months after cessation of the supplements and alcohol intake (108160). It is unclear if this case of liver injury was due to testolone, ligandrol, the combination, unapproved substance(s) not reported on the label, and/or alcohol use. The U.S. Food and Drug Administration (FDA) has warned that supplements containing SARMs, such as testolone, have been associated with liver toxicity (94879, 94880, 94881).\nless\nOther\nA dose escalation study of testolone 50-150 mg daily for about 8 weeks found that some of the most common treatment-emergent adverse events included dehydration and decreased weight (108159). Conversely, one patient in a clinical study experienced weight gain, which was thought to be related or possibly related to the use of oral testolone 100 mg daily for about 8 weeks (108159).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using oral testolone for athletic performance, there is insufficient reliable information about the clinical effects of testolone for this purpose.\nBreast cancer. Although there is interest in using oral testolone for breast cancer, there is insufficient reliable information about the clinical effects of testolone for this condition.\nIn a small, dose-finding clinical study in postmenopausal patients with an advanced form of ER+/HER2- breast cancer taking testolone for a median of about 8 weeks, there was one partial response (5.9%) and nine (52.9%) patients with stable disease. Doses were 50 mg, 100 mg, or 150 mg daily. In patients taking 100 mg daily, median progression-free survival was 2.2 months and a clinical benefit was observed in 18.2% of patients (108159).\nless\nCachexia. Although there is interest in using oral testolone for cachexia, there is insufficient reliable information about the clinical effects of testolone for this condition.\nMuscle strength. Although there is interest in using oral testolone for muscle strength, there is insufficient reliable information about the clinical effects of testolone for this purpose.\nMuscular dystrophy. Although there is interest in using oral testolone for muscular dystrophy, there is insufficient reliable information about the clinical effects of testolone for this condition.\nOsteoporosis. Although there is interest in using oral testolone for osteoporosis, there is insufficient reliable information about the clinical effects of testolone for this condition.\nSarcopenia. Although there is interest in using oral testolone for sarcopenia, there is insufficient reliable information about the clinical effects of testolone for this condition.\nUrinary incontinence. Although there is interest in using oral testolone for urinary incontinence, there is insufficient reliable information about the clinical effects of testolone for this condition.\nMore evidence is needed to rate testolone for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of testolone.",
            "Interactions with Drugs": "HEPATOTOXIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, concomitant use might have additive hepatotoxic effects.\nIn a case report, a 52-year-old male was diagnosed with liver injury thought to be related to the use of products containing testolone (108160). Also, elevated liver enzymes were commonly reported in a dose escalation study of testolone (108159).\nless",
            "Interactions with Supplements": "HEPATOTOXIC HERBS AND SUPPLEMENTS\nTheoretically, concomitant use might increase the risk for hepatotoxicity.\nThere is some concern that testolone can adversely affect the liver (108159, 108160). See other ingredients with hepatotoxic effects here.\nless",
            "Overdose": "Presentation\nIn a dose escalation study, the maximum tolerated dose was determined to be 100 mg daily based on the frequency of dose-limiting toxicities (108159).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with testolone.",
            "Pharmacokinetics": "Absorption\nA single oral dose of testolone 100 mg increases plasma concentrations rapidly over a 24-hour period. Time to maximal levels varied between 6 and 71 hours and often occurred in the secondary or tertiary peak. The half-life was approximately 44.7 hours (108159).",
            "Mechanism of Action": "General\nTestolone is a selective androgen receptor modulator (SARM) (108162).\nAndrogenic effects\nTestolone selectively binds to the androgen receptor with high specificity. The binding affinity is slightly lower than that of the natural androgen dihydrotestosterone. It has a low affinity for the progesterone receptor (108158, 108162). In addition, the activity of testolone is greater in muscle and breast cancer cells, when compared with prostate cells (108158, 108162). In patients with breast cancer, levels of surrogate markers of androgen receptor activation, including prostate specific antigen and sex hormone binding globulin, were affected (108159).\nAnti-cancer effects\nIn vitro, testolone binds to the androgen receptor on endocrine-resistant breast cancer cells and reduces proliferation. In various animal breast cancer models, tumor growth is inhibited. The mechanism of action may be related to increased androgen receptor activity, as well as decreased expression and activity of estrogen receptor 1 (ESR1), with downregulation of many target genes (108158)."
        }
    },
    "Tetrahydrocannabivarin (THCV)": {
        "sections": {
            "Overview": "Tetrahydrocannabivarin is a non-psychoactive analogue of tetrahydrocannabinol (THC) that occurs naturally in the Cannabis sativa plant (101291). There is interest in its use for analgesic and anticonvulsant effects, as well as for various neurological and metabolic disorders. Both delta-8- and delta-9-tetrahydrocannabivarin isomers exist (101312, 115779, 115805). However, delta-8-tetrahydrocannabivarin is not the focus of this monograph.",
            "Safety": "POSSIBLY SAFE when used orally, short-term. Tetrahydrocannabivarin 10 mg has been used safely in clinical research for up to 13 weeks (97021, 101305). There is insufficient reliable information available about the safety of tetrahydrocannabivarin when used for more than 13 weeks.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, tetrahydrocannabivarin seems to be well tolerated. No side effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. It is unclear if oral tetrahydrocannabivarin is beneficial in patients with diabetes.\nOne small clinical study in adults with type 2 diabetes shows that taking tetrahydrocannabivarin 5 mg orally twice daily for 13 weeks does not improve lipid levels, but does modestly reduce fasting plasma glucose by 21.6 mg/dL and improve beta-cell function, when compared with placebo (97021).\nless\nObesity. Although there is interest in using oral tetrahydrocannabivarin for obesity, there is insufficient reliable information about the clinical effects of tetrahydrocannabivarin for this condition.\nSchizophrenia. Although there is interest in using oral tetrahydrocannabivarin for schizophrenia, there is insufficient reliable information about the clinical effects of tetrahydrocannabivarin for this condition.\nSmoking cessation. Although there is interest in using oral tetrahydrocannabivarin for smoking cessation, there is insufficient reliable information about the clinical effects of tetrahydrocannabivarin for this purpose.\nMore evidence is needed to rate tetrahydrocannabivarin for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tetrahydrocannabivarin.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tetrahydrocannabivarin.",
            "Pharmacokinetics": "Absorption\nResearch in rats shows that the time to reach the maximum serum concentration after a single dose of tetrahydrocannabivarin ranges from 1.2 to 2.3 hours. The maximum serum concentration and area under the concentration-time curve exhibit dose dependent effects following single and 14-day repeated doses of tetrahydrocannabivarin (113098). Other research in rats shows that oral administration of tetrahydrocannabivarin results in rapid absorption and a maximum plasma concentration after 30 minutes (101291).\nDistribution\nResearch in mice and rats shows that tetrahydrocannabivarin reaches a maximum concentration in the brain 30 minutes after oral administration (101291).\nExcretion\nResearch in mice and rats show that tetrahydrocannabivarin has an apparent elimination half-life of 1 hour 29 minutes after oral administration (101291).",
            "Mechanism of Action": "General\nTetrahydrocannabivarin is a naturally-occurring cannabinoid that can also be derived from another cannabinoid, cannabidivarin. It is similar in structure to delta-9-tetrahydrocannabinol (THC) but with a slightly longer lipophilic alkyl chain (101291). In vitro research shows that tetrahydrocannabivarin has some activity at human CB1 and CB2 receptors (107341, 107413). The nature of this activity seems to depend on which receptor is expressed, and these effects change qualitatively and quantitatively when the two receptors are expressed together (107413).\nAnti-inflammatory effects\nAnimal research shows that tetrahydrocannabivarin reduces inflammation and inflammatory pain by activating cannabinoid CB2 receptors (101303). In vitro research also shows that tetrahydrocannabivarin has anti-inflammatory effects by inhibiting nitric oxide (NO) production via CB2 and by inhibiting or mitigating signalling pathways involved in inflammation, resulting in reduced pro-inflammatory markers such as interleukin (IL)-6, IL-1beta, tumor necrosis factor alpha, and cyclooxygenase-2 (101308, 115483).\nAnticonvulsant effects\nAnimal research shows that tetrahydrocannabivarin reduces experimentally induced seizures by modulating the cannabinoid CB1 receptor (101306).\nGastrointestinal effects\nThere is interest in using tetrahydrocannabivarin for reducing symptoms of nausea. Animal research suggests that tetrahydrocannabivarin has anti-nausea effects (101297). However, the exact mechanism of this effect is unknown.\nGenitourinary effects\nIn vitro research shows that tetrahydrocannabivarin decreases bladder contractions induced by acetylcholine but not those induced by electrical stimulation (101307).\nMetabolic effects\nThere is interest in whether cannabinoids such as tetrahydrocannabivarin might benefit diabetes. Animal research shows that tetrahydrocannabivarin reduces glucose intolerance and increases insulin sensitivity in obese mice. The mechanism of these effects is unknown, but is thought to be linked to tetrahydrocannabivarin's CB1 neutral antagonism and modulation at CB2 (101311).\nMusculoskeletal effects\nThere is interest in using tetrahydrocannabivarin for preventing dyskinesia caused by the Parkinson disease medication levodopa. Research in mice with dopamine deficiency shows that administering tetrahydrocannabivarin intraperitoneally along with levodopa delays the onset and reduces the severity of dyskinesia when compared with using levodopa alone (104906).\nNeurologic effects\nThere is interest in using tetrahydrocannabivarin for its anti-psychotic effects for conditions like schizophrenia and also for reducing psychotic effects of medications. In vitro research shows that tetrahydrocannabivarin increases activation of the serotonin 1A receptor which suggests antipsychotic effects (101304). Tetrahydrocannabivarin also seems to reduce certain negative neurologic effects of synthetic delta-9-tetrahydrocannabinol (THC). Clinical research in healthy patients shows that taking tetrahydrocannabivarin 10 mg daily for 5 days reduces memory loss and other intoxicating effects of THC 1 mg given once intravenously (101305).\n\nThere is interest in tetrahydrocannabivarin for improving eating style in obesity by regulating reward and aversion in the brain. Clinical research in healthy volunteers shows that tetrahydrocannabivarin increases activation in the anterior cingulate cortex, caudate, putamen, and midbrain to pleasant stimuli. It also increases activation in the amygdala, insula, and orbitofrontal cortex to aversive stimuli (101310). Additional clinical research in healthy adults shows that taking tetrahydrocannabivarin 10 mg affects functional connectivity between the amygdala and cognitive control networks, which might affect control over food intake (101309). Ex vivo research in mouse autaptic hippocampal neurons shows that tetrahydrocannabivarin acts as a CB1 antagonist and can potently inhibit endogenous cannabinoid signaling through presynaptic inhibition (107342).\n\nAdditional animal research has demonstrated cataleptic, hypothermic, anti-nociceptive, hypolocomotive, and anxiolytic effects with tetrahydrocannabivarin (107341, 115783)."
        }
    },
    "Theacrine": {
        "sections": {
            "Overview": "Theacrine is a purine alkaloid, structurally similar to caffeine, found in several species of tea and coffee as well as in the seeds of Herrania and Theobroma plant species. It was first isolated from Camellia sinensis leaves in 1937. Theacrine is the major purine alkaloid found in Camellia assamica var. kucha, a tea plant grown above an altitude of 1000 meters in the Yunnan Province of China (88778, 88780, 88783).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. A specific theacrine product (TeaCrine) has been used safely at doses of up to 300 mg daily for 8 weeks (99951).\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nOrally, theacrine seems to be well tolerated. No adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Preliminary clinical research shows that theacrine does not improve measures of athletic performance. However, these studies were small, and may have been underpowered.\nOne small clinical trial in elite male and female soccer players shows that taking theacrine (TeaCrine, Compound Solutions, Inc.) 275 mg alone or 125 mg in combination with caffeine 150 mg 30 minutes prior to exercise does not improve time to exhaustion, control of heart rate, or perceived exertion when compared with placebo (99950). Another small clinical trial in resistance trained males shows that taking theacrine (TeaCrine, Compound Solutions, Inc.) 300 mg alone or 150 mg in combination with caffeine 150 mg 90 minutes prior to exercise does not improve endurance or rowing time trial performance when compared with placebo (103274).\nless\nCognitive function. Oral theacrine has mostly been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking theacrine does not improve concentration or most other measures of cognitive function (88784, 99950, 99952). Studies have used single doses of 200-275 mg of a specific theacrine product (TeaCrine; Compound Solutions, Inc.) alone, in combination with caffeine 150 mg, or in a proprietary combination with caffeine 150 mg, white willow bark, SAMe, Rauwolfia vomitoria, vitamin B12, and citrus bioflavonoids (TheaTrim, Purus Labs). However, the validity of these results is limited because the studies were likely underpowered. Furthermore, some research shows that taking theacrine 200 mg daily for 7 days might improve subjective measures of cognitive function, such as increased energy, reduced fatigue, and improved concentration, in some healthy individuals (88784).\n\nA small clinical study in young males shows that taking a combination product containing theacrine 50mg, caffeine 125 mg, and methylliberine 75mg as a single dose orally before a video game test improves inhibitory control, attention to internal processing, reaction times, and self-reported alertness when compared with either caffeine 125 mg alone or placebo. Caffeine alone is associated with increased anxiety and headache when compared with taking the combination product (109926).\nless\nFatigue. Although there is interest in using oral theacrine for fatigue, there is insufficient reliable information about the effects of theacrine for this purpose.\nMental alertness. Oral theacrine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in males aged 18-63 years who are current or former law enforcement or military personnel shows that taking theacrine 50 mg, caffeine 150 mg, and methylliberine 100 mg immediately before two 75-minute consecutive computerized tests of reaction times, vigilance, and marksmanship, improves reaction times and vigilance in the second test when compared with the first. Similar improvements are seen with the combination product and with subjects taking caffeine 300 mg alone. All three groups, including placebo, show improvements in decision making and in subjective feelings of arousal when compared with baseline, but not marksmanship scores (109927).\nless\nMuscle strength. Oral theacrine has only been evaluated in combination with caffeine; its effect when used alone is unclear.\nA small clinical study in resistance trained males shows that taking theacrine (TeaCrine, Compound Solutions, Inc.) 300 mg alone or 150 mg in combination with caffeine 150 mg 90 minutes prior to resistance training does not improve muscle strength or power, measured by bench press and squat exercises, when compared with placebo (103274). However, the study has been inadequately powered to detect a difference between groups.\nless\nMore evidence is needed to rate theacrine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of theacrine.",
            "Interactions with Drugs": "CNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, theacrine might alter the effects of CNS depressants.\nAnimal research shows that low doses of theacrine have sedating effects, whereas high doses might have stimulant effects (88778). Depending on the dose of theacrine used, it might increase or decrease the effects of CNS depressants. However, these effects have not yet been reported in humans.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, theacrine might increase or decrease sedative effects.\nAnimal research shows that low doses of theacrine have sedating effects, whereas high doses might have stimulant effects (88778). Theoretically, theacrine might increase or decrease the effects of supplements with sedative properties. See products with sedative-hypnotic effects here.\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with theacrine.",
            "Pharmacokinetics": "Absorption\nThe time to peak plasma levels of theacrine after oral dosing is about 2 hours (109927).\nExcretion\nThe half-life of theacrine after a single oral dose of 25-125 mg is about 16-26 hours (109927).",
            "Mechanism of Action": "General\nTheacrine is a purine alkaloid which is structurally similar to caffeine. Theacrine makes up 40% of the purine alkaloid content found in expanding buds, 75% of that in young leaves, and 60% in mature leaves of the tea plant Camellia assamica var. kucha (88783). The concentration of theacrine in dried C. assamica var. kucha leaves ranges from 1.58% to 1.8% (88778, 88779, 88780).\nHepatic effects\nIn an animal model, the hepatoprotective effects of theacrine were found to be associated with reduced production of inflammatory mediators, as well as the antioxidant activity of theacrine (88780).\nLocomotor effects\nTheacrine is traditionally used to increase energy and improve athletic performance. Some research in animal models suggests that theacrine increases locomotor activity. However, responses may be dependent on dose or route of administration (88778, 88782). Like caffeine, theacrine may follow a bi-phasic dose-response curve, with low doses decreasing activity and high doses increasing activity (88782). The locomotor effects of theacrine relate to its activity at adenosine and dopamine receptors. Theacrine potentially acts as an adenosine receptor antagonist and increases dopamine levels (88782, 99951). Chronic exposure to theacrine does not appear to be associated with locomotor sensitization or tolerance (88782)."
        }
    },
    "Theaflavin": {
        "sections": {
            "Overview": "Theaflavin, also referred to interchangeably as theaflavins, is produced when fresh tea leaves are fermented to produce black tea. Theaflavin includes a group of closely related reddish-yellow polyphenol pigments that are important to the color and flavor of black tea (99648, 104584).",
            "Safety": "LIKELY SAFE when ingested in quantities typically found in brewed black tea. An 8 oz cup of black tea contains about 8.8 mg of theaflavin (99651).\nPOSSIBLY SAFE when ingested in medicinal amounts, short-term. Theaflavin has been used with apparent safety in a dose of 100 mg daily for up to 10 weeks (99649). A theaflavin-enriched green tea extract has been used with apparent safety in a dose of 75 mg daily for up to 12 weeks (11308).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information available about the adverse effects of theaflavin. Orally, theaflavin seems to be generally well tolerated. No adverse effects have been reported in clinical trials (99649, 11308).",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nHyperlipidemia. Preliminary clinical research in Chinese adults with mild to moderate untreated hyperlipidemia shows that taking a theaflavin-enriched green tea extract providing 75 mg of theaflavin daily for 12 weeks reduces total cholesterol by 11% and low-density lipoprotein (LDL) cholesterol by 16% when compared with placebo (11308).\nMore evidence is needed to rate theaflavin for this use.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of theaflavin.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn an animal diabetic model, giving theaflavin reduced fasting blood glucose, with an effect comparable to metformin (104617). A fermented green tea product containing theaflavin also appears to reduce blood glucose levels in healthy humans and in an animal model (99648). Theoretically, concomitant use with antidiabetes drugs might cause additive hypoglycemic effects. Use with caution.\nORGANIC ANION-TRANSPORTING POLYPEPTIDE SUBSTRATES (OATP)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro, theaflavin inhibits organic anion-transporting polypeptide (OATP)2B1. OATP2B1 is expressed in the small intestine and liver and is responsible for the uptake of drugs and other compounds (104584). This interaction has not been shown in humans. However, theaflavin might reduce the absorption of drugs that are OATP2B1 substrates. Use with caution.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheaflavin has been shown to reduce blood glucose levels in animal and clinical research (99648, 104617). Theoretically, it might have additive effects with herbs with hypoglycemic potential. Some of these herbs include devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, and Siberian ginseng.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with theaflavin.",
            "Pharmacokinetics": "Absorption\nAfter holding 30 mL of black tea in the mouth for 2-5 minutes, elevated levels of theaflavin remain in the saliva for an extended duration, declining with a half-life of 49-76 minutes (99652).\nDistribution\nAfter oral consumption of black tea in mice, theaflavins are detected in intestinal tissue, liver, and prostate (99651). In humans, theaflavins have been detected in prostate tissue after oral consumption (99651).\nMetabolism\nTheaflavin gallates are hydrolyzed in the saliva by esterase enzymes (99652).",
            "Mechanism of Action": "General\nTheaflavin and its galloyl esters are flavonoids with a benzotropolone structure found in black tea, and to a lesser extent in oolong tea. Theaflavin, which is interchangeably called theaflavins, consists of theaflavin-3-gallate A, theaflavin-3'-gallate B, and theaflavin-3-3'-digallate (15664, 99648, 99649, 112773). These theaflavins are formed during the fermentation process that produces black tea from green tea leaves. They are oxidized forms of their parent catechins, which are epicatechin, epicatechin 3-gallate, epigallocatechin, and epigallocatechin 3-gallate, produced by the actions of polyphenol oxidase and peroxidase enzymes (99648, 99650). Theaflavins are reddish-yellow pigments that are important for the color and taste of black tea (15656, 15657). Theaflavins comprise 10-30% of the total flavonoid content of black tea (99649, 99650).\nAnti-cancer effects\nIn vitro research suggests that theaflavin might have activity against liver and gastric cancer cells and leukemia cells (15657). Theaflavin seems to exert an antiproliferative effect on tumor cells by down-regulating epidermal growth factor, which regulates cell proliferation, differentiation, and transformation (15660). Other research on cancer cells suggests that theaflavins act as aromatase inhibitors and also act as HER2/neu tyrosine kinase inhibitors, suggesting a role in treating and preventing hormone-dependent breast cancer (15661). Theaflavin has also been shown to induce apoptosis in human leukemia cells (15662).\nAnti-diabetes effects\nIn animal diabetic models, theaflavin reduces fasting blood glucose, increases insulin levels, and improves insulin resistance and glycosylated hemoglobin levels, with an effect comparable to metformin (104617, 112773, 112774). A fermented green tea product containing theaflavin also appears to reduce blood glucose levels in healthy humans and in an animal model (99648). Possible mechanisms of action include inhibition of alpha-glucosidase, resulting in inhibited intestinal glucose production (15665). In addition, theaflavin seems to normalize levels of enzymes involved in glucose metabolism, which may be related to its antioxidant effects (104617).\n\nTheaflavin also protects against nephropathy in patients with type 2 diabetes. Long-term hyperglycemia and oxidative stress result in accumulation of advanced glycation end products (AGEs) which damage the structure and function of the kidneys via inflammation, fibrosis and apoptosis. Theaflavin inhibits formation of AGEs, and prevents inflammation and fibrosis by inhibiting the mitogen activated protein kinase (MAPK) / nuclear factor (NF)-kappa-B signaling pathway. Levels of inflammatory markers (tumor necrosis factor-alpha, interleukin (IL)-1b, and IL-6), and fibrosis markers (transforming growth factor (TGF)-beta-1, fibronectin, and type IV collagen) are reduced (112774).\nAnti-hyperlipidemic effects\nIn vitro, black tea polyphenols, including theaflavins, inhibit enzymes involved in cholesterol synthesis (99649). They also reduce total cholesterol, low-density lipoprotein (LDL), and triglyceride levels in obese animals (112773). Possible mechanisms include reduced intestinal absorption of cholesterol, increased fecal excretion of fat and cholesterol, reduced hepatic cholesterol accumulation, and up-regulation of LDL receptors in liver cells (11308).\nAnti-inflammatory effects\nIn animal models of stroke, theaflavin seems to limit ischemia by inhibiting inflammatory processes including lipid peroxidation, leukocyte infiltration, and inflammation related genes such as ICAM-1 (15666).\nAnti-viral effects\nTheaflavin has activity against HIV replication. Theaflavin seems to inhibit HIV entry into host cells by targeting gp41, a viral glycoprotein that facilitates entry by fusion to the host cell membrane (15658). Other research suggests that theaflavin, particularly theaflavin digallate, can inhibit replication of the severe acute respiratory syndrome (SARS) virus (15659). Theaflavin also has activity against influenza A and B viruses (15657).\nCardiovascular effects\nResearch in healthy individuals suggests that single 100-200 mg doses of theaflavin might improve microvascular circulation and contribute to the vascular effects of black tea (99650).\nHepatic effects\nResearch in obese animals shows that theaflavin reduces hepatic lipid accumulation and pathological liver changes, reduces alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, and ameliorates non-alcoholic fatty liver disease (112773). Theaflavin regulates glycolipid metabolism, reducing synthesis and accumulation of lipids in the liver, via activation of the SIRT6/AMPK/SREBP-1/FASN signaling pathway. Expression of sirtuin 6 (SIRT6, a deacetylase enzyme) is increased, as is phosphorylation of adenosine monophosphate activated protein kinase (AMPK). Expression of sterol regulatory element-binding protein-1 (SREBP-1) and fatty acid synthase (FASN) are reduced (112773).\nWeight loss effects\nGiving theaflavins or a theaflavin-enriched green tea extract to obese mice inhibits weight gain and lowers total fat composition of the body, but does not reduce food consumption, when compared with placebo (99648, 112773). Black tea polyphenols including theaflavin increase fecal lipid excretion and increase energy expenditure in brown adipose tissue (99649). One small clinical study in healthy, non-obese Japanese adults shows that taking theaflavin 50-100 mg daily modestly reduces body weight by 1% and total body fat by about 5%, and increases skeletal muscle by about 2%, when compared to baseline. However, it is unclear if these effects are due to theaflavin or natural weight loss (99649). It is also unclear whether theaflavin has similar effects in people who are obese."
        }
    },
    "Theanine": {
        "sections": {
            "Overview": "Theanine is a major nonprotein amino acid that is chemically similar to glutamic acid (91748). It is found in tea and was first isolated from green tea in the 1940s (1463, 91743, 91745, 91748, 94127, 96335, 96336, 96342). Theanine is also found in some mushrooms (12188). L-theanine is the predominant isomer of theanine that is found naturally in tea. Most clinical research has evaluated L-theanine (96335).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. L-theanine has been used safely in clinical research in doses of up to 900 mg daily for 8 weeks (12188, 36439, 96331, 96332, 96334, 96341, 97923, 101986, 104976). There is insufficient reliable information available about the safety of L-theanine when used long-term.\nCHILDREN: POSSIBLY SAFE when used orally and appropriately, short-term. A specific L-theanine product (Suntheanine, Taiyo Kagaku) 200 mg twice daily has been used safely in males aged 8-12 years for up to 6 weeks (91744).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, L-theanine seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Drowsiness, headaches.\nNeurologic/CNS\nOrally, L-theanine may cause headaches (36439). Patients have also reported drowsiness, increased duration of sleep, and increased dream activity after oral L-theanine use (96331).\n\nA case of subtle facial tic starting within 4 days of taking L-theanine 400 mg daily has been reported for a pediatric patient. Although the tics reportedly ceased once theanine was discontinued, the child had exhibited tics in the past. Therefore, the adverse effect was not thought to be related to L-theanine (91744).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCognitive function. Oral L-theanine may improve some aspects of cognitive function. It is unclear if using L-theanine in conjunction with caffeine can enhance the effects of either ingredient.\nA single dose of L-theanine 100 mg seems to improve vigilant attention, reducing error rates in cognitive tests when compared with placebo (91747). However, taking L-theanine (Suntheanine, Taiyo Kagaku) 200 mg daily for 4 weeks does not improve verbal fluency, memory, motor speed, or executive function in an adult population, although it may moderately improve verbal fluency in a subgroup of people with lower cognitive function at baseline (101986).\n\nWhen L-theanine is combined with caffeine, a meta-analysis and multiple individual clinical studies show that the combination improves alertness, as well as accuracy during a test that requires switching attention between different tasks, but does not improve reaction time (38116, 91750, 96335, 96336). Some research also shows that L-theanine plus caffeine improves cognitive performance and reduces task-induced fatigue when compared with baseline and placebo. However, it is unclear if this is due to the individual ingredients or the combination (38116, 96335, 96336). Some research suggests that the combination is no better than either individual ingredient alone (91747, 96335, 96336).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. It is unclear if oral L-theanine, taken continuously or as a single dose, improves cognition in older adults.\nA small clinical study in healthy, Japanese adults aged 50-69 years shows that taking a specific product (Suntheanine; Taiyo International.) containing L-theanine 101 mg daily after breakfast for 12 weeks does not improve mini-mental state exam (MMSE) scores when compared with placebo. However, a single-dose analysis from this study shows that administration of L-theanine 101 mg may improve the quality of working memory and reaction times during a cognitive function test when compared with placebo (108553). Patients were permitted to consume polyphenol-rich beverages during the study period; however, consumption was not documented, limiting the validity of this finding.\nless\nAlzheimer disease. Although there is interest in using oral theanine for Alzheimer disease, there is insufficient reliable information about the clinical effects of theanine for this condition.\nAnxiety. It is unclear if oral L-theanine is beneficial in patients with anxiety. Results of clinical research are conflicting.\nA preliminary clinical study shows that taking a single dose of a specific L-theanine product (Suntheanine, Taiyo Kagaku) 200 mg does not reduce experimentally-induced anticipatory anxiety when compared with placebo (12188). However, another preliminary clinical study in healthy adults with stress-related anxiety shows that taking L-theanine 200 mg daily for 4 weeks reduces anxiety scale scores and sleep disturbance when compared with placebo (101986).\nless\nAttention. It is unclear if oral theanine improves attention.\nA small clinical study in healthy males shows that taking a single dose of L-theanine 200 mg improves selective attention similar to a single dose of caffeine 160 mg (96337). However, other small clinical studies in adults show that taking L-theanine 100-400 mg does not improve most measures of attention, especially sustained attention or attention in executive control tasks, but doses of 100-200 mg may improve performance in simple attentional tasks when compared with placebo (96338, 111396). Some of these studies suggest that taking L-theanine with caffeine appears to provide more benefit than either individual ingredient alone (96337, 96338).\nless\nAttention deficit-hyperactivity disorder (ADHD). Oral L-theanine seems to improve some aspects of ADHD, including cognition and sleep.\nSome preliminary clinical research in children with ADHD shows that taking a one-time dose of L-theanine 2.5 mg/kg increases cognition scores, but does not improve results on sustained attention or inhibitory control tests, when compared with placebo. Taking L-theanine with caffeine 2 mg/kg also increases cognition scores and improves performance on a sustained attention test, but does not improve inhibitory control, when compared with placebo (104141). Other preliminary clinical research in males aged 8-12 years with ADHD shows that taking a specific L-theanine product (Suntheanine, Taiyo Kagaku) 200 mg orally twice daily for 6 weeks increases the percent of time spent in restful sleep by about 5% and decreases the number of bouts of nocturnal activity by about 6 when compared with placebo (91744).\nless\nCancer. Although there is interest in using oral theanine for cancer, there is insufficient reliable information about the clinical effects of theanine for this condition.\nChemotherapy-induced diarrhea. Oral L-theanine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with colon cancer shows that taking L-cystine 700 mg and L-theanine 280 mg (Ajinomoto Co. Inc.) orally once daily, starting one week before chemotherapy with TS-1 (Taiho Pharmaceutical) and continuing for 28 days, increases the rate of therapy completion by 49%, reduces the incidence of diarrhea by 37%, reduces appetite loss by 33%, and improves the reported tolerability of chemotherapy when compared with chemotherapy alone (96334). However, this combination does not appear to be beneficial in patients with gastric cancer, or in those with colorectal cancer receiving 4 courses of capecitabine-based adjuvant chemotherapy. (96334, 101985).\nless\nCognitive impairment. Oral L-theanine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne very small clinical study in adults with mild cognitive impairment shows that taking a product containing L-theanine 120 mg and green tea extract 720 mg (LGNC-07, LG Household & Health Care, Ltd) orally twice daily after meals for 16 weeks modestly improves memory and attention when compared with baseline. However, taking this product does not appear to improve memory and attention when patients with self-reported memory problems, but without mild cognitive impairment, are also considered (96339).\nless\nDepression. It is unclear if oral L-theanine is beneficial in patients with depression.\nA small clinical study shows that taking a specific L-theanine product (Suntheanine, Taiyo Kagaku Co. Ltd.) 250 mg at bedtime for 8 weeks reduces symptoms and improves sleep quality when compared to baseline in individuals with mild major depressive disorder (MDD) (96331). The validity of these findings is limited by the lack of a comparator group. Another small clinical study in adults with MDD shows that taking L-theanine 200 mg daily with sertraline for 6 weeks reduces depression symptoms and increases remission rates but does not improve treatment response rates when compared with sertraline and placebo (112278). The validity of these effects is limited by the small sample size and short study duration. Additionally, it is unclear if the reduction in depressive symptoms is clinically significant.\nless\nErythema. Oral L-theanine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in healthy females with self-perceived skin sensitivity shows that taking a specific supplement containing L-theanine, ashwagandha, and saffron (InnerCalm, Arbonne) daily for 8 weeks reduces facial pigmentation when compared to baseline (111399). The validity of this finding is limited by a lack of a placebo group. It is unclear if these effects are due to L-theanine, other ingredients, or the combination.\nless\nGeneralized anxiety disorder (GAD). It is unclear if oral L-theanine is beneficial for reducing anxiety in people with GAD.\nOne small clinical study in adults with GAD shows that taking L-theanine 225 mg twice daily for 4 weeks, then 450 mg twice daily for 4 weeks, in conjunction with prescribed antidepressants, does not reduce anxiety scores when compared with antidepressants and placebo (104976).\nless\nHypertension. Although there is interest in using oral theanine for hypertension, there is insufficient reliable information about the clinical effects of theanine for this condition.\nInfluenza. Oral L-theanine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking a combination of green tea catechins (THEA-FLAN 90S, Ito-en Co.) 378 mg, standardized to contain epigallocatechin gallate 270 mg and L-theanine (Suntheanine, Taiyo Kagaku) 210 mg daily for 5 months reduces the risk of developing clinically diagnosed influenza when compared with placebo. However, the combination does not seem to prevent laboratory-confirmed influenza infection (54021).\nless\nInsomnia. It is unclear if oral L-theanine is beneficial for insomnia.\nA very small clinical study in young healthy adults with sleep quality worsened by caffeine intake shows that taking L-theanine 50 mg (Suntheanine, Taiyo Kagaku Co. Ltd) once 10 minutes before bedtime suppresses caffeine-induced elevations in wake after sleep onset time but does not improve parameters of sleep quality including sleep onset latency, sleep time, or number of times waking after sleep onset when compared with placebo (112275).\n\nL-theanine has also been studied in combination with other ingredients. A small clinical study in adults with insomnia or disturbed sleep patterns shows that a specific product (RLX2; LiveLife Biosciences AG) containing L-theanine 50 mg and a specific casein peptide, alpha-s1-casein tryptic hydrolysate, 150 mg, taken one hour before bedtime for 4 weeks, increases sleep duration by 45 minutes and improves habitual sleep efficiency and daytime dysfunction when compared with baseline (108556). Another very small clinical study in healthy adults shows that taking a combination product containing tryptophan, glycine, magnesium, tart cherry powder, and L-theanine 2 hours before bedtime decreases sleep onset latency and increases total sleep duration, leading to better sleep efficiency and reduced morning sleepiness, when compared with placebo (111184). Another combination product containing L-theanine, ashwagandha, and saffron (InnerCalm, Arbonne), taken daily for 8 weeks, seems to improve sleep quality when compared to baseline (111399). However, the validity of this finding is limited by a lack of a control group.\n\nIt is unclear if the effects described above are due to L-theanine, other ingredients, or the combination.\nless\nObsessive-compulsive disorder (OCD). It is unclear if oral L-theanine is beneficial for OCD.\nA small clinical study in adults with OCD shows that taking L-theanine 100 mg twice daily for 10 weeks with fluvoxamine reduces OCD symptoms, particularly obsessive symptoms, and increases the proportion of patients with a complete response to treatment but does not improve compulsive symptoms, partial response rates, or remission rates when compared with placebo and fluvoxamine (112276).\nless\nPostoperative recovery. Oral theanine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study of adults with esophageal cancer undergoing esophagectomy shows that taking theanine 280 mg and cystine 700 mg daily, staring 4 days before surgery and continued for 13 days after surgery, does not improve measures of physical activity but does improve exercise tolerance and some measures of quality of life when compared with placebo (111400). It is unclear if these findings are due to theanine, cystine, or the combination.\nless\nSchizophrenia. It is unclear if oral L-theanine is beneficial in patients with schizophrenia; the available evidence is limited and conflicting.\nOne small preliminary clinical study in adults with schizophrenia or schizoaffective disorder shows that taking L-theanine (Biosynergy) 200 mg orally twice daily for 8 weeks along with antipsychotic medications improves positive symptoms, anxiety, and general psychopathology symptoms, such as poor impulse control and disorientation, when compared with placebo. However, theanine does not improve general disease severity, negative symptoms, depression, cognitive function, extrapyramidal side effects, or quality of life (96341).\n\nIn contrast, two small clinical studies show that taking L-theanine 400 mg (Suntheanine, BioSynergy Health Alternatives) with antipsychotics and with or without pregnenolone 50 mg daily for 8 weeks reduces negative symptoms, general psychopathology symptoms, and anxiety when compared with placebo in patients with schizophrenia or schizoaffective disorder. However, there were no improvements in positive schizophrenia symptoms, extrapyramidal side effects, or symptoms of depression (97923, 112277). The inconsistency of results might be due to the small study sizes and the subjectivity of the outcomes measured.\nless\nStress. It is unclear if oral L-theanine is beneficial in patients with stress.\nOne very small clinical study shows that taking L-theanine 200 mg prior to a stress-inducing exam reduces tension-anxiety and may prevent blood pressure increases caused by psychological stress when compared with placebo (91746). Other preliminary clinical research in pharmacy students shows that taking theanine 200 mg twice daily for one week prior, and then for the first 10 days of a pharmacy practice period, decreases subjective stress scores when compared with placebo (91745). Another small clinical study in healthy young adults shows that drinking a beverage containing L-theanine 200 mg alone or combined with L-arginine 50 mg after a psychological stressor reduces stress, as measured by salivary alpha-amylase activity, when compared with placebo. The combination of L-arginine and L-theanine did not differ from L-theanine alone, suggesting that the combination does not act synergistically to reduce markers of stress (110393).\n\nHowever, not all research has been positive. A small clinical study shows that taking a specific L-theanine product (Suntheanine, Taiyo Kagaku) 200 mg induces subjective feelings of tranquility in relaxed people, but not those with experimentally-induced anticipatory anxiety, when compared with placebo (12188). Also, a small, clinical crossover study in healthy, moderately stressed adults shows that taking a single dose of a specific product (Alphawave; Ethical Naturals) containing L-theanine 200 mg prior to a stress-inducing exam does not improve anxiety at any time point when compared with placebo (108554). Due to the single-dose nature of this study, the effects of continued administration of this product are unclear.\n\nL-theanine has also been evaluated in combination with other ingredients. A small clinical study in adults with stress shows that taking a specific combination product (Mg-Teadiola, Sanofi-Aventis Group), containing green tea extract 125 mg (providing 50 mg L-theanine), magnesium 150 mg, vitamin B6 0.2 mg, vitamin B9 0.1 mg, vitamin B12 1.25 mcg, and rhodiola 222 mg, orally once daily for 28 days modestly improves stress and anxiety scores when compared with placebo. Improvements in stress scores, but not anxiety scores, appear to persist at 28 days after treatment completion (108672). It is unclear if any effects are due to L-theanine, other ingredients, or the combination.\nless\nTourette syndrome. It is unclear if oral L-theanine is beneficial in children with Tourette syndrome.\nA small, nonblinded clinical study in children aged 4-17 years with untreated Tourette syndrome or with chronic tic disorder and associated symptoms of anxiety shows that taking a liquid nutritional supplement providing L-theanine 200 mg and vitamin B6 2.8 mg daily for 2 months improves scores on the Yale Global Tic Severity Scale, but does not reduce anxiety, when compared with patients receiving psychoeducation (108555). This study may have been inadequately powered to detect a difference between groups.\nless\nMore evidence is needed to rate theanine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nL-theanine is typically used in doses of 200-400 mg daily for 4-8 weeks. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nL-theanine is the predominant isomer of theanine that is found naturally in tea. Most clinical research has evaluated L-theanine. It is not known if D-theanine has the same clinical effects as L-theanine (96335).\n\nTheanine can be prepared by one of three methods: isolation from tea leaves, chemical synthesis, or biosynthesis. Due to the high cost and low yield of theanine from tea leaf extraction, this method is less commonly used in commercial settings. However, supplements prepared by chemical synthesis may contain a racemic mixture of both L-theanine and D-theanine.\n\nOne specific L-theanine product (Suntheanine, Taiyo Kagaku) is prepared from ethylamine and glutamic acid using a specific biosynthetic strategy (94128). This product is used alone (101986) or has been combined with caffeine in some clinical studies (96335, 96336).\n\nA combination product (LGNC-07, LG Household & Health Care, Ltd) containing L-theanine and green tea extract has also been used in clinical research. Each capsule of this product contains green tea extract 360 mg, theanine 60 mg, silicon dioxide 5.7 mg, and magnesium stearate 4.3 mg (96339).\n\nA commercially available supplement containing L-theanine 280 mg and L-cystine 700 mg (Ajinomoto) is available in the United States and Japan (101985).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheanine might lower blood pressure, potentiating the effects of antihypertensive drugs.\nAnimal research shows that theanine can lower blood pressure in spontaneously hypertensive animals (7687, 77354). Theoretically, concomitant use of theanine and antihypertensive drugs might potentiate the antihypertensive activity.\nless\nCNS DEPRESSANTS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, theanine might have additive sedative effects when used in conjunction with CNS depressants. However, it is unclear if this concern is clinically relevant.\nTheoretically, theanine may compete with glutamate and/or increase plasma gamma-aminobutyric acid (GABA) levels, which could cause CNS depression (96334). In one clinical study, some subjects taking oral theanine reported drowsiness (96331).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, theanine may lower blood pressure.\nAnimal research shows that theanine can lower blood pressure (7687, 77354). Theoretically, combining theanine with other herbs or supplements with hypotensive effects might increase the risk of hypotension.\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with theanine.",
            "Pharmacokinetics": "Absorption\nTheanine is absorbed through the intestines (77320, 77326). The peak concentration of L-theanine in the plasma occurs at about 50 minutes after oral intake (91743, 91747, 96337). There appears to be similar absorption of L-theanine from both supplements and green tea (91743).\nDistribution\nFollowing absorption, L-theanine is distributed to the plasma and erythrocytes (91743). L-theanine can cross the blood brain barrier and appears to do so in a dose-dependent manner (96331, 96341).\nMetabolism\nL-theanine is hydrolyzed in the intestines to ethylamine and glutamic acid (91743, 96333, 96334). The elimination half-life of L-theanine from plasma ranges from 0.8-1.2 hours (91743).\nExcretion\nA small amount of L-theanine is retained in erythrocytes, but most L-theanine and its metabolites are excreted in the urine 3-24 hours after oral intake (91743). Only about 2.4% to 3.1% of ingested L-theanine is excreted unmetabolized; most ingested L-theanine is excreted as ethylamine and glutamic acid (91743).",
            "Mechanism of Action": "General\nTheanine is the major amino acid found in tea. Tea contains 1% to 3% theanine (7685, 7690, 96335, 96341). This can be as much as 60 mg per 200 mL serving, but is typically between 4.5 mg and 24.5 mg (96335, 96336, 96337). The predominant form is L-theanine (98%) (96335). Theanine is also found in some mushrooms (12188, 96335, 96336, 96342).\nAnti-inflammatory effects\nPreliminary clinical research shows that administering L-theanine along with L-cysteine perioperatively decreases biomarkers of inflammation after surgery. It is thought that this combination reduces blood levels of interleukin (IL)-6 following surgery by preventing decreases in glutathione levels (91742).\nAnticancer effects\nThere is interest in using theanine adjunctively for cancer. In studies involving doxorubicin, theanine increases its concentration in tumors by blocking efflux of the drug from tumor cells (7688, 7690, 8668, 8669). Theanine also appears to increase the concentration of doxorubicin in tumor cells by inhibiting glutamate transporters (77323, 77330). Theanine seems to enhance the effects of doxorubicin on drug sensitive and multi-drug resistant tumors (7688, 8668, 8669). Theanine may also enhance the suppressive action of doxorubicin on metastatic tumors (8312). Animal research also shows that theanine decreases doxorubicin-induced toxicity related to oxidative damage by increasing glutamate concentrations (53718). Theanine also appears to decrease diarrhea and loss of appetite and improve rates of chemotherapy completion in patients with colon cancer (96334).\n\nAnimal research shows that theanine inhibits the efflux of pirarubicin from ovarian cancer cells (77321). Similarly, theanine inhibits the efflux of idarubicin from leukemia cells in animal models (7689). Additionally, theanine seems to decrease the toxicity of idarubicin by reversing adverse effects on leukocytes and bone marrow cells (7689).\nAntidepressant effects\nL-theanine resembles L-glutamate in structure, and competes with glutamate at its receptors, although it has a lower affinity for these receptors. It is likely that L-theanine's antidepressant effects are related to its effects on the glutamate pathway, regulating the amounts of glutamate and glutamine in the brain (96331). In animals, supplementation with L-theanine leads to recovery of impairment and augmentation of synaptic plasticity in the brain. Glutamate signaling regulates synaptic plasticity, and it is speculated that L-theanine's effects on depression could thus be related to its effect on synaptic plasticity (96331).\nAntioxidant effects\nAfter absorption, L-theanine breaks down to glutamic acid and ethylamine. Within the cell, cysteine and glutamic acid are combined with glycine to form the antioxidant glutathione (GSH). L-theanine's effect on attenuating toxicity secondary to chemotherapy is thought to be secondary to increases in intracellular GSH concentrations within organs that are affected by chemotherapy (96334).\nAnxiolytic effects\nL-theanine's anxiolytic effects might be due to its effects on glutamate receptors and the possibility it increases inhibitory neurotransmitters such as glycine or gamma-aminobutyric acid (GABA) (96331).\nAttention effects\nL-theanine, alone and in combination with caffeine, has been studied for its effects on alpha-wave activity as a measure of attention. L-theanine appears to increase alpha activity when measured during rest. In clinical research, a lower dosage of L-theanine did not significantly decrease tonic (background) alpha, indicating a possible dose-dependent effect. Consuming either L-theanine or caffeine alone was no different than placebo. However, when L-theanine 100 mg was combined with caffeine 50 mg, tonic alpha decreased significantly (96338).\nCardiovascular effects\nThere is interest in using theanine for hypertension. In animal models, theanine decreases norepinephrine levels (7686, 77339), which decreases systolic and diastolic blood pressure (7687, 8670, 77354). However, preliminary clinical research in healthy adults shows that taking a one-time dose of L-theanine 200 mg does not reduce blood pressure or heart rate when compared with placebo (104142). There is some evidence that theanine might induce an excitatory effect when used in very small doses, suggesting that the effects of theanine may be dose-dependent (8665).\n\nSome research shows that theanine suppresses the stimulant effects of caffeine (7685, 8665, 36435). However, other studies have not demonstrated this antagonistic effect (38116, 91748).\n\nGreen tea, which contains L-theanine, might prevent atherosclerosis by inhibiting the proliferation of smooth muscle cells in blood vessel walls. However, theanine doesn't seem to affect smooth muscle (8666). There is evidence to suggest theanine might prevent the development of atherosclerosis by inhibiting lipid peroxidation of low-density lipoproteins (LDL) (8667).\nCognitive effects\nL-theanine seems to have some effects on cognitive function. In animals, supplementation with L-theanine lead to recovery of impairment and augmentation of synaptic plasticity in the brain. Glutamate signaling regulates synaptic plasticity, and it is speculated that theanine's effects on cognition could thus be related to its effect on synaptic plasticity (96331). Theanine may also affect alpha and theta wave activity. Increases in alpha power indicate relaxation (96335, 96336), whereas increases in theta power tend to indicate cognitive alertness. In clinical research, taking a product containing L-theanine and green tea extract (LGNC-07, LG Household & Health Care, Ltd) increased theta power when patients had their eyes open and when they were reading, but decreased theta power when patients had their eyes closed (96339). Other clinical research in healthy, moderately stressed adults shows that taking a single dose of a specific product (Alphawave; Ethical Naturals) containing L-theanine 200 mg prior to a stress-inducing test increases alpha power when patients have their eyes open, but does not affect theta power, when compared with placebo (108554).\n\nL-theanine also appears to protect against the toxic effects of caffeine and may inhibit the excitatory effects of caffeine at higher doses allowing for improved performance on certain cognitive tests (96336, 96341).\nImmunomodulating effects\nIn vitro research shows that L-theanine may help the body's immune system response when fighting infection by boosting the disease-fighting capacity of gamma-delta T cells (54021, 77329).\n\nTheanine is also a precursor of glutamate, and when combined with cystine (a dipeptide of cysteine), may increase glutathione concentrations. Glutathione levels may correlate with the activity of natural killer (NK) cells and regulate inflammatory responses in neutrophils. Theanine also induces priming of peripheral blood gamma-delta T cells (96332, 96333). It is thought that resistance training and prolonged exercise lead to negative effects on the immune system including decreased lymphocyte proliferation and NK cell activity. Clinical research shows that ingestion of a combination product containing L-cystine 700 mg and L-theanine 280 mg (Ajinomoto Co., Inc.) may attenuate decreases in NK cell activity seen in the placebo group, when individuals are exposed to high-intensity and high-frequency exercise (96332). It may also attenuate increases in C-reactive protein and neutrophils (96333). However, supplementation with this combination did not appear to affect plasma interleukin-6 (IL-6), IL-8, serum immunoglobulin M (IgM), leucocyte count, salivary IgA levels, or lymphocyte proliferation activity compared to placebo (96332, 96333).\nNeurologic/CNS effects\nL-theanine has been used for its purported relaxing and anti-anxiety effects. It's thought that L-theanine might work for anxiety by increasing levels of GABA and serotonin (12188, 36439, 91750). L-theanine is also thought to work for stress-induced anxiety by reducing the release of glutamate, an excitatory neurotransmitter (91745).\n\nL-theanine inhibits the reuptake of glutamate and is a glutamate receptor antagonist in the hippocampus. In animals, L-theanine may be neuroprotective via actions on the GABAA receptor (96337).\n\nThere is interest in using L-theanine for dementia. Levels of glutamate increase and cause neuronal death during periods of cerebral ischemia. L-theanine demonstrates a protective effect by decreasing ischemic neuronal death in the forebrains of animal models (7685, 77342). The antagonistic effects of L-theanine on glutamate and N-methyl-D-aspartate (NMDA) receptors might provide neuroprotection (7685, 77328).\n\nThere is interest in using L-theanine for schizophrenia or schizoaffective disorder given its antioxidant, neuroprotective, and relaxant effects. L-theanine has been reported to have antioxidant effects in vitro, via inhibition of low-density lipoprotein (LDL) oxidation. L-theanine is considered to be neuroprotective and may protect against cerebral ischemia, glutamate toxicity, and may stimulate the release of nerve growth factor. It may decrease glutamate reuptake through inhibition of the glutamate transporter. Research in animals suggests the neuroprotective effects of theanine are due to its ability to block N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and GABAA receptors. L-theanine is structurally similar to glutamate and may act as a gamma-aminobutyric acid (GABA) agonist and increase GABA levels in the brain, leading to relaxation. GABA then can influence levels of dopamine and serotonin. Also, L-theanine simulates the production of alpha waves in the brain also leading to relaxation and mental alertness (96341). Theanine also appears to lower cortisol production through relaxation and reduction of stress (96342).\n\nIn clinical research, treatment with L-theanine 400 mg daily for 8 weeks improved anxiety and positive symptoms of schizophrenia and schizoaffective disorder (96341, 96342). Further research suggests there is an association between the beneficial effects of L-theanine on clinical symptoms and brain-derived neurotropic factor (BDNF) and the cortisol to dehydroepiandrosterone sulfate (DHEAS) ratio (96342). BDNF has multiple effects on the development of neurons. It is also involved in neuronal survival and the plasticity of synapses of various neurons in the central nervous system including dopaminergic, cholinergic, and serotonergic. In research, decreases in BDNF were associated with improvements in the reduction of dysphoric mood and anxiety. The ratio of cortisol to DHEAS (or dehydroepiandrosterone) is used to detect the balance between anabolic and catabolic processes in mental disorders. In research, increases in the cortisol to DHEAS*100 molar ratio was associated with improvements in positive symptoms scores, specifically activation and dysphoric mood. Decreases in this ratio were associated with a reduction in anxiety scores. These changes may mediate the effects of L-theanine on clinical symptoms, but the true meaning of these associations is unknown. Also, levels of serum insulin, cholesterol, cortisol, DHEA, nor DHEAS did not predict improvement in clinical symptoms.\n\nThere is also interest in using L-theanine for depression. Animal research shows that L-theanine might decrease serotonin and 5-hydroxyindole acetic acid (5HIAA) concentrations in the brain. L-theanine might enhance the degradation of serotonin, and it might also directly inhibit the enzyme responsible for serotonin synthesis (7687, 8670, 77354). Theoretically, theanine may compete with glutamate and/or increase plasma gamma-aminobutyric acid (GABA) levels (96331, 96334). Preliminary clinical research in adults with depression has found that increases in plasma GABA levels may be associated with very short-term improvement in response to treatment with selective serotonin reuptake inhibitors (SSRIs). However, these associations have not been consistently replicated (109010, 109011).\n\nThe effects of theanine on depression, alone or in combination with SSRIs, have not been studied. However, preliminary clinical research in adults with mild depression shows that taking L-theanine 250 mg orally for 8 weeks reduces symptoms and improves sleep quality when compared with baseline (96331).\nWeight loss effects\nAnimal research suggests L-theanine may act synergistically with caffeine and other constituents in green tea to cause weight loss (11960). In animals, L-theanine increases liver glycogen synthesis and reduces gluconeogenesis (101987)."
        }
    },
    "Thiamine": {
        "sections": {
            "Overview": "Thiamine is a water-soluble B vitamin. Thiamine is not made endogenously in humans, therefore it needs to be consumed in the diet or taken as a supplement (77494). Thiamine is frequently used in combination with other B vitamins in vitamin B complex formulations (15).",
            "Safety": "LIKELY SAFE when used orally and appropriately. A tolerable upper intake level (UL) has not been established for thiamine, and doses up to 50 mg daily have been used without adverse effects (15, 6243). ...when used intravenously or intramuscularly and appropriately. Injectable thiamine is an FDA-approved prescription product (15, 105445).\nCHILDREN: LIKELY SAFE when used orally and appropriately in dietary amounts. A tolerable upper intake level (UL) has not been established for healthy individuals (6243).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in dietary amounts of 1.4 mg daily. A tolerable upper intake level (UL) has not been established for healthy individuals (3094, 6243).",
            "Adverse Effects": "General\nOrally and parenterally, thiamine is generally well tolerated.\nSerious Adverse Effects (Rare)\nParenterally: Hypersensitivity reactions including angioedema and anaphylaxis.\nImmunologic\nOrally, thiamine might rarely cause dermatitis and other allergic reactions. Parenterally, thiamine can cause anaphylactoid and hypersensitivity reactions, but this is also rare (<0.1%). Reported symptoms and events include feelings of warmth, tingling, pruritus, urticaria, tightness of the throat, cyanosis, respiratory distress, gastrointestinal bleeding, pulmonary edema, angioedema, hypotension, and death (15, 35585, 105445).\n\nIn one case report, a 46-year-old female presented with systemic allergic dermatitis after applying a specific product (Inzitan, containing lidocaine, dexamethasone, cyanocobalamin and thiamine) topically by iontophoresis; the allergic reaction was attributed to thiamine (91170).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nEFFECTIVE\nThiamine deficiency. Oral thiamine prevents and treats thiamine deficiency syndromes.\nThiamine deficiency is treated with oral thiamine 5-30 mg daily as a single dose or in divided daily doses for one month. For severe deficiency, thiamine up to 300 mg daily can be used (15).Thiamine deficiency can occur in people with malabsorption conditions such as alcohol use disorder, cirrhosis, and gastrointestinal diseases; in those with inadequate intake due to anorexia, nausea, and vomiting; and in those with increased requirements, including pregnancy, increased carbohydrate intake, increased physical activity, hyperthyroidism, infection, and liver disease. However, deficiency is rare with these conditions (15). The elderly might also be at increased risk for subclinical thiamine deficiency (11076).\nless\nWernicke-Korsakoff syndrome (WKS). Parenteral thiamine is effective for treating symptoms of WKS.\nParenteral administration of thiamine 5-200 mg daily for 2 days decreases the risk of developing WKS and decreases symptoms of WKS in acute alcohol withdrawal. Between 30% and 80% of alcoholics are suspected to have thiamine deficiency (11075). An optimal dose for treating WKS has not been established; however, early research suggests that a 200 mg intramuscular dose may be more effective than lower doses (11075). In contrast, a moderate-sized clinical trial in adults with a history of heavy alcohol use who were asymptomatic or symptomatic for WKS shows that there is no benefit to administering high doses (300 mg 3 times daily) compared with medium (100 mg 3 times daily) or low (100 mg daily) doses of parenteral thiamine on cognitive or neurological functioning (111690). The study may have been inadequately powered to detect a difference between groups.\nless\nPOSSIBLY EFFECTIVE\nDysmenorrhea. Oral thiamine might reduce pain in some patients with dysmenorrhea.\nA clinical study in adolescent Iranian females with dysmenorrhea shows that taking thiamine 100 mg alone or along with fish oil 500 mg daily for 2 months moderately reduces pain intensity and duration when compared with placebo (89341). Another preliminary clinical study in Indian females 12-21 years of age with moderate to severe primary dysmenorrhea shows that taking thiamine 100 mg daily for 90 days eliminates pain in 87% of participants when compared to baseline (77820). The validity of this finding is limited by the lack of a placebo group. Furthermore, available research was conducted in India and Iran, so it is unclear if these findings are generalizable to other geographic locations.\nless\nPOSSIBLY INEFFECTIVE\nCoronary artery bypass graft (CABG) surgery. Intravenous thiamine does not seem to improve outcomes after CABG surgery.\nA small clinical study in adults undergoing CABG surgery with cardiopulmonary bypass shows that giving intravenous thiamine 200 mg immediately prior to surgery and immediately after surgery does not improve clinical outcomes or lactate levels when compared with placebo (97010). Larger doses of thiamine also don't seem to be beneficial. Another small clinical study in patients receiving CABG with cardiopulmonary bypass shows that giving thiamine 600 mg intravenously on the day of surgery, and 400 mg daily for three postoperative days, does not improve postoperative outcomes when compared with placebo (103000).\nless\nHeart failure. Most research suggests that oral or intravenous thiamine does not improve outcomes in patients with heart failure.\nObservational research suggests that having heart failure is associated with 2.5-fold increased odds of having thiamine deficiency, possibly because of diuretic use, intestinal malabsorption, and metabolism changes. However, it is unclear if thiamine supplementation is beneficial. A meta-analysis of 2 small clinical trials in adults with systolic heart failure and unclear thiamine status shows that thiamine 200-300 mg given orally or by IV for 7-28 days improves left ventricular ejection fraction (LVEF) by 3% when compared with control (97012). However, other meta-analyses and clinical studies in adults with heart failure with or without thiamine deficiency show that taking intravenous, intramuscular, or oral thiamine 100-500 mg daily does not improve LVEF fraction, left ventricular end-diastolic volume, dyspnea, mortality, hospitalization, or exercise tolerance when compared with placebo or control (103002, 111682, 111686, 111688).\nless\nMosquito repellent. Oral thiamine does not seem to repel mosquitos.\nClinical research in healthy volunteers shows that taking thiamine does not improve mosquito repellency when compared with taking vitamin C as a control (18016).\nless\nSepsis. Intravenous or oral thiamine, alone or in combination with vitamin C and hydrocortisone, does not seem to reduce mortality or prevent organ failure in sepsis or septic shock.\nMultiple meta-analyses of small clinical studies in patients with septic shock show that intravenous or oral thiamine 100-500 mg 2-3 times daily for 3-7 days is no better than placebo for improving mortality, end-organ damage, number of ventilator-free days, and duration of intensive care unit (ICU) stay (105443, 107717, 107727, 111689). One meta-analysis suggests that administration of thiamine alone increases the risk of mortality in these patients (111689). Subgroup analyses including only higher quality studies also fail to show a benefit of thiamine (107717). Another recent small clinical trial in patients with septic shock shows that receiving the same dose of intravenous thiamine does not increase vasopressor-free days when compared with placebo (105441).\n\nIntravenous thiamine 200 mg every 12 hours has also been evaluated in combination with intravenous vitamin C 1.5-2 grams and hydrocortisone 50-200 mg every 6-12 hours for 4-10 days (HAT therapy). While some retrospective research found HAT therapy to be beneficial (100315, 102980, 111689), high-quality, prospective clinical research has shown no benefit (105447, 109956, 111689). Meta-analyses in patients with sepsis and septic shock shows that receiving HAT therapy does not improve mortality, kidney injury, number of ventilator-free days, or ICU length of stay when compared with control (102129, 104027, 104028, 104032, 102998, 105447, 109956, 111642, 111689). Additionally, the meta-analyses suggest that HAT therapy does not reverse shock or improve sequential organ failure assessment (SOFA) scores (109556, 111642). However, one meta-analysis found that HAT therapy shortened the duration of vasopressor use when compared with placebo (111642). Long-term follow up from a study in patients with sepsis-induced respiratory and/or cardiovascular dysfunction shows that receiving HAT therapy does not improve cognitive, psychological, or functional status after 6 months and, for immediate memory scores and development of posttraumatic stress disorder, HAT therapy was less beneficial when compared with placebo (111299).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcute kidney injury (AKI). It is unclear if oral or intravenous thiamine is beneficial for treating or preventing AKI.\nObservational research in adults admitted to the intensive care unit (ICU) with AKI has found that treatment with thiamine (dose unspecified) within the first 48 hours of admission is associated with 39% lower odds of in-hospital mortality and 28% higher odds of kidney function recovery when compared with patients that did not receive thiamine. Receiving thiamine was also associated with a 0.5-day reduction in ICU length of stay (107719).\nless\nAge-related macular degeneration (AMD). It is unclear if oral thiamine is beneficial for AMD.\nThe National Health and Nutrition Examination Survey (NHANES) observational study has found that higher thiamine intake from foods and supplements is associated with a 38% lower relative odds of late AMD, but not early AMD, in adults 40 years and older when compared with lower intake (113552). However, observational studies in older adults have found no clear association between dietary thiamine intake and risk of early or late AMD over an average follow-up of 10 years (116749, 116750). It is unclear if these differing findings are due to the inclusion of thiamine supplements in the first study or due to other confounding factors.\nless\nAnxiety. Although there is interest in using oral thiamine for anxiety, there is insufficient reliable information about the clinical effects of thiamine for this purpose.\nCardiac arrest. It is unclear if intravenous thiamine reduces the risk of death after resuscitation from cardiac arrest.\nA small clinical study in adults resuscitated from cardiac arrest shows that receiving intravenous thiamine 100 mg every 8 hours for 7 days does not reduce 28-day mortality when compare with a normal saline placebo (105442).\nless\nCardiovascular disease (CVD). It is unclear if oral thiamine is beneficial for treating or preventing CVD.\nPopulation research in Korea has found that insufficient dietary thiamine intake (daily intake of less than 1.22 mg in males or 1.03 mg in females) is associated with a 16% increased odds of developing angina or myocardial infarction when compared with sufficient dietary thiamine. However, the effects of thiamine supplementation on CVD have not been studied (107725).\nless\nCarpal tunnel syndrome. Oral thiamine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical study in adults with mild to moderate carpal tunnel syndrome shows that taking a combination product containing thiamine along with alpha-lipoic acid, acetyl-L-carnitine, phosphatidylserine, turmeric, and vitamins C, E, B2, B6, and B12 twice daily for 60 days reduces symptom severity and pain, but does not improve measures of hand and wrist function, when compared with control (111702). The validity of this study is limited by the lack of blinding and dosing information. Additionally, it is unclear if the effects are due to thiamine, other ingredients, or the combination.\nless\nCataracts. Small studies suggest that increased dietary thiamine might help prevent cataracts.\nObservational research has found that a high dietary intake of thiamine 10 mg daily is associated with 40% lower odds of nuclear cataracts (6378). Other population research has found that higher dietary intake of thiamine is associated with a modestly reduced risk of age-related lens opacification (14301).\nless\nCervical cancer. It is unclear if oral thiamine reduces the risk of developing cervical cancer.\nEpidemiological research has found that increasing intake of thiamine from dietary and supplemental sources, along with folic acid, riboflavin, and vitamin B12, is associated with a lower odds of precancerous cervical lesions (11074).\nless\nChild development. It is unclear if supplementing breastfeeding females with oral thiamine improves infant neurocognitive development.\nPreliminary clinical research shows that supplementing breastfeeding females with oral thiamine, 1.2-10 mg daily for 22 weeks, starting at 2 weeks postpartum, does not improve most cognitive or neurodevelopmental scores in the child when compared with placebo. However, one subgroup analysis suggests that thiamine supplementation may improve language scores (107726).\nless\nCognitive function. Oral thiamine has only been studied in combination with other ingredients; its effect when used alone is unclear.\nObservational research in adults 60 years and older has found that higher dietary thiamine intake is associated with better cognitive function when compared with lower intake (116112). However, a clinical study in healthy, middle-aged adults shows that taking a combination product containing thiamine hydrochloride 50 mg, other group B vitamins, bacopa, and ginkgo daily for 12 weeks does not improve measures of memory, attention, cognition, mood, or stress reactivity when compared with placebo (111334).\nless\nCoronavirus disease 2019 (COVID-19). It is unclear if intravenous or oral thiamine improves clinical outcomes in patients hospitalized with COVID-19.\nA small observational study of adults admitted to the intensive care unit with COVID-19 has found that treatment with intravenous or oral thiamine 100 mg daily for an average of 7 days is associated with a 63% reduction in the odds of death within 30 days when compared with control. However, there was no associated reduction in duration of hospitalization or mechanical ventilation (107721). In addition, a small observational study of adults with encephalopathy that were mechanically ventilated secondary to COVID-19 has found that taking thiamine 500 mg three times daily orally for 5 days improves neurological manifestations, including ophthalmoparesis and ataxia, when compared with baseline. The validity of this study is limited by the lack of a comparator group (107722).\nless\nCritical illness (trauma). It is unclear if oral or intravenous thiamine is beneficial in patients with critical illness.\nA meta-analysis of critically ill patients shows that treatment with oral or intravenous thiamine 100-600 mg daily for up to 7 days does not affect the need for mechanical ventilation, duration of hospital stay, or mortality when compared with control (107727).\nless\nDelirium. It is unclear if oral or intravenous thiamine helps to prevent or treat delirium.\nIn critically ill patients, a meta-analysis of clinical research shows that treatment with oral or intravenous thiamine 100-600 mg daily for up to 7 days reduces the odds of developing delirium by 42% when compared with control (107727). However, some observational research in adults with septic shock has found that receiving intravenous thiamine 400 mg daily with vitamin C 6 grams daily, both in divided doses, is not associated with reduced delirium when compared with control (103001).\n\nIn non-critically ill, hospitalized adults with altered mental status, retrospective, observational research has also found that administration of oral or intravenous thiamine is not associated with improved cognitive function or reduced in-hospital mortality when compared with control (107723). Preliminary clinical research in adults undergoing an allogeneic hematopoietic stem cell transplant also shows that administering thiamine 200 mg three times a day intravenously for 7 days does not prevent delirium or shorten duration of delirium when compared with placebo (107718).\nless\nDementia. It is unclear if oral thiamine is beneficial for the prevention of dementia.\nObservational research in patients with alcohol use disorder has found that taking thiamine is associated with a 24% to 46% lower risk of developing dementia when compared with not taking thiamine (102999).\nless\nDepression. It is unclear if oral thiamine is beneficial in patients with depression.\nMeta-analyses of population research in adults has found that high dietary consumption of thiamine is associated with a 10% to 31% lower risk of having depression when compared with low dietary consumption of thiamine. However, this research did not evaluate the effects of thiamine supplementation on depression (107133, 107725). One small clinical study in adults with major depressive disorder shows that taking thiamine 300 mg daily in conjunction with fluoxetine 20 mg daily leads to greater improvements in depressive symptoms at 6 weeks when compared to fluoxetine with placebo. This benefit was no longer present at 12 weeks. This suggests that thiamine may accelerate improvement in symptoms during initiation of fluoxetine therapy (97013).\nless\nDiabetes. It is unclear if oral thiamine is beneficial for type 2 diabetes or gestational diabetes.\nA meta-analysis of 6 clinical studies in adults with type 2 diabetes shows that taking thiamine 100-300 mg or its derivative benfotiamine 120-900 mg daily for 1-3 months does not reduce glycated hemoglobin (HbA1c), fasting blood glucose, or postprandial blood glucose when compared with placebo (111681). A large, prospective cohort study in adults without type 2 diabetes suggests that the risk of new-onset diabetes is minimized in adults consuming thiamine 0.75-1.10 mg daily from the diet, while lower and higher thiamine intake levels are associated with an increased risk of new-onset diabetes (111685).\n\nThiamine has also been studied for preventing gestational diabetes. A large, prospective cohort study in pregnant adults suggests that higher supplementation with thiamine during the first and second trimesters is associated with a lower risk of gestational diabetes when compared with lower levels of total thiamine intake. However, this effect was not found for dietary intake of thiamine, only supplementation. Additionally, the participants were mostly Han Chinese adults, limiting the generalizability of the findings to other populations (111680).\nless\nDiabetic nephropathy. It is unclear if oral thiamine is beneficial for diabetic nephropathy.\nA small clinical study in patients with early-stage diabetic nephropathy and microalbuminuria shows that taking thiamine 100 mg three times daily for 3 months decreases urinary albumin excretion, but does not affect glomerular filtration rate (GFR), when compared with placebo (16556).\nless\nDiabetic neuropathy. Although there is interest in using oral thiamine for diabetic neuropathy, there is insufficient reliable information about the clinical effects of thiamine for this condition.\nDry eye. Oral thiamine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with dry eye suggests that adding unspecified doses of thiamine and mecobalamin to treatment with daily artificial tears and corticosteroid drops might slightly improve overall symptoms when compared with only artificial tears and corticosteroid drops for 1 month. There were no differences between groups at 2 months (105444). This finding is limited due to incomplete reporting and a lack of adjustment for multiple hypothesis testing.\nless\nDyslipidemia. It is unclear if oral thiamine is beneficial for treating or preventing dyslipidemia.\nA meta-analysis of 3 clinical studies in adults with type 2 diabetes shows that taking thiamine 100-300 mg or its derivative benfotiamine 120-900 mg daily for 1-3 months does not improve low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides when compared with placebo (111681). Observational research in Korea suggests that insufficient dietary thiamine intake (daily intake of less than 1.22 mg in males or 1.03 mg in females) is associated with 10% higher odds of developing dyslipidemia when compared with sufficient dietary thiamine intake. However, the effects of thiamine supplementation on dyslipidemia have not been studied (107725).\nless\nEmergence delirium. It is unclear if intravenous thiamine helps to prevent emergence delirium in patients after surgery.\nOne clinical study in adults in the intensive care unit (ICU) after gastrointestinal surgery shows that receiving intravenous thiamine 200 mg daily for 3 days is associated with up to 84% lower odds of emergence delirium on the first two days, but not on the third day, when compared with a normal saline control (105440).\nless\nFatigue. It is unclear if oral thiamine is beneficial in patients with fatigue.\nA small clinical crossover study in patients with chronic fatigue and inflammatory bowel disease (IBD) shows that taking thiamine 600-1800 mg daily for 20 days reduces fatigue scores when compared with placebo (105438). Taking oral thiamine 300 mg daily for an additional 12 weeks did not seem to affect fatigue scores when compared with placebo. However, an observational follow-up study found that those who self-continued thiamine for an additional 24 weeks after the study ended reported lower fatigue scores when compared with those who did not self-continue thiamine (107720).\nless\nGlaucoma. Although there is interest in using oral thiamine for glaucoma, there is insufficient reliable information about the clinical effects of thiamine for this condition.\nHerpes zoster (shingles). It is unclear if subcutaneous thiamine is beneficial in patients with shingles.\nA small clinical trial shows that receiving subcutaneous thiamine 100 mg injections six times weekly for 4 weeks reduces itching by at least 30% in 67% of patients with herpes zoster. However, thiamine does not appear to significantly reduce pain in most patients (90396).\nless\nHypertension. It is unclear if oral thiamine is beneficial in treating or preventing hypertension.\nPopulation research in Korea has found that insufficient dietary thiamine intake (daily intake of less than 1.22 mg in males or 1.03 mg in females) is associated with a 5% increased odds of developing hypertension when compared with sufficient dietary thiamine. However, the effects of thiamine supplementation on hypertension have not been studied (107725).\nless\nImpaired glucose tolerance (prediabetes). It is unclear if oral thiamine is beneficial in patients with prediabetes.\nA very small clinical trial in patients with prediabetes shows that taking thiamine 100 mg by mouth three times daily for 6 weeks modestly decreases 2-hour postprandial plasma glucose levels when compared to baseline and decreases fasting blood glucose levels when compared with placebo (91168).\nless\nKidney failure. Oral thiamine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary, low-quality, clinical research in adults with kidney failure undergoing regular hemodialysis shows that taking oral thiamine 90 mg daily with folic acid 30 mg daily for 96 weeks reduces overall mortality by 67% and improves cognitive scores by 31% when compared with no intervention (107724). It is unclear if this effect is due to thiamine, folic acid, or the combination.\nless\nMigraine headache. It is unclear if dietary thiamine is beneficial for the prevention or treatment of migraine headache.\nA large, retrospective, cross-sectional study suggests that higher dietary intake of thiamine is associated with lower odds of severe headache or migraine, especially in females (111684). The validity of these effects is limited by the subjective outcome measures and retrospective study design.\nless\nPain (acute). Oral thiamine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical study in adults with acute cervical sprains shows that taking thiamine 100 mg, vitamin B12 0.5 mg, vitamin B6 50 mg, and dexketoprofen 25 mg 3 times daily for 7 days modestly reduces pain scores and disability at days 3, 5 and 7 when compared with dexketoprofen alone (115689). It is unclear whether these improvements are clinically significant, as well as whether any effects are due to thiamine, other ingredients, or the combination.\nless\nPneumonia. It is unclear if thiamine is beneficial for patients with pneumonia.\nA large retrospective cohort study in adults hospitalized with pneumonia and active alcohol use disorder suggests that parenteral administration of thiamine is associated with reduced 14-day mortality and more frequent discharges home, but not a shorter length of stay or fewer ICU transfers, when compared with no thiamine use. Furthermore, parenteral thiamine doses above 200 mg do not appear to improve mortality but may be associated with longer length of stay and less frequent discharges home when compared with low oral doses of thiamine or parenteral thiamine at doses under 200 mg (111679). The validity of these effects is limited by the retrospective study design.\nless\nVentilator-associated pneumonia (VAP). It is unclear if oral or parenteral thiamine is beneficial for patients with VAP.\nA retrospective study in adults with VAP in the intensive care unit (ICU) suggests that supplementation with intravenous or oral thiamine may be associated with reduced ICU and in-hospital mortality (111683). The validity of these effects is limited by the retrospective study design.\nless\nMore evidence is needed to rate thiamine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: In adults, the daily recommended dietary allowance (RDA) for thiamine is 1.2 mg for males 18 years and older, 1 mg for females 18 years of age, and 1.1 mg for females 19 years and older. The RDA during pregnancy and lactation is 1.4 mg (6243). See Effectiveness section for condition-specific information.\n\nCertain foods might reduce the bioavailability of thiamine in the body. Excessive ingestion of tannins, such as in coffee and tea, can convert thiamine into a form that cannot be absorbed (9535, 10539, 10540, 10544). Although this interaction has been linked to thiamine deficiency in a rural Thai population consuming more than 1 liter of tea daily and/or chronically chewing fermented tea leaves (10537, 10538), people with adequate thiamine and vitamin C consumption do not seem to be at risk for deficiency (10538, 10539, 10540).\n\nAdditionally, frequent ingestion of raw fish or shellfish can contribute to thiamine deficiency. Raw seafood contains thiaminase enzymes, which degrade thiamine (9535, 10537, 10538). Since these enzymes are destroyed by heat, consumption of cooked seafood does not affect thiamine levels.\nParenterally:Thiamine has been used in intramuscular, intravenous, and subcutaneous formulations. See Effectiveness section for condition-specific information.\nChildren\nOral:\nGeneral: For infants, the daily adequate intake (AI) for thiamine is 0.2 mg for 0-6 months of age and 0.3 mg for 7-12 months of age. For older children, the daily recommended dietary allowance (RDA) is 0.5 mg for 1-3 years of age, 0.6 mg for 4-8 years of age, 0.9 mg for 9-13 years of age, 1.2 mg for males 14-17 years of age, and 1 mg for females 14-18 years of age (6243).\nStandardization & Formulation\nIn foods, thiamine is typically present as thiamine diphosphate. In supplements, thiamine is often present as thiamine hydrochloride or thiamine mononitrate (94194).",
            "Interactions with Drugs": "TRIMETHOPRIM (Proloprim)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nINSIGNIFICANT\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTrimethoprim might increase blood levels of thiamine.\nIn vitro, animal, and clinical research suggest that trimethoprim inhibits intestinal thiamine transporter ThTR-2, hepatic transporter OCT1, and renal transporters OCT2, MATE1, and MATE2, resulting in paradoxically increased thiamine plasma concentrations (111678).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nBETEL NUT\nChronic, regular chewing of betel nuts may increase the risk of thiamine deficiency.\nBetel nuts reduce thiamine activity, probably by chemical inactivation (10537, 10538, 35332).\nless\nHORSETAIL\nHorsetail might degrade thiamine and increase the risk of deficiency.\nHorsetail (Equisetum) contains a thiaminase-like compound that can destroy thiamine in the stomach and theoretically cause symptomatic thiamine deficiency (10573). The Canadian government requires that equisetum-containing products be certified free of thiaminase activity (10573). Avoid use of horsetail in people at risk for thiamine deficiency.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nALCOHOL USE DISORDER\nAlcohol use disorder increases the risk of thiamine deficiency. Patients with alcohol use disorder often have low levels of thiamine due to decreased intake, impaired absorption, and decreased storage of water-soluble vitamins. Thiamine deficiency also seems to contribute to alcohol-induced peripheral neuropathy (11075, 11077).\nless\nHEMODIALYSIS\nPatients receiving hemodialysis seem to be at risk for thiamine deficiency. Thiamine supplementation may be needed in these patients (11053).\nless\nLIVER DISEASE\nChronic liver disease, especially cirrhosis, increases the risk of thiamine deficiency, regardless of alcohol use. Patients with liver disease often have impaired thiamine absorption and storage which increases the risk of deficiency (105439).\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nSERUM THEOPHYLLINE\nLarge amounts of thiamine can interfere with Schack and Waxler spectrophotometric determination of serum theophylline concentrations (15).\nless\nURIC ACID\nThiamine can cause false positive results in the phosphotungstate method for uric acid determination (15).\nless\nUROBILINOGEN\nThiamine can cause false positive results in the urine spot test with Ehrlich's reagent for urobilinogen (15).\nless",
            "Nutrient Depletions": "5-FLUOROURACIL\nDepletion Rating\nINSUFFICIENT EVIDENCE\nClinical significance is not known.\nTheoretically, 5-fluorouracil might reduce thiamine activation.\nPeople receiving 5-fluorouracil-containing chemotherapy regimens may be at risk for thiamine deficiency. 5-fluorouracil might interfere with activation of thiamine or increase its breakdown (10552). However, there isn't enough research to recommend routine thiamine supplementation. Thiamine deficiency has been reported with other chemotherapy regimens, but this is likely due to reduced dietary intake associated with cancer and its treatment (10553, 10554).\nless\nANTIBIOTIC DRUGS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nTheoretically, antibiotics might reduce thiamine absorption; however, this is not likely to be clinically significant.\nInterference with the normal gastrointestinal flora by antibiotics may reduce bacterial synthesis of thiamine. However, the majority of the daily thiamine requirement is obtained from the diet, rather than synthesis by the GI flora (9502). Therefore, this isn't likely to be clinically significant, and thiamine supplements aren't necessary.\nless\nCONTRACEPTIVE DRUGS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nTheoretically, contraceptive drugs might reduce thiamine absorption; however, this is not likely to be clinically significant.\nSome studies have reported a small reduction in activity of the thiamine-dependent enzyme erythrocyte transketolase in females taking oral contraceptives, suggesting mild thiamine deficiency (10548, 10555). However, other studies have found no effect (10527, 10556). Routine use of thiamine supplements with oral contraceptives isn't necessary.\nless\nDIURETIC DRUGS\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nHigh doses of diuretics can increase thiamine excretion and increase the risk of deficiency.\nIncreased urinary thiamine excretion and thiamine deficiency may occur in some people treated with diuretics, especially in high doses (e.g., more than 80 mg furosemide daily) for several months (1283, 1284, 1286, 10507, 10508, 91173). Although most case reports involve furosemide, animal data suggest that the effect may occur with any diuretic (10509). Diuretic-induced thiamine deficiency appears to be most common in elderly people with inadequate dietary intake and to be rare in people less than 60 years of age (1283, 10506, 10507). Thiamine deficiency in people taking diuretics is a concern because it might worsen heart failure (1284, 1285, 1286, 10507, 91173). Limited research suggests that supplementation with thiamine 200 mg daily may improve left ventricular ejection fraction and functional capacity in some thiamine-deficient people treated with high doses of furosemide for heart failure (1284, 1286, 10508). However, other studies have found no improvement (1285). It's too soon to recommend routine thiamine supplementation for people on prolonged, high-dose diuretic therapy. Monitor for thiamine deficiency.\nless\nMETFORMIN (Glucophage)\nDepletion Rating\nINSUFFICIENT EVIDENCE\nClinical significance is not known.\nTheoretically, metformin might reduce thiamine activity.\nThiamine is involved in the entrance of glycolytic pyruvate into the mitochondrial Kreb's cycle. Reducing thiamine activity might lead to increased amounts of pyruvate being converted to lactic acid. This effect might be responsible for some of the cases of lactic acidosis associated with metformin. This theoretical effect is based on preclinical animal research with phenformin, a similar drug that was produced prior to metformin (9536). This has not yet been substantiated in humans or with the use of metformin (11466).\nless\nPHENYTOIN (Dilantin)\nDepletion Rating\nINSUFFICIENT EVIDENCE\nClinical significance is not known.\nTheoretically, phenytoin might reduce thiamine levels.\nSome evidence suggests that chronic treatment with phenytoin might reduce levels of thiamine in plasma and cerebrospinal fluid, and reduce uptake of thiamine into nerve tissue (10510, 10511, 10512). Theoretically, this could contribute to side effects of phenytoin such as polyneuropathy and cerebellar ataxia (10510, 10511). However, it isn't clear whether affected patients also had other factors contributing to thiamine deficiency, such as dietary insufficiency. There isn't enough evidence to recommend routine thiamine supplementation.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with thiamine. A tolerable upper intake level (UL) for thiamine has not been established for healthy individuals (6243).",
            "Pharmacokinetics": "Absorption\nOrally, thiamine is absorbed at the proximal part of the small intestine. At smaller doses it is absorbed by active transport, and at higher doses it is absorbed by passive diffusion (77376).\nDistribution\nThiamine is distributed into the skeletal muscle, the heart, the liver, the kidneys, and the brain (77395).\nMetabolism\nThiamine is phosphorylated during intestinal uptake. Most of thiamine in the adult human body occurs as the metabolically active form thiamine diphosphate (thiamin pyrophosphate or TDP) (77806).\nExcretion\nThiamine and its metabolites are excreted in the urine, and urinary thiamine is used as a biomarker for the assessment of thiamine intake (77359, 77429, 77492, 77807).",
            "Mechanism of Action": "General\nThiamine is a water-soluble B-complex vitamin, previously known as vitamin B1 or aneurine. Dietary sources of thiamine include beef, brewer's yeast, legumes (beans, lentils), nuts, oats, pork, rice, seeds, wheat, whole-grain cereals, and yeast. Thiamine is also found in fruit (such as oranges), milk, and milk products (47094, 77372, 77482). In industrialized countries, foods made with white rice or white flour are often fortified with thiamine because most of the naturally occurring thiamine is lost during the refinement process. Thiamine is not endogenously synthesized in humans. Thiamine can be synthesized by prokaryotes, yeasts, and plants (35570, 77517, 77519).\n\nThiamine deficiency leads to decreased transketolase activity in erythrocytes and increased pyruvic acid concentration in the blood (15). Pyruvic acid is converted to lactic acid. Therefore, lactic acidosis can also occur in patients with thiamine deficiency (15). In Crohn's disease, decreased serum thiamine levels have been reported (6269).\nAnti-diabetic effects\nThiamine is required for carbohydrate metabolism. It combines with adenosine triphosphate (ATP) to form thiamine diphosphate, a coenzyme in carbohydrate metabolism, wherein the decarboxylation of pyruvic acid and alpha-ketoglutaric acid occurs. This coenzyme is also a part of transketolation reactions. Thiamine is also a coenzyme in the utilization of pentose in the hexose monophosphate shunt (15, 77473, 77499, 77502).\n\nPreliminary animal data also suggests thiamine deficiency in diabetics may exacerbate the development of diabetic nephropathy (11467). In diabetic nephropathy, it is thought that dysfunction of glomerular endothelial cells, podocytes, and tubular epithelial cells, may be reversed by increasing the plasma concentration of thiamine. This might improve glomerular and tubular structure and function and vascular inflammation thereby decreasing urinary albumin excretion (16556).\nCarcinogenic effects\nThiamine activates the transketolase enzyme which then may promote nucleic acid ribose synthesis and cancer cell proliferation (77371, 77834). It is unclear if thiamine intake should be limited in some cancer patients (77375, 77834).\nCardiovascular effects\nSevere thiamine deficiency can precipitate a specific type of heart failure called wet beriberi. Beriberi is characterized by anorexia; abdominal discomfort; constipation; peripheral neurologic changes; sleep disturbance; poor memory; and, sometimes, cardiovascular symptoms, including dyspnea, edema, palpitations, vasodilation, warm extremities, and high output cardiac failure (3041). Beriberi can be reversed by thiamine supplementation.\n\nThiamine may also be beneficial for other types of heart failure. Thiamine deficiency can occur due to cardiomyopathy, heart failure, and medications commonly given to heart failure patients (44141, 44090, 56398, 77358, 77385, 77476, 77494, 97012).\n\nSome research shows that thiamine may improve endothelium-dependent vasodilatation (EDV) in healthy, prediabetic, and diabetic patients which may in turn prevent cardiovascular complications (77473). Other clinical research shows that taking thiamine 100 mg three times daily for 6 months results in mild decreases in diastolic blood pressure from baseline in normotensive patients with hyperglycemia (91169).\n\nSome research has evaluated the use of thiamine in improving outcomes after coronary artery bypass graft (CABG) surgery. The parenteral administration of thiamine before and after surgery does not improve clinical outcomes, lactate levels, or pyruvate dehydrogenase (PDH) levels in patients with or without low thiamine levels undergoing CABG surgery. However, thiamine administration was associated with increased global oxygen consumption and basal cellular oxygen consumption, although the significance of this finding is unclear (97010).\nInsect repellant\nThere is interest in using thiamine and other B vitamins as a repellent for mosquitos and other insects. The theory is that oral ingestion of thiamine produces an odor detectable by mosquitos that repels them. However, there is no reliable evidence that thiamine works for this use (18016).\nMetabolic effects\nSome experts state that taking thiamine 10-20 mg daily (up to 600-4000 mg daily for Leigh syndrome) might help to temporarily correct metabolic disorders associated with genetic diseases such as subacute necrotizing encephalopathy (SNE, Leigh syndrome), maple syrup urine disease (branched-chain aminoacidopathy), and lactic acidosis associated with pyruvate carboxylase deficiency and hyperalaninemia (15).\nNeurologic effects\nSyndromes associated with thiamine deficiency are beriberi and Wernicke-Korsakoff syndrome (WKS) (3041, 77830, 77838). WKS is characterized by confusion, aphonia, ataxia, nystagmus, ophthalmoplegia, and coma. It's often associated with chronic alcohol use disorder, in which thiamine deficiency occurs due to decreased intake, impaired absorption, and decreased storage of thiamine (11075). Ethanol also decreases the phosphorylation of thiamine, reducing its conversion to the active form (11077).\nRenal effects\nThere is some interest in the use of thiamine to prevent and treat acute kidney injury (AKI) secondary to sepsis. Pathophysiologic research has indicated that AKI may be associated with acute hypoxia of the renal cells due to anaerobic metabolism. It is hypothesized that thiamine supplementation may facilitate aerobic metabolism as a cofactor of pyruvate dehydrogenase (PDH). In one clinical study, supplementation with thiamine twice daily for 7 days was associated with a reduction in AKI, serum creatinine, and requirement for renal replacement therapy (97009).\nRespiratory effects\nThere is interest in using thiamine to treat mechanically ventilated, critically ill patients, who are often found to have thiamine deficiency. However, preliminary clinical research in mechanically ventilated adults in the intensive care unit shows that a single dose of thiamine 200 mg intravenously does not affect oxygen consumption or serum lactate levels when compared with placebo (107716)."
        }
    },
    "Threonine": {
        "sections": {
            "Overview": "Threonine is an essential amino acid, meaning that it is not synthesized by the body and must be obtained from the diet. In the diet, threonine is found in the greatest amounts in animal protein sources (94500). Although threonine exists in four different stereoisomers, only L-threonine is biologically active in humans (60072).",
            "Safety": "LIKELY SAFE when used orally in food amounts. Threonine as L-threonine in doses of 7-14 mg/kg daily (about 0.5-1 gram daily) has been suggested to be the minimum amount required to maintain a positive nitrogen balance in humans and is generally considered to be safe (60072, 94096).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts. Taking threonine in doses up to 4 grams daily for up to 12 months seems to be safe (681, 12056, 12057, 12059, 60069).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, threonine seems to be well tolerated.\nDermatologic\nOrally, skin rash has been reported in people who have taken threonine (681).\nless\nGastrointestinal\nOrally, some patients can experience minor gastrointestinal upset including diarrhea (12056). Other side effects reported in people who have taken threonine include flatus and constipation (681).\nless\nNeurologic/CNS\nOrally, headache has been reported in people who have taken threonine (681).\nless\nPulmonary/Respiratory\nOrally, rhinorrhea has been reported in people who have taken threonine (681).\nless\nOther\nOrally, a two-fold increase in serum ammonia levels occurred in one patient following administration of threonine 4 grams daily (681).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY INEFFECTIVE\nAmyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). Several small clinical studies suggest that oral threonine does not improve symptoms or slow the progression of ALS.\nSmall clinical trials show that taking threonine 2 grams daily for 7 days or 4 grams daily, divided into two or four doses, for up to 12 months does not seem to slow the progression of early-stage ALS or reduce symptoms when compared with placebo (681, 12057, 60069). There is also concern that threonine might actually worsen pulmonary function in these patients. The decline in forced vital capacity (FVC) associated with threonine therapy was about 2.5 times greater than that with placebo (681).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nFamilial spastic paraparesis (FSP). It is unclear if oral threonine is beneficial in patients with FSP.\nA small clinical study in patients with FSP shows that taking threonine 1.5 grams to 2 grams three times daily for 2 weeks slightly improves some measures of motor impairment and spasticity when compared with placebo. However, these improvements do not seem to be clinically significant (12059).\nless\nMultiple sclerosis (MS). It is unclear if oral threonine is beneficial in patients with MS.\nA small clinical study in individuals with inactive or slowly progressive MS shows that taking threonine 2.5 grams three times daily for 8 weeks does not significantly reduce spasticity when compared with placebo (60073).\nless\nSpasticity. It is unclear if oral threonine is beneficial in patients with spasticity.\nA small clinical study in patients with spasticity arising from spinal cord injuries, multiple sclerosis, or syringomyelia shows that taking threonine 2 grams three times daily for 2 weeks slightly improves leg muscle tone when compared with placebo (12056). However, methodological concerns limit the validity of this finding.\nless\nMore evidence is needed to rate threonine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nThreonine is most often used in doses of 1.5 grams to 2.5 grams three times daily for up to 8 weeks. A dose of up to 4 grams daily has been used for up to 12 months. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of threonine.",
            "Interactions with Drugs": "NMDA ANTAGONISTS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nMODERATE\nOccurrence\nLIKELY\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, threonine might decrease the effects of NMDA antagonists.\nThreonine increases central nervous system (CNS) glycine levels (12058). Glycine seems to bind a site on NMDA receptors and enhance the activity of the receptors (681, 12057).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nALANINE\nThe effects of threonine might be reduced when taken with alanine.\nThreonine might compete with other amino acids to cross the blood brain barrier into the central nervous system (CNS). Theoretically, high plasma levels of amino acids such as alanine might decrease how much threonine enters the CNS and therefore decrease its effectiveness (12058).\nless\nBRANCHED-CHAIN AMINO ACIDS\nThe effects of threonine might be reduced when taken with branched-chain amino acids.\nThreonine competes with other amino acids to cross the blood brain barrier into the central nervous system (CNS). Theoretically, high plasma levels of other amino acids might decrease how much threonine enters the CNS and therefore decrease its effectiveness (12058). The branch-chained amino acids include leucine, isoleucine, and valine.\nless\nPHENYLALANINE\nThe effects of threonine might be reduced when taken with phenylalanine.\nThreonine might compete with other amino acids to cross the blood brain barrier into the central nervous system (CNS). Theoretically, high plasma levels of amino acids such as phenylalanine might decrease how much threonine enters the CNS and therefore decrease its effectiveness (12058).\nless\nSERINE\nThe effects of threonine might be reduced when taken with serine.\nThreonine might compete with other amino acids to cross the blood brain barrier into the central nervous system (CNS). Theoretically, high plasma levels of amino acids such as serine might decrease how much threonine enters the CNS and therefore decrease its effectiveness (12058).\nless\nTRYPTOPHAN\nThe effects of threonine might be reduced when taken with tryptophan.\nThreonine might compete with other amino acids to cross the blood brain barrier into the central nervous system (CNS). Theoretically, high plasma levels of amino acids such as tryptophan might decrease how much threonine enters the CNS and therefore decrease its effectiveness (12058).\nless\nTYROSINE\nThe effects of threonine might be reduced when taken with tyrosine.\nThreonine might compete with other amino acids to cross the blood brain barrier into the central nervous system (CNS). Theoretically, high plasma levels of amino acids such as tyrosine might decrease how much threonine enters the CNS and therefore decrease its effectiveness (12058).\nless",
            "Interactions with Conditions": "AMYOTROPHIC LATERAL SCLEROSIS (ALS, Lou Gehrig's disease)\nThere is some concern that threonine might decrease pulmonary function in patients with ALS. Until more is known, use with caution. One study of patients with ALS shows that taking threonine 1 gram orally four times daily for 6 months significantly reduces forced vital capacity (FVC) when compared with placebo (681). However, more evidence is needed to determine if threonine was actually the cause of this adverse outcome.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with threonine.",
            "Pharmacokinetics": "Absorption\nFollowing oral ingestion, plasma threonine levels rise rapidly. Fasting levels of threonine are approximately 113 mcgMol/L (681). After 2 weeks of taking 6 grams daily, plasma threonine levels rose to an average of 498 mcgMol/L (12056). Peak levels of threonine occur within 2 hours following administration (681).",
            "Mechanism of Action": "General\nThreonine is an essential amino acid (94500).\nNeurological effects\nResearchers have investigated threonine as a potential treatment for spasticity and amyotrophic lateral sclerosis (ALS) because it is a precursor to glycine. Glycine is the major inhibitory neurotransmitter in the spinal cord. But glycine itself poorly penetrates the central nervous system (CNS). Threonine has better penetration of the CNS. Threonine seems to boost glycine levels in the spinal cord (681, 12056, 12058). But it doesn't significantly increase glycine levels in the brain (12058). In patients with spasticity, increasing glycine might reduce spasticity related to spinal cord injury (12056). ALS is theorized to be cause by excess excitatory amino acids in the CNS such as glutamate. Increasing the inhibitory neurotransmitter, glycine, is thought to counter these excitatory amino acids (681, 12057)."
        }
    },
    "Thuja": {
        "sections": {
            "Overview": "Thuja is an evergreen tree that grows up to 60 meters in height. It is native to Europe, and is also found throughout North America and East Asia (40888, 113415).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Thuja that is thujone-free has Generally Recognized As Safe (GRAS) status for use in foods in the US (4912).\nPOSSIBLY UNSAFE when used orally in medicinal amounts. Large doses of thuja have been reported to cause seizures, severe vomiting, organ toxicity, and death in some cases (6002, 40888).\nThere is insufficient reliable information available about the safety of thuja when used topically.\nPREGNANCY: LIKELY UNSAFE when used orally due to abortifacient activity (12); avoid using.\nLACTATION: LIKELY UNSAFE when used orally due to toxicity (11); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, large doses of thuja have been reported to cause toxicity involving headache, nervous agitation, seizures, gastric irritation, vomiting, abdominal pain, and diarrhea. Thuja toxicity has also been reported to cause liver damage, renal toxicity, and death in some cases (6002, 40888).\nDermatologic\nContact dermatitis, presenting as an itchy papular squamous eruption on the hands, developed in a 46-year-old female who handled thuja plants while gardening. It resolved when contact with thuja was avoided. The causative ingredient of thuja was identified as limonene (113415).\n\nIn one case report, a 5-year-old female presented with a papillary eccrine adenoma. In an effort to avoid excisional biopsy, an ointment containing thuja was applied to the lesion for 6 months, resulting in peripheral extension and central necrosis of the lesion, eventually necessitating complete excision (106048).\nless\nGastrointestinal\nOrally, large doses of thuja have been reported to cause toxicity involving gastric irritation, vomiting, abdominal pain, and diarrhea (6002, 40888).\nless\nHepatic\nOrally, large doses of thuja have been reported to cause toxicity involving liver damage and death (6002, 40888). In one case report, a healthy 40-year-old female taking thuja and black cohosh for 1 month presented with 3 days of severe abdominal pain and AST and ALT levels exceeding 5 times the upper limit of normal. Symptoms improved within 5 days of supplement discontinuation and levels normalized within 2 weeks (106047). It is unclear if this reaction was due to thuja, black cohosh, or other factors.\nless\nNeurologic/CNS\nOrally, large doses of thuja have been reported to cause toxicity involving nervous agitation, seizures, and death (6002, 40888).\nless\nRenal\nOrally, large doses of thuja have been reported to cause toxicity involving renal toxicity and death (6002, 40888).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCommon cold. Clinical research in patients with moderate cold symptoms shows that taking three tablets of a specific combination product (Esberitox, Schaper & Brmmer GmbH & Co. KG) containing dry extracts of echinacea root, thuja leaf, and wild indigo root three times daily for 7-9 days improves the severity of cold symptoms, general well-being, and overall response rate when compared with placebo (6392). It is unclear if these effects are due to thuja leaf, the other ingredients, or the combination.\nMore evidence is needed to rate thuja for this use.",
            "Dosing & Administration": "Adult\nOral:\nCommon cold: Three tablets of a specific product (Esberitox, Schaper & Brmmer GmbH & Co. KG) containing 3.2 mg per tablet of dry extract of wild indigo root, echinacea root, and thuja leaf, taken three times daily for 7-9 days, has been used (6392).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of thuja.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICONVULSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nThuja products can contain thujone, which might lower the seizure threshold (1304). Theoretically, this could decrease the effectiveness of anticonvulsants drugs.\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nThuja might stimulate immune function (1305). Theoretically, taking thuja might decrease the effects of immunosuppressive therapy. Immunosuppressant drugs include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), and other corticosteroids (glucocorticoids).\nSEIZURE THRESHOLD LOWERING DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nThuja products can contains significant amounts of thujone, a neurotoxin (1304). Theoretically, patients taking drugs that lower the seizure threshold might be at greater risk of seizure if they also take thuja. Advise patients taking these drugs to avoid thuja products. Some drugs that lower the seizure threshold include anesthetics (propofol, others), antiarrhythmics (mexiletine), antibiotics (amphotericin, penicillin, cephalosporins, imipenem), antidepressants (bupropion, others), antihistamines (cyproheptadine, others), immunosuppressants (cyclosporine), narcotics (fentanyl, others), stimulants (methylphenidate), theophylline, and others.",
            "Interactions with Supplements": "THUJONE-CONTAINING HERBS\nConcomitant use of thuja and other herbs containing thujone might increase the risk of thujone toxicity. Thujone-containing herbs include oak moss, oriental arborvitae, sage, tansy, tree moss, and wormwood (12).",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nAUTOIMMUNE DISEASES\nThuja might stimulate immune function (1305). Theoretically, thuja might exacerbate autoimmune diseases by stimulating disease activity. Advise patients with autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or others to avoid or use thuja with caution.\nless\nSEIZURE DISORDERS\nThuja contains thujone which can cause seizures. Theoretically, thuja might lower the seizure threshold and worsen seizure control in patients with seizure disorders (1304).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with thuja.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of thuja.",
            "Mechanism of Action": "General\nThe applicable parts of thuja are the leaf and the oil extracted from the leaf. Thuja leaf oil contains many constituents, including thujone, thujyl alcohol, borneol, camphene, limonene, myrcene, alpha-terpene, alpha terpinene, terpinolene, p-coumaric acid, umbelliferone, catechin, gallocatechin, kaempferol, kaempferol-3-O-alpha-rhamnoside, mearnsitrin, myricetin, myricitrin, procyanidins B-2 and B-3, prodelphinidin, quercetin, quercitrin, amentoflavone, afzelin, tannic acid, alpha-pinene, fenchone, isothujone, carvotanacetone, origanol, myricene, camphene, glycoproteins, and polysaccharides (40888, 113413, 113414, 113415).\nAnticancer effects\nIn animal research, thuja extract inhibited lung metastasis induced by melanoma cells (40890). In vitro, thuja extract demonstrated dose-dependent cytotoxic effects against several cancer cell lines, including breast, cervix, neuroblastoma, colon, liver, and prostate cancer (40891).\nAntidiabetic effects\nIn an animal model of diabetic neuropathy, hydroethanolic extracts of the aerial parts of thuja, given orally for 30 days, reduce fasting blood sugar, increase serum insulin, decrease advanced glycation end-products, increase pain resistance, and improve neuronal function. Thuja extract also reduces oxidative stress by increasing levels of superoxide dismutase, catalase, and glutathione, and reducing activity of inflammatory markers by binding to the active sites of interleukin (IL)-1-beta, IL-6, tumor necrosis factor alpha, and transforming growth factor-beta-1 (113414).\nAntiviral effects\nIn vitro, thuja polysaccharides dose-dependently inhibit HIV-1-specific antigen expression and HIV-dependent cell death (1305, 1306, 40888). In vitro, a water extract of thuja leaf has dose-dependent virucidal activity against influenza A virus. It inhibits binding and entry of the virus into cells, inhibits neuraminidase activity, reduces protein and RNA expression, and interferes with hemagglutination. The thuja extract ingredient with the strongest antiviral activity is amentoflavone, but other compounds are thought to act synergistically, including myricetin, quercetin, and quercitrin (113413).\nImmunological effects\nCertain constituents of thuja might have immunostimulant effects. In vitro, thuja polysaccharide g-fraction (TPSg) induces the CD4+ fraction of the human peripheral blood T cell subset and induces production of certain cytokines, including interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-alpha (1306, 40892, 40891). In vitro, thuja produces a concentration-dependent increase in the number of antibody-producing lymphocytes. The numbers of anti-sheep red blood cell-IgM-producing plasma cells and other immunoglobulin-secreting plasma cells also increase. Other in vitro research shows that thuja can increase nitric oxide production in macrophages in a concentration-dependent manner (40891). However, clinical research in 23 cancer patients shows that a combination product containing thuja does not affect cytokine production (40893).\nIrritant effects\nThuja is reported to have urinary tract irritant and uterine stimulant activity (12).\nNeurologic effects\nThujone, a constituent of thuja, is a neurotoxin that can cause convulsions (1304). It is thought to lower the seizure threshold through inhibition of GABA type A receptors (17078)."
        }
    },
    "Thunder God Vine": {
        "sections": {
            "Overview": "Thunder god vine is a perennial vine commonly grown in southeast China. Extracts are used in traditional and pharmaceutical Chinese medicine (97677, 97681, 97684, 97686, 97687, 97689, 97692). Traditional uses include inflammation and fever.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately (4046, 10231, 10674, 10675, 10676, 100825). Thunder god vine extract has been used with apparent safety at doses of up to 120 mg daily for up to 1 year (97678, 97681, 97683, 97684, 97685, 97687, 97688, 97692, 106276, 106277)(112874, 112875, 112876, 112877) or at doses of up to 2 mg/kg daily for up to 5 years (10231, 77923, 112877). ...when thunder god vine tincture is used topically and appropriately, short-term (10233).\nPREGNANCY: LIKELY UNSAFE when used orally. Thunder god vine is thought to be teratogenic (4047); avoid using.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, thunder god vine is generally well tolerated.\nMost Common Adverse Effects\nOrally: Diarrhea, dizziness, gastrointestinal upset, headache, leukopenia, menstrual irregularities, nausea, and skin redness.\nSerious Adverse Effects (Rare)\nOrally: Aplastic anemia, hypertension, infertility, kidney damage, liver dysfunction, myelosuppression, and tachyarrhythmias.\nCardiovascular\nOrally, thunder god vine has been associated with ventricular tachyarrhythmias (77918) and diastolic hypertension (10676). Swelling of the lower limbs has also been reported (97683).\nless\nDermatologic\nOrally, thunder god vine can cause hair loss and skin conditions, such as rash and redness (4046, 10675, 10676, 77931, 97684, 104137). A meta-analysis of Chinese studies found that hair loss and skin reactions were reported in less than 5% of patients taking thunder god vine extract (104137).\nless\nGastrointestinal\nOrally, thunder god vine can cause gastrointestinal upset, nausea, vomiting, and diarrhea (10675, 10676, 77869, 97681, 97682, 97683, 97684, 97686, 97688, 97692, 104137)(106278, 106281, 112877). A meta-analysis of Chinese studies found that gastrointestinal upset was reported in around 14% of patients taking thunder god vine extract (104137). However, when compared to standard treatments for kidney disease, a meta-analysis shows that the probability of gastrointestinal adverse events was lower in patients taking thunder god vine (106278).\nless\nGenitourinary\nOrally, thunder god vine has been reported to cause menstrual changes and amenorrhea (4046, 10675, 10676, 11009, 97681, 97682, 97683, 104137, 112874). A meta-analysis of Chinese studies found that amenorrhea was reported in around 10% of females taking thunder god vine extract (104137).\n\nThunder god vine has also been reported to induce infertility in males (10230, 77947). Preliminary clinical research shows that taking thunder god vine reduces sperm concentration, motility, and motility grade when compared with baseline. Normalization of sperm function seems to return six weeks after discontinuation of treatment (11133). Also, in one trial, erectile dysfunction occurred in one patient, which improved with a dose reduction from 1.5 mg/kg daily to 1 mg/kg daily (106281).\nless\nHematologic\nOrally, hyperkalemia has occurred in patients with diabetes taking thunder god vine (97685). However, it is unclear whether this was related to the thunder god vine, diabetes, or conventional medications. Deaths related to aplastic anemia associated with the use of non-standardized forms of thunder god vine have been reported (97684). A case of severe myelosuppression, lung infection, sepsis, and septic shock is reported in a 50-year-old female with stage 5 chronic kidney disease after taking a decoction providing thunder god vine 12 grams daily for 11 days. Despite discontinuing the product and receiving intensive medical treatment, the patient died (112872).\nless\nHepatic\nOrally, thunder god vine has been reported to cause transient elevations of serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in up to 9% of study participants (77869, 97678, 97682, 97683, 97684, 97685, 97686, 97688, 97691, 104137)(106278, 106281). However, in one study, elevations in ALT resulting in levels up to two times the upper limit of normal occurred in approximately 47% of participants with SAPHO syndrome. Only one patient had a severe elevation defined as more than three times the upper limit of normal (106281). Deaths related to severe liver dysfunction associated with the use of non-standardized forms of thunder god vine have been reported (97684).\nless\nImmunologic\nOrally, thunder god vine has been reported to cause leukopenia in up to 6% of study participants (97684, 97685, 97686, 97688, 97691, 97692, 104137, 106278). Deaths related to leukopenia associated with the use of non-standardized forms of thunder god vine have been reported (97684).\nless\nMusculoskeletal\nOrally, thunder god vine use for 5 or more years has been reported to cause decreased bone mineral content in females (10231).\nless\nNeurologic/CNS\nOrally, thunder god vine can cause dizziness and headache (10675, 106278).\nless\nRenal\nOrally, thunder god vine has been reported to cause kidney damage (77934). In a meta-analysis of 1555 cases involving treatment with thunder god vine preparations, 78 patients, or about 6%, experienced nephrotoxicity. However, due to various limitations, this risk might have been an overestimation (100823). A meta-analysis of Chinese studies found that proteinuria was reported in 13.5% of patients taking thunder god vine extract, while 6% to 8% of patients had elevated serum creatinine or blood urea nitrogen levels (104137).\n\nThere are three case reports of acute renal injury due to honey contaminated with thunder god pollen. The pollen contains the compound triptolide, which is excreted in the kidneys. Two of the three adults recovered, whereas the third died of acute kidney failure with toxic myocarditis (97680).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCrohn disease. Oral thunder god vine seems to prevent relapse of Crohn disease in patients who are in remission.\nPreliminary clinical research in patients with Crohn disease shows that taking thunder god vine 1 mg/kg daily for 52 weeks reduces the rate of clinical and endoscopic recurrence after surgery-induced remission by an additional 4.5- or 2.5-fold, respectively, when compared with mesalamine 4 grams daily (97686). When compared with azathioprine 2 mg/kg daily, taking thunder god vine 1.5 mg/kg daily for 52 weeks is as effective for preventing clinical recurrence after surgery, but is less effective for preventing endoscopic recurrence (97692). Furthermore, taking thunder god vine 2 mg/kg daily for 52 weeks is approximately 3-fold more effective than mesalamine 3 grams daily for preventing clinical recurrence following medication-induced remission. Thunder god vine 1 mg/kg daily appears to be as effective as mesalamine (97691).\nless\nGraves' ophthalmopathy. Oral thunder god vine in combination with conventional therapy seems to improve symptoms of Graves' ophthalmopathy.\nA meta-analysis of 19 low-quality clinical studies in patients in China with Graves' ophthalmopathy shows that taking thunder god vine extract 15-600 mg or 1-1.5 mg/kg daily along with conventional therapy for 3-4 months improves ocular symptoms and reduces the degree of exophthalmos when compared with conventional therapy alone. The most common doses of the extract are 30-60 mg daily or 1 mg/kg daily for 3-4 months (104136).\nless\nIgA nephropathy. Oral thunder god vine seems to increase the number of patients in remission from IgA nephropathy.\nA meta-analysis of small to moderate-sized clinical trials in patients with IgA nephropathy shows that taking thunder god vine daily, with or without conventional treatment for 3-12 months, improves total and complete remission rates based on 16 and 17 studies, respectively, when compared with conventional treatment alone. Thunder god vine may also reduce 24-hour proteinuria (112873). However, the interpretation of these findings is limited by the lack of information on the dosing of thunder god vine. An earlier meta-analysis of 4 clinical studies in adults with IgA nephropathy shows that taking thunder god vine 1-1.5 mg/kg or 60 mg daily for 6 months, alone or with other medications, increases the complete and total remission rate by 53% and 27%, respectively, when compared with taking prednisone or other treatments without thunder god vine (97688). An additional meta-analysis of small clinical studies shows that taking thunder god vine reduces 24-hour proteinuria by 0.6 grams daily when compared with placebo or conventional medicine (97689). This effect may be dose-dependent. In one study, taking thunder god vine 2 mg/kg daily for 6-8 weeks before reducing to 1 mg/kg daily as maintenance resulted in complete remission in 88% of patients, compared with no remission in patients taking thunder god vine 1 mg/kg daily (97678).\nless\nLichen planus. Oral thunder god vine in combination with conventional therapy seems to improve symptoms and prevent recurrence of lichen planus.\nA meta-analysis of 18 low-quality clinical studies in patients in China with oral lichen planus shows that taking thunder god vine extract along with conventional therapy for 1-12 weeks reduces pain, resolves sores, and reduces the risk for recurrence by 63% when compared with conventional therapy alone (104138).\nless\nNephrotic syndrome. Oral thunder god vine, taken alone or in combination with conventional therapy, seems to improve symptoms and prevent recurrence of nephrotic syndrome.\nMost clinical research shows that taking thunder god vine 0.5-2 mg/kg daily for 4-8 weeks is beneficial for primary nephrotic syndrome in adults and children (10677, 97677, 97684). A meta-analysis of mainly preliminary clinical research shows that taking thunder god vine increases the odds of total or complete remission by 4.8- or 6.3-fold, respectively, when compared with prednisone (97677). Furthermore, the combination of thunder god vine and prednisone increases the odds of remission by 2.1-fold when compared with prednisone alone (97677). Another meta-analysis of mainly preliminary clinical research shows that taking thunder god vine polyglycosides alone or with routine treatments increases the odds of complete or partial remission by 2.8- to 4.1-fold when compared with routine treatments alone (106278). Meta-analyses also show that taking thunder god vine reduces 24-hour proteinuria and serum creatinine levels, and increases serum albumin levels, when compared with placebo or conventional medicine (97689, 106278). One meta-analysis suggests that the reduction in urinary protein over 24 hours is 0.7 grams daily (97689).\n\nIn patients with nephrotic syndrome due to idiopathic membranous nephropathy, observational research has found that taking thunder god vine 40-60 mg daily with prednisone, prednisolone, or tacrolimus for up to 9 months seems to be as effective as tacrolimus with prednisone or prednisolone for achieving partial and complete remission (97681, 100827).\nless\nRheumatoid arthritis (RA). Oral thunder god vine, used alone or in combination with conventional therapy, seems to improve symptoms of RA. It is unclear if topical thunder god vine is beneficial for RA.\nOral thunder god vine has been evaluated as monotherapy and in conjunction with disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA). A meta-analysis of up to 40 moderate to high quality, small to moderate-sized clinical trials in adults with RA shows that taking thunder god vine glycosides, usually 30-60 mg daily in 3-4 divided doses for 12 or 24 weeks in combination with methotrexate or leflunomide, reduces the duration of morning stiffness, the tender or swollen joint count, overall pain, and inflammatory factors, and improves the total clinical effective rate, when compared with standard treatments alone (106276). Likewise, 2 similar meta-analyses of mostly small to moderate-sized clinical trials in adults with RA shows that taking thunder god vine 10-60 mg daily with methotrexate treatment for 12-24 weeks improves remission rates, tender and swollen joint counts, and morning stiffness when compared with methotrexate alone (97690, 112874). Additionally, a large clinical trial in adults with moderate to severe RA shows that taking thunder god vine 20 mg 3 times daily in combination with a tumor necrosis factor (TNF) inhibitor for 24 weeks improves disease activity and reduces tender and swollen joint counts when compared with taking thunder god alone, methotrexate alone, or taking methotrexate with the TNF inhibitor (112875).\n\nA network meta-analysis of 21 mostly moderate quality clinical studies in patients with RA, including 5 moderate to large-sized clinical trials evaluating oral thunder god vine, dose not described, alone or in combination with methotrexate or leflunomide for 12-24 weeks, suggests that taking thunder god vine in combination with methotrexate is the most likely option to provide a 20% improvement in tender and swollen joints and other symptoms followed by thunder god vine monotherapy ranked second. Taking thunder god vine with methotrexate was ranked second most likely to provide a 50% or 70% improvement, with the combination of cyclosporine and leflunomide ranked the most likely (110519). A similar, earlier network meta-analysis shows that taking thunder god vine alone is most likely to result in an additional 20% to 70% improvement in tender and swollen joints when compared indirectly with leflunomide, methotrexate, cyclosporine, or sulfasalazine (97679).\n\nClinical research shows that applying a tincture of thunder god vine topically over affected joints decreases joint tenderness, stiffness, and swelling when compared with placebo (10233).\n\nMost clinical studies were conducted in China; it is unclear if the effects of thunder god vine are generalizable to other geographic regions.\nless\nPOSSIBLY INEFFECTIVE\nAnkylosing spondylitis. Oral thunder god vine does not seem to improve symptoms of ankylosing spondylitis.\nAlthough some preliminary clinical research in adults with ankylosing spondylitis shows that taking thunder god vine improves pain and function when compared to baseline (97687), a meta-analysis of 11 moderate-quality randomized controlled trials disagrees with these findings and suggests that taking thunder god vine glycosides is no more effective than control for improving symptoms such as morning stiffness, swelling, or pain. Control treatments included various Chinese herbal compounds or sulfasalazine. Also, when taken in combination with leflunomide in one trial, thunder god vine was no more effective than leflunomide alone (106280). The most common doses used are 30-60 mg daily in divided doses for 4-12 weeks (97687, 106280).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtopic dermatitis (eczema). It is unclear if oral thunder god vine is beneficial for eczema.\nA meta-analysis of mainly preliminary clinical research shows that taking thunder god vine preparations in combination with topical glucocorticoids, glycyrrhizin, or other natural medicine preparations further improves symptoms of eczema when compared with glucocorticoids or natural agents alone (100824). This analysis is limited by the variability of the combination treatments; it is unclear which treatment might have caused a beneficial effect.\nless\nBehcet disease. Although there is interest in using oral thunder god vine for Behcet disease, there is insufficient reliable information about the clinical effects of thunder god vine for this condition.\nCancer. Although there is interest in using oral thunder god vine for cancer, there is insufficient reliable information about the clinical effects of thunder god vine for this condition.\nChronic kidney disease (CKD). It is unclear if oral thunder god vine is beneficial for chronic glomerulonephritis of various causes.\nPreliminary clinical research in patients with chronic glomerulonephritis of various causes shows that taking thunder god vine polyglycosides 20 mg three times daily for 2 months in combination with irbesartan, hydrochlorothiazide, and dipyridamole modestly improves serum creatinine, blood urea nitrogen, and proteinuria when compared with the medication regimen alone. There were also modest improvements in levels of inflammatory mediators, suggesting improved immune function (106277). Additionally, one meta-analysis shows that taking thunder dog vine reduces urinary protein by 0.25 grams over 24 hours in patients with chronic glomerulonephritis (97689).\nless\nConnective tissue disease-associated interstitial lung disease (CT-ILD). Some small clinical studies suggest that oral thunder god vine may be beneficial for CT-ILD.\nA meta-analysis of a small number of preliminary clinical trials shows that taking thunder god vine for 6-12 months in combination with conventional therapy including glucocorticoids and/or immunosuppressants modestly improves lung function and lung volume when compared with conventional therapy alone. There were also some modest beneficial effects on symptoms, specifically cough, shortness of breath, and Velcro crackles, but not dyspnea (106279).\nless\nDiabetic nephropathy. Some small clinical studies suggest that oral thunder god vine may be beneficial for diabetic nephropathy.\nPreliminary clinical research in adults with diabetic nephropathy of unclear severity shows that taking thunder god vine 40 mg three times daily for 3 months, followed by 20 mg three times daily for 3 months, reduces urinary protein levels by 33% to 39%, but does not affect glomerular filtration, when compared with taking valsartan 160 mg daily. Increases in serum creatinine of at least 25% occurred in approximately 60% fewer patients taking thunder god vine (97685). Thunder god vine has also been investigated in patients with end-stage diabetic nephropathy. A meta-analysis of mainly preliminary clinical studies in these patients shows that adding thunder god vine preparations to conventional treatment with angiotensin receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors reduces 24-hour urinary protein and increases serum albumin, but does not affect serum creatinine, when compared with conventional therapy alone (100826). Additionally, meta-analyses of small to moderate-sized, low-quality clinical studies in patients with diabetic nephropathy shows that lower dose thunder god vine, under 1 mg/kg or 60 mg daily for 6 months, taken in conjunction with conventional treatment, reduces 24-hour urinary protein and serum creatinine and increases serum albumin based on 21, 18, and 13 studies, respectively, when compared with conventional treatment alone (112876). All clinical studies were conducted in China; it is unclear if the effects of thunder god vine are generalizable to other geographic regions.\nless\nHIV/AIDS. Although there is interest in using oral thunder god vine for HIV/AIDS, there is insufficient reliable information about the clinical effects of thunder god vine for this condition.\nKidney transplant. It is unclear if oral thunder god vine is beneficial for improving survival after a kidney transplant.\nPreliminary clinical research shows that taking thunder god vine, 1-2 mg/kg daily beginning 7-14 days prior to transplantation and continuing for 5 years thereafter, reduces rejection rate and improves survival when compared to an untreated control group (77923). Other preliminary clinical research shows that taking thunder god vine, cyclosporine, and prednisone normalizes graft function approximately 7.3 days faster, and modestly improves 1-2 year graft survival rates, when compared with taking azathioprine, cyclosporine, and prednisone (77944).\nless\nMembranous nephropathy. Some small clinical studies suggest that oral thunder god vine may be beneficial for membranous nephropathy, particularly when used in conjunction with conventional therapy.\nA meta-analysis of 3 small to moderate-sized clinical trials in adults with membranous nephropathy shows that taking thunder god vine 1-1.5 mg/kg daily for 3-6 months increases the odds of complete or partial remission by 4.8-fold and reduces 24-hour urinary protein levels when compared with conventional treatments. (106278). A network meta-analysis of up to 29 small to large clinical trials in adults with idiopathic membranous nephropathy shows that taking thunder god vine 1-2 mg/kg daily or 20-40 mg 3 times daily for 2-6 months then tapering to 20-60 mg daily for up to a year in conjunction with conventional treatments such as glucocorticoids and immunosuppressants improves total remission rates and reduces 24-hour urinary protein when compared with conventional treatment alone (112877). Additionally, in patients with nephrotic syndrome due to idiopathic membranous nephropathy, observational research has found that taking thunder god vine 40-60 mg daily with prednisone, prednisolone, or tacrolimus for up to 9 months seems to be as effective as tacrolimus with prednisone or prednisolone for achieving partial and complete remission (97681, 100827). The majority of the studies were conducted in China; it is unclear if findings are generalizable to other geographic regions.\nless\nMultiple sclerosis (MS). Although there is interest in using oral thunder god vine for MS, there is insufficient reliable information about the clinical effects of thunder god vine for this condition.\nPsoriasis. It is unclear if oral thunder god vine is beneficial for psoriasis.\nA small clinical study in patients with moderate to severe plaque psoriasis shows that taking thunder god vine 20 mg three times daily for 8 weeks is as effective as acitretin 30 mg daily for reducing overall symptoms (97683). The validity of these findings is limited by the short-term treatment and the lack of a placebo group. Another small clinical study in adults with moderate to severe plaque psoriasis shows that taking thunder god vine and acitretin for 8 weeks improves clinician-assessed psoriasis severity scores when compared with acitretin and licorice extract or acitretin alone. Doses of thunder god vine, acitretin, and licorice extract were not provided (110520). The validity of these findings is limited by the short-term treatment, lack of blinding, and lack of a placebo group.\nless\nSAPHO syndrome. It is unclear if oral thunder god vine is beneficial for SAPHO syndrome.\nPreliminary clinical research in patients with SAPHO syndrome using only anti-inflammatory agents as needed shows that taking thunder god vine glycosides modestly improves osteoarticular pain and overall measures of disease activity within 2-4 weeks when compared with baseline. Patients received either 1 mg/kg for 12 weeks or 1.5 mg/kg daily for 4 weeks followed by 1 mg/kg daily over the next 8 weeks (106281). The validity of these findings is limited by the lack of a comparator group.\nless\nSystemic lupus erythematosus (SLE) nephritis. It is unclear if oral thunder god vine is beneficial for SLE nephritis.\nThere is preliminary evidence that thunder god vine may be beneficial for nephritis associated with SLE (97689). However, taking thunder god vine in addition to prednisone does not appear to reduce symptoms better than prednisone alone (77934).\nless\nUrticaria. Some small clinical studies suggest that oral thunder god vine may be beneficial for urticaria.\nA meta-analysis of mostly preliminary clinical research shows that adding thunder god vine preparations to antihistamines improves symptoms of chronic urticaria when compared with antihistamines alone (100825).\nless\nMore evidence is needed to rate thunder god vine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nThunder god vine extract has most often been used in doses of 1-2 mg/kg daily for 2-12 months or 30-120 mg daily for 2-6 months. See Effectiveness section for condition-specific information.\n\nTo reduce toxicity, thunder god vine extracts used in clinical trials are mainly comprised of ethanol-ethyl acetate and chloroform-methanol extracts of the peeled roots (97684).\nTopical:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nMost clinical trials have used thunder god vine extracted from the root available from pharmaceutical companies in China (Huangshi Feiyun Pharmaceutical Co.; Zhejiang DND Pharmaceutical Co. Ltd.; Mei-Tong Pharmaceutical Ltd.; Jiansu General Pharmaceuticals Co. Ltd.; Taizhou Pharmaceutical Co.) (97678, 97681, 97682, 97685, 97686, 97687, 97691, 97692). Thunder god vine extracts are produced from at least five companies in China with approval by the China State Food and Drug Administration (97687). These extracts are mainly ethanol-ethyl acetate and chloroform-methanol extracts of the peeled roots to reduce toxicity (97684).\n\nIn some studies, thunder god vine extract (Zhejiang DND pharmaceutical company) contained triptolide 1.2 mcg per 10 mg and wilforlide 36.6 mcg per 10 mg (97682, 106281).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, thunder god vine might increase the levels and clinical effects of CYP1A2 substrates.\nIn vitro research shows that triptolide, a constituent of thunder god vine, inhibits CYP1A2 enzymes in human microsomes (100828). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 3A4 (CYP3A4) INHIBITORS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, CYP3A4 inhibitors might increase the levels and adverse effects of thunder god vine constituents.\nInhibitors of CYP3A4 can increase the concentration of triptolide, a thunder god vine constituent, and its derivative (5R)-5-hydroxytriptolide. In vitro research shows that triptolide and (5R)-5-hydroxytriptolide are about 94% and 64% metabolized by CYP3A4, respectively (100829).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, thunder god vine might increase the levels and clinical effects of CYP3A4 substrates.\nIn vitro research shows that triptolide, a constituent of thunder god vine, inhibits CYP3A4 enzymes in human microsomes (100828). This interaction has not been reported in humans.\nless\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, thunder god vine might enhance the effects of immunosuppressant drugs.\nLarge doses of thunder god vine may suppress immune function (10230, 112876).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nIMMUNOSUPPRESSION\nTheoretically, thunder god vine might exacerbate immunosuppression. Large doses of thunder god vine may suppress immune function (10230).\nless\nOSTEOPOROSIS\nPatients with osteoporosis or who are at risk for osteoporosis should avoid thunder god vine. Thunder god vine can decrease bone mineral density (10231).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nThere is a case report of death associated with intake of an unknown amount of fresh thunder god vine. The patient developed severe gastrointestinal symptoms, as well as leukopenia, hypotension, tachyarrhythmias, cardiac damage, kidney failure, and hypovolemic shock and died within 15 hours of presentation to the hospital (8658).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with thunder god vine.",
            "Pharmacokinetics": "Absorption\nOral consumption of thunder god vine results in increased plasma levels of the constituents triptolide, wilforlide A, and triptonide (77924). Triptolide is highly absorbed when taken orally (100828).\nDistribution\nThe thunder god vine constituent, triptolide, distributes into the liver, kidney, heart, spleen, and lungs (100828).\nMetabolism\nIn animal research, the thunder god vine constituent, triptolide, is extensively metabolized via hydroxylation. Triptolide metabolites are further metabolized by UDP-glucuronosyltransferases, N-acetyltransferases, sulfotransferases, and glutathione S-transferases (100828).\nExcretion\nIn animal rat models, triptolide has a 0.42-hour half-life after oral administration (100828).",
            "Mechanism of Action": "General\nThe applicable parts of thunder god vine are the leaf and root. The active constituents of thunder god vine are terpenoids. Many di- and tri-terpenoids have been identified including tripchlorolide, triptolidenol, triptolide, tripdiolide, triptonide, 16-hydroxytriptolide, and wilforlides (840, 10230, 97679, 97682).\nAnti-arthritic effects\nThunder god vine is traditionally used for rheumatoid arthritis. In vitro, thunder god vine inhibits the production of nitric oxide by chondrocytes, the cells in the joint (77879). Constituents from thunder god vine inhibit the production of prostaglandin E2 from synovial cells of rheumatoid arthritis patients (77945) and inhibit the proliferation of synovial fibroblasts (77892). Some constituents inhibit the inflammatory messaging within chondrocytes and synovial fibroblasts (77907). In clinical trials, oral thunder god vine reduces levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor, interleukin-6, and tumor necrosis factor-alpha, suggesting a reduction of joint inflammation (97682, 97687, 97690, 112874).\nAnti-cancer effects\nThunder god vine is of interest for cancer. In vitro, thunder god vine or its constituents induce the apoptosis of cancer cells and suppress cancer cell proliferation, angiogenesis, and metastasis. In animal research, thunder god vine inhibits the growth of tumors (77886, 77959, 97689).\nAnti-inflammatory effects\nThunder god vine has anti-inflammatory effects. An extract of the root of thunder god vine exerts anti-inflammatory activity by inhibiting the activity of cyclooxygenase (COX) 1 and 2 and 5-lipoxygenase (12480). Thunder god extracts, and various constituents such as tripterine and triptolide, inhibit cellular processes involved in inflammation (11130, 12480, 77871, 77911, 77922, 77946). Additionally, clinical research shows thunder god vine lowers levels of interleukin-6, tumor necrosis factor-alpha, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor (97682, 97687, 97690, 112874).\nAntiviral effects\nThe neotripterifordin, tripterifordin, and salaspermic acid constituents of thunder god vine exhibit potent anti-HIV replication activity in vitro (4048, 4049, 77954). Other constituents demonstrate antiviral effects against herpes simplex-1 virus, human cytomegalovirus, measles virus, Epstein-Barr, and influenza A (77936, 77956).\nFertility effects\nThunder god vine leaf and root demonstrate antifertility effects in males by inhibiting sperm transformation, maturation, and mobility. Triptolide, tripdiolide, and possibly other compounds seem to be responsible for this effect (11130, 11131). Male fertility appears to return to normal six weeks after discontinuation (4046, 11133).\nGastrointestinal effects\nThunder god vine is traditionally used for Crohn disease. The constituent triptolide inhibits intestinal inflammation in animal models by inhibiting inflammatory cytokine processes (97691). Triptolide also reduces intestinal permeability by inhibiting actions of tumor necrosis factor (TNF)-alpha (97691).\nImmunosuppressive effects\nThunder god vine has immunosuppressive effects. The immunosuppressive effects of thunder god vine are attributed to the constituent triptolide. Triptolide inhibits lymphocyte activation and T-cell expression of interleukin-2 (5305, 11132). In vitro, various constituents in thunder god vine inhibit the production of cytokines involved in the immune response (1442, 10674, 77948, 77953). An alcoholic extract, known as T2, that contains triptolide and tripdiolide, inhibits T-cell and B-cell proliferation, as well as immunoglobulin production by B-cells (1442). T2 also inhibits the release of prostaglandin 2 (PGE 2) from mononuclear leukocytes (5305). A water extract of thunder god vine inhibits the activity of cellular adhesion molecules of leukocytes and endothelial cells, including integrins and selectins (1206, 8409).\nNephroprotective effects\nThunder god vine is traditionally used for kidney disease. In isolated glomeruli, the extract protects the filtration barriers. It also demonstrates anti-inflammatory and antioxidant effects in kidney cells (97684). A meta-analysis of studies in mice and rats with diabetic kidney disease suggests that thunder god vine reduces albuminuria and serum creatinine when compared with no treatment but does not improve these outcomes when compared with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (110517). Additionally, meta-analyses of clinical trials in patients with IgA nephropathy and in patients with diabetic nephropathy show that taking thunder god vine daily with or without conventional treatment increases serum albumin and decreases serum creatinine when compared with conventional treatment alone (112873, 112876).\nRespiratory effects\nClinical research shows that thunder god vine might be beneficial for lung function in patients with interstitial lung disease. In animal research, the beneficial effect on pulmonary epithelial cells was related to the regulation of immune and/or inflammatory regulatory factors (106279).\nToxic effects\nThunder god vine contains constituents that can have toxic effects in animals and humans. Constituents have been shown to induce apoptosis of mitochondria and heart muscle cells, and to promote inflammation or oxidative stress (97689). Thunder god vine extracts can inhibit growth factor response in CD34+ bone marrow cells (77867)."
        }
    },
    "Thyme": {
        "sections": {
            "Overview": "Thyme is an herb that is native to the Mediterranean region of Europe and the Caribbean. It has a very distinct fragrance and has been traditionally used for cosmetic, culinary, and medicinal purposes. Spanish thyme (Thymus zygis) is often used interchangeably with thyme (Thymus vulgaris) (78340, 94033, 94036).",
            "Safety": "LIKELY SAFE when used in amounts commonly found in foods. Thyme has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when thyme is used orally and appropriately in supplemental amounts. Orally, thyme, in combination with other herbs, has been used safely for up to 23 days (13557, 49219, 49223, 78133). ...when diluted thyme oil is used topically, short-term. Diluted thyme oil has been used with apparent safety for up to 7 months (5177).\nThere is insufficient reliable information available about the safety of thyme oil when used orally or when inhaled.\nCHILDREN: LIKELY SAFE when used in amounts commonly found in foods. Thyme has Generally Recognized as Safe (GRAS) status in the US (4912).\nCHILDREN: POSSIBLY SAFE when thyme is used orally in medicinal amounts in combination with English ivy. Thyme has been used with apparent safety in combination with English ivy for up to 10 days (78181).\nCHILDREN: There is insufficient reliable information available about the safety of thyme oil when used orally or topically in children.\nPREGNANCY AND LACTATION: LIKELY SAFE when used in amounts commonly found in foods. Thyme has Generally Recognized as Safe (GRAS) status in the US (4912). There is insufficient reliable information available about the safety of thyme when used in medicinal amounts during pregnancy and breast-feeding; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, thyme is well tolerated when used in food and seems to be well tolerated when used medicinally. Topically, thyme seems to be generally well tolerated.\nMost Common Adverse Effects\nOrally: Allergic reactions, diarrhea, dizziness, headache, heartburn, nausea, or vomiting.\n\nTopically: Contact dermatitis and skin irritation.\nDermatologic\nTopically, thyme, thyme oil, or the constituent thymol can cause contact dermatitis and skin irritation (13463, 78252, 78362, 78384, 77982, 78154, 78310, 78313, 78384). In one study of 100 patients with contact allergies, 5% were attributed to thyme oil as an allergen contained in wound dressings (78362). Toothpastes containing thymol have been associated with cheilitis and glossitis (13463).\nless\nGastrointestinal\nOrally, thyme and thyme oil may cause heartburn, nausea, vomiting, stomach upset, or diarrhea (13557, 94033). In a clinical study, two patients using extracts of thyme herb and ivy leaves experienced temporary stomach ache and mild nausea (78181).\n\nIntravaginally, cream containing thyme and garlic has been associated with reports of nausea and vomiting in one clinical study (88387). It is not clear if these adverse effects were associated with thyme, garlic, or the combination.\nless\nGenitourinary\nIntravaginally, cream containing thyme and garlic has been associated with reports of vaginal dryness and vaginal irritation in one clinical study (88387). It is not clear if these adverse effects were associated with thyme, garlic, or the combination.\nless\nImmunologic\nOrally, thyme can cause allergic reactions; however, this is uncommon (13463). Allergic reactions to thyme might be more common in people who are also allergic to oregano and other Lamiaceae species (3808).\nless\nNeurologic/CNS\nOrally, thyme may case headache or dizziness (94033).\nless\nPulmonary/Respiratory\nBy inhalation, occupational exposure to thyme dust can cause acute airway obstruction (783, 13463, 13464, 77982, 78098).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. It is unclear if a topical thyme flower and leaf extract reduces wrinkles.\nA small clinical trial in healthy females aged 40-60 years with wrinkles shows that applying a specific gel preparation (ThymLec 2%, PhytoPharmaTech) containing thyme flower and leaf 1-3% extract in lecithin on the face twice daily for 60 days reduces facial wrinkles when compared with inactive control gel, but not when compared with an active comparator gel containing propanediol, ornithine, phospholipids, and glycolipids (105909).\nless\nAlopecia areata. Topical thyme oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne small clinical study shows that applying a combination of the essential oils from thyme, rosemary, lavender, and cedarwood improves hair growth in up to 44% of patients after 7 months of treatment when compared with baseline (5177). The validity of this finding is limited by the lack of a comparator group. Additionally, it is unclear if this effect is due to thyme, other ingredients, or the combination.\nless\nBronchitis. Oral thyme has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nSome research has evaluated thyme in combination with cowslip. One observational study in adults and children has found that taking a specific product (Bronchipret) containing thyme and cowslip relieves symptoms of bronchitis and increases production of sputum (13557). A clinical study in patients with acute bronchitis shows that taking a similar combination extract (Bronchicum Tropfen) containing thyme and cowslip root 1 mL five times daily for 7-9 days seems to reduce severity and duration of coughing when compared with placebo (49219). Other thyme and cowslip preparations such as Bronchicum Elixir S and Bronchcium Tropfen seem to be similarly beneficial for bronchitis (49223).\n\nThyme has also been studied in combination with other ingredients. A large clinical study in patients with acute bronchitis shows that taking a specific syrup (Bronchipret Saft, Bionorica AG) containing thyme and English ivy leaf 5.4 mL three times daily for 11 days reduces the frequency and duration of cough when compared with placebo (78152). Additionally, an observational study in children with acute bronchitis has found that taking this combination product in an age-specific dosing schema is associated with reduced bronchitis severity and coughing fits when compared to baseline (78181). However, due to the lack of a comparator group, it is unclear if these changes are due to the product or to the natural resolution of the condition.\nless\nColic. Although there is interest in using oral thyme for colic, there is insufficient reliable information about the clinical effects of thyme for this condition.\nCommon cold. Although there is interest in using oral thyme for the common cold, there is insufficient reliable information about the clinical effects of thyme for this condition.\nCough. Oral thyme has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large open-label, uncontrolled study in adults with acute cough due to an upper respiratory tract infection who purchased a specific syrup (Bronchipret drops, Bionorica AG) containing thyme and English ivy leaf extracts suggests that taking this product as 2.6 mL three times daily for at least 4 days may improve patient-reported bronchitis symptom severity, cough severity, and quality of life, with over 90% of patients reporting overall satisfaction and product tolerability (110401). However, due to the lack of a comparator group, it is unclear if these changes are due to the product or the natural resolution of the condition. Additionally, the validity of these findings is limited by poor study methodology.\nless\nDementia. It is unclear if aromatherapy with thyme oil is beneficial in patients with dementia.\nOne very small clinical study in patients with advanced dementia shows that attaching a pad containing thyme oil to the collar area of the shirt does not reduce agitation when compared with lavender oil or unscented grapeseed oil (12213).\nless\nDevelopmental coordination disorder (DCD). Oral thyme oil has only been evaluated in combination with other oils; its effect when used alone is unclear.\nOne very small clinical study in children with DCD shows that taking thyme oil, in combination with evening primrose oil, fish oil, and vitamin E (Efalex, Efamol Ltd.), seems to modestly improve movement disorders when compared with baseline (5708). The validity of this finding is limited by the lack of a comparator group. Additionally, it is unclear if this effect is due to thyme, other ingredients, or the combination.\nless\nDysmenorrhea. It is unclear if drinking thyme tea is beneficial for the prevention of dysmenorrhea.\nOne small observational study in adolescents living in Ethiopia has found that drinking thyme tea is associated with a lower occurrence of primary dysmenorrhea when compared with those who did not drink thyme tea (105910).\nless\nDyspepsia. Although there is interest in using oral thyme for dyspepsia, there is insufficient reliable information about the clinical effects of thyme for this condition.\nHalitosis. It is unclear whether oral thyme is beneficial for halitosis.\nOne small retrospective study in adults with gingival halitosis who received periodontal treatment and oral hygiene instructions suggests that drinking thyme tea twice daily for 1 week is associated with a reduction in volatile sulfur compounds, which is a marker for halitosis, when compared with chlorhexidine or oral hygiene alone (111716). However, the interpretation of this finding is limited by the lack of thyme dosing information and the narrow focus on intraoral halitosis, excluding most extraoral halitosis-associated conditions.\nless\nLaryngitis. Although there is interest in using oral and topical thyme for laryngitis, there is insufficient reliable information about the clinical effects of thyme for this condition.\nOral mucositis. Although there is interest in using oral and topical thyme for oral mucositis, there is insufficient reliable information about the clinical effects of thyme for this condition.\nTonsillitis. Although there is interest in using oral and topical thyme for tonsillitis, there is insufficient reliable information about the clinical effects of thyme for this condition.\nMore evidence is needed to rate thyme for these uses.",
            "Dosing & Administration": "Adult\nOral and Topical:Research is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nIn general, thyme contains thymol 30% to 70%, carvacrol 3% to 15%, and several other constituents (13448, 13463). The chemical composition of the essential oils found in thyme varies dramatically, even amongst commercially available products (94036, 94037). Environmental conditions including soil composition, the season, time of day and the way the plant was harvested, in addition to how the plant is stored and subsequently processed can affect the essential oil composition. Lastly, how the oil is extracted and subsequently analyzed can also affect the composition of the essential oils (94035, 94036, 94037).\n\nThe European Pharmacopeia 5.0, states that the minimum content of essential oil in thyme is 12 mL/kg (94037).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concurrent use of anticholinergic drugs and thyme essential oil might reduce the effects of anticholinergic drugs.\nIn vitro evidence suggests that thyme essential oil and specific essential oil constituents like thymohydroquinone and carvacrol can inhibit acetylcholinesterase (AChE) (78155). However, this effect has not been observed in humans.\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, thyme leaf extract might have additive effects with anticoagulant or antiplatelet drugs.\nIn vitro and animal research suggests that thyme leaf extract has antiplatelet effects (13457, 18335, 49445). However, this effect has not been observed in humans.\nless\nCHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concurrent use of cholinergic drugs and thyme essential oil might cause additive cholinergic effects.\nIn vitro evidence suggests that thyme essential oil and specific essential oil constituents like thymohydroquinone and carvacrol can inhibit acetylcholinesterase (AChE) (78155). However, this effect has not been observed in humans.\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, thyme might competitively inhibit the effects of estrogen replacement therapy.\nIn vitro research shows that thyme has estrogen receptor-binding activity and phytoestrogen content (3701). However, this effect has not been observed in humans.\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nThyme leaf extract might have antiplatelet effects.\nTheoretically, concomitant use of thyme leaf extract with herbs that affect platelet aggregation might have additive effects (13457, 18335, 49445). See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCROSS-ALLERGENICITY\nPatients allergic to plants from the Lamiaceae species are more likely to have allergic reactions to thyme. Cross-reactivity to oregano and other Lamiaceae species has been reported in an individual allergic to thyme (3808).\nless\nHORMONE-SENSITIVE CANCERS/CONDITIONS\nTheoretically, thyme might worsen hormone-sensitive conditions. There is preliminary evidence that thyme binds to estrogen receptors and contains phytoestrogens (3701). Until more is known, patients with hormone-sensitive conditions should use caution. Some of these conditions include breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids.\nless\nPOSTOPERATIVE\nTheoretically, thyme supplements might cause excessive bleeding if used perioperatively. Thyme leaf extract has demonstrated antiplatelet effects in animal and in vitro research (13457, 18335, 36029, 49445). Tell patients to discontinue thyme supplements at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with thyme.",
            "Pharmacokinetics": "Absorption\nThymol, the primary constituent of thyme is rapidly absorbed in the upper gastrointestinal tract (13449).\nMetabolism\nThymol, the primary constituent of thyme is metabolized to thymol sulfate and thymol glucuronide. Its half-life is about 10 hours (13449).\nExcretion\nIn human and animal urine, thymol sulfate, thymol glucuronide, and thymohydroquinone, not free thymol, were found after thymol consumption; excretion (approximately 16% of the dose) continued for 24 hours (13449, 78022, 78349).",
            "Mechanism of Action": "General\nThe applicable parts of thyme are the leaf, flower, and oil. Thyme contains thymol 30% to 70%, carvacrol 3% to 15%, and several other constituents including borneol, geraniol, linalool, and alpha-pinene. It also contains flavonoids such as apigenin and luteolin, polyphenolic acids such as caffeic acid, triterpene acids such as ursolic and rosmaric acid, as well as terpinene, tannins, saponins and other constituents (13448, 13463).\nAnti-inflammatory effects\nIn vitro research shows that thyme extract might have anti-inflammatory activity. This effect is attributed to the ability of thyme to scavenge nitric oxide radicals (13458).\nAntimicrobial effects\nPreliminary research suggests that thyme has antimicrobial activity and modest antibacterial effects (13450, 13451). It also seems to have antiviral activity against influenza A and respiratory syncytial virus (13449). Other preliminary research suggests thyme has activity against fungi such as Candida albicans and other Candida species. It seems to potentiate the antifungal activity of amphotericin B (13452, 13453). Thymol is active against fungal microorganisms that cause onychomycosis such as Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Epidermophyton floccosum, and Epidermophyton stockdale (13447).\nAntioxidant effects\nThyme and its constituents thymol and carvacrol might have antioxidant effects and DNA protective effects (13450, 13454, 13455). The antioxidant effect of thyme might increase the production of nitric oxide and improve atherosclerosis and endothelial dysfunction , according to preliminary research (13460).\nAntiplatelet effects\nPreliminary research suggests that thyme has antiplatelet activity (13457).\nAntispasmodic effects\nIn vitro research shows that thyme extract has antispasmodic effects (13456).\nDrug metabolism effects\nThyme seems to affect phase I and phase II xenobiotic metabolizing enzymes. In an animal model, thyme seems to induce the phase I enzyme 7-ethoxycoumarin-O-deethylase (ECOD) enzyme. Thyme also seems to induce the phase II enzymes glutathione-S-transferase (GST) and quinine reductase (QR). Thymol and carvacrol are thought to be responsible for these effects (13164).\nInsect repellant effects\nPreliminary research suggests the thyme constituent, alpha-terpinene, might be an effective mosquito repellent (13462).\nSkin aging effects\nThere is interest in using thyme extract for reducing wrinkles in aging skin. In vitro, thyme flower and leaf extract increased adiponectin and stimulated the adipogenesis process, which may lead to increased conversion of fibroblast-like precursor cells into lipid-laden adipocytes. These adipocytes are thought to function like skin fillers to reduce wrinkles (105909).\nWound healing effects\nThyme oil might improve the healing of burn wounds by promoting the formation of new tissue (13461)."
        }
    },
    "Thymus extract": {
        "sections": {
            "Overview": "The thymus is a lobular gland that is responsible for the production of T-lymphocytes and various hormones. Thymus extract is derived from bovine thymus glands. The quality and potency of these products can vary significantly (6614).",
            "Warnings": "Thymus extract is derived from raw bovine thymus glands and is at risk for contamination (1825). However, so far there are no reports of disease transmission to humans due to use of contaminated thymus extract.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Purified thymus extract has been used with apparent safety in clinical trials (938, 1175, 1176, 1177, 1178, 6691, 6694, 6696, 6697, 6698, 6699). Since thymus extract is derived from raw bovine thymus gland, there is some concern for contamination with diseases (1825). However, so far there are no reports of disease transmission to humans due to use of contaminated thymus extract.\nThere is insufficient reliable information available about the safety of thymus extract when used subcutaneously or intramuscularly.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, thymus extract seems to be well tolerated. No adverse effects have been reported in clinical trials.\nImmunologic\nIn one case report, severe anaphylactic reaction associated with thymostimulin administration occurred in a 36-year-old male being treated for a neck tumor (78453).\nless\nOther\nThymus extract is derived from raw bovine thymus glands gathered from slaughterhouses, which could include sick or diseased animals (6620). Products made from contaminated or diseased organs might present a human health hazard. However, there are no reports of disease transfer to humans from contaminated thymus extract.\n\nThere is also some concern that thymus extract that is obtained from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be unsafe. However, there are no reports of BSE transfer to humans from contaminated thymus extract. Countries where BSE has been reported include Great Britain, France, The Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium (1825).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDilated cardiomyopathy. Small clinical trials show that adding subcutaneous thymomodulin to conventional treatment improves clinical and laboratory measures in patients with symptomatic dilated cardiomyopathy and reduced left ventricular ejection fraction (LVEF).\nClinical research in adults with symptomatic dilated cardiomyopathy and reduced LVEF shows that using subcutaneous thymomodulin (calf thymus extract) 10 mg three times weekly for 3 months in combination with conventional therapy improves LVEF after 2 years and also improves exercise tolerance, LVEF, clinical symptoms, and survival after a 7-year follow-up period when compared with conventional therapy alone. Thymomodulin was similarly effective to treatment with interferon-alpha (78542, 78556, 78558). The conventional treatments used in these studies, which were conducted in the early 1990s, involved an escalating regimen of salt reduction, digoxin, furosemide, captopril, metolazone, and warfarin.\nless\nRespiratory tract infections. Low-quality clinical research in adults and children with recurrent respiratory tract infections suggest that oral thymus extract may modestly reduce infection frequency and symptom severity and duration.\nLow-quality clinical studies show that taking thymus extract 120 mg orally daily, for 20 days of each month for up to 4 consecutive months during fall and winter, reduces the number of infections or coughing attacks in adults and children with recurrent respiratory infections when compared with placebo or no treatment (6697, 6698, 6699). One study also shows that oral thymomodulin modestly reduces the use of antibiotics and the duration of infection when compared with no treatment (938).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAllergic rhinitis (hay fever). Although there has been interest in using oral thymus extract for hay fever, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nAsthma. It is unclear if oral thymus extract is beneficial in children with asthma.\nPreliminary clinical research in children 2-12 years of age with asthma shows that taking thymomodulin (calf thymus extract) 80 mg orally daily for 90 days reduces the frequency of acute asthma attacks when compared to baseline (6694). The validity of these findings is limited by the lack of a comparator group and the lack of information on the use of maintenance asthma therapy.\nless\nCancer. Although there has been interest in using oral thymus extract for cancer, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nChronic fatigue syndrome (CFS). Although there has been interest in using oral thymus extract for CFS, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nFood allergies. Small clinical trials suggest that oral thymomodulin improves food tolerance in children with food allergies.\nTwo small clinical studies in children 7 months to 14 years of age with food allergies shows that taking thymomodulin (calf thymus extract) 120 mg daily for three months while on an elimination diet improves tolerance to allergenic foods when compared to an elimination diet alone (1175, 1176).\nless\nHepatitis. Although there has been interest in using oral thymus extract for hepatitis, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nHerpes labialis (cold sores). Although there has been interest in using oral thymus extract for cold sores, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nHerpes zoster (shingles). Although there has been interest in using oral thymus extract for shingles, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nRheumatoid arthritis (RA). Although there has been interest in using oral thymus extract for RA, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nSystemic lupus erythematosus (SLE). Although there has been interest in using oral thymus extract for SLE, there is insufficient reliable information about the clinical effects of thymus extract for this purpose.\nMore evidence is needed to rate thymus extract for these uses.",
            "Dosing & Administration": "Adult\nOral:\nThymomodulin (calf thymus extract) 80-120 mg daily has been commonly used for up to 4 months. See Effectiveness section for condition-specific information.\nParenteral:Research is limited; typical dosing is unavailable.\nChildren\nOral:\nThymomodulin (calf thymus extract) 80-120 mg daily has been commonly used for up to 4 months in children at least 7 months of age. See Effectiveness section for condition-specific information.\nParenteral:Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nThymus extract is derived from bovine thymus glands, resulting in high variability related to quality and potency. There is concern that thymus extract may act as a vector for bovine-derived disease. There are no reports of disease transfer to humans from contaminated thymus extract; however, most clinical research has used purified thymus extract products.",
            "Interactions with Drugs": "IMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, patients taking immunosuppressants may be at an increased risk of infection from contaminated thymus extract.\nThymus extract is derived from raw bovine thymus glands and is at risk for contamination (1825). Tell patients to avoid thymus extract products unless these products are certified as pathogen-free.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "IMMUNOSUPPRESSION\nTheoretically, patients with compromised immune systems may be at an increased risk of infection from thymus extract. Thymus extract is derived from raw bovine thymus glands and is at risk for contamination (1825). Tell patients to avoid thymus extract products, unless these products are certified as pathogen-free.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with thymus extract.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of thymus extract.",
            "Mechanism of Action": "General\nThymus extract is derived from bovine thymus glands. The thymus is a lobular gland located under the breastbone near the thyroid gland that is responsible for the production of T-lymphocytes and various hormones, including thymosin, thymomodulin, thymulin, thymic humoral factor, hormonal thymic factor, and serum thymic factor (6614).\nAnti-inflammatory effects\nIn humans, nonathymulin, a synthetic thymic peptide hormone, improved global assessment and objective parameters related to arthritis (78482). In an animal model, synthetic thymic peptides reduced joint swelling and synovitis (78551). The exact mechanism of action is not well understood.\nAnticancer effects\nCalf thymus extract contains two natural killer cytotoxicity-stimulating factors, CSFa and CSFb, which reduce tumor development in mice (78491). In animal models, thymic factors reduced tumor metastases (78427, 78575). Also, postnatal administration of thymus factor in a tumor-bearing rat model increased lifespan and decreased tumor quantity (78559). In vitro, thymic peptides increased IL-2 activated killer cell activity (78576).\nAntioxidant effects\nIn humans treated with interferon-alpha, treatment with thymomodulin (calf thymus extract) significantly increased serum antioxidant capacity (78442). In vitro, thymic peptide increased glutathione levels and glutathione disulfide reductase activity and inhibited the negative oxidative effects of oxidants (78538, 78547, 78553).\nImmunomodulatory effects\nThe thymus is involved in human immune function. There is interest in using thymus extract for various immunomodulatory effects. In clinical research and in vitro, calf thymus extract (thymomodulin) and thymostimulin have been shown to increase T- and B-lymphocyte counts, the number of rosette-forming cells, and the response of T-lymphocytes (78524, 78522, 78445, 78434, 78526, 78528, 78487, 78462, 78481, 78550)(6678, 78472, 78571, 78540, 6685, 78509, 78513, 78476, 78526, 78527)(78524, 78522, 78445, 78434, 78528, 78550, 6678, 78532, 78549, 78451)(78519, 78493, 78574, 6689).\n\nIn vitro research shows that a thymic derivative enhances the functions of mature T-lymphocytes with cascading effects on B-cell and macrophage functions (6689). Also, thymomodulin regulates the maturation of human and murine pre-T lymphocytes and the function of mature human and animal B and T lymphocytes (78485, 6689, 78472). Synthetic thymic hormone T alpha 1 may influence T-cell production and maturation and activate natural killer cell-mediated cytotoxicity (78441). It is also thought that immunosuppressive effects of p15-like factors can be neutralized by thymic peptides (78554). Thymus extract has been shown to stimulate production of interleukin-2 (78475) and T helper type 1 (Th1) immune responses (78555, 78441, 78546). In animal models, as well as in cells isolated from human subjects, thymic peptide upregulated counts and/or activity of peripheral blood cells (78427, 78578, 78424).\n\nIn humans, thymus extract increased spontaneous fluorescence of neutrophils, an indicator of increased neutrophil activity (78439, 78442). In patients with breast cancer, addition of thymostimulin to myelosuppressive chemotherapy enhanced hematological recovery, including increased neutrophil count (78557). In cancer patients, t-activin significantly increased the number of natural killer cells (CD16+) (78561). In patients with recurrent respiratory infections, thymomodulin increased the T4+/T8+ ratio (1177).\n\nNon-human studies indicate the potential for thymomodulin and other thymus extracts to increase bone marrow production and functional activity of white blood cells (78543). In both mice and humans, thymus extract stimulates myelopoiesis (78527). Thymomodulin can promote myelopoiesis as demonstrated by an increase of granulocyte-macrophage colonies in agar (78485). The use of calf thymus extract facilitated chemotherapy by stimulation of myelopoiesis (78447). In humans, thymomodulin may increase the low colony formation, as well as stimulate colony-stimulating factor (CSF) production by human leukocytes, presumably by influencing the interactions between monocytes and lymphocytes (78527).\n\nThymomodulin might also affect immune globulin (Ig) activity. In children with food allergies, thymomodulin significantly decreased total and specific IgE serum levels (1175). In patients with recurrent respiratory infections, thymomodulin significantly increased levels of salivary IgA (6697). In exercising individuals, thymomodulin had a protective effect on the decrease in the IgG2 subclass (78532).\n\nIn humans with immune deficiencies, thymic peptide increased secretion of monocyte chemotactic protein-1 (MCP-1) and IL-8 (78563), and enhanced cell-mediated immune reaction to recall antigens (78577). Thymomodulin also increased cell-mediated immunity and possibly restored the immune capability of patients (78573).\nLipid effects\nIn animal model, a calf thymus protein inhibited HMG-CoA reductase activity (78436).\nThyroid effects\nIn animals, purified thymus gland extract administered intramuscularly reduced serum T4 levels in rats, but did not significantly decrease average thyroid gland weights or serum T3 levels (78514)."
        }
    },
    "Thyroid Extract": {
        "sections": {
            "Overview": "Thyroid extract is derived from animal thyroid gland tissue. Thyroid extract supplements may contain dried and/or ground raw tissue from animal thyroid glands or they may contain extracts of these tissues. Thyroid extract contains both triiodothyronine (T3) and thyroxine (T4) (29981).",
            "Safety": "POSSIBLY UNSAFE when taken orally. Thyroid extract contains triiodothyronine (T3) and thyroxine (T4) (29981). However, the potency of these hormones varies, making dose titration difficult (29982, 29983, 29984, 109614). Using thyroid extract increases the risk of hyperthyroidism and associated cardiac and neurological complications (28621, 29987, 97621).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, thyroid extract may be unsafe due to hormone potency inconsistencies.\nMost Common Adverse Effects\nOrally: Elevated levels of triiodothyronine (T3) and/or thyroxine (T4).\nSerious Adverse Effects (Rare)\nOrally: Thyroid storm or thyrotoxic crisis.\nDermatologic\nIn one case report, a teenage female taking thyroid extract developed multiple nevi on the skin (28622). In another case report, a 30-year-old female with allergic rhinitis and multinodular goiter developed allergic urticaria after treatment with desiccated thyroid extract (28619).\nless\nEndocrine\nClinical research shows that many patients treated with thyroid extract experience abnormally high levels of triiodothyronine (T3) and/or thyroxine (T4) (28621, 29987, 97621). In some patients, these elevated hormone levels result in thyrotoxic crisis or thyroid storm, with symptoms including nausea, vomiting, myalgia, fever, tachycardia, hypertension, agitation, and altered mental state (28621, 29987, 97621). In one case, a healthy 62-year-old female took a thyroid extract that was accidentally compounded to provide T3 and T4 at levels of 720,000 and 30,000 micrograms, respectively, daily. The patient required plasmapheresis for two days to reduce levels of T3 and T4 and reduce the symptoms of thyroid storm (97621).\nless\nImmunologic\nA 30-year-old female with allergic rhinitis and multinodular goiter developed allergic urticaria after treatment with desiccated thyroid extract (28619).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nHypothyroidism. Although there has been interest in using oral thyroid extract for hypothyroidism, there is insufficient reliable information about the clinical effects of thyroid extract for this purpose.\nInfertility. It is unclear if oral thyroid extract is beneficial in females with infertility.\nA small clinical study in female patients with infertility caused by luteal-phase deficiency shows that taking a specific thyroid extract (Thyranon) 25 mg daily to start, and then doubling the dose every 2 weeks to a maximum 100 mg daily, for three menstrual cycles increases pregnancy rate when compared with placebo. Of the patients receiving thyroid extract, 8 out of 17 became pregnant by the fourth month, while only 1 out of 7 patients in the placebo group became pregnant (28618).\nless\nThyroid cancer. Although there has been interest in using oral thyroid extract after treatment for thyroid cancer, there is insufficient reliable information about the clinical effects of thyroid extract for this purpose.\nMore evidence is needed to rate thyroid extract for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nA laboratory analysis shows wide variation in the amount of thyroid hormones present in commercially available thyroid extract products. Of the 19 products analyzed, eight contained measurable amounts of triiodothyronine (T3) and nine contained measurable amounts of thyroxine (T4). These products contained between 0.45-32 mcg of T3 per daily serving and 3.3-210 mcg of T4 per daily serving. Several products contained no detectable T3 or T4 (109614).",
            "Interactions with Drugs": "LEVOTHYROXINE (Synthroid, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, thyroid extract might increase the effects and adverse effects of levothyroxine.\nThyroid extract contains triiodothyronine (T3) and thyroxine (T4) (29981, 97621). Taking thyroid extract increases blood levels of T3 and T4, in some cases to abnormally high levels (28621, 29987, 97621).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "THYROGLOBULIN (Tg)\nThyroid extract might increase Tg levels and interfere with Tg assays. Tg tests are used to monitor for disease recurrence in patients with thyroid cancer. In two cases, Tg levels measured using immunometric assays and liquid chromatography-mass spectrometry were increased in patients with thyroid cancer who were taking desiccated thyroid extract. In both cases, Tg levels returned to normal upon discontinuation of thyroid extract and initiation of levothyroxine (109613).\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with thyroid extract.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of thyroid extract.",
            "Mechanism of Action": "General\nThyroid extract is derived from animal thyroid gland tissue. Thyroid extract contains triiodothyronine (T3) and thyroxine (T4) (29981). However, there is some concern that the potency of these hormones vary among different brands of thyroid extract (29982, 29983, 29984, 97621). Thyroid extract also contains thyroglobulin, inactive metabolites, and impurities (29988).\nEndocrine effects\nThe thyroid hormones T3 and T4, found in varying amounts in thyroid extract, are involved in physiological processes in the body. The main functions involve the regulation of metabolic function and the control of growth and development (29989). Metabolic actions include regulating basal metabolic rate, controlling the movement of fluid and electrolytes, regulating the metabolism of nutrients, and influencing the maturation of the bones and brain (29989)."
        }
    },
    "Tianeptine": {
        "sections": {
            "Overview": "Tianeptine is an atypical antidepressant that is available as a prescription medication in some European, Asian, and Latin American countries. It is not approved for use as a medication by the US Food and Drug Administration (FDA), but is sold as a research chemical. Tianeptine is on the FDA Advisory List of ingredients that do not qualify for dietary use. It is sold as a dietary supplement by companies in China, Mexico, and India (100786, 100793, 115889). Tianeptine has been associated with cases of abuse, withdrawal, and serious adverse effects including death (100786, 100789, 100790, 100796, 100806, 115889).",
            "Safety": "POSSIBLY UNSAFE when used orally. Tianeptine 25-37.5 mg daily has been used with apparent safety under the guidance of a healthcare provider for up to 12 weeks in clinical studies (100792, 100794, 100795). However, there are concerns about the potential for addiction, abuse, and misuse of tianeptine. Excessive tianeptine exposure mimics opioid toxicity and can cause drowsiness, confusion, respiratory depression, constricted pupils, coma, and death. Chronic use can lead to tolerance and symptoms of withdrawal (100786, 100788, 100789, 100790, 100793, 100796, 100799, 100800, 100806, 115889).\nLIKELY UNSAFE when used intravenously. Excessive tianeptine exposure mimics opioid toxicity and can cause drowsiness, confusion, respiratory depression, constricted pupils, coma, and death. Chronic use can lead to tolerance and symptoms of withdrawal (100786, 100788, 100789, 100790, 100793, 100796, 100799, 100800, 100806). Tianeptine is not approved in the US or elsewhere for intravenous use.\nPREGNANCY: POSSIBLY UNSAFE when used orally. Although tianeptine is approved as a prescription drug in certain countries and has been used during pregnancy under the guidance of a healthcare provider when medically necessary (100831), its use is discouraged. Tianeptine use can lead to neonatal abstinence syndrome (NAS), especially when used recreationally, throughout pregnancy. In case reports, babies born to mothers taking high doses of tianeptine (e.g. 650 mg or more daily) during pregnancy presented with NAS. Symptoms included diarrhea, fever, frequent yawning and sneezing, global hypertonia, high-pitched crying, jitteriness, poor feeding, sweating, undisturbed tremors, vomiting, and weak or excessive sucking. This tianeptine-induced NAS mimicked opiate-induced NAS and was treated successfully with morphine (100787, 116139).\nLACTATION: There is insufficient reliable information available about the use tianeptine during lactation. However, tianeptine is a tricyclic antidepressant, and tricyclic antidepressants can be excreted into breast milk (100831). Avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, prescription doses of tianeptine (25-37.5 mg daily) are generally well tolerated, but are occasionally associated with severe adverse effects, and have the potential for abuse and addiction.\nMost Common Adverse Effects\nOrally: Constipation, diarrhea, dizziness, drowsiness, headache, insomnia, nausea, vomiting.\nSerious Adverse Effects (Rare)\nOrally: Agitation, asthenia, confusion, coma, hypertension, liver damage, myalgias, tachycardia, tremor.\nCardiovascular\nOrally, prescription or recreational use of tianeptine has been associated with cardiovascular effects such as tachycardia and high blood pressure (100789, 100831, 115958).\nless\nGastrointestinal\nOrally, prescription or recreational use of tianeptine has been associated with nausea, vomiting, diarrhea, and constipation (100789, 100792, 100831, 111549, 115958, 116138).\nless\nHepatic\nOrally, tianeptine has been linked to cases of acute allergic hepatitis. It has also been associated with cholestatic or hepatocellular liver damage, occurring after 6 days to 8 weeks of tianeptine use (100797, 100807).\nless\nMusculoskeletal\nOrally, tianeptine used in prescription doses (25-37.5 mg daily) may cause asthenia, tremor, and muscle pain (100831). Withdrawal symptoms have occurred after therapeutic doses and may include myalgias, tremors, and myoclonic jerking (106881).\nless\nNeurologic/CNS\nOrally, tianeptine can cause insomnia, drowsiness, dizziness, and headache when used in prescription doses (25-37.5 mg daily) (100831, 111549). Orally, recreational use of tianeptine has been associated with agitation, anxiety, confusion, drowsiness, and seizures (100790, 115958, 116138). In one case, tianeptine misuse was linked to toxic leukoencephalopathy. A 24-year-old male with a 2-year history of tianeptine misuse presented with toxic leukoencephalopathy and respiratory depression, leading to a progressive decline in neurologic status and death (100790).\n\nOrally, long-term use of tianeptine can result in tolerance and withdrawal symptoms. Prescribed doses of tianeptine (25-37.5 mg daily) might cause abuse, dependence, and withdrawal in patients with a past history of drug dependence (100831).\nless\nPulmonary/Respiratory\nOrally, tianeptine has been associated with aspiration pneumonia. In a case report, a 42-year-old male presented with respiratory depression and aspiration pneumonia due to concomitant use of high-dose tianeptine and alprazolam. His respiration improved after administration of naloxone, and he recovered with supportive care (100799).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDepression. Limited research shows that the efficacy of prescription doses of tianeptine in major depression is similar to that of selective serotonin reuptake inhibitors (SSRIs).\nA meta-analysis of clinical research in patients with moderate-to-severe major depression shows that short-term use of prescription tianeptine improves depression symptoms similarly to SSRIs (100794, 100795). A network meta-analysis of 34 studies in adults with depression receiving maintenance therapy with 1 of 20 different antidepressants shows that tianeptine reduces the risk of 6-month relapse by 74% when compared with placebo, with no significant differences between tianeptine and other antidepressants (111548). Also, a preliminary clinical study in patients with depression shows that taking tianeptine 25 mg or 37.5 mg daily for 3 months reduces depression scores by 66% when compared to baseline (100792). The validity of this study is limited by the lack of a control group.\n\nTianeptine has also been evaluated in adults with Alzheimer disease who have depression. A retrospective observational study suggests that taking prescription tianeptine daily for 12 months is associated with similar improvements in depression symptoms, as measured using the Hamilton Depression Rating Scale and Cornell Scale for Depression in Dementia, when compared with some SSRIs and bupropion. However, the depression subscale of the Neuropsychotic Inventory test suggests that tianeptine use may be associated with improvements in symptoms of depression over other antidepressants (111549). The validity of these findings is limited by the retrospective nature of the study.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlzheimer disease. It is unclear if oral tianeptine is beneficial in patients with Alzheimer disease.\nA retrospective observational study in older adults with Alzheimer disease and depression suggests that taking tianeptine daily for 12 months is associated with improvements in some measures of cognitive function, including short term memory, verbal episodic memory, verbal fluency, and linguistic ability, when compared with SSRIs and bupropion. However, tianeptine seems to be similarly effective to SSRIs and bupropion in visual attention, task switching, information processing speed, behavioral and psychological functioning, and tasks of daily living (111549). The validity of these findings is limited by the retrospective nature of the study.\nless\nAnxiety. Although there has been interest in using oral tianeptine for anxiety, there is insufficient reliable information about the clinical effects of tianeptine for this condition.\nAsthma. It is unclear if oral tianeptine is beneficial in patients with asthma.\nPreliminary clinical research in children with asthma shows that taking tianeptine 12.5-18.75 mg daily for up to 24 weeks may improve lung function and symptoms when compared with baseline (100832). The validity of this study is limited by the lack of a control group. Preliminary clinical research shows that tianeptine may also be beneficial in adults with asthma (100833).\nless\nIrritable bowel syndrome (IBS). Oral tianeptine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA clinical study in patients with IBS with diarrhea shows that taking tianeptine 37.5 mg, along with Bacillus subtilis 100 million colony forming units (CFUs) and Streptococcus faecium 900 million CFUs three times daily, improves overall IBS symptoms to the same degree as taking amitriptyline 10 mg daily with the same probiotic regimen for 4 weeks (100805). The effect of tianeptine alone is unclear.\nless\nOpioid withdrawal. Although there has been interest in using oral tianeptine for opioid withdrawal, there is insufficient reliable information about the clinical effects of tianeptine for this purpose.\nPain (chronic). Although there has been interest in using oral tianeptine for chronic pain, there is insufficient reliable information about the clinical effects of tianeptine for this purpose.\nMore evidence is needed to rate tianeptine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nPrescription tianeptine has been used in doses of 25-37.5 mg daily under the supervision of a healthcare professional.\nStandardization & Formulation\nTianeptine is available as a prescription drug in certain countries. It is formulated as coated tablets that contain 12.5 mg of tianeptine per tablet (100831). Prescription tianeptine is not available in the US. Tianeptine has been inappropriately sold as a research chemical and then used as a dietary supplement or injected agent (100789, 100796).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nALCOHOL (Ethanol)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Epidemiologic study)\nAlcohol increases the clearance and might reduce the levels and clinical effects of tianeptine.\nClinical research shows that alcohol decreases tianeptine absorption rate and lowers tianeptine plasma levels by about 30% (100803). Furthermore, an analysis of alcohol blood levels in 112 patients suggests that alcohol use disorder is associated with a 124% increase in clearance of tianeptine (100791).\nless\nASPIRIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nChronic use of aspirin might increase the levels and clinical effects of tianeptine.\nAspirin is converted to salicylic acid in the body. In vitro research shows that salicylic acid binds to the same protein sites as tianeptine, displacing protein-bound tianeptine and leading to higher levels of tianeptine in the blood (100808).\nless\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTianeptine has sedative effects; high doses may have additive effects with other CNS depressants.\nHigher doses of tianeptine have opioid like effects and may have additive effects with other sedative drugs (100796, 100804). In one case report, a 42-year-old male presented with respiratory depression and aspiration pneumonia due to concomitant use of high-dose tianeptine and alprazolam (100799).\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nTianeptine may increase the toxicity of MAOIs.\nConcomitant use of tianeptine and non-selective MAOIs might increase the risk of cardiovascular collapse, hypertension, fever, convulsions, and death (100831).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTianeptine has opioid-like sedative effects at higher doses (12216, 74008). Theoretically, concomitant use of tianeptine with herbs that have sedative properties might enhance the risk for adverse effects. See other products with sedative effects here.",
            "Overdose": "Presentation\nExposure to high doses of tianeptine can cause symptoms similar to opioid toxicity, including altered mental status, respiratory depression, tachycardia, constricted pupils, lethargy, gastrointestinal distress, hypertension, loss of consciousness, coma, and death (100786, 100789, 100796, 106881, 111545, 115958). Acute toxic effects have occurred after doses of 1.5-10 grams, with an average dose of about 1.9 grams according to a review of 65 cases (100786, 100790, 100793, 100796, 100800, 100806, 106881).\n\nWithdrawal symptoms can occur with therapeutic doses of tianeptine, but are more likely after chronic use of 250 mg daily or more (100793, 100800, 100806, 100831). Withdrawal effects of tianeptine resemble those of opioids and include myalgia, chills, sweating, anxiety, agitation, irritability, tremor, nausea, vomiting, diarrhea, tachycardia, hypertension, lacrimation, and yawning (100789, 100793, 100800, 106880, 115958).\n\nIn a case report, a 28-year-old female with a history of bipolar schizoaffective disorder developed psychosis with aggressive, violent behavior, somatic delusions, and disorganized speech after using tianeptine, about 100 mg daily, purchased online. The psychosis resolved when tianeptine was stopped (106880).\nTreatment\nTreatment of acute tianeptine toxicity has often included benzodiazepines, naloxone, and/or supportive care. (100788, 100789, 100790, 100799, 100800, 111545, 115958).\n\nIn one case, a 32-year-old male lost consciousness after a polysubstance overdose with tianeptine 50 mg and etizolam. The overdose was initially treated with naloxone 8 mg and a sternal rub to restore consciousness. In the emergency department, early withdrawal symptoms were treated with IV hydration, methadone, trazodone, clonidine, ibuprofen, loperamide, diazepam, and ondansetron. Upon discharge, the patient was transitioned to gabapentin and buprenorphine. Researchers suggest that tianeptine likely caused the overdose, as the patient recently switched to a more potent formulation, but the presence of potential contaminants is unknown (111545).",
            "Pharmacokinetics": "Absorption\nOrally, tianeptine reaches a maximum concentration in the blood after about 1 hour and has a 99% systemic bioavailability. In healthy volunteers, a single oral 12.5 mg dose of tianeptine results in a maximum serum concentration of about 334 ng/mL (100802, 100803).\nDistribution\nAfter intravenous administration, tianeptine has a volume of distribution of 0.47 L/kg (100803). Orally, the apparent volume of distribution of tianeptine is 0.8 L/kg. It is about 94% protein-bound (100802).\nMetabolism\nTianeptine is extensively metabolized via beta-oxidation into metabolites with a shorter lateral chain (100802, 100803).\nExcretion\nOrally, tianeptine has an elimination half-life of about 2.5 hours. It is minimally renally eliminated (100802, 100803). Intravenously, tianeptine has a total clearance of around 230-270 mL/minute (100803, 111550).",
            "Mechanism of Action": "General\nTianeptine is an atypical tricyclic antidepressant. Its exact mechanism is unknown. It has been shown to increase the rate of serotonin re-uptake, which is thought to enhance serotonin concentrations in the synapse. Tianeptine has opioid activity at higher doses (100796, 100802, 100804).\nAnalgesic effects\nIn animal research, tianeptine's analgesic properties are mediated by mu-opioid receptors (116140).\nCentral nervous system effects\nTianeptine is thought to work for depression by increasing neuroplasticity. It seems to increase spontaneous activity of pyramidal cells in the hippocampus, accelerate their recovery, and increase the rate of serotonin re-uptake (100796, 100804). At higher doses, tianeptine is an atypical mu-opioid receptor agonist, which may contribute to its antidepressant effects. Its primary metabolite, MC5, seems to have similar effects in animal research (100789, 100802, 100804, 106880).\n\nLower doses do not seem to have opioid effects. In healthy patients, taking a lower dose (12.5 mg) of tianeptine by mouth reduces plasma noradrenaline and serotonin levels and increases plasma dopamine and platelet serotonin levels over 4 hours. It does not seem to affect adrenaline, heart rate, or systolic blood pressure (100798).\nNeuropathic pain effects\nAnimal research shows that tianeptine and pregabalin have additive analgesic effects in a rat model of neuropathic pain. When administered concomitantly, tianeptine and pregabalin reduce pain at doses lower than each drug administered alone (111546).\nOpioid-like effects\nAnimal research shows that tianeptine is a mu-opioid receptor agonist with opioid-like adverse effects including motor impairment, constipation, and respiratory depression which can be blocked by pre-treatment with naltrexone. However, there is a notable lack of increasing tolerance and dependence in animals administered tianeptine at increasing doses, suggesting lower abuse potential with tianeptine compared with other opioids (111547).\n\nThere has been some interest in using tianeptine to reverse the respiratory depressant effects of other opioids. This is based on laboratory research showing that tianeptine modulates AMPA receptors which are involved in respiratory drive. However, clinical research shows that tianeptine actually worsens opioid-induced respiratory depression. Researchers theorize that this is due to the mu-opioid receptor agonist effects of tianeptine overriding its potential respiratory stimulating effects (111550).\nRespiratory effects\nThere is interest in using tianeptine for asthma because it reduces free serotonin levels. Patients with symptomatic asthma have higher levels of free serotonin in the blood compared to asymptomatic patients, and the level appears to correlate with asthma severity (100832)."
        }
    },
    "Timothy Grass": {
        "sections": {
            "Overview": "Timothy grass is a common cool-season grass variety located throughout the world. It is native to Europe, northern Africa, and parts of India and Pakistan. However, it is now naturalized across the world and can be found in many countries, including Australia, Canada, Mexico, the United States, Argentina, Chile, Uruguay, Peru, the West Indies, and China. Approximately 17% of the population of Europe is sensitized to timothy grass (97282). Due to the prevalence of allergic reactivity to timothy grass pollen, the pollen extract is a common component in prescription allergy immunotherapy treatments.",
            "Safety": "POSSIBLY SAFE when a specific prescription extract (GRASTEK, Alk Abello A/S) is used sublingually and appropriately. This product has been safely used in clinical trials for up to 34 weeks (15480, 15483, 15485, 97287). ...when administered subcutaneously by a healthcare provider in doses of less than 1.5 mcg pollen extract. Timothy grass pollen allergen extract has been safely administered in clinical trials for up to 2 years (15479, 15489, 97281, 97282, 97285).\nPOSSIBLY UNSAFE when used subcutaneously at doses of 1.5 mcg pollen extract or greater. Severe reactions, including anaphylaxis and angioedema, have occurred in patients receiving these doses (97282, 97286).\nThere is insufficient reliable information available about the safety of non-prescription timothy grass products when used orally.\nCHILDREN: POSSIBLY SAFE when a specific prescription extract (GRASTEK, Alk Abello A/S) is used sublingually and appropriately. This product has been safely used in clinical trials for up to 34 weeks in children 5 years of age and older (97284, 97287). ...when administered subcutaneously by a healthcare provider. Timothy grass has been safely administered in children ages 3-16 years for up to 3 years (15482, 15484).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nTimothy grass pollen is a common airborne allergen, causing allergic rhinitis in sensitive individuals. It is highly cross reactive with a variety of other grasses (97287).\n\nSublingually, timothy grass pollen allergen extract can cause local reactions at the site of application, including pruritus, oral blisters, nasopharyngitis, rhinitis, and throat irritation, which occur more frequently at the onset of treatment and with higher doses (15480, 15483, 15485, 15486, 97287). In a dose escalation study, doses up to 100 mcg per day were tolerated without exacerbation of asthma or serious adverse effects (15485).\n\nSubcutaneously, timothy grass pollen allergen extract can cause local reactions at the injection site (15481, 15482, 15489, 97282), as well as systemic reactions which occur more frequently at higher doses and include urticaria, angioedema, and anaphylaxis (97282).\nDermatologic\nWhen taken sublingually, timothy grass pollen allergen extract can cause local reactions at the site of application. These reactions include oral, nasal, and ear pruritus, oral blisters, nasopharyngitis, rhinitis, and throat irritation. Such reactions are generally early-occurring and self-resolving (15480, 15483, 15485, 15486, 97287). Subcutaneous administration of timothy grass pollen allergen extract can cause local reactions at the injection site (15481, 15482, 15489, 97282). Reactions to timothy grass pollen allergen extract, regardless of the route of administration, tend to occur more frequently at increased doses.\nless\nImmunologic\nTimothy grass pollen is a common airborne allergen, causing allergic rhinitis upon exposure by sensitive individuals. Timothy grass is cross-reactive with a variety of other grasses, including cocksfoot, Kentucky bluegrass, perennial rye, sweet vernal, redtop, and meadow fescue. It is also partially cross-reactive with Johnson grass (97287). Subcutaneous administration of timothy grass pollen allergen extract has been associated with systemic reactions, including anaphylaxis, angioedema, allergic pruritus, cough, and rhinorrhea (97282, 97286). Severe reactions, including anaphylaxis and angioedema, have only been reported with higher doses of 1.5-3 mcg of pure timothy grass pollen allergen 5 (97282, 97286).\nless",
            "Effectiveness": "Allergic rhinitis (hay fever). Timothy grass prescription products have been shown to reduce allergic rhinitis symptoms in children and adults with timothy grass allergy. There is no reliable evidence to suggest that non-prescription or homeopathic timothy grass products would be beneficial.\nPrescription sublingual timothy grass tablets have been shown to reduce the severity of allergic rhinitis in children and adults with a positive reaction to timothy grass. Clinical research shows that placing a specific sublingual tablet containing timothy grass pollen allergen extract (GRASTEK, Alk Abello A/S) under the tongue once daily for 12 weeks prior to the grass pollen season, and continuing until the end of the season, reduces daily symptom severity by 20% and daily rescue medication use by 35% when compared with placebo (15480, 15483, 15486, 97287). This product appears to improve allergy-related quality of life better than taking loratadine alone (15486), and demonstrates similar efficacy in adults and children 5 years of age and older (97284, 97287). This sublingual tablet is approved by the US Food and Drug Administration (FDA) for this indication.\n\nFDA-approved subcutaneous immunotherapy with timothy grass pollen extract has also been shown to reduce severity of allergic rhinitis. When administered subcutaneously, dose escalation regimens are typically used, with a maximum targeted dose that is determined by the baseline degree of reactivity to the allergen. One dose-finding study found that dose escalation sequences administered over 3, 5, or 7 weeks targeting the maximum dose were associated with comparable safety (97286). The majority of studies have employed a 5- or 6-week dose escalation of weekly injections, followed by maintenance injections administered either bi-weekly or monthly thereafter (15479, 15482, 97281, 97282, 97285).\n\nThere is insufficient reliable information available about the effectiveness of timothy grass for any other use.\nless",
            "Dosing & Administration": "Adult\nSublingual:\nAllergic rhinitis (hay fever): A specific standardized timothy grass pollen allergen extract (GRASTEK, Alk Abello A/S) containing 2800 Bioequivalent Allergy Units (BAU), corresponding to 15 mcg, is approved by the US Food and Drug Administration (FDA) to be placed under the tongue daily starting 8-12 weeks before, and continuing throughout, grass pollen season for up to 34 weeks total (15480, 15483, 15486, 97287). Non-prescription timothy grass products have not been evaluated for this use.\nSubcutaneous:Allergic rhinitis (hay fever): Short-term dose escalation regimens, followed by long-term maintenance regimens, are typically used for subcutaneous immunotherapy treatment (97281, 97282, 97285).\nChildren\nSublingual:\nAllergic rhinitis (hay fever): In children 5 years of age or older, a specific standardized timothy grass pollen allergen product (GRASTEK, Alk Abello A/S) containing 2800 Bioequivalent Allergy Units (BAU), corresponding to 15 mcg, is approved by the US Food and Drug Administration (FDA) to be placed under the tongue daily starting 8-12 weeks before, and continuing throughout, grass pollen season for up to 34 weeks total (97287). Non-prescription timothy grass products have not been evaluated for this use.\nSubcutaneous:Allergic rhinitis (hay fever): A specific subcutaneous immunotherapy timothy grass pollen allergen extract (Alutard SQ, Alk Abello) 20 mcg twice weekly starting 8 weeks before and continued through grass pollen season has been used (15482).\nStandardization & Formulation\nA sublingual tablet formulation of timothy grass pollen allergen extract (GRASTEK, ALK-Abello A/S) has been standardized to contain 2,800 Bioequivalent Allergy Units (BAU), which is equivalent to 75,000 Standardized Quality Units, or approximately 15 mcg of timothy grass pollen allergen 5 (Phl p 5) (97287). This product is an FDA-approved prescription product in the US.\n\nPollen extracts for injection may be standardized against a variety of units, including skin-prick test (SPT) units, standardized quality (SQ) units, and treatment standardized units (TSU). Each unit is associated with a specific mcg/mL quantity of pure timothy grass pollen allergen 5 (Phl p 5) (97282, 97286). One product, Depigoid Phleum (LETI Pharma), contains depigmented and glutaraldehyde polymerized timothy grass pollen allergens 1 and 5 (Phl p 1 and 5) (97285).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of timothy grass.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of timothy grass.",
            "Mechanism of Action": "General\nThe applicable part of timothy grass is the pollen extract, which contains allergy-causing glycoproteins. Timothy grass pollen contains up to 20% arabinogalactan proteins, consisting of 95% polysaccharide and 5% protein (15487).\nImmune effects\nThe glycoproteins in the pollen extract of timothy grass cause allergy to timothy grass as well as cross-sensitivity to almost all grasses and corn species. High levels of cross-reactivity have been confirmed for cocksfoot, Kentucky bluegrass, perennial rye, sweet vernal, redtop, and meadow fescue. Partial cross-reactivity with Johnson grass has also been confirmed (97287). Animal research suggests starch granules in timothy grass pollen may be responsible for allergy.\n\nSmall doses of timothy grass pollen allergen are used to desensitize allergic patients (15479, 15482, 15488, 15491, 97281, 97282, 97285). Subcutaneous injection of timothy grass pollen allergen in a variety of proprietary formulations causes increased levels of the inhibitory cytokine interleukin-10 during pollen season and blocks IgG activity, resulting in a reduction of allergy symptoms (15479, 97282, 97285). Sublingual administration of timothy grass pollen allergen in humans and animals causes dose-dependent increases in allergen-specific IgE, IgG, and IgA antibody response, suggesting an allergen-specific effect on the immune system with allergen-specific T lymphocytes (15483, 15492, 15493).\n\nAnimal research suggests that intratracheal instillation of timothy grass pollen cytoplasmic granules induce antibodies and immune responses similar to those obtained with intact pollen (15490)."
        }
    },
    "Tin": {
        "sections": {
            "Overview": "Tin (Sn) is a metallic element with an atomic number of 50 and an atomic weight of 118.71. It can exist as a pure metallic compound or as part of tin compounds. Compounds containing tin include those in which tin combines with other elements such as chloride, fluoride, sulfur, or oxygen (28635, 28641). Tin is considered to be an ultratrace mineral, meaning the estimated or suspected dietary requirement is typically less than 1 mg per day (75111).",
            "Safety": "LIKELY SAFE when tin in the form of stannous fluoride is used topically and appropriately. Stannous fluoride is approved for use by the US Food and Drug Administration (FDA) as an ingredient in dentifrices, gels, and other dental hygiene products. The concentration of stannous fluoride in dentifrices in the US is 0.454% (98554).\nThere is insufficient reliable information available about the safety of tin when used orally in medicinal amounts.\nCHILDREN: LIKELY SAFE when tin in the form of stannous fluoride is used topically and appropriately in children aged 6 years and older. Stannous fluoride is approved for use by the US Food and Drug Administration (FDA) as an ingredient in dentifrices, gels, and other dental hygiene products. The concentration of stannous fluoride in dentifrices in the US is 0.454% (98554). There is insufficient reliable information available about the safety of tin when used orally in medicinal amounts.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, intake of food contaminated with large amounts of tin may cause gastrointestinal effects, including diarrhea, stomach pain, nausea, and anemia (28635).\n\nTopically, dentifrices and mouthwashes containing tin as stannous fluoride or stannous chloride may cause teeth staining or tongue discoloration (28648, 94409, 101106, 106016).\n\nWhen inhaled long-term, tin may cause stannosis (28635).\nDermatologic\nWhen used topically on the teeth, stannous fluoride or stannous chloride dentifrice gels or pastes can cause teeth staining or tongue discoloration (28648, 94409, 101106, 106016).\nless\nGastrointestinal\nOrally, intake of food contaminated with large amounts of tin may cause gastrointestinal effects. Several cases of gastrointestinal events, including diarrhea, stomach pain, nausea, and/or gastroenteritis have been reported for patients who ingested foods contaminated with tin from tin cans. The dose of tin contained in these foods ranged from 250-1000 mg/kg body weight (28635). Consumption of food containing lower amounts of inorganic tin (100-200 ppm) has not been associated with adverse gastrointestinal effects (28650).\nless\nHematologic\nOrally, intake of food contaminated with large amounts of tin has caused anemia (28635).\nless\nPulmonary/Respiratory\nMultiple cases of stannosis, a benign form of pneumoconiosis, have been reported for patients exposed to inhalable tin dust, long-term (15 to 20 years). The exposure levels for these cases have not been reported (28635).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIKELY EFFECTIVE\nGingivitis. Dentifrices containing various forms of tin have shown some benefit for improving symptoms of gingivitis; most research has evaluated the use of stannous fluoride.\nMost research shows that dentifrices containing tin as stannous fluoride reduce gingivitis by a small but clinically meaningful amount. One meta-analysis of clinical research shows that stannous fluoride dentifrices modestly reduce gingivitis when compared with placebo or vehicle control when evaluated using the gingival index or modified gingival index (87068). A clinical study in healthy adults with gingivitis shows that a dentifrice containing stannous fluoride 0.454% and stabilized with zinc phosphate (Colgate Total, Colgate-Palmolive Company), applied twice daily for 6 months, reduces gingival inflammation when compared with baseline. However, the validity of these findings is limited by a lack of statistical comparison to sodium monofluorophosphate (106017). Another meta-analysis of 13 trials shows that using a dentifrice containing stannous fluoride is at least as effective as a dentifrice containing triclosan for reducing symptoms of gingivitis, including gingival bleeding (94409). Also, a clinical study in patients with mild to moderate gingivitis shows that a specific stannous fluoride dentifrice (Crest Pro-Health Clinical Gum Protection, Proctor & Gamble) reduces the number of gingival bleeding sites by 74% after 3 months when compared to baseline; this improvement is significant when compared with a control fluoride dentifrice (98566).\n\nResearch on the use of other forms of tin has also shown benefit. One large meta-analysis of clinical research shows that gluconate chelated stannous fluoride 0.454% dentifrices applied for up to 3 months improve the average number of bleeding sites by 51% when compared with sodium fluoride or sodium monofluorophosphate dentifrice and 31% when compared with triclosan, regardless of baseline disease severity (106014). Another clinical study in healthy adults with gingivitis shows that an amine fluoride dentifrice containing stannous chloride applied twice daily for 12 weeks reduces gingivitis and gingival bleeding when compared with baseline. Stannous chloride seems to be slightly more effective than sodium monofluorophosphate for reducing gingivitis at 12 weeks (101106).\nless\nPOSSIBLY EFFECTIVE\nDental hypersensitivity. Most research shows that tin is beneficial for reducing dental hypersensitivity, although it may not be as effective as other ingredients.\nTwo meta-analyses of clinical research show that topical application of gel or dentifrice containing tin in the form of stannous fluoride 0.4% for up to 8 weeks improves dental hypersensitivity when compared with placebo (28649, 98560). However, it seems to take about 2 weeks before improvements occur. This is in contrast to topical fluoride solution 0.717%, which relieves hypersensitivity in approximately 3-5 minutes (28649, 98562). Another clinical study in healthy adults with dental hypersensitivity shows that a dentifrice containing anhydrous stannous fluoride 0.454% with sodium fluoride 0.072% applied twice daily for 8 weeks improves sensitivity and tactile threshold scores when compared with baseline. However, stannous fluoride is less effective than sodium monofluorophosphate for improving sensitivity scores (106015).\n\nTin has also been evaluated in endurance athletes, who are at increased risk for dental erosion. A small clinical study shows that a once daily oral hygiene regimen providing stannous fluoride in both a mouth rinse and chitosan-containing dentifrice improves dental erosion in endurance athletes after about 2 years of use when compared with a fluoridated dentifrice. However, dental hypersensitivity and saliva pH were unaffected (106016).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nDental plaque. Overall, using a dentifrice containing tin in the form of stannous fluoride seems to modestly reduce plaque; however, the improvement might not be clinically meaningful.\nOne analysis of clinical research shows that using dentifrices with stannous fluoride reduces plaque by only a small amount when compared with placebo or vehicle control (87068). When compared to other active dentifrices, results from clinical research are conflicting. Some research shows that stannous fluoride dentifrices reduce plaque by a moderate amount when compared with sodium fluoride dentifrices when measured using the Turesky modification of the Quigley & Hein index, but not when measured by the plaque index (28648). A clinical study in healthy adults with gingivitis shows that a dentifrice containing stannous fluoride 0.454% and stabilized with zinc phosphate (Colgate Total, Colgate-Palmolive Company), applied twice daily for 6 months, reduces plaque when compared with baseline. However, the validity of these findings is limited by a lack of statistical comparison to sodium monofluorophosphate (106017). Additional research shows that stannous fluoride dentifrices reduce plaque similarly to triclosan dentifrices according to the Rustogi Modified Navy Plaque Index. However, when measured using the Turesky modification of the Quigly-Hein Plaque Index, triclosan dentifrices seem to reduce plaque more than stannous fluoride (94409).\n\nA clinical study in healthy adults with gingivitis shows that an amine fluoride dentifrice containing stannous chloride applied twice daily for 12 weeks is 33% more effective than a sodium monofluorophosphate dentifrice for reducing dental plaque, as measured by the plaque index, when compared with baseline (101106).\nless\nDry mouth. Preliminary clinical research shows that using a specific gel (Enamelon Preventive Treatment Gel, Premier Dental products Co.) containing tin as stannous fluoride 0.4% each evening for 14 days reduces symptoms of dry mouth, with 70% of patients rating the product at least 'good' for improving symptoms such as discomfort, as well as for improving lubrication and moisturization. However, it seems to be less effective than Biotene Oral Balance moisturizing gel, which was rated at least 'good' for the relief of these symptoms by 84% of patients (98565).\nHalitosis. A meta-analysis of four clinical studies including 100 patients shows that using a dentifrice containing tin as stannous fluoride 0.4% (Crest Pro-Health) three times over a 28-hour period improves bad breath by 7.7% at 3-4 hours after a single use, 10.6% after two uses and a sleep (morning breath), and 24.5% after a third use that morning, when compared to a control fluoride toothpaste in individuals with halitosis (98561). The long-term effects of this dentifrice on halitosis are unknown.\nMore evidence is needed to rate tin for these uses.",
            "Dosing & Administration": "Adult\nTopical:\nDental hypersensitivity: Dentifrices, dentifrice gels, and mouth rinses containing tin as stannous fluoride 0.4% to 0.454%, applied at least once daily for 2-8 weeks, have been used (28649, 98560, 106015, 106016).\n\nDental plaque: Dentifrices and dentifrice gels containing tin as stannous fluoride 0.4% to 0.454%, applied at least once daily for up to 2 years, have been used (28648, 94409, 106017). A dentifrice containing tin as stannous chloride, applied twice daily for 12 weeks, has been used (101106).\n\nDry mouth: A gel containing tin as stannous fluoride 0.4% applied in the mouth each evening for 14 days has been used (98565).\n\nGingivitis: Dentifrices and dentifrice gels containing tin as stannous fluoride 0.4% to 0.454%, applied at least once daily for up to 2 years, have been used (28648, 94409, 98566, 106017). Dentifrices containing tin as stannous fluoride 0.454% chelated to gluconate, applied for up to 3 months, have been used (106014). A dentifrice containing tin as stannous chloride, applied twice daily for 12 weeks, has also been used (101106).\n\nHalitosis: A dentifrice gel containing tin as stannous fluoride 0.4%, applied three times over a 28-hour period, has been used (98561).\nStandardization & Formulation\nThe most common form of tin used in commercial products is stannous fluoride. Stannous fluoride is typically used as a source of fluoride in dental products. The concentration of stannous fluoride in these products ranges from 0.4% to 0.454% (28648, 28649, 94409, 106014, 106015, 106017).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCOPPER\nIn animal research, dietary tin 200 mcg/gram decreased the retention of copper in tissues and increased copper excretion (28667). Theoretically, dietary tin might reduce copper levels.\nIRON\nIn animal research, moderate-to-high levels of dietary tin decreased levels of serum iron (28663). Theoretically, dietary tin might reduce iron levels.\nZINC\nIn animal research, dietary tin decreased the retention of zinc in tissues and increased zinc excretion (28667). Theoretically, dietary time might reduce zinc levels.",
            "Interactions with Lab Tests": "RADIONUCLIDE ANGIOGRAPHY\nThe presence of tin II ion in blood has been implicated as a pharmaceutical factor contributing to technical difficulty experienced during the process of erythrocyte labeling with 99mTc pertechnetate followed by incubation with tin (28642).\nless",
            "Overdose": "In general, the toxicity of inorganic tin is low due to its poor bioavailability and rapid excretion (28637, 28641, 28651, 28652, 28653, 28656). Oral exposure to inorganic tin has not been associated with fatalities (28635). The Agency for Toxic Substances and Disease Registry (ATSDR) of the US Department of Health and Human Services has derived an intermediate-duration oral minimal risk level (MRL) of 0.3 mg/kg daily for inorganic tin in the form of stannous chloride. This was based on a no-observed-adverse-effect level (NOAEL) of 32 mg/kg daily for hematological effects in rats (28635).",
            "Pharmacokinetics": "Absorption\nApproximately 5% of ingested inorganic tin salts are absorbed in the gastrointestinal tract; however, organotin compounds are absorbed from the gastrointestinal tract more readily (28637).\nDistribution\nOnce absorbed from the gastrointestinal tract, inorganic tin salts are widely distributed in tissues, such as lung, bone, liver, and kidneys (28637). In animals, the thymus is found to contain higher levels of tin (28673). Methylated metals, such as methyl tin, show increased mobility, more efficient transport in the body, and increased potential for passing through barriers such as the placental and blood-brain barriers (28674).\nExcretion\nInorganic tin salts that are absorbed in the gastrointestinal tract are rapidly excreted in the feces (28637).",
            "Mechanism of Action": "General\nTin (Sn) is a metallic element with an atomic number of 50. It exists as a pure metallic compound or as part of inorganic and organic compounds (28641).\nAntibacterial effects\nThe antibacterial effects of tin in the form of stannous fluoride are thought to be partially due to a block of selenium metabolism in the bacterial pathogen (28668). In human research, use of a dentifrice and mouthwash containing both amine fluoride and stannous fluoride resulted in a trend toward reduced amounts of Streptococcus mutans and Lactobacillus in saliva when compared with dentifrice and mouthwash containing sodium fluoride (28669). Anhydrous preparations of stannous fluoride appear to result in a stable, uncomplexed form of the tin ion with antibacterial activity and the ability to be deposited onto surfaces reducing plaque formation (28670). In aqueous preparations, however, the tin ion is stabilized using strong complexing ions resulting in a reduced ability for deposition on to surfaces and reduced antibacterial effects.\nDental mineralizing effects\nTin in the form of stannous fluoride promotes remineralization of partially demineralized tooth enamel. It reduces erosion by increasing resistance of enamel to an acid attack and then reacting with the enamel to form a protective tin fluorophosphate coating on the tooth surface (28666, 28671, 28672, 98559). This protection seems to last for hours after treatment (98559).\nDentin-desensitizing effects\nAnhydrous preparations of in tin the form of stannous fluoride form a tin-rich deposit when brushed onto dentin (28670) blocking the dentinal tubules and preventing stimulation of free nerve endings (28649).\nImmunomodulating effects\nIn rats, tin influences the activity of heme oxygenase commonly associated with immune function and thymus homeostasis (75111). Also, it has been suggested that the thymus may secrete tin-bearing factors involved in increasing immunity toward malignancies, and these compounds may slow age-related immune function loss (28636)."
        }
    },
    "Tinospora Cordifolia": {
        "sections": {
            "Overview": "Tinospora cordifolia is a common deciduous climbing shrub native to India that grows on other trees, including the mango and neem trees (92226). It is also found in the tropics of Africa and Australia. Tinospora cordifolia is used in Ayurvedic medicine, with traditional uses ranging from gastrointestinal, liver, and genitourinary conditions to infections and skin diseases (92226, 92229, 92231).",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using Tinospora cordifolia for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "POSSIBLY SAFE when the stem extract is used orally and appropriately, short-term. Tinospora cordifolia aqueous stem extract has been used with apparent safety at a dose of 900 mg daily for up to 8 weeks (15085). Powdered stem extract has also been used with apparent safety at a dose of up to 3 grams daily for up to 2 weeks or a dose of 1500 mg daily for up to 26 weeks (92230, 106846, 111503).\n\nThere is insufficient reliable information available about the safety of other parts of Tinospora cordifolia when used orally or when any part of the plant is used topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Tinospora cordifolia seems to be well tolerated. Topically, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Headache and nasal pain.\n\nTopically: Burning, erythema, and pruritus.\nSerious Adverse Effects (Rare)\nOrally: Liver injury has been reported.\nDermatologic\nTopically, Tinospora cordifolia has been reported to cause pruritus, erythema, and burning (92220).\nless\nHepatic\nOrally, liver injury is reported after consumption of Tinospora cordifolia. In 2 case series, autoimmune hepatitis, acute hepatitis, worsening of chronic liver disease, or acute liver failure is reported in 49 patients after consuming various forms and doses of Tinospora cordifolia alone or in combination with other ingredients for a median of 42-90 days. Of these patients, 2 required a liver transplant and 4 died (110533, 110534).\n\nLiver injury is also reported in patients taking combination supplements containing Tinospora cordifolia. One case reports a 50-year-old female who presented with a 2-week history of constant right upper quadrant abdominal pain, nausea, loss of appetite, and fatigue, along with severely elevated alanine transaminase (ALT) and aspartate aminotransferase (AST), after taking a specific combination product containing Tinospora cordifolia 900 mg, stinging nettle 600 mg, and quercetin 600 mg (HistaEze) daily for 4 to 5 weeks (112404). Another case reports a 54-year-old female who developed acute hepatitis with elevated ALT, AST, alkaline phosphatase, gamma-glutamyl transferase, and bilirubin after consuming a multi-ingredient product containing approximately 1900 mg of Tinospora cordifolia and 11 other Ayurvedic herbals daily for 2.5 months (112405). In both cases, liver function returned to normal within 3 months of discontinuing the supplement (112404, 112405). It is unclear whether the liver injury in these cases is due to Tinospora cordifolia, other ingredients, or the combination.\nless\nNeurologic/CNS\nOrally, Tinospora cordifolia has been reported to cause headache in a clinical trial (15085).\nless\nPulmonary/Respiratory\nOrally, Tinospora cordifolia extract has been reported to cause nasal pain in a clinical trial (15085).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDiabetes. Oral Tinospora cordifolia seems to reduce glycated hemoglobin and fasting blood glucose in adults with type 2 diabetes.\nA meta-analysis of 2 moderate-sized clinical trials in adults with type 2 diabetes shows that taking Tinospora cordifolia extract 500 mg or 1500 mg daily for 9 or 26 weeks, respectively, reduces glycated hemoglobin by 0.5% when compared with no additional medicine. Additionally, meta-analysis of 2 small to moderate-sized clinical trials in adults with type 2 diabetes shows that taking Tinospora cordifolia extract 1500 mg daily for 26 weeks as tablets or as a decoction 5 mL daily for 9 weeks reduces fasting blood glucose by 4 mg/dL when compared with placebo or no additional medicine (111503). However, all studies were conducted in India; it is unclear if these findings can be extrapolated to other geographic locations.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAllergic rhinitis (hay fever). It is unclear if oral Tinospora cordifolia extract is beneficial in patients with allergic rhinitis.\nOne small clinical trial in patients with allergic rhinitis shows that taking a specific Tinospora cordifolia aqueous stem extract (Tinofend, Verdure Sciences) 300 mg three times daily for 8 weeks decreases sneezing, as well as nasal itching, discharge, and obstruction, when compared with placebo (15085).\nless\nAsthma. Although there has been interest in using oral Tinospora cordifolia for asthma, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nAthletic performance. It is unclear if oral Tinospora cordifolia extract is effective for improving athletic performance.\nOne small clinical study in healthy males shows that taking Tinospora cordifolia stem powdered extract 150-300 mg daily for 28 days improves speed during cycling and hand grip strength when compared to baseline; however, these improvements are not significant when compared with placebo (92230).\nless\nCancer. Although there has been interest in using oral Tinospora cordifolia for cancer, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nCoronavirus disease 2019 (COVID-19). Although there has been interest in using oral Tinospora cordifolia for COVID-19, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nDiabetic foot ulcers. It is unclear if oral Tinospora cordifolia is beneficial in patients with diabetic foot ulcers.\nOne small clinical study in patients with diabetic foot ulcers shows that taking Tinospora cordifolia extract (dose unknown), in conjunction with standard treatment, for one month reduces the total number of debridements by 24% and the extent of phagocytosis in the wound when compared with placebo plus standard treatment. However, Tinospora cordifolia does not appear to improve the wound severity, size, or depth when compared with placebo (92227).\nless\nGout. Although there has been interest in using oral Tinospora cordifolia for gout, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nHepatitis. Although there has been interest in using oral Tinospora cordifolia for hepatitis, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nHyperlipidemia. Although there has been interest in using oral Tinospora cordifolia for hyperlipidemia, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nHypertriglyceridemia. It is unclear if oral Tinospora cordifolia extract is beneficial in patients with hypertriglyceridemia.\nOne small clinical study in patients with hypertriglyceridemia shows that taking Tinospora cordifolia stem extract 3 grams daily for 14 days reduces levels of triglycerides and low-density lipoprotein (LDL) cholesterol by around 170 mg/dL and 25 mg/dL, respectively, while increasing high-density lipoprotein (HDL) cholesterol levels by 12 mg/dL when compared to baseline. Patients in a control group taking metformin saw smaller improvements in these lipid levels, although a statistical comparison between Tinospora cordifolia and metformin was not reported (106846).\nless\nOsteoarthritis. Oral Tinospora cordifolia has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical study in adults with osteoarthritis shows that taking a specific Ayurvedic formulation (shunthi-guduchi) containing Tinospora cordifolia 440 mg, Indian gooseberry 1000 mg, and ginger 200 mg, with or without Boswellia serrata 600 mg, in divided doses daily for 24 weeks improves pain and functionality as effectively as celecoxib or glucosamine sulfate (89557). However, the clinical validity of these results is limited by the lack of a placebo control. Also, it is unclear if these findings are due to Tinospora cordifolia, other ingredients, or the combination.\nless\nPeptic ulcers. Although there has been interest in using oral Tinospora cordifolia for peptic ulcers, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nRheumatoid arthritis (RA). Although there has been interest in using oral Tinospora cordifolia for RA, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nScabies. It is unclear if topical Tinospora cordifolia lotion is beneficial in patients with scabies.\nOne small clinical study in children and young adults shows that topical application of Tinospora cordifolia lotion 3 days weekly for 2 weeks is as effective as permethrin 5% lotion for clearing the symptoms of scabies. At 28 days from the initiation of treatment, complete cure occurs in 70% of patients applying Tinospora cordifolia, compared with 50% of patients applying permethrin (92220).\nless\nSexual desire. Although there has been interest in using oral Tinospora cordifolia for increasing sexual desire, there is insufficient reliable information about the clinical effects of Tinospora cordifolia for this purpose.\nMore evidence is needed to rate Tinospora cordifolia for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable. Tinospora cordifolia aqueous and powdered stem extract have been used at varying doses in clinical studies. See Effectiveness section for condition-specific information.\nTopical:\nResearch is limited; typical dosing is unavailable.\nChildren\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nOne ayurvedic formulation for oral use, shunthi-guduchi, contains Indian gooseberry 166.66 mg, ginger 33.33 mg, and Tinospora cordifolia 73.33 mg per capsule. The addition of Boswellia serrata 100 mg is known as SGCG; without Boswellia serrata the formulation is known as SGC (89557).\n\nOne marketed Tinospora cordifolia product (Tinofend, Verdure Sciences) contains aqueous stem extract 300 mg, containing more than 5% bitter principles (15085).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nA (High-quality meta-analysis (quantitative systematic review))\nTheoretically, Tinospora cordifolia might increase the risk of hypoglycemia when taken with antidiabetes drugs.\nClinical research in adults with type 2 diabetes shows that Tinospora cordifolia can reduce fasting blood glucose and glycated hemoglobin (111503). Additionally, animal research shows that Tinospora cordifolia has hypoglycemic effects (15079, 15080, 15082, 15083, 106847).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Tinospora cordifolia might increase levels of drugs metabolized by CYP1A2.\nIn vitro research shows that Tinospora cordifolia extract inhibits CYP1A2 at high concentrations (98225). However, this interaction has not been reported in humans.\nless\nCYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Tinospora cordifolia might increase levels of drugs metabolized by CYP2C19.\nIn vitro research shows that Tinospora cordifolia extract inhibits CYP2C19 at high concentrations (98225). However, this interaction has not been reported in humans.\nless\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Tinospora cordifolia might increase levels of drugs metabolized by CYP2C9.\nIn vitro research shows that Tinospora cordifolia extract inhibits CYP2C9. Animal research shows that Tinospora cordifolia extract 400 mg/kg twice daily for 14 days reduces the clearance and increases plasma levels of glyburide, a CYP2C9 substrate (98225). However, this interaction has not been reported in humans.\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Tinospora cordifolia might increase levels of drugs metabolized by CYP2D6.\nIn vitro research shows that Tinospora cordifolia extract inhibits CYP2D6 at high concentrations (98225). However, this interaction has not been reported in humans.\nless\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Tinospora cordifolia might reduce the effectiveness of immunosuppressants.\nIn vitro and animal research shows that Tinospora cordifolia has immunostimulant effects (15081, 15086, 15089).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, Tinospora cordifolia might have hypoglycemic effects.\nTaking Tinospora cordifolia with other products with hypoglycemic potential might increase the risk of hypoglycemia. Clinical research in adults with type 2 diabetes shows that Tinospora cordifolia can reduce fasting blood glucose and glycated hemoglobin (111503). Additionally, the hypoglycemic effects of Tinospora cordifolia have been documented in animal studies (15079, 15080, 15082, 15083, 106847). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nAUTOIMMUNE DISEASES\nTheoretically, Tinospora cordifolia might have immunostimulant effects, which could exacerbate autoimmune diseases by stimulating disease activity. Until more is known, advise patients with autoimmune diseases to avoid or use Tinospora cordifolia with caution. The immunostimulant effects of Tinospora cordifolia have been documented in in vitro and animal studies (15081, 15086, 15089).\nless\nPERIOPERATIVE\nTinospora cordifolia might have hypoglycemic effects (15079, 15080, 15082, 15083, 106847, 111503), which might interfere with blood glucose control if used perioperatively. Tell patients to discontinue Tinospora cordifolia at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Tinospora cordifolia.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Tinospora cordifolia.",
            "Mechanism of Action": "General\nThe applicable part of Tinospora cordifolia is the whole plant. The whole plant extract contains the bitter principles columibin, chasmanthin, and palmarin. The leaves contain calcium, phosphorus, and alkaloids including tinosporide, tinosporic acid, tinosporol, and protoberberine. Other constituents identified in the plant include lignans, diterpenes, furan lactones, phenyl propane glycosides, arabinogalactan, cordifol, and cordifolide. The stem contains the alkaloids berberine, palmitine, tembertarine, and magniflorin (92228, 92232). Tinosporin, a constituent, has been identified in the leaves, stem, and roots (15092, 92223, 92228).\nAnalgesic effects\nIn animal models, an aqueous methanolic extract of the whole Tinospora cordifolia plant has analgesic, anti-inflammatory, and anti-pyretic effects (92222).\nAnti-allergic effects\nFor allergic rhinitis, Tinospora cordifolia is thought to produce immunostimulatory effects and decrease mast cell release of histamine (15085).\nAnti-cancer effects\nThere is interest in using Tinospora cordifolia for treating cancer. An alcohol extract of Tinospora cordifolia has antitumor effects in animal models of lymphoma. This extract increases macrophage phagocytosis and increases the secretion of IL-1 and tumor necrosis factor (TNF). It also seems to slow tumor growth and increase survival in tumor-bearing animal hosts (15078). In combination with radiation, a Tinospora cordifolia stem extract increases survival of mice in a cancer model (92228). In vitro, Tinospora cordifolia extracts have cytotoxic activity against cervical cancer cells which is comparable to doxorubicin (15084). The cytotoxic effects of Tinospora cordifolia extract appear to be due to pro-oxidant and lipid peroxidative effects with a decrease in glutathione-S-transferase activity (92223, 92228).\n\nIn other animal models, Tinospora cordifolia extracts seem to decrease angiogenesis (15090).\nAnti-diabetic effects\nClinical research in adults with type 2 diabetes shows that Tinospora cordifolia can reduce fasting blood glucose and glycated hemoglobin (111503). Additionally, in animal research, aqueous and alcoholic extracts of Tinospora cordifolia seem to lower blood glucose and lipid levels in models of diabetes (15079, 15080, 15082, 15083, 92229, 106847). Tinospora cordifolia might affect glucose levels by increasing pancreatic excretion of insulin, increasing tissue utilization of glucose, decreasing glucose absorption from the gastrointestinal tract, or a combination of these (15079). Constituents of Tinospora cordifolia, including palmatine, jatorrhizine, mangnoflorine, and berberine, are reported to have insulin mimicking and releasing effects (98225).\nAnti-inflammatory effects\nIn animal models, an aqueous methanolic extract of the whole Tinospora cordifolia plant has analgesic, anti-inflammatory, and anti-pyretic effects (92222). In an animal model of rheumatoid arthritis, the anti-inflammatory effects of an extract of Tinospora cordifolia aerial parts are related to decreased production of inflammatory cytokines (92231).\nAnti-osteoporotic effects\nIn an ovariectomized animal model, a Tinospora cordifolia ethanolic stem extract reduces bone loss without mimicking the hormonal effects of estrogen on the reproductive organs (92224). Tinospora cordifolia stem and aerial extracts also reduce bone turnover, possibly by inhibiting degradation by osteoclasts (92224, 92231).\nAnti-pyretic effects\nIn animal models, an aqueous methanolic extract of the whole Tinospora cordifolia plant has analgesic, anti-inflammatory, and anti-pyretic effects (92222).\nAntioxidant effects\nTinospora cordifolia has antioxidant effects. In animal and in vitro research, Tinospora cordifolia water extract decreases markers of oxidative damage (15082, 15087, 15088, 15091, 15092, 92229). However, in a cancer cell line, the cytotoxic effects of a Tinospora cordifolia extract appear to be due to pro-oxidant and lipid peroxidative effects with a decrease in glutathione-S-transferase activity (92223).\nCognitive effects\nThere is interest in using Tinospora cordifolia to limit the behavioral and cognitive changes that occur due to aging and menopause. A 12-week study in acyclic female rats suggests the anxiety index is lower when Tinospora cordifolia powder is added to normal feeds, but not when added to high-fat feeds. However, adding Tinospora cordifolia to normal or high-fat feeds may improve memory (110532).\nEndocrine effects\nIn vitro, the proliferative effects of an ethanolic extract of Tinospora cordifolia stem on prostate cells appears to be due to androgenic effects (92225).\nHepatoprotective effects\nIn moderate alcoholics without liver disease, intake of Tinospora cordifolia stem extract reduces levels of liver enzymes, low density lipoprotein (LDL)-cholesterol, and triglycerides. This extract also reduces urinary excretion of various nutrients, especially pyridoxine, niacin, and biotin (92232).\nImmunomodulating effects\nSeveral constituents of Tinospora cordifolia have immunomodulating effects. These include clerodane furano diterpene glycoside, cordioside, syringin, cordifolioside A and B, and cordiol (15086). Tinospora cordifolia also contains an immunostimulatory alpha-glucan polysaccharide. In vitro, this alpha-glucan activates natural killer (NK) cells, T cells, and B cells. It also induces production of interleukin (IL)-1, IL-6, IL-12, IL-18, interferon-gamma, tumor necrosis factor (TNF)-alpha and monocyte chemoattractant protein (MCP)-1 (15089). Both water and alcohol extracts of Tinospora cordifolia stems seem to have immunostimulatory effects. In animal models, these extracts significantly increase leukocyte counts and inhibit cyclophosphamide-induced immunosuppression. An alcohol extract of Tinospora cordifolia stems also inhibits cyclophosphamide-induced anemia (15081).\nMetabolic effects\nThere is interest in using Tinospora cordifolia to limit the metabolic changes that occur with aging and menopause. A 12-week study in acyclic female rats suggests that adding Tinospora cordifolia powder to normal feeds attenuates weight gain, but not when added to high-fat feeds. However, Tinospora cordifolia decreases triglycerides and blood glucose when added to normal or high-fat feeds (110531).\nRenoprotective effects\nIn vitro and animal research suggests that Tinospora cordifolia extracts may have renoprotective effects. In a rat model of diabetes, Tinospora cordifolia improved serum creatinine and urea levels and reduced inflammation and fibrosis in the kidneys, possibly through activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma) dependent pathways (106847)."
        }
    },
    "Tiratricol": {
        "sections": {
            "Overview": "Tiratricol is a metabolite of thyroid hormone in humans. In the body, about 1% of all thyroxine (T4) is converted to tiratricol. When taken by mouth, 1000 mcg of tiratricol can result in effects similar to those seen with about 50 mcg of T4 (110032). In France, tiratricol is available by prescription (1629, 1630).",
            "Warnings": "In 1999, the US Food and Drug Administration (FDA) issued a warning to manufacturers of tiratricol products, stating that tiratricol does not meet the legal definition of a dietary supplement (1605). The American Thyroid Association and the Thyroid Society for Education and Research endorsed this warning, stating that the use of tiratricol at the doses recommended by supplement manufacturers can cause thyrotoxicosis (110032).",
            "Safety": "POSSIBLY SAFE when used orally under medical supervision (1607, 1609, 1610, 1615, 1616, 1617, 1618, 110018).\nPOSSIBLY UNSAFE when used orally without medical supervision. Experts warn that tiratricol is a potent thyroid hormone that can cause thyrotoxicosis (110032); unsupervised use has been associated with serious adverse effects (1620, 1621, 1622, 1623, 1624, 1625).\nPREGNANCY: POSSIBLY SAFE when used orally under medical supervision for treating fetal hypothyroidism (1613, 1614).\nPREGNANCY: LIKELY UNSAFE when used orally without medical supervision due to possible risk of fetal heart damage (1627, 1628); avoid using.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tiratricol is well tolerated.\nMost Common Adverse Effects\nOrally: Diarrhea, fatigue, insomnia, lethargy, nervousness, tachycardia, tremors, and weight changes.\nSerious Adverse Effects (Rare)\nOrally: Cardiac arrhythmia, heart attack paralysis, stroke.\nCardiovascular\nOrally, tiratricol has been associated with increased pulse and blood pressure, tachycardia, chest pain, cardiac arrhythmias, and heart attacks (1605).\nless\nEndocrine\nOrally, tiratricol is associated with symptoms of both thyrotoxicosis and hypothyroidism. Two young adults presented with symptoms of hypothyroidism, including lethargy, muscle weakness, and weight gain despite loss of appetite, after taking tiratricol 3000-4000 mcg daily for 5 weeks or 6000 mcg daily for 3 weeks (98213). Both patients had low thyroid stimulating hormone (TSH) and thyroxine (T4) levels, but significantly elevated triiodothyronine (T3) levels (98213). An 87-year old female also presented with low TSH and elevated T3 after taking tiratricol, but had symptoms of thyrotoxicosis, including nervousness, tremors, insomnia, weight loss, and fatigue (98214). Another case report describes a 32-year old female who developed galactorrhea, hyperprolactinemia, and hypothyroidism while taking tiratricol 1050 mcg daily for 8 months (1620).\nless\nGastrointestinal\nOrally, tiratricol has been associated with diarrhea and abdominal cramps (1605).\nless\nNeurologic/CNS\nOrally, tiratricol has been associated with tremors, nervousness, insomnia, and strokes (1605). It can also cause muscle weakness. In one case, hypokalemic thyrotoxic periodic paralysis was reported in a 23-year old male who took tiratricol 2000-3000 mcg daily for 2 months and developed leg paralysis (98215).\nless\nOcular/Otic\nOrally, tiratricol has been associated with diplopia. In one case, toxic internuclear ophthalmoplegia (loss of movement of one eye, leading to diplopia) was reported in a young adult taking tiratricol with dexfenfluramine for about 3 days. This resolved when both drugs were stopped (1621).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nHyperlipidemia. Although there has been interest in using oral tiratricol for hyperlipidemia, there is insufficient reliable information about the clinical effects of tiratricol for this condition.\nHypothyroidism. It is unclear if oral tiratricol is beneficial for treatment of hypothyroidism following ablative therapy for differentiated thyroid carcinoma.\nIn small clinical trials in patients that have undergone ablative therapy for differentiated thyroid carcinoma and are receiving levothyroxine, tiratricol reduces pituitary thyroid stimulating hormone (TSH) secretion (1617, 1618). However, combined treatment with low dose tiratricol along with physiologic doses of levothyroxine results in greater inhibition of pituitary TSH secretion in only 50% of patients and produces similar effects on peripheral tissues when compared with supraphysiologic doses of levothyroxine alone (1618).\nless\nPituitary resistance to thyroid hormone (PRTH). It is unclear if oral tiratricol is beneficial in PRTH.\nTiratricol has been evaluated for PRTH, with mixed findings. Though some cases have described the ability of tiratricol to suppress the secretion of thyroid stimulating hormone (TSH), others have reported its inability to attenuate the peripheral effects of thyroid hormone (1607, 1608, 1609, 1610, 1614, 1615).\nless\nMonocarboxylate transporter 8 (MCT8) deficiency. It is unclear if oral tiratricol is beneficial for children or adults with this condition.\nA small retrospective chart review in patients with MCT8 deficiency, mostly aged 10 years and under, suggests that taking a specific tiratricol product (Emcitate [previously Teatrois]; Rare Thyroid Therapeutics) may reduce levels of triiodothyronine (T3), thyroid stimulating hormone (TSH), and free and total thyroxine (T4) levels when compared to baseline. Tiratricol also stabilized height- and weight-for-age scores versus baseline and improved these scores when compared to untreated historical controls. The tiratricol dose was titrated to a target T3 level, with the target dose reached in 5 months, on average. After titration, the mean maintenance dose of tiratricol was 38 mcg/kg/day (110018). The validity of these findings is limited by its retrospective design and the use of a historical control.\nless\nMore evidence is needed to rate tiratricol for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tiratricol.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tiratricol might increase the hypoprothrombinemic effects of oral anticoagulants.\nTiratricol is related to thyroid hormones such as levothyroxine. The hypoprothrombinemic effects of oral anticoagulants, including warfarin (Coumadin), are increased by levothyroxine due to increased catabolism of vitamin K-dependent clotting factors (15). It is not known if tiratricol has a similar effect.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tiratricol might interfere with blood glucose control.\nTiratricol is related to thyroid hormones, such as levothyroxine, which can interfere with blood glucose control and necessitate adjustment of diabetes drug therapy (15). It is not known if tiratricol has these effects.\nless\nCHOLESTYRAMINE (Questran)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, cholestyramine might decrease the absorption of tiratricol.\nTiratricol is related to thyroid hormones such as levothyroxine. Absorption of levothyroxine is reduced by cholestyramine (15). It is not known if tiratricol absorption is affected.\nless\nTHYROID HORMONE\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nConcomitant use of tiratricol with thyroid hormones may have additive effects.\nTiratricol is a thyroid hormone (1617) and should only be used under medical supervision.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTiratricol might increase the effects of products with anticoagulant activity.\nTiratricol is related to thyroid hormones such as levothyroxine. Concomitant use of levothyroxine with products that affect platelet aggregation could theoretically increase the risk of bleeding in some people (15). See other products with antiplatelet activity here. See other products with anticoagulant activity here.\nless\nHERBS WITH THYROID ACTIVITY\nTiratricol is a thyroid hormone with physiologic effects.\nTheoretically, tiratricol might enhance the effects and adverse effects of herbs that affect thyroid function.\nless\nVITAMIN K\nTiratricol might antagonize the effects of vitamin K.\nTiratricol is related to thyroid hormones such as levothyroxine, which antagonize the prothrombinemic effects of vitamin K by increasing catabolism of vitamin K-dependent clotting factors (15). It is not known if tiratricol has these effects.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCARDIOVASCULAR DISEASE\nTiratricol is related to thyroid hormones, such as levothyroxine, which can aggravate symptoms of various cardiovascular conditions (15). It is not known if tiratricol has similar effects.\nless\nDIABETES\nTiratricol is related to thyroid hormones, such as levothyroxine, which can interfere with blood glucose control, possibly requiring adjustment of diabetes drug therapy (15). It is not known if tiratricol has similar effects.\nless",
            "Interactions with Lab Tests": "TRIIODOTHYRONINE (T3)\nThere is considerable cross-reactivity in assays between tiratricol and T3 due to their structural similarity (98214, 106722). Patients receiving tiratricol therapy should have their T3 hormone response measured using an alternative assay methodology, such as mass spectrometry, to avoid misinterpretation of T3 levels (106722).\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tiratricol.",
            "Pharmacokinetics": "Absorption\nAbout 67% of an oral dose of tiratricol is absorbed, and peak plasma levels occur within 40 minutes (1631).\nMetabolism\nTiratricol is deiodinated and rapidly glucuronidated in the liver. It has a half-life of about 6 hours (1631, 98213, 98215).",
            "Mechanism of Action": "General\nTiratricol is a metabolite of thyroid hormone in humans, with a structure closely related to thyroxine (T4) and triiodothyronine (T3). It occurs in small amounts in the body as a minor metabolite of T4 (1633, 1634).\nThyroid effects\nTiratricol acts at the anterior pituitary gland causing a decrease in thyroid stimulating hormone (TSH), which in turn lowers levels of T4 in euthyroid individuals. Levels of T3 in the periphery are increased, which would be expected to cause thyrotoxicosis, with increased metabolic rate, body temperature, tachycardia, and weight loss. However, the overall thyroid effects of tiratricol in an individual seem to vary, possibly depending on dose and the basal thyroid status. Some data suggest that tiratricol has fewer peripheral effects than T3 or T4, possibly due to its rapid clearance and short half-life. This results in limited peripheral calorigenic potency, no increase in basal metabolic rate or sleeping energy expenditure, weight gain, and an overall hypothyroid state (98213, 98215). However, tiratricol has also been reported to have peripheral thyromimetic effects, resulting in tachycardia, tremor, heat intolerance, and weight loss (98214, 98215). A mouse model of monocarboxylate transporter 8 (MCT8) deficiency suggests that receiving high-dose intracerebroventricular tiratricol decreases plasma T3 and T4 levels and may impact the expression of T3 regulating genes (111722). Another mouse model of MCT8 deficiency suggests that receiving daily subcutaneous high-dose tiratricol in the early postnatal period promotes CNS function and maturation (111740).\nWeight effects\nA small clinical study in patients with mild obesity receiving a low-calorie diet suggests that that taking tiratricol does not reduce weight when compared with matched controls receiving a low-calorie diet alone (1611). Another small clinical study suggests that taking tiratricol reduces weight in patients with mild obesity receiving a low-calorie diet, but not in those with a normal weight receiving a normal diet (1612)."
        }
    },
    "Tocotrienols": {
        "sections": {
            "Overview": "Vitamin E is an essential fat-soluble nutrient that includes two distinct chemical analogues: tocotrienols and tocopherols. Tocotrienols are unsaturated vitamin E derivatives that possess an isoprenoid side chain, while tocopherols are saturated vitamin E derivatives (29991). This monograph focuses on tocotrienols. Commercial tocotrienols are primarily obtained from natural sources, such as annatto, palm, or rice bran oil (72223, 99690, 104428). They are also found in wheat germ, barley, other grains, and nuts (107390). The first report occurred in 1964; however, interest in tocotrienols did not increase until the 1980s and 1990s for their purported cholesterol-lowering and anticancer effects (29991).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Tocotrienols have been used with apparent safety at doses of up to 600 mg daily for up to 18 months (99690, 99695, 99696, 104427, 104428, 112286). Tocotrienols have also been used with apparent safety at a dose of 200 mg daily for up to 5 years (99697).\nThere is insufficient reliable information available about the safety of tocotrienols when applied topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, tocotrienols appear to be well-tolerated. No adverse effects have been reported in clinical trials.\nMost Common Adverse Effects\nTopically: Mild itching.\nDermatologic\nTopically, a cream containing 5% tocotrienols has been reported to cause mild itching in 7% of patients in one clinical study (99699). Contact dermatitis has been reported in 33% of patients using a cream containing vitamin E as a mixture of tocopherols and tocotrienols (4721). However, it is unclear if this effect resulted from tocopherols, tocotrienols, or the combination.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDiabetes. Oral tocotrienols may improve glycemic control in adults with type 2 diabetes.\nA meta-analysis of 8 clinical trials of adults with type 2 diabetes shows that taking a tocotrienol-rich fraction, primarily derived from palm fruit, 250-400 mg daily for 2-18 months leads to slight improvements in glycated hemoglobin (HbA1c) when compared with placebo (112286). The benefit was primarily among those with a higher baseline HbA1c, a duration of diabetes less than 10 years, and in studies with a duration of less than 6 months. Most studies were rated high quality with a low risk of bias, but most were also small with moderate heterogeneity. Most of the studies were conducted in Malaysia, where tocotrienol-rich palm oil was already regularly consumed as part of the diet, potentially limiting the generalizability of the findings to other populations with different baseline tocotrienol intakes.\nless\nPOSSIBLY INEFFECTIVE\nHypercholesterolemia. Oral tocotrienols are not likely to induce clinically meaningful improvements in cholesterol levels.\nA meta-analysis of 19 small clinical trials shows that taking tocotrienols 50-600 mg daily for 1-6 months does not decrease levels of total cholesterol, low density lipoprotein (LDL) cholesterol, or triglycerides when compared with control. Tocotrienols were shown to increase levels of high-density lipoprotein (HDL) cholesterol by a modest and clinically insignificant amount. Sub-group analyses did not find that baseline lipid levels, or dose and duration of tocotrienol supplementation, notably alter results (104430). These findings are limited because the studies included not only patients with hypercholesterolemia, but also healthy patients and patients with various conditions such as type 2 diabetes, metabolic syndrome, and kidney disease.\n\nTocotrienols have also been studied in combination with tocopherols (28730, 85107, 104430) and polymethoxylated flavones (99694) without notable benefit.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. Oral tocotrienols have only been evaluated in combination with other ingredients; their effect when used alone is unclear.\nA small study in healthy adults over 40 years of age with self-diagnosed, subjective memory decline shows that taking a specific combination supplement (BGG Japan Co.) containing tocotrienols 50mg and astaxanthin 9 mg daily for 12 weeks modestly improves composite and verbal memory when compared with placebo (105099). This study was funded by the supplement manufacturer.\nless\nAging. Although there is interest in using oral tocotrienols for aging, there is insufficient reliable information about the clinical effects of tocotrienols for this condition.\nAlopecia areata. Although there is interest in using topical tocotrienols for alopecia areata, there is insufficient reliable information about the clinical effects of tocotrienols for this condition.\nAlzheimer disease. Although there is interest in using oral tocotrienols for Alzheimer disease, there is insufficient reliable information about the clinical effects of tocotrienols for this condition.\nBreast cancer. It is unclear if oral tocotrienols are beneficial for improving early breast cancer outcomes or preventing recurrence.\nClinical research in Malaysian patients with early-stage breast cancer shows that taking tocotrienols 200 mg daily, in conjunction with tamoxifen 20 mg daily for up to 5 years, does not improve survival or reduce the rate of cancer recurrence when compared with taking tamoxifen with placebo (99697). The validity of this study is limited by the lack of randomization and insufficient power to evaluate an effect on cancer-related mortality.\nless\nChronic kidney disease (CKD). Although there is interest in using oral tocotrienols for CKD, there is insufficient reliable information about the clinical effects of tocotrienols for this condition.\nDiabetic nephropathy. It is unclear if oral tocotrienol-rich vitamin E is beneficial for slowing diabetic nephropathy progression.\nA small clinical study in patients with diabetic nephropathy shows that taking a specific tocotrienol-rich vitamin E supplement (Tocovid SupraBio, Hovid Nutriworld) 200 mg twice daily for 12 weeks seems to modestly reduce serum creatinine, with a corresponding increase in estimated glomerular filtration rate (eGFR), when compared with placebo. According to a sub-group analysis, these improvements remained statistically significant in patients with low tocopherol levels (less than 42 mcmol/L) at baseline, but not in those with higher levels at baseline (103010). Another small clinical study shows that taking this same supplement regimen for 12 months reduces serum creatinine levels and improves eGFR at 8 months, but not 12 months, when compared with placebo. In a subgroup analysis of patients with stage 3 chronic kidney disease, these benefits persisted at 12 months when compared with placebo (107390).\nless\nFamilial dysautonomia. It is unclear if oral tocotrienols are beneficial for familial dysautonomia outcomes.\nA small clinical study in patients with familial dysautonomia shows that taking tocotrienols 100 mg for 3-4 months decreases the number of hypertensive crises by at least 50% in about 80% of patients when compared to baseline (28720). However, another small clinical study shows that taking tocotrienols 50 mg or 100 mg daily for 3 months improves subjective symptom reports, but does not improve objective clinical measurements, when compared to baseline (99700). The validity of these findings is limited by small study sizes and the absence of comparator groups.\nless\nHypertrophic scars. It is unclear if topical tocotrienols improve hypertrophic scar appearance or vascularity.\nA clinical study in adults with recently healed surgical scars shows that applying a cream containing 5% tocotrienols twice daily for 6 weeks does not improve scar appearance or vascularity at the end of treatment or 10 weeks after treatment completion when compared with a placebo cream (99699). It is unclear if a cream containing a greater concentration of tocotrienols might be beneficial.\nless\nImpaired glucose tolerance (prediabetes). It is unclear whether oral tocotrienols are beneficial in patients with prediabetes.\nA small clinical trial in adults with untreated prediabetes shows that taking delta-tocotrienol 300 mg orally daily for 12 weeks reduces fasting plasma glucose and insulin levels and improves glycated hemoglobin and the homeostatic model assessment for insulin resistance (HOMA-IR) when compared with placebo (107856).\nless\nMetabolic syndrome. Oral tocotrienols have only been evaluated in combination with other ingredients; their effect when used alone is unclear.\nA moderate sized clinical trial in adults with metabolic syndrome shows that taking delta-tocotrienols 500 mg and resveratrol 300 mg daily for 24 weeks improves body weight, waist circumference, blood pressure, fasting blood glucose, serum triglycerides, total cholesterol, high-density lipoprotein cholesterol, and markers of inflammation and oxidative stress compared with placebo (112144). It is unclear if these effects are due to the tocotrienols, resveratrol, or the combination.\nless\nNonalcoholic fatty liver disease (NAFLD). Small clinical studies suggest that oral tocotrienols may modestly improve steatosis and other outcomes in patients with NAFLD.\nA small clinical trial in adults with NAFLD shows that taking tocotrienols 200 mg twice daily for one year might reduce steatosis, as measured by ultrasound hepatic echogenic response, when compared with placebo (99695). Another small clinical trial in overweight or obese adults with NAFLD shows that taking a specific product (American River Nutrition, Inc.) containing 90% delta-tocotrienol and 10% gamma-tocotrienol, as 300 mg twice daily for 24 weeks, modestly reduces fatty liver index (FLI), hepatic steatosis measured by ultrasound, and liver enzyme levels when compared with placebo (104428). These findings are limited because liver biopsy was not used to determine disease progression. Assessment by liver ultrasound examination has limited accuracy when used in obese patients and when testing for steatohepatitis or fibrosis.\nless\nPostmenopausal conditions. It is unclear if oral tocotrienols are beneficial for improving symptoms in postmenopausal patients.\nA small clinical study in postmenopausal patients shows that taking a specific product (DeltaGold70) 430 mg or 860 mg daily, containing 300 mg or 600 mg tocotrienols, respectively, for 12 weeks does not improve quality of life, body weight, or body fat percentage when compared with placebo (99690).\nless\nStroke. It is unclear if oral tocotrienols are beneficial for improving outcomes in patients after stroke or transient ischemic attack (TIA).\nObservational research in patients after an ischemic stroke or TIA has found that taking tocotrienols 400 or 800 mg daily for one year is associated with reduced resistance to aspirin in patients using aspirin with clopidogrel, but not in patients using only aspirin or only clopidogrel, when compared with placebo (104429).\nless\nWound healing. Although there is interest in using topical tocotrienols for wound healing, there is insufficient reliable information about the clinical effects of tocotrienols for this condition.\nMore information is needed to rate tocotrienols for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTocotrienols have been used most often in doses of 200-600 mg daily for up to 6 months (103010, 104428). See Effectiveness section for condition-specific information.\nTopical:\nResearch is limited; typical dosing is unavailable. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nIn clinical research, tocotrienol supplements are often available as mixed isomers such as alpha-tocotrienol with gamma-tocotrienol (Tocovid) 200 mg, high gamma-tocotrienol extract from rice bran oil (Nutriene, Yasoo Health), palm oil enriched in alpha-tocopherol, alpha-tocotrienol, gamma-tocotrienol, and delta-tocotrienol (PalmVitee) 200 mg, and many others (3238, 3240, 72223).",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Lower quality RCT)\nConcomitant use of tocotrienols with anticoagulant or antiplatelet agents might increase the risk of bleeding. However, this has not been reported in humans.\nTaking tocotrienols orally inhibits experimentally-induced platelet aggregation in humans (3237, 104429). Theoretically tocotrienols might increase the risk of bleeding if taken with antiplatelet or anticoagulant drugs. However, tocotrienols 400-800 mg daily have been used with aspirin and/or clopidogrel for 1 year with no clear cumulative antiplatelet effects and no reports of bleeding (104429).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tocotrienols.",
            "Pharmacokinetics": "Absorption\nIn animals and humans, dietary tocotrienols are absorbed with dietary triglycerides into plasma in chylomicron lipoproteins (28722). In healthy individuals, the bioavailability, including the peak plasma concentration and plasma concentration time curve, of tocotrienols from self-emulsifying formulations was increased compared to the bioavailability from a non-self-emulsifying formulation of the soya oil (28724).\nDistribution\nIn animals, dietary tocotrienols are deposited into adipose tissue along with dietary triglycerides (28722). In fasting humans, it has been suggested that dietary tocotrienols do not increase plasma tocotrienol concentrations, but platelet concentrations of delta-tocotrienol double (28722, 67551). However, in human studies, intake of tocotrienols increased plasma levels of alpha-, gamma-, and delta-tocotrienols in a dose-dependent manner (28695, 99692, 99693), reaching a maximum concentration after approximately 5-7 hours (99692, 99693). Additionally, one clinical study shows that taking tocotrienols 200 mg twice daily for 12 weeks results in an average steady state alpha-tocotrienol plasma concentration of 2.5 mM/L (99696).\n\nOral tocotrienols can reach the brain (28688, 99696). In the human epidermis, alpha-tocotrienol and gamma-tocotrienol make up 1% and 3% of total tocols (tocopherols and tocotrienols), respectively (28704). After taking tocotrienols 200 mg twice daily for 12 weeks, epidermal concentrations of alpha-, gamma-, and delta-tocotrienol increased significantly when compared with control. Taking this same dose of tocotrienols also increases the abdominal adipose concentration of tocotrienol by 10-fold when compared with control (99696). In human research, tocotrienol intake increased tocotrienol levels in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol (28728, 28729).\nMetabolism\nIn humans, oral tocotrienyl acetate is metabolized to alpha- and gamma-carboxyethyl-hydroxychromans with a 1% to 2% recovery of the alpha-compounds and a 4% to 6% recovery of the gamma-compounds in urine (28725). In vitro, the conversion of the tocotrienols to the carboxychromanols was found to be due to a CYP4F2-catalyzed omega-hydroxylation reaction (28726).\nExcretion\nIn humans, the half-life for tocotrienols is approximately 4-7 hours (28723, 99692, 99693).",
            "Mechanism of Action": "General\nNatural tocotrienols exist in four isomers: alpha-, beta-, gamma-, and delta-tocotrienols (29991).\nAnti-diabetes effects\nTocotrienols increase insulin sensitivity by restoring expression of insulin receptor substrate 1 and glucose transporter type 4. They also increase Akt signaling in skeletal muscles and upregulate peroxisome proliferator-activated receptor-gamma (107856). In clinical research, delta-tocotrienol has been shown to upregulate the expression of insulin release genes when compared with placebo (107855).\nAnti-inflammatory activity\nA meta-analysis of 13 trials shows that tocotrienols reduce C-reactive protein (CRP) levels, although this effect was primarily driven by one study using a high dose of 600 mg delta-tocotrienol daily. This analysis did not find any effect on interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-alpha) (107389). However, a study of delta-tocotrienol 250 mg daily reported reductions in high-sensitivity CRP, TNF-alpha, and IL-6 (107855).\nAntiaging effects\nTocotrienols reduce the formation of reactive oxygen species (ROS) and lower ROS-mediated lipid peroxidation and erythrocyte hemolysis in vitro (28685). Theoretically, this activity may contribute to the purported antiaging effects of tocotrienols.\nAnticancer effects\nTocotrienols, or tocotrienol-rich fractions of products, have shown anticancer effects in animal models and in vitro. In animal models, benefits of tocotrienols include reduced tumor volume and suppression of carcinogenesis (14047, 28702, 28705). In vitro, tocotrienols have shown anti-proliferative effects (14049, 28687, 28701, 28702, 28707, 28711, 28713). Potential mechanisms of action have been proposed based on in vitro research. These include the induction of S phase arrest (28702) and cell cycle arrest at the G1 phase and apoptosis (28707, 28709, 28712), as well as effects on levels of the total retinoblastoma protein (Rb) and its phosphorylation at the Ser780, Ser795, Ser 807/811, and Thr826 positions (28708), downregulation of the extracellular signal-regulated kinase (ERK) signaling pathways and Bcl-2, upregulation of Bax, activation of caspase-3, and subsequent poly(ADP-ribose) polymerase cleavage (28709), inhibition of NF-kappaB activation (28710), reduction in the expression of cyclins B1 and D1 and cyclin-dependant kinases 1 and 4 (28708), p53-dependent induction of WAF1/p21 (14049), induction of cAMP production upstream from EGF-dependent MAPK and phosphoinositide 3-kinase/Akt mitogenic signaling (28716), and altered expression of various genes, such as c-myc-binding protein MM-1, 23-kDa highly basic protein, interferon-inducible protein 9-27 (IFITM-1) (14048), and interferon-inducible transmembrane protein-1 and CD59 glycoprotein precursor (14047). Also, gamma- and delta-tocotrienols reduced tumor promotion by inhibiting Epstein-Barr virus early antigen (EBV EA) expression (28717). Other studies in vitro have suggested that Bax/Bcl-2 and poly(ADP-ribose) polymerase cleavage do not play a role in the mechanism of action of tocotrienols (28715).\nAntioxidant activity\nTocotrienols have shown antioxidant effects in vitro (28691, 28692, 28703). Using an oxygen radical absorbance capacity (ORAC) assay, the antioxidant activity of 30% tocotrienols was found to be 1229 mM of Trolox equivalent per gram (28703). Alpha- and gamma-tocotrienol have been shown to inhibit human glutathione S-transferase P1-1 (GST P1-1) in a concentration-dependent manner (28691). In humans and animals, dietary tocotrienols incorporated into circulating human lipoproteins; in vitro, these isolated lipoproteins react with peroxyl radicals (28692). However, in the human epidermis, epidermal levels of tocotrienols were not correlated with free radical scavenging activity (28704). Unlike tocopherols, tocotrienols distribute uniformly in the cellular bilayer and penetrate tissues with saturated fatty layers. This gives them about 50 times greater antioxidant activity than tocopherols (107390).\nAutonomic effects\nIn humans with familial dysautonomia, tocotrienols increase the expression of monoamine oxidase A, IKBKAP mRNA, and the IKAP protein in peripheral blood cells (28720, 28721, 99700). However, in one clinical trial, IKBKAP mRNA expression returned to pretreatment levels after 6 months of continuous tocotrienol supplementation. It is hypothesized that this reduction in levels is due to the development of tolerance to the effects of tocotrienols (99700).\nCardiovascular effects\nProposed cardioprotective mechanisms of action of the tocotrienols include their antioxidant effects and ability to act as pharmacological preconditioning agents (28689). Also, in vitro evidence suggests that tocotrienols, especially delta-tocotrienol, inhibit adhesion molecule expression and monocytic cell adherence (28693, 28718).\nCYP450 effects\nIn vitro, the tocotrienols specifically bind to and activate the steroid and xenobiotic receptor (SXR) resulting in tissue-specific induction and increased expression of some SXR target genes, such as cytochrome P450 (CYP) 3A4 in hepatocytes (28719). However, in intestinal cells, tocotrienols induce glucuronosyltransferase 1A1 (UGT1A1) and multidrug resistance protein-1 (MDR1), but not CYP3A4. In vitro, delta-tocotrienol increased the expression of CYP1A1 gene (28702).\nHepatic effects\nThere is interest in using tocotrienols to treat liver disease. After oral administration, tocotrienols are distributed to the liver, where they have been shown to exert a potent antioxidant activity on microsomal lipid peroxidation (99695, 104428). Gamma-tocotrienols have also demonstrated the ability to inhibit hepatic triglyceride accumulation (99695). Some preliminary clinical research in adults with non-alcoholic fatty liver disease (NAFLD) shows that taking tocotrienols for up to one year reduces plasma levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, C-reactive protein, and malondialdehyde. Taking tocotrienols has also been shown to improve hepatic echogenic response and fatty liver index in this population (99695, 104428). Also, a case series of seven patients with end-stage liver disease shows that taking tocotrienols improves measures of liver dysfunction when compared with taking tocopherol (99696).\nHypolipidemic effects\nIn human research, some, but not all, clinical trials suggest that tocotrienols reduce levels of total and low-density lipoprotein (LDL) cholesterol, as well as triglycerides (3237, 3238, 3240, 28695, 28730, 72223, 85107). In vitro, tocotrienols cause posttranscriptional suppression of HMG-CoA reductase (28698), likely due to the stimulation of HMG-CoA reductase degradation (28699).\nNeuroprotective effects\nIn vitro, alpha-tocotrienol protected HT4 and primary neuronal cells against toxicity induced by glutamate and other toxins by a mechanism thought to be independent of antioxidant effects. It was suggested that the potential mechanism of action involved c-Src kinase and lipoxygenase (28688).\n\nThere is also interest in whether tocotrienols reduce progression of neuropathy by improving nerve conduction. Small clinical studies in patients with diabetes show that taking a tocotrienol-rich supplement (Tocovid) for up to 1 year seems to modestly increase nerve conduction velocity when compared with placebo. Theoretically, tocotrienols might improve nerve velocity and sensation by increasing blood levels of nerve growth factor (104427, 107388)."
        }
    },
    "Tolu Balsam": {
        "sections": {
            "Overview": "Tolu balsam is the oleo resin exuded from slits cut in the trunk of Myroxylon balsamum. It is purified by melting, straining, and solidifying the resin. It differs from Peru Balsam, which is prepared from the resin obtained from scorched tree trunks. Tolu balsam has traditionally been used for its purported antibacterial, antiparasitic, and expectorant effects (18). It is also used as a fixative and fragrance in soaps and cosmetics and as a flavoring agent in gum, foods, and beverages.",
            "Safety": "LIKELY SAFE when the oleo resin and extract are used orally in amounts commonly found in foods. Tolu balsam has Generally Recognized As Safe (GRAS) status for use in foods in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately in larger amounts as medicine, short-term. Traditionally, Tolu balsam has been used at an average daily dose of 600 mg (2, 18).\n\nThere is insufficient reliable information available about the safety of the topical use of Tolu balsam.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Tolu balsam is safe when used in the amounts found in foods. It is generally well tolerated when used in medicinal amounts.\nDermatologic\nTopically, Tolu balsam has been reported to cause allergic reactions (11).\nless\nRenal\nOrally, Tolu balsam has been reported to cause kidney irritation (12).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCough. Although there has been interest in using oral Tolu balsam for cough, there is insufficient reliable information about the clinical effects of Tolu balsam for this purpose.\nNipple fissures. Although there has been interest in using topical Tolu balsam for nipple fissures, there is insufficient reliable information about the clinical effects of Tolu balsam for this purpose.\nRespiratory tract infections. Although there has been interest in using oral and inhaled Tolu balsam for respiratory tract infections, including bronchitis, laryngitis, and croup, there is insufficient reliable information about the clinical effects of Tolu balsam for this purpose.\nMore evidence is needed to rate Tolu balsam for these uses.\nless",
            "Dosing & Administration": "Adult\nOral:\nTraditionally, a Tolu balsam syrup has been used at a typical dose of 600 mg daily.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Tolu balsam.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Tolu balsam.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Tolu balsam.",
            "Mechanism of Action": "General\nThe applicable part of Tolu balsam is the oleo resin (18). There is insufficient reliable information available about the mechanism of action and active ingredients of Tolu balsam."
        }
    },
    "Tomato": {
        "sections": {
            "Overview": "Tomato is a fruit that grows on a vine. It is commonly consumed as a food. It also contains various nutrients, such as lycopene, that have sparked interest in its use as a medicine (1497).",
            "Safety": "LIKELY SAFE when the ripe or unripe tomato fruit or its products are consumed in amounts found in foods (2406, 9439, 10418, 106653, 106654). ...when tomato leaf is consumed in regular food amounts (18).\nPOSSIBLY SAFE when a tomato extract is used orally for medicinal purposes. A specific tomato extract (Lyc-O-Mato, LycoRed Ltd) has been used with apparent safety in clinical studies lasting up to 8 weeks (7898, 14287, 102182).\nPOSSIBLY UNSAFE when the tomato leaf or unripe green tomato fruit is used orally in excessive amounts. Tomato leaf and unripe green tomatoes contain tomatine, which has been associated with toxicity when consumed in large quantities (18, 102957).\nThere is insufficient reliable information available about the safety of the tomato vine.\nPREGNANCY AND LACTATION: LIKELY SAFE when the tomato fruit or its products are consumed in typical food amounts. There is insufficient reliable information available about the safety of tomato extracts when used during pregnancy or lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tomato leaves and ripe or unripe tomato fruit are well tolerated in typical food amounts. Tomato extracts also seem to be well tolerated. Tomatine, a glycoalkaloid found in tomato leaves and unripe green tomatoes, can cause serious side effects when consumed in excessive amounts.\nSerious Adverse Effects (Rare)\nOrally: Bradycardia, diarrhea, respiratory disturbances, spasms, vomiting, and death with excessive consumption of tomatine, a glycoalkaloid found in tomato leaves and unripe green tomatoes.\nCardiovascular\nOrally, the glycoalkaloid tomatine in tomato leaf or green tomatoes can cause bradycardia when consumed in excessive amounts (18, 102957).\nless\nGastrointestinal\nOrally, the glycoalkaloid tomatine in tomato leaf or green tomatoes can cause severe mucous membrane irritation, vomiting, diarrhea, and colic when consumed in excessive amounts (18, 102957).\nless\nImmunologic\nIn a case report, a 31-year-old female working in the supermarket developed an airborne allergy to tomato stem proteins with symptoms of severe rhinoconjunctivitis. This woman did not have a food allergy to tomato fruit (102467).\nless\nNeurologic/CNS\nOrally, the glycoalkaloid tomatine in tomato leaf or green tomatoes can cause dizziness, stupor, headache, and mild spasms when consumed in excessive amounts (18, 102957).\nless\nPulmonary/Respiratory\nOrally, the glycoalkaloid tomatine in tomato leaf or green tomatoes can cause respiratory disturbances when consumed in excessive amounts. In severe cases, death by respiratory failure might occur (18, 102957).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY INEFFECTIVE\nBladder cancer. Consuming tomatoes and tomato-based products does not appear to reduce the risk of bladder cancer.\nObservational studies have found no association between tomato and tomato-based product intake and the risk of bladder cancer (2407).\nless\nBreast cancer. Consuming tomatoes and tomato-based products does not appear to reduce the risk of breast cancer.\nObservational studies have found no association between tomato or tomato-based product intake and risk of breast cancer (15747).\nless\nDiabetes. Consuming tomatoes and tomato-based products does not appear to prevent the development of type 2 diabetes or improve glycemic control in patients with type 2 diabetes.\nObservational studies have found that increasing intake of tomato or tomato-based products does not significantly decrease the risk of developing type 2 diabetes (14004, 14361). Additionally, a small clinical study in non-smoking male patients with type 2 diabetes shows that consuming raw tomato 200 grams daily for 8 weeks does not improve plasma glucose levels when compared to baseline (102477). The validity of this finding is limited by the lack of comparator group.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. It is unclear if tomato improves skin appearance.\nA small study of females aged 35-55 shows that taking a certain tomato pulp product (Lumenato, Lycored) 1 capsule daily for 12 weeks improves patient reported skin appearance scores when compared to baseline (110523). The interpretation of this result is limited by the lack of a placebo group.\nless\nBenign prostatic hyperplasia (BPH). Oral tomato powder has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical trial in patients with BPH shows that taking 5 grams of a whole tomato food supplement consisting of tomato powder and polyphenols extracted from olives daily for 2 months improves quality of life and reduces lower urinary tract symptoms including urinary frequency, urinary urgency, and nocturia when compared to baseline. No improvements in these symptoms were reported with placebo (106656). It is unclear if these findings are due to tomato, olive polyphenols, or the combination.\nless\nCardiovascular disease (CVD). It is unclear if consuming tomato-based foods reduces the risk of cardiovascular events.\nObservational research has found that increased consumption of tomato-based foods is associated with an insignificant trend towards a reduced risk of myocardial infarction, stroke, and other cardiovascular events (10418, 102178).\nless\nCataracts. It is unclear if consuming tomatoes reduces the risk of cataracts.\nObservational research has found that eating more than 3 servings of tomatoes each week may decrease the risk of developing cataracts (9439).\nless\nCervical cancer. It is unclear if consuming tomatoes reduces the risk of cervical cancer.\nObservational research has found that increased tomato intake is associated with a decreased risk of cervical cancer (2407).\nless\nColorectal cancer. Research on the benefits of consuming tomatoes or tomato-based products for the prevention of colorectal cancer is conflicting and limited to observational studies only.\nSome observational research has found that increasing tomato or tomato-based product intake is associated with a reduced risk of colorectal cancer (2404, 2407). However, higher quality observational research has found that tomato-based product intake is not associated with risk of colorectal cancer (15747).\nless\nExercise-induced asthma. It is unclear if oral tomato extract is beneficial in patients with exercise-induced asthma.\nA small clinical study in patients with exercise-induced asthma shows that taking a specific tomato extract (Lyc-O-Mato, LycoRed Ltd) 30 mg daily for 1 week seems to reduce exercise-induced asthma when compared with placebo. The tomato extract seems to prevent decreases in forced expiratory volume (FEV1) in response to exercise (7898).\nless\nGastric cancer. Research on the benefits of consuming tomatoes or tomato-based products for the prevention of gastric cancer is conflicting and limited to observational studies only.\nSome observational studies have found that increasing tomato or tomato-based product intake is associated with a reduced risk of gastric cancer in some subgroups of patients (2407, 15747, 102480). However, other observational research has found that tomato-based product intake is not associated with risk of gastric cancer (15747). In 2005, the US Food and Drug Administration (FDA) approved a qualified health claim regarding tomatoes and gastric cancer risk. However, the FDA concludes that it is highly unlikely that tomatoes reduce the risk of gastric cancer (102375).\nless\nHyperlipidemia. Small clinical studies suggest that consuming tomato sauce or semi-dried tomatoes may modestly reduce low-density lipoprotein (LDL) cholesterol levels in patients with hyperlipidemia.\nOne small, open-label clinical trial in patients with hyperlipidemia shows that consuming a specific vine-ripened tomato sauce (OsteoCol, C.G. Food, SRL) 150 mL daily for 6 weeks reduces total cholesterol and LDL cholesterol levels when compared to baseline. Patients adherent to the tomato sauce regimen showed an 11 mg/dL and 12 mg/dL reduction in total and LDL cholesterol, respectively, while those consuming a sterol-enriched yogurt saw total and LDL cholesterol levels decrease by 18 mg/dL and 16 mg/dL, respectively. Patients with a baseline LDL cholesterol level of greater than 152 mg/dL saw the greatest benefit from this tomato sauce (106653). Another small clinical study in Japanese patients with borderline high cholesterol shows that taking 50 grams of a semi-dried tomato containing lycopene 22-27.8 mg daily for 12 weeks modestly reduces LDL cholesterol levels but does not affect high-density lipoprotein (HDL) cholesterol levels when compared with taking 50 grams of a tomato without lycopene (102180). This suggests that any benefit of tomato on blood lipid levels is likely due to its lycopene content.\nless\nHypertension. Small clinical studies and observational research suggest that oral tomato extract or dietary tomato consumption may modestly reduce blood pressure in patients with hypertension.\nSeveral small clinical trials in patients with hypertension show that taking a specific tomato extract product (Lyc-O-Mato, LycoRed, Ltd.), providing lycopene 15-30 mg daily, for 6-8 weeks, reduces systolic blood pressure by around 7-13 mmHg and diastolic blood pressure by around 4-6 mmHg when compared to baseline (14287, 60415, 102182). The validity of these findings is limited by the lack of a comparator group. Additionally, a large observational study, conducted over 3 years, suggests that moderate consumption of tomato-based products (i.e., 44-82 grams daily) is associated with marginally lower blood pressure when compared with higher and lower consumption in older adults with grade 1 hypertension. However, this association is not seen in patients with grade 2 or 3 hypertension (113145). Interpretation of these results is limited by self-reported data and lack of generalizability outside of confounders relating to a Mediterranean lifestyle.\n\nEvidence on the use of tomato in patients with pre-hypertension is mixed. One small clinical study in patients with pre-hypertension shows that taking a specific tomato extract (Fruitflow, Provexis Plc, UK.) 150 mg as a single dose seems to modestly reduce blood pressure over a 24-hour period when compared with placebo (102478). This study is limited by its small size and short duration. Another small clinical study in pre-hypertensive patients shows that taking a specific tomato extract (Lyc-o-Mato, LycoRed Ltd) containing lycopene 15 mg daily for 8 weeks does not reduce blood pressure when compared with placebo (42079).\n\nThe impact of dietary tomato consumption on preventing hypertension has also been evaluated. A large prospective observational study in Chinese adults without a history of smoking or myocardial infarction suggests moderate dietary intake of tomatoes (i.e. up to 33.3 grams daily) is associated with a 49-58% reduction in the risk of developing new onset hypertension when compared with no consumption after about 6 years' follow up. However, the associated risk reduction was less with higher consumption (110525). These results may not apply to patients in countries where dietary trends are different, and the validity of these findings is limited by the potential for confounding. Another large observational study, conducted over 3 years in older adults at high cardiovascular risk, suggests that higher consumption (i.e., at least 1 large-sized tomato daily) is associated with reduced risk of hypertension by 36% when compared with moderate and lower consumption (113145). However, interpretation of these results is limited by self-reported data, and lack of generalizability outside of confounders relating to a Mediterranean lifestyle.\nless\nLung cancer. It is unclear if consuming tomatoes reduces the risk of lung cancer; the available research is conflicting.\nSome observational studies have found an association between increased tomato and tomato-based product consumption and a reduced risk of lung cancer; however, many of these studies were not stratified based on the patient's smoking status. Higher quality, large-scale observational studies have not found any association between tomato product intake and lung cancer risk (15747).\nless\nMuscle strength. It is unclear if consuming tomatoes improves muscle strength or attenuates declines in muscle strength.\nA small observational study in Japanese adults 22-68 years of age found that more frequent tomato consumption (2 or more times weekly) is associated with an attenuated rate of handgrip strength decline over 3 years when compared with less frequent tomato consumption (102473).\nless\nOvarian cancer. Research on the benefits of consuming tomatoes or tomato-based products for the prevention of ovarian cancer is conflicting and limited to observational studies only.\nSome observational research has found that increased tomato or tomato juice intake is not associated with risk of ovarian cancer; however, consuming tomato sauce two or more times weekly is associated with a decreased risk (2407). Other observational research has found that increased dietary intake of lycopene, particularly from tomato sauce, is associated with a reduced risk of ovarian cancer in premenopausal patients (10133). In 2005, the US Food and Drug Administration (FDA) approved a qualified health claim regarding tomato sauce and ovarian cancer risk. However, the FDA concludes that it is highly uncertain that tomato sauce reduces the risk of ovarian cancer (102375).\nless\nPancreatic cancer. Research on the benefits of consuming tomatoes or tomato-based products for the prevention of pancreatic cancer is conflicting and limited to observational studies only.\nA large-scale observational study have found that that tomato or tomato-based product intake is not associated with a decreased risk of pancreatic cancer (15747). However, other observational studies have found that raw tomato intake, and high tomato intake in general, is associated with a reduced risk of pancreatic cancer (2407, 15747, 15750). In 2005, the US Food and Drug Administration (FDA) approved a qualified health claim regarding tomatoes and pancreatic cancer risk. However, the FDA concludes that it is highly unlikely that tomatoes reduce the risk of pancreatic cancer (102375).\nless\nProstate cancer. Consuming tomatoes or tomato-based products may slightly lower the risk of prostate cancer; however, observational research is mixed and high-quality clinical trials addressing tomato intake and prostate cancer risk are lacking.\nSome observational studies have found that consuming tomato products, including tomatoes, tomato sauce, pizza, or tomato juice, one time or more per week, is associated with a modest reduction in the risk of prostate cancer (2406, 7772, 7895, 12878, 15747, 102476). However, other observational research has found that tomato consumption is not associated with a reduced risk of prostate cancer (14125, 15172, 15747, 92171). One small clinical study in patients with high-grade prostatic intraepithelial neoplasia shows that taking tomato extract capsules containing lycopene 30 mg daily for 6 months does not impact benign tissue endpoints when compared with placebo (102471). In 2005, the US Food and Drug Administration (FDA) approved a qualified health claim stating that one-half to one cup of tomatoes or tomato sauce weekly may reduce the risk of prostate cancer. However, the FDA concludes that there is little scientific evidence to support this claim (102375).\nless\nRadiation dermatitis. It is unclear if drinking tomato juice is beneficial in patients with radiation dermatitis.\nOne small, uncontrolled clinical trial in patients undergoing radiotherapy for breast cancer shows that drinking tomato juice 160 mg daily for 6 months after radiotherapy improves the severity of dermatitis within 1 month of treatment when compared to baseline (106654). The lack of a comparator group limits the validity of these findings; it is unclear how tomato juice consumption compared with the natural resolution of radiation dermatitis.\nless\nMore evidence is needed to rate tomato for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTomato extracts are most often dosed based on lycopene content, providing 15-30 mg of lycopene daily for up to 8 weeks. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nA specific tomato extract (Fruitflow, Provexis Plc) 150 mg has been standardized to contain up to 9 mg nucleoside derivatives, up to 10 mg phenolic conjugates, and up to 7 mg flavonoid derivatives (102478).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nBETA-CAROTENE\nBeta-carotene might alter the absorption of lycopene from tomatoes or tomato extracts.\nSome evidence suggests that taking beta-carotene supplements 20-60 mg daily increases the absorption of lycopene from supplements and from the diet (2403, 23015). However, other studies have reported that beta-carotene supplements have no effect on lycopene serum levels (23017, 23018), or that they decrease lycopene serum levels (23016). These differences may be due to other factors affecting absorption, such as whether the supplements were taken with or between meals, and how much fat was present, which increases absorption (94226).\nless\nCALCIUM\nTheoretically, calcium might reduce the absorption of lycopene from tomatoes or tomato extracts.\nOne small clinical study shows that taking a specific calcium carbonate supplement (Cacit 500, Warner Chilcott) 500 mg while eating a meal containing lycopene 19 mg reduces the bioavailability of lycopene by 83%. The mechanism of this effect is not known; however, it is suspected that calcium inhibits the uptake of lycopene in the gastrointestinal tract (95578).\nless\nLUTEIN\nLutein might reduce the absorption of lycopene from tomatoes or tomato extracts.\nThere is some evidence that taking a single 24 mg oral dose of lutein decreases the absorption of lycopene from supplements and from the diet, possibly due to competition for transport in chylomicrons. However, taking lutein 12 mg orally daily for 3 weeks does not affect plasma levels of lycopene (92165, 94227).\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nConsuming an excessive amount of tomato leaves or unripe green tomatoes can cause severe mucous membrane irritation, vomiting, diarrhea, colic, dizziness, stupor, headache, bradycardia, respiratory disturbances, and mild spasms. In very severe cases, death by respiratory failure might occur. These toxic effects are due to tomatine, a glycoalkaloid found in tomato leaves and unripe green tomatoes (18, 102957).\n\nThere is insufficient reliable information available about the presentation of overdose with ripe tomato fruit.\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with tomato.",
            "Pharmacokinetics": "Absorption\nLycopene is better absorbed from tomato products, such as tomato paste, than from fresh tomatoes (1497). Consumption of tomato juice can also significantly increase serum lycopene levels (1498, 6607). Consuming a lycopene-rich tomato paste extract causes a 2-fold increase in lycopene serum levels in healthy volunteers (14053).",
            "Mechanism of Action": "General\nThe applicable parts of tomato are the fruit, leaf, and vine. Tomato fruits are the major dietary source of the carotenoid lycopene. Lycopene is better absorbed from tomato products, such as tomato paste and tomato juice, than from fresh tomatoes (1497, 1498, 6607). One cup (240 mL) of tomato juice contains approximately 23 mg lycopene, depending on the brand (1499). Other bioactive constituents in tomato fruits include beta-carotene, phytoene, and phytofluene (106655). Tomato stems and unripe, green tomatoes contain a mildly toxic glycoalkaloid called tomatine, which is used by the tomato plant to protect itself against insects and microbes (102957).\nAnti-cancer effects\nTheoretically, the lycopene found in tomato is thought to reduce the risk of prostate cancer. Decreased serum or tissue lycopene concentrations are associated with an increased risk of prostate cancer (1447, 1496, 2405, 2406, 2407).\nAnti-inflammatory effects\nThere is interest in tomatoes to reduce inflammation. A meta-analysis of mostly small, low-quality clinical studies in adults suggests tomato consumption may decrease the inflammatory mediator tumor necrosis factor alpha but does not decrease c-reactive protein or interleukin 6 (110521). The validity of these findings is limited by the heterogeneity of the included studies, which utilized various tomato regimens and enrolled patients of varying health status.\nAntioxidant effects\nPreliminary clinical research shows that tomato powder has greater antioxidant effects than lycopene, suggesting that the antioxidant capacity of tomato powder is enhanced by other constituents beyond lycopene, including beta-carotene, phytoene, and phytofluene (106655).\nCardiovascular effects\nThere is interest in tomatoes for the reduction of cardiovascular risk factors. In healthy patients, consuming a low fiber diet (LFD) and tomato paste pure 80 grams daily for 7 days reduces stiffness index, but does not affect flow mediated dilatation, blood pressure, or lipid levels, when compared with LFD without tomato paste (102470). Other research suggests that tomato might affect blood pressure. However, it is not clear which constituents are most likely to cause this reduction. In a clinical study in patients with stage one hypertension, drinking tomato juice 200 grams enriched with polyphenols from an ethanolic tomato extract daily for 4 weeks did not reduce blood pressure when compared with drinking regular tomato juice with lower polyphenol content (102472). A clinical feeding study in healthy patients suggests that consuming a single dose of raw tomatoes 7 grams/kg, tomato sauce 3.5 g/kg, or tomato sauce with refined olive oil 3.5 g/kg seems to reduce total cholesterol, triglycerides, and inflammatory biomarkers over 6 hours when compared with a sugar control, suggesting that it may reduce the risk for atherosclerosis (102479). A crossover study in healthy adults suggests that taking a specific tomato extract (Fruitflow II, Provexis Plc, UK.) for 4 weeks improves serum markers of oxidative stress (i.e. malondialdehyde, total antioxidant capacity) and reduces platelet activation and aggregation when compared with placebo (110522). Animal research also shows that the glycoalkaloid tomatine, present in unripe green tomatoes, can lower cholesterol levels by binding cholesterol and forming a compound that cannot be absorbed in the intestinal tract (102957).\nCentral nervous system effects\nA small crossover study in healthy males suggests dietary tomato consumption is a bioavailable source of gamma-aminobutyric acid (GABA) (110524).\nCholinergic effects\nThe glycoalkaloid called tomatine, present in tomato stems, tomato leaves, and unripe green tomatoes, inhibits acetylcholinesterase in vitro. Theoretically, the neurologic toxicity that can occur after excessive consumption of tomatine is due to acetylcholinesterase inhibition and the precipitation of cholinergic crisis (102957).\nGlycemic effects\nThere is interest in using tomatoes to improve glycemic control. One small crossover trial in healthy females shows that drinking tomato juice 200 grams 30 minutes before consuming carbohydrates reduces postprandial glucose levels when compared with water. Consuming raw tomato did not have this effect (106652). Also, a small study in non-smoking male patients with type 2 diabetes found no improvement in glucose levels with the consumption of raw tomato 200 grams daily for 8 weeks (102477).\nImmunomodulating effects\nResearchers have speculated that tomato products might stimulate immune function. However, there is evidence that long-term consumption of tomato juice has no effect on cell-mediated immune function (6607).\nPhotoprotective effects\nThere is interest in using the carotenoids in tomato, such as lycopene, to protect from ultraviolet (UV) skin damage. In a small clinical study, healthy patients consuming tomato paste 55 grams (containing lycopene 16 mg) in olive oil daily for 12 weeks seemed to be more tolerant to a higher UV light exposure when compared to baseline, but not when compared to the control group consuming olive oil alone. Some biochemical markers of mitochondrial DNA and dermal extracellular matrix damage such as matrix metalloproteinase (MMP)-1 were reduced in the tomato group when compared with control (60452).\nSkin effects\nThere is interest in using the carotenoids in tomato to improve the appearance of aging skin. A small study in healthy patients aged 24-36 years shows that taking a certain tomato pulp product (Lumenato, Lycored) 1 capsule daily for 4 weeks increases plasma levels of phytoene, phytofluene, and zeta-carotene when compared to baseline (110523). The validity of these findings is limited by the lack of a placebo group."
        }
    },
    "Tonka Bean": {
        "sections": {
            "Overview": "Tonka beans are the seeds of the tonka bean tree (5944). Tonka bean has been historically used as a tonic and an aphrodisiac.",
            "Safety": "LIKELY UNSAFE when used orally. The FDA deems any food containing tonka bean or tonka bean extract to be impure (6). Rarely, coumarin, a constituent of tonka bean, has been associated with hepatotoxicity ranging from elevated liver enzymes to severe hepatic damage (6, 297).\nThere is insufficient reliable information available about the safety of the topical use of tonka bean.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally (6, 297); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tonka bean may be unsafe.\nMost Common Adverse Effects\nOrally: Diarrhea, dizziness, insomnia, nausea, and vomiting.\nSerious Adverse Effects (Rare)\nOrally: Liver toxicity, paralysis of the heart.\nCardiovascular\nOrally, large doses of tonka bean extract can paralyze the heart (4502).\nless\nGastrointestinal\nOrally, coumarin, a constituent of tonka bean, has been associated with nausea, vomiting, and diarrhea (286, 287).\nless\nHepatic\nOrally, coumarin, a constituent of tonka bean, rarely has been associated with hepatotoxicity, ranging from asymptomatic elevations in aspartate aminotransferase (AST) (286) to severe hepatic damage (6, 286, 297, 298).\nless\nNeurologic/CNS\nOrally, coumarin, a constituent of tonka bean, has been associated with dizziness and insomnia (287).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of tonka bean.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nTonka bean is sometimes standardized to its coumarin content (6002).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nCoumarin, a constituent of tonka bean, can cause stupor, headache, nausea, and vomiting when consumed at very high dosages (e.g., 4 grams) (5944).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with tonka bean.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tonka bean.",
            "Mechanism of Action": "General\nThe applicable parts of tonka bean are the fruit and seed. Tonka bean seeds usually contain coumarin 1% to 3%, but may contain up to 10% (6, 4502). Tonka bean seeds also contain coumaric-acid-beta-glucoside, o-coumaric acid, linoleic acid, oleic acid, sitosterol, stearic acid, stigmasterol, and umbelliferone (296). The fruit contains melilotoside-1-p-coumaryl-beta-d-glucose (296).\nAnalgesic effects\nSome information suggests tonka bean might have narcotic and spasmolytic properties (4502).\nAnti-inflammatory effects\nThere is some evidence that coumarin, a constituent of tonka bean, can reduce edema and inflammation by increasing venous and lymphatic return (295).\nEndocrine effects\nIn an animal study, oral administration of an isoflavone-rich fraction of tonka bean callus extract to prepubescent female rats for up to the third estrus increases the weight of the pituitary gland (108651)."
        }
    },
    "Toothed Clubmoss": {
        "sections": {
            "Overview": "Toothed clubmoss is a plant. It is used in medicine. Toothed clubmoss is also used as a source of huperzine A (103325).",
            "Safety": "There is insufficient reliable information available about the safety of toothed clubmoss.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\n\nOrally, huperzine A, a constituent of toothed clubmoss, can cause dizziness, nausea, and sweating (3140).\nGastrointestinal\nOrally, huperzine A, a constituent of toothed clubmoss, can cause nausea (3140).\nless\nNeurologic/CNS\nOrally, huperzine A, a constituent of toothed clubmoss, can cause dizziness and sweating (3140).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of toothed clubmoss.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of toothed clubmoss.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn animal models, toothed clubmoss and huperzine A, an active constituent of toothed clubmoss, reversed cognitive deficits induced by scopolamine (3135, 103325). Theoretically, concurrent use of anticholinergic drugs and toothed clubmoss might decrease the effectiveness of toothed clubmoss or the anticholinergic drug.\nSome anticholinergic drugs include atropine, benztropine (Cogentin), biperiden (Akineton), procyclidine (Kemadrin), and trihexyphenidyl (Artane).\nless\nCHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHuperzine A, a constituent of toothed clubmoss, has demonstrated acetylcholinesterase inhibitory properties (3082, 103325). Theoretically, concurrent use of toothed clubmoss with cholinergic drugs might have additive effects and increase the risk of cholinergic side effects.\nCholinergic drugs include bethanechol (Urecholine), donepezil (Aricept), echothiophate (Phospholine Iodide), edrophonium (Enlon, Reversol, Tensilon), neostigmine (Prostigmin), physostigmine (Antilirium), pyridostigmine (Mestinon, Regonol), succinylcholine (Anectine, Quelicin), and tacrine (Cognex).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "VARIOUS DISEASES\nAcetylcholinesterase (AchE) inhibitors are used with caution or are contraindicated in people with asthma, chronic obstructive pulmonary disease, cardiovascular disease, obstruction of the intestinal or urogenital tracts, gastrointestinal ulcer disease, or seizures (15). Avoid using toothed clubmoss in people with these conditions until more is known about its effects in humans.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of toothed clubmoss.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of toothed clubmoss.",
            "Mechanism of Action": "General\nToothed clubmoss is a plant. It is a source of huperzine alkaloids, such as huperzine A (3082, 103325).\nNeurological effects\nThe toothed clubmoss constituent huperzine A is of interest for Alzheimer disease and to improve memory in general. Some benefits of toothed clubmoss on memory have been demonstrated in an animal model (103325). Huperzine A is a reversible acetylcholinesterase (AchE) inhibitor that crosses the blood-brain barrier (3082)."
        }
    },
    "Tormentil": {
        "sections": {
            "Overview": "Tormentil is a plant in the Rosaceae family that is found in temperate, arctic, and alpine zones in the Northern Hemisphere (78592). It has traditionally been used for diarrhea and inflammation of the oral mucosa (107433).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Tormentil extract has been used with apparent safety in doses of up to 3 grams daily for up to 3 weeks (12, 78590). ...when used topically and appropriately (12).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, tormentil seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Abdominal pain, heartburn, and a feeling of fullness.\nGastrointestinal\nOrally, tormentil has been reported to cause mild abdominal pain, heartburn, and feelings of fullness in one clinical trial. These adverse effects occurred at the same frequency for doses ranging from 1.2 grams daily to 3 grams daily (78590).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nRotaviral diarrhea. It is unclear if oral tormentil root extract is beneficial in children with rotaviral diarrhea.\nA small clinical study in children 3 months to 7 years of age with rotaviral diarrhea living in Russia shows that taking an undeclared, age-based dose of tormentil root extract three times daily for up to 5 days reduces the duration of diarrhea by approximately 2 days when compared with placebo. Taking tormentil root extract also reduced intravenous fluid requirements when compared with placebo (10667).\nless\nUlcerative colitis. It is unclear if oral tormentil extract is beneficial in patients with ulcerative colitis.\nA small, open-label clinical study in patients with active ulcerative colitis shows that taking tormentil extract 1.2-3 grams daily for 3 weeks modestly reduces symptoms of ulcerative colitis and improves markers of inflammation when compared to baseline (78590). The validity of these findings is limited by a lack of placebo control.\nless\nMore information is needed to rate tormentil for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nIf possible, avoid taking tormentil with milk. Theoretically, milk may bind to the tannins in tormentil, decreasing its effects (12).\nTopical:\nResearch is limited; typical dosing is unavailable. Traditionally, a tincture of tormentil has been used as a mouth or throat rinse, with 10-20 drops of a 1:10 tincture added to one glass of water.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nAn ethanolic dry extract of tormentil rhizome (ratiogast, Ratiopharm) is provided in capsules containing 200 mg of extract. The extract contains 15% to 22% tannins, as well as unspecified quantities of triterpenes and flavonoids (78590).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tormentil.",
            "Pharmacokinetics": "Absorption\nIn clinical research, tannins from tormentil extract have not been shown to be systemically absorbed (78590).",
            "Mechanism of Action": "General\nThe applicable part of tormentil is the root. It contains 17% to 22% tannins, as well as proanthocyanidins, flavonoids, and triterpenes, including the triterpene glycoside termentoside (78593, 78588, 78584, 78582, 78592).\nAnti-inflammatory effects\nIn laboratory research, a water extract of tormentil demonstrated potent inhibition of cyclooxygenase, as well as inhibition of prostaglandin biosynthesis (44946).\nAntibacterial effects\nIn laboratory research, polyphenols extracted from tormentil have exhibited antibacterial activity against Gram negative and Gram positive species of the Azobacter, Bacillus, and Pseudomonas genera, including Bacillus cereus, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus (78591). A methanolic extract of tormentil root demonstrated only weak antimicrobial activity against S. aureus, P. aeruginosa, and E. coli in vitro (105747).\nAntioxidant effects\nIn a rat model of diabetes, topical application of a methanolic extract of tormentil root to excision wounds increases plasma concentrations of nitric oxide and glutathione and decreases concentrations of thiobarbituric-acid reactive substances, an indirect measurement of lipid peroxidation (105747).\nAntiplatelet effects\nAnimal research shows that tormentil extract has contrasting effects on thrombus formation, coagulation, and fibrinolysis. In mouse and rat models of diabetes with electrically- or laser-induced thrombosis, lower doses of tormentil extract decreased thrombus formation, likely through antiplatelet effects. However, higher doses failed to demonstrate antiplatelet effects and, in some cases, increased thrombus formation and decreased fibrinolysis. More research is needed to determine if tormentil has antiplatelet or pro-coagulant effects (107433).\nWound healing effects\nIn a rat model of diabetes, daily topical application of a methanolic extract of tormentil root to full-thickness excision wounds increases the wound contraction rate and decreases the wound area similar to that seen in non-diabetic rats. The extract also increases wound collagen levels (105747)."
        }
    },
    "Tragacanth": {
        "sections": {
            "Overview": "Tragacanth is a low shrub that grows in Turkey, Syria, Lebanon, Iran and Iraq. The gum-like latex that oozes when cutting the bark is used for medicinal purposes (18).",
            "Warnings": "Tragacanth is commonly adulterated with karaya gum (16).\n\nIt is important to use tragacanth in conjunction with adequate fluid intake to prevent esophageal closure or obstruction of the ileus (18).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Tragacanth has Generally Recognized as Safe (GRAS) status in the US (4912). ...when used topically, in the amounts found in cosmetics. Tragacanth is not considered to be irritating, sensitizing, or phototoxic (4072).\nPOSSIBLY SAFE when used orally in medicinal amounts (4068). However, insufficient fluid intake with tragacanth might lead to esophageal closure or intestinal obstruction (18).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using amounts greater than those found in foods.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tragacanth is generally well tolerated.\nSerious Adverse Effects (Rare)\nOrally: Tragacanth can lead to intestinal obstruction and esophageal closure when used without adequate fluid intake (18).\nGastrointestinal\nOrally, tragacanth can lead to intestinal obstruction and esophageal closure when used without adequate fluid intake (18).\nless\nImmunologic\nTragacanth can cause asthma symptoms in people who are sensitive to quillaia bark (6).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nConstipation. Although there is interest in using oral tragacanth for constipation, there is insufficient reliable information about the clinical effects of tragacanth for this condition.\nDiarrhea. Although there is interest in using oral tragacanth for diarrhea, there is insufficient reliable information about the clinical effects of tragacanth for this condition.\nMore evidence is needed to rate the effectiveness of tragacanth for these uses.",
            "Dosing & Administration": "Adult\nOral:\n\nResearch is limited; typical dosing is unavailable.\n\nTheoretically, taking tragacanth with food might impair nutrient absorption due to the hydrocolloidal fiber content of tragacanth (19).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tragacanth.",
            "Interactions with Drugs": "ORAL DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tragacanth might alter absorption of oral drugs.\nTragacanth contains hydrocolloidal fiber which can decrease, increase, or not affect oral drug absorption (19). To avoid changes in absorption, take tragacanth 30-60 minutes after oral medications.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tragacanth.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tragacanth.",
            "Mechanism of Action": "General\nThe applicable part of tragacanth shrub is the resin exudate from the trunk and branches (18). Tragacanth contains the water-soluble polysaccharides tragacanthin and water-insoluble bassorin (11). When added to water, tragacanthin dissolves to form a viscous colloidal solution; bassorin swells to form a thick gel (11). Among plant gums, tragacanth produces the most viscous solution (11).\nAntimicrobial effects\nLaboratory research suggests tragacanthin polysaccharides might offer some protection from hantavirus infections (4070). Tragacanth is highly susceptible to bacterial digestion, even in the presence of preservatives (11).\nAntineoplastic effects\nIn folk medicine, tragacanth has been used for eye, liver, and throat cancer (18). Tragacanth appears to inhibit growth of cancer cells in vitro (11).\nDental effects\nThe mucilaginous, adhesive properties of tragacanth justify its use as a component in denture adhesives (6).\nGastrointestinal effects\nWhen ingested, the bulk of tragacanth stretches the intestinal wall, increasing peristalsis (18). It increases stool weight and decreases GI transit time (6).\nMetabolic effects\nSome preliminary data indicate that people with diabetes who ingest tragacanth along with a high sugar load have lower peak serum glucose and insulin levels (4069). Although tragacanth increases stool weight and decreases GI transit time, it does not appear to affect cholesterol, triglyceride, or phospholipid levels as do other soluble fibers (6)."
        }
    },
    "Trailing Arbutus": {
        "sections": {
            "Overview": "Trailing arbutus's alternate name of gravel plant is similar to that of gravel root. Be careful not to confuse the two.",
            "Safety": "POSSIBLY SAFE when the leaves are used orally short-term (12).\nUNSAFE when the fresh or dried leaves are used orally long-term because they could cause hydroquinone toxicity (18).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, chronic use of trailing arbutus may lead to hydroquinone toxicity. Symptoms of toxicity include tinnitus, vomiting, delirium, convulsions, and collapse (11). Liver damage, cachexia, hemolytic anemia, and hair depigmentation may also occur with long term use (18). Overdosage could lead to inflammation of the mucous membranes of the bladder and urinary tract, and may be accompanied by bloody urine, difficulty with urination, and painful urination (18).",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of trailing arbutus.",
            "Dosing & Administration": "Adult\nORAL: Trailing arbutus is taken as a tea or extract (18).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The applicable parts of trailing arbutus are the above ground parts. Trailing arbutus is not suitable for long term use due to its hydroquinone glycoside content (18). Arbutin may have urinary antiseptic properties due to hydrolysis to its hydroquinone by the intestinal flora (7, 11). As a result, long term use is stated to lead to hydroquinone toxicity (18)."
        }
    },
    "Transfer Factor": {
        "sections": {
            "Overview": "Transfer factor, also called dialyzable leukocyte extract, is a mixture of low molecular weight peptides from peripheral blood leukocytes. Transfer factors are believed to transfer antigen-specific cell-mediated immunity from an immune or sensitized donor to a nonimmune or non-sensitized recipient (78663).",
            "Safety": "POSSIBLY SAFE when used orally or parenterally and appropriately. Human-derived transfer factor has been used safely in studies lasting up to 2 years (3062, 7562, 7797, 7798) and bovine-derived transfer factor has been safely used in small studies lasting up to 3 months (1445, 1507). Some evidence suggests these products are safe; however, some preparations are derived from animals and there is concern about contamination with diseased animal parts (see Adverse Reactions) (1825). There are no reports of disease transmission to humans due to use of contaminated bovine transfer factor.\nCHILDREN: POSSIBLY SAFE when used orally or parenterally and appropriately. Human-derived transfer factor administered subcutaneously has been used safely for up to 6 years (7794). Oral bovine transfer factor has been used safely for up to 6 months (350).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally or parenterally, transfer factor seems to be well tolerated (350, 1445, 1507, 3062, 3063, 7562, 7794, 7797, 7798, 7799, 78668, 78669, 78702, 78714, 78774, 78796). Adverse effects may include fever (1507). Parenterally, transfer factor can cause nausea, fatigue, and tenderness, pain, and swelling at the injection site (3062, 7562, 7799, 78809). Orally, severe acne has been reported (78820).\n\nThere is some concern that bovine-derived transfer factor that is produced from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be contaminated with diseased tissue. Countries where BSE has been reported include Great Britain, France, the Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium (1825). However, there have been no reports of BSE transfer to humans from contaminated transfer factor products. Until more is known, tell patients to avoid these products unless country of origin can be determined. Patients should avoid products that are produced in countries where BSE has been found.\nDermatologic\nOrally, transfer factor may cause severe acne in some patients (78820).\nless\nGastrointestinal\nParenterally, nausea has been reported in a patient following treatment with transfer factor (78809)\nless\nMusculoskeletal\nParenterally, transfer factor may cause tenderness, pain, and swelling at the injection site (3062, 7562, 7799, 78809).\nless\nNeurologic/CNS\nParenterally, fatigue has been reported for up to 4 hours in a patient using transfer factor (78789).\nless\nOther\nOrally or parenterally, transfer factor may cause fever (1507, 78789, 78809).\n\nThere is some concern that bovine-derived transfer factor that is produced from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be contaminated with diseased tissue. Countries where BSE has been reported include Great Britain, France, the Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium (1825). However, there have been no reports of BSE transfer to humans from contaminated transfer factor products. Until more is known, tell patients to avoid these products unless country of origin can be determined. Patients should avoid products that are produced in countries where BSE has been found.\nless",
            "Effectiveness": "POSSIBLY EFFECTIVE\nHerpes zoster (shingles). Administering transfer factor subcutaneously seems to prevent varicella-zoster in children with leukemia. A single subcutaneous treatment with human-derived transfer factor prepared from donors with varicella-zoster antibodies seems to almost completely protect nonimmune children with acute lymphocytic leukemia against varicella-zoster infection (384). However, the same treatment does not seem to prevent recurrent varicella-zoster infection or restore immunity in people receiving bone marrow transplant for leukemia (3278).\nIn addition to having a prophylactic effect, some preliminary clinical evidence suggests that human-derived transfer factor may help treat herpes zoster. Administering human-derived transfer factor subcutaneously seems to reduce the duration of pain by about 5 days compared to treatment with acyclovir in patients with acute-stage herpes zoster infection (78842).\nless\nPOSSIBLY INEFFECTIVE\nLung cancer. Most research shows that administering human-derived transfer factor intramuscularly or subcutaneously, in combination with lung resection and chemotherapy, does not increase survival in patients with lung cancer (5447, 7800, 78793). However, some preliminary evidence suggests that transfer factor might improve survival in lung cancer patients with Stage IIIA or IIIB disease (78824).\nMelanoma. Administering human-derived transfer factor intramuscularly or subcutaneously, as adjuvant therapy, does not seem to affect disease progression or prolong survival when used for up to 2 years following surgery for Stage I and Stage II melanoma (3062, 3063, 78691).\nMultiple sclerosis (MS). Most research suggests that transfer factor given subcutaneously does not improve disease progression in people with MS (7799, 78670, 78796). While some research suggests that transfer factor might slow disease progression in people with mild to moderate symptoms, a positive effect is seen only after 18 months to 2 years of therapy (7798).\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. Preliminary clinical research suggests that subcutaneous injection of whole or fractionated human-derived transfer factor once weekly for 2 weeks does not improve acne in patients with acne vulgaris (78677).\nAmyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). Preliminary clinical research shows that once monthly injections with human-derived transfer factor from healthy donors does not affect the course of ALS (78751).\nCervical cancer. Preliminary clinical research suggests that administering transfer factor subcutaneously, once monthly for 2 years, significantly reduces the risk of recurrence after surgery and irradiation compared to placebo in patients with invasive cervical cancer (78693).\nChronic fatigue syndrome (CFS). Transfer factor, obtained from relatives or other human donors, does not seem to improve CFS symptoms when administered intramuscularly biweekly, either alone or in combination with cognitive behavioral therapy (7562). However, some preliminary clinical evidence suggests that taking transfer factor orally improves symptoms in some patients with CFS (78820).\nCrohn disease. Preliminary clinical research suggests that administering transfer factor intramuscularly does not improve clinical condition compared to placebo in patients with Crohn's disease (78712).\nGenital herpes. One preliminary clinical study in patients with recurrent genital herpes shows that taking herpes simplex virus (HSV)-specific transfer factor orally reduces relapse indices from 56.3 to 28.2 compared to baseline (78817). Another preliminary clinical study in patients with severe recurrent genital herpes or other recurrent herpes infections shows that receiving transfer factor subcutaneously may reduce the frequency or severity of recurrence in some patients (78818).\nHepatitis B. Some preliminary clinical evidence suggests that transfer factor derived from patients with acute hepatitis B, given intramuscularly, might be useful for treating chronic active hepatitis B infection (7797). Other preliminary clinical research shows that transfer factor derived from patients with acute hepatitis B, given subcutaneously, does not improve biochemical parameters in patients with chronic active hepatitis B infection (78775).\nHerpes keratitis. Results from several small clinical trials suggest that transfer factor might reduce the risk of herpes keratitis relapse (78803, 78816).\nHerpes labialis (cold sores). One preliminary clinical study in patients with recurrent herpes labialis shows that taking herpes simplex virus (HSV)-specific transfer factor orally reduces relapse indices from 68.7 to 12.9 compared to baseline (78817). Another preliminary clinical study in patients with severe recurrent herpes labials or other recurrent herpes infections shows that receiving transfer factor subcutaneously may reduce the frequency or severity of recurrence in some patients (78818).\nHIV/AIDS. Preliminary clinical research shows that taking HIV-1-specific transfer factor orally for 15 days and then once weekly for 6 months along with zidovudine is no more effective than zidovudine alone for improving hematological parameters and clinical progression in HIV-1 infected patients with asymptomatic disease, persistent generalized lymphadenopathy, or AIDS-related complex (78814).\nHodgkin lymphoma. Preliminary clinical research shows that administering transfer factor subcutaneously once every 3 months for 21 months does not reduce the incidence of infections compared to placebo in patients with Hodgkin lymphoma (78683).\nHuman papillomavirus (HPV). Preliminary clinical research shows that taking transfer factor orally every 72 hours for 4 weeks resolves symptoms in 90% of women and results in normal colposcopy images in 89% of women with chronic cervicitis due to HPV infection. Women taking the placebo had no improvement in symptoms (97664). Other preliminary clinical research shows that taking transfer factor orally for 5 weeks, while also using it topically every 72 hours for the first 2 weeks, repeating every 3 months if a persistent lesion was found, at least doubles the number of patients free of cervical lesions related to HPV infection after 2 years when compared to treatment with cryo- or electro-surgery (97665). However, transfer factor given subcutaneously does not seem to improve wart regression in patients with HPV (78621).\nIntestinal parasite infection. There is some preliminary evidence that oral transfer factor weekly for up to 3 months might be beneficial for people with cryptosporidiosis related to AIDS. Transfer factor from bovine sources seems to improve stool frequency and help eradicate oocysts in some patients (1445, 1480).\nLeishmania lesions. There is some evidence that transfer factor obtained from patients with antibodies to leishmania can heal persistent cutaneous leishmania lesions (3930, 8105).\nLeukemia. Preliminary clinical research shows that administering transfer factor subcutaneously reduces time to neutrophil and leukocyte count recovery compared to control in patients with acute leukemia (78809).\nMycosis fungoides. Preliminary clinical research shows that administering transfer factor intramuscularly once weekly for one year does not improve clinical status compared to placebo in patients with mycosis fungoides (78789).\nNasopharyngeal cancer. There is conflicting evidence about the effects of using transfer factor for nasopharyngeal carcinoma. One case report suggests that administering transfer factor with specific activity against Epstein-Barr virus intramuscularly improves survival in patients with nasopharyngeal carcinoma, while other research shows that it does not (78680, 78823).\nOsteosarcoma. Preliminary clinical research suggests that administering human-derived transfer factor subcutaneously does not reduce tumor recurrence or improve survival in patients with resected, nonmetastatic osteosarcoma (78701).\nProstate cancer. Preliminary clinical evidence suggests that 2-5 units of transfer factor, given intramuscularly once monthly, might improve disease progression in patients with hormone-resistant, metastatic prostate cancer (78825).\nRheumatoid arthritis (RA). Preliminary clinical research suggests that transfer factor, given subcutaneously, does not provide therapeutic benefit to patients with juvenile rheumatoid arthritis (78702).\nMore evidence is needed to rate transfer factor for these uses.",
            "Dosing & Administration": "Adult\nOral:\nChronic fatigue syndrome (CFS): Capsules of human-derived transfer factor with activity against cytomegalovirus/Epstein-Barr virus or with unspecified activity has been used. Days of treatment ranged from 90 to 450 days (78820).\n\nGenital herpes: A herpes simplex virus (HSV)-specific transfer factor has been used twice weekly for 2 weeks and then weekly for 6 months (78817).\n\nHerpes keratitis: Bovine transfer factor with activity against herpes simplex virus 4 x 108 cell equivalents weekly for 2 weeks, then 108 cell equivalents weekly for 6-12 months thereafter has been used (78803, 78816).\n\nHerpes labialis (cold sores): A herpes simplex virus (HSV)-specific transfer factor has been used twice weekly for 2 weeks and then weekly for 6 months (78817).\n\nHIV/AIDS: HIV-1-specific transfer factor 2 x 107 cell equivalents for 15 days and then once weekly for 6 months has been used (78814).\n\nHuman papilloma virus (HPV): Transfer factor taken every 72 hours for 4 weeks has been used (97664). Taking transfer factor orally for 5 weeks, while also using it topically every 72 hours for the first 2 weeks, repeating every 3 months if a persistent lesion was found, has been used (97665).\n\nIntestinal parasite infection: Bovine transfer factor 5 x 108 lymph node cell equivalents weekly for up to 3 months has been used (1445, 1480).\nSubcutaneous:Cervical cancer: Two units of transfer factor administered by subcutaneous injection beginning three weeks after surgery and before undergoing radiation, and monthly for two years thereafter, has been used (78693).\n\nGenital herpes: Human-derived transfer factor with anti-herpes activity 2 x 108 cell equivalent per ampoule, given at the first sign of symptoms, has been used. In some patients, a second injection was given at the time of severe relapse, which typically occurred 3-5 months after the first injection. In other patients, second and third injections were given at 1 and 3 weeks after the first injection (78818).\n\nHerpes labialis (cold sores): Human-derived transfer factor with anti-herpes activity 2 x 108 cell equivalent per ampoule, given at the first sign of symptoms, has been used. In some patients, a second injection was given at the time of severe relapse, which typically occurred 3-5 months after the first injection. In other patients, second and third injections were given at 1 and 3 weeks after the first injection (78818).\n\nHerpes zoster (shingles): One unit of transfer factor, prepared from the blood of nonselected donors, has been administered by subcutaneous injection daily for 7 days (78842).\n\nLeukemia: One unit of transfer factor (equivalent to 5 x 108 leukocytes exposed to Sendai virus prior to extraction to induce interferon-alpha) given by subcutaneous injection daily until the leukocyte count was >2.5 x 109/L and the platelet count was >80 x 109/L, or until day 14 of treatment, has been used (78809).\nIntramuscular:\nHepatitis B: Transfer factor from 2 x 108 lymphocytes by intramuscular injection every 2 weeks for 6 months has been used (7797).\n\nNasopharyngeal cancer: One donor unit of transfer factor with activity against Epstein-Barr virus 109 lymphocyte equivalents, given once weekly for three months then once monthly for 18 months, has been used (78680).\n\nProstate cancer: Once monthly intramuscular injections of 2-5 units of transfer factor for up to 9 years have been used (78825).\nTopical:\nHuman papilloma virus (HPV): Taking transfer factor orally for 5 weeks, while also using it topically every 72 hours for the first 2 weeks, repeating every 3 months if a persistent lesion was found, has been used (97665).\nChildren\nSubcutaneous:Herpes zoster (shingles): A single dose of human-derived transfer factor, specific for varicella, of 100 million lymphocyte equivalents per 7 kg of body weight has been given subcutaneously to children aged 5 months to 14 years (384).\nStandardization & Formulation\nOne unit of human transfer factor has been defined as the extract originating from 1-2 x 109 leukocytes or 5 x 108 lymphocytes (78629, 78709).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of transfer factor.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of transfer factor.",
            "Mechanism of Action": "General\nTransfer factor refers to a heterogenous mixture of dialyzable polypeptide molecules extracted from leukocytes of humans and animals, such as cows and mice (1493, 1494). Bovine transfer factor is structurally similar to human-derived transfer factor (7788). Transfer factor contains more than 200 different substances including peptides and polynucleotides (7790, 78629, 78638, 78690, 78716). The molecules in transfer factor are generally less than 12,000 Daltons (78736, 78813, 97665).\n\nTransfer factors are products of T-lymphocytes that transfer the ability to express delayed-type hypersensitivity and cell-mediated immunity from sensitized donors to non-immune recipients (7793). Transfer factors are derived from sources that have developed immunity to certain infectious diseases. For example, bovine transfer factor for cryptosporidiosis is prepared by first inoculating calves with cryptosporidium and then harvesting of lymph nodes (1410, 1420, 1445, 1480, 7791). Human-derived transfer factor is prepared from blood of donors with antigen-specific immune responses (1476, 1507).\n\nThere is some evidence that transfer factors can be stored for 12 months and retain potency (7790).\nImmune effects\nThe theory is that use of transfer factor from sensitized donors, human or animal, can cause deficient recipients to express cell-mediated immunity (1493). This effect is antigen-specific and results in expression of delayed type hypersensitivity and production of lymphokines (1493, 1495, 1507, 7788). In humans, taking transfer factor improves levels of various cytokines in the cervical epithelium (97664). Animal studies indicate that transfer factor prepared from bovine lymphocytes or bovine colostrum confers cell-mediated immunity to specific antigens on recipients of different species (1475, 1477, 1478, 7791, 7792).\n\nThe exact mechanism of action of transfer factors is unknown; however, a specific amino acid sequence in transfer factor has been identified, and antigen specificity is well-established (1475, 1477, 1478, 7793). Although the recipient of transfer factor acquires the ability to express the cell-mediated immune responses of the donor, the serum of the recipient will not cause a similar response if used to inoculate an unsensitized individual. The production of transfer factor appears to be regulated by immune response genes, but the immunologic activities of transfer factor are not (7789). It is possible that transfer factors might cause an immune response by different mechanisms than active immunization (7793).\n\nResearch suggests that transfer factors specific to a variety of bacteria, viruses, protozoa, and other parasites might be useful for microbial diseases (7790). However, there is no evidence that non-specific transfer factor products, such as those marketed on the internet, are effective for any indication.\n\nThe immune effects of transfer factor have been shown to be associated with antiviral responses in humans and in animal models (97664) and anti-cancer and antiviral effects in animal models (78612, 78648, 78658, 78681)."
        }
    },
    "Traveler's Joy": {
        "sections": {
            "Overview": "",
            "Safety": "LIKELY UNSAFE when used orally or topically due to the constituent protoanemonin, which is a severe local irritant (18).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally or topically (18).",
            "Adverse Effects": "General\nOrally, traveler's joy can cause severe irritation of the gastrointestinal tract, including colic and diarrhea. Irritation of the urinary tract can also occur.\n\nTopically, skin contact can cause blisters and burns that are difficult to heal (18).",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of traveler's joy.",
            "Dosing & Administration": "Adult\nNo typical dosage.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The applicable part of traveler's joy is the fresh leaf. When the fresh plant is crushed or cut into small pieces, the glycoside ranunculin is enzymatically changed into a severely irritating protoanemonin, which, in turn, rapidly degrades into the less toxic anemonin (18). Both protoanemonin and ranunculin are destroyed to an unknown extent during the drying process (2)."
        }
    },
    "Tree of Heaven": {
        "sections": {
            "Overview": "Tree of heaven is a flowering tree that grows to about 30 meters in height. It is native to China and North Vietnam (108935). The dried trunk and root bark have been used in folk medicine (18).",
            "Safety": "There is insufficient reliable information available about the safety of tree of heaven.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information available about the safety of tree of heaven. Orally, large amounts of the bark have been reported to cause queasiness, dizziness, headache, limb tingling, and diarrhea (18).\nGastrointestinal\nOrally, large amounts of tree of heaven bark have been reported to cause queasiness and diarrhea (18).\nless\nNeurologic/CNS\nOrally, large amounts of tree of heaven bark have been reported to cause dizziness, headache, and limb tingling (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of tree of heaven.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tree of heaven.",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tree of heaven extract might reduce platelet aggregation and increase the risk of bleeding if used with antiplatelet or anticoagulant drugs. In vitro evidence shows that tree of heaven crude extract attenuates epinephrine and adenosine diphosphate-induced platelet aggregation (102452). This interaction has not been seen in humans. Until more is known, use with caution in patients taking anticoagulant or antiplatelet drugs.",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nConcomitant use of herbs and supplements that might affect platelet aggregation could theoretically increase the risk of bleeding in some people. In vitro evidence shows that tree of heaven crude extract attenuates epinephrine and adenosine diphosphate-induced platelet aggregation (102452). Herbs that affect platelet aggregation include angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, and others.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tree of heaven.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tree of heaven.",
            "Mechanism of Action": "General\nThe applicable parts of tree of heaven are the dried trunk and root bark, and the fruit. The bark of the tree of heaven is said to have astringent, antipyretic, and antispasmodic properties (18). The bark contains tannins, indole alkaloids of the beta-carbolic type, terpenoids, steroids, and flavonoids (18).\nAntimicrobial effects\nSome evidence suggests the quassionoid constituents, including ailanthone and quassin, have antiprotozoan, anthelmintic, antileukemic, and cytotoxic properties (18).\nAntioxidant effects\nIn vitro, an extract of tree of heaven fruit demonstrates antioxidant activity, with strong reducing power and diphenylpicrylhydrazyl (DPPH) scavenging effects. It has only limited hydroxyl radical scavenging. In a cell injury model of oxidative stress, protective effects of the extract are mediated by increases in the superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) systems. Tree of heaven is thought to supply hydrogen or electrons, to break free radical chains, and to regulate the FoxO and P13K/AKT oxidative stress-related signaling pathways (108935).\nCardiovascular effects\nIn vitro evidence shows that tree of heaven crude extract attenuates epinephrine- and adenosine diphosphate-induced platelet aggregation (102452). Also, ex vivo evidence shows that crude extract of the tree of heaven bark relaxes rat aorta and reduces contraction force in rabbit atrium, theoretically by blocking calcium channels (102452).\nGastrointestinal effects\nEx vivo, crude extract of the tree of heaven bark demonstrates concentration-dependent spasmolytic effects on rabbit jejunum (18, 102452). Animal studies in mice treated with castor oil show that tree of heaven bark extract has antidiarrheal effects (102452)."
        }
    },
    "Tree Tobacco": {
        "sections": {
            "Overview": "Tree tobacco, a perennial shrub that grows to be about 5 meters in height, is native to Argentina, but now grows worldwide (28734). The leaves of tree tobacco are toxic when used orally due to the presence of anabasine, a toxic alkaloid (28734, 28735).",
            "Safety": "LIKELY UNSAFE when tree tobacco is used orally. Tree tobacco contains anabasine, which is poisonous (28734, 28735, 28739). Symptoms of poisoning include asystole, bulbar palsy, severe muscle weakness and spasm, vomiting leading to aspiration, respiratory compromise, seizures, hypertension, coma, and death (28735, 28736, 28737, 28738, 28739, 98622, 98623, 106641).\nThere is insufficient reliable information available about the safety of tree tobacco when used topically.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when tree tobacco is used orally. Tree tobacco contains anabasine, which is poisonous and teratogenic (28734, 28735, 28738).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tree tobacco is generally regarded as unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity. Tree tobacco can cause nausea, vomiting, diarrhea, abdominal pain, changes in blood pressure and heart rate, muscle weakness and paralysis, respiratory distress, and neurological symptoms including vertigo, confusion, fatigue, headache, hallucinations, spasms, weakness, and coma. Death has occurred in up to 40% of reported cases of tree tobacco poisoning (28735, 28736, 28737, 28738, 28739, 98622, 98623, 106641).\nCardiovascular\nOrally, tree tobacco has been reported to cause hypertension, hypotension, bradycardia, tachycardia, and asystole (28735, 98623, 106641). Hypertension tends to occur early, within 4 hours of consumption (98623).\nless\nGastrointestinal\nOrally, tree tobacco has been reported to cause nausea, vomiting, diarrhea, dry mouth, salivation, and abdominal pain (28734, 28736, 98622, 98623, 106641). Nausea and vomiting tend to occur early, within 4 hours of consumption (98623).\nless\nMusculoskeletal\nOrally, tree tobacco has been reported to cause neuromuscular weakness and paralysis (28736, 98622, 106641).\nless\nNeurologic/CNS\nOrally, tree tobacco has been reported to cause vertigo, confusion, fatigue, headache, photophobia, spasms, tingling, severe sweating, progressively worsening aphasia, neuromuscular blockage, seizures, coma, and bulbar palsy (28734, 98622, 98623, 106641). Dizziness and confusion tend to occur early, within 4 hours of consumption (98623). Weakness, coma, and paralysis occur later (98623).\nless\nOcular/Otic\nOrally, tree tobacco has been reported to cause disturbed vision and hearing (28734, 98622).\nless\nPsychiatric\nOrally, tree tobacco has been reported to cause hallucinations that last for several hours (26911).\nless\nPulmonary/Respiratory\nOrally, the mistaken and intentional intake of tree tobacco has been reported to cause acute respiratory distress requiring short-term intubation in elderly females (98622, 98623, 106641). It has also been reported to cause rapid or slowed breathing (28734, 98623).\nless\nOther\nOrally, tree tobacco poisoning has resulted in death in as many as 40% of reported cases (28735, 98623).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of tree tobacco.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tree tobacco.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "In humans, ingestion of as few as three leaves of tree tobacco can be fatal (26911). Supportive care has been suggested as treatment for tree tobacco poisoning (28739, 106641).\n\nAnabasine, a toxic alkaloid in tree tobacco, is a teratogenic chemical that can cause reproductive defects when taken orally while pregnant (28734). In goats, sheep, swine, and cattle, administration of tree tobacco or anabasine during pregnancy induced cleft palate and congenital malformations of bones and joints in offspring (28740, 28741, 28742, 28743, 28744, 28745, 28746, 28747, 28748, 28749)(28750, 28751, 28752, 28753).\n\nIn animals, the LD50 of anabasine is reportedly 22 mg/kg (28734).",
            "Pharmacokinetics": "General: Limited information is available regarding the pharmacokinetics of tree tobacco. To date, evidence regarding the pharmacokinetics of tree tobacco focuses on its anabasine constituent.\nDistribution\nAnabasine was found in samples from patients who died from eating tree tobacco as follows: blood 1.2-2.2 mg/L, urine 2-74 mg/L , heart 10 mg/kg, kidney 16 mg/kg, brain 11 mg/kg, lung 11 mg/kg, liver 1.7 mg/kg, bile 2.7 mg/L, and gastric contents 113 mg/L (28737, 28738).\nExcretion\nThe half-life of anabasine in humans is reported to be about 16 hours. Anabasine is excreted in the urine (29993).",
            "Mechanism of Action": "General\nThe applicable part of tree tobacco is the leaf. The fresh leaves of tree tobacco contain racemic anabasine (0.05%), nicotine (0.002%), nornicotine (0.007%), myosmine (0.008%) and cotinine (0.006%) (28762, 28763). Dried leaves of tree tobacco were found to contain 0.175% to 0.23% anabasine (28741). The leaves and bark have been found to contain more anabasine than the wood (28752). Tree tobacco also contains chlorinated amides such as N-(2',6'-diethylphenyl)-2-chloroacetamide and N-(butyloxymethyl)-N-(2',6'-diethylphenyl)-2-choroacetamide (28764), scopoletin, triacontanol, stigmasterol-3-beta-O-D-glucopyranoside (28764), quercetin, and rutin (28766). Tree tobacco contains cholesterol derivatives including 7-dehydrocholesterol, vitamin D3, and its metabolites (28767). Infection of tree tobacco roots by fungi such as Glomus intraradices may induce the formation of glycosylated cyclohexenone derivatives (28765).\nInsecticidal effects\nTree tobacco is used as an insecticide. Laboratory evidence suggests that application of tree tobacco extract 1.72 mcL per square centimeter has 50% effectiveness as a repellent against Anopheles gambiae sensu stricto (28755).\nNeurologic effects\nNicotine and anabasine alkaloids present in tree tobacco have a very complex pharmacology involving interaction with nicotinic receptors in ganglia and the brain and stimulation of the release of catecholamines from the adrenal medulla and the brain (28759, 28760, 29992). The actions of these alkaloids are frequently biphasic, with low doses inducing stimulatory effects and high doses causing depressant effects. Anabasine is a selective a7 nicotinic acetylcholine receptor agonist (28760). Anabasine also has the ability to inhibit acetylcholinesterase, which may contribute to its toxic effects (28761). However, anabasine appears to be only a weak acetylcholinesterase inhibitor, suggesting that its primary toxic effects stem from neuromuscular blockade (29992)."
        }
    },
    "Tree Turmeric": {
        "sections": {
            "Overview": "Tree turmeric is a shrub that is found in northern India and Nepal. It contains high levels of the constituent berberine (96141, 96143). Tree turmeric has been used widely in Ayurveda and traditional Chinese medicine (96141, 96143, 101158).",
            "Safety": "LIKELY SAFE when a specific product (Berberol, PharmExtracta) containing tree turmeric extract 588 mg and milk thistle extract 105 mg is used. This product has been safely used twice daily for up to 12 months (95019, 96140, 96141, 96142, 101158).\nThere is insufficient reliable information available about the safety of other forms of tree turmeric when used orally or topically in medicinal amounts.\nCHILDREN: LIKELY UNSAFE when used orally in newborns. The berberine constituent of tree turmeric can cause kernicterus in newborns, particularly preterm neonates with hyperbilirubinemia (2589). There is insufficient reliable information available about the safety of tree turmeric in older children.\nPREGNANCY: LIKELY UNSAFE when used orally. The berberine constituent of tree turmeric is thought to cross the placenta and may cause harm to the fetus. Kernicterus has developed in newborn infants exposed to berberine (2589).\nLACTATION: LIKELY UNSAFE when used orally. The berberine constituent of tree turmeric and other harmful constituents can be transferred to the infant through breast milk (2589).",
            "Adverse Effects": "General\nOrally and topically, no adverse effects have been reported with the use of tree turmeric alone. However, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Gastrointestinal symptoms, especially nausea, with the use of a specific product containing tree turmeric and milk thistle (Berberol, PharmExtracta).\nGastrointestinal\nOrally, the most common adverse effects of a specific product (Berberol, PharmExtracta) containing tree turmeric and milk thistle extracts include gastrointestinal symptoms, especially nausea (95019, 96140, 96141, 96142).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBurns. Although there has been interest in using topical tree turmeric for burns, there is insufficient reliable information about the clinical effects of tree turmeric for this purpose.\nDiabetes. Oral tree turmeric has only been evaluated in combination with other ingredients for the management of type 1 and type 2 diabetes; its effect when used alone is unclear.\nClinical research in patients with type 2 diabetes shows that taking a specific combination product (Berberol, PharmExtracta) containing tree turmeric extract 1176 mg and milk thistle extract 210 mg improves some measures of diabetes control. A clinical study in patients with type 2 diabetes, obesity, and metabolic syndrome shows that taking this specific product daily for 12 months reduces glycated hemoglobin (HbA1c) by approximately 18% when compared to baseline. This reduction was significant when compared with the 5% reduction in the placebo group. Fasting blood glucose and insulin resistance were also improved, with a reduction in fasting blood glucose of approximately 25% for patients in the treatment group, compared to 10% in the placebo group (97624). Several other small clinical studies in adults with poorly controlled type 2 diabetes shows that taking this same product for 12 months improves HbA1c, fasting blood glucose, and insulin resistance when compared to baseline (96140, 96141). A treatment duration of 3 months does not appear to be effective for improving fasting blood glucose levels in these patients; however, it does seem to improve HbA1c when compared with baseline (96141). This product has also been evaluated in patients with type 1 diabetes. A clinical study in patients with type 1 diabetes shows that taking this product with meals for 6 months reduces the amount of insulin needed to achieve adequate glycemic control by 14.5% and lowers fasting blood glucose levels by 10% when compared with placebo (96142).\nless\nHypercholesterolemia. Oral tree turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA meta-analysis of four mostly low-quality clinical studies in hypercholesterolemic adults shows that taking a specific combination product (Berberol, PharmExtracta) containing tree turmeric extract 588 mg and milk thistle extract 105 mg twice daily for 3 months, along with diet and exercise, reduces levels of low-density lipoprotein (LDL) cholesterol by an average of 33 mg/dL when compared with diet and exercise alone (101158). These studies lasted for no more than 12 months and some studies allowed for inclusion of patients who required a reduction in statin dose due to adverse effects (95019, 96140, 101158). Taking this product does not appear to significantly lower triglyceride levels or increase high-density lipoprotein (HDL) cholesterol levels in most of these patients (95019, 96140, 101158). Other clinical research in adults with hypercholesterolemia shows that a similar product (Berberol K, PharmExtracta) containing tree turmeric extract of berberine 500 mg, milk thistle extract 105 mg, and monacolin K and KA 10 mg, taken once daily for 3 months along with diet and exercise, reduces levels of LDL cholesterol by about 28% when compared with diet and exercise alone (97625). It is possible that any benefit of this product is due to the monacolin content. Further, since this product is standardized to monacolin content, it is considered by the US Food and Drug Administration to be a new drug rather than a dietary supplement.\n\nAnother clinical study in adults with hypercholesterolemia shows that taking a different combination product (Zeta Colest, Erbozeta) containing 400 mg of tree turmeric extract providing 340 mg of berberine, red yeast rice extract, milk thistle extract, and guggul extract daily for 8 weeks, along with following a Mediterranean diet, reduces levels of LDL and total cholesterol by approximately 18% and 15%, respectively, when compared with the Mediterranean diet plus placebo (116928). However, it is unclear these effects are due to tree turmeric, other ingredients, or the combination.\nless\nMenorrhagia. Although there has been interest in using oral tree turmeric for menorrhagia, there is insufficient reliable information about the clinical effects of tree turmeric for this purpose.\nTrachoma. Although there has been interest in using oral tree turmeric for trachoma, there is insufficient reliable information about the clinical effects of tree turmeric for this purpose.\nWound healing. Although there has been interest in using topical tree turmeric for wound healing, there is insufficient reliable information about the clinical effects of tree turmeric for this purpose.\nMore evidence is needed to rate tree turmeric for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Tree turmeric may counteract the potential beneficial effects of some probiotics. In vitro research shows that berberine, a constituent of tree turmeric, can inhibit the growth of certain probiotic species, including Bifidobacterium longum and Bifidobacterium bifidum, but does not appear to inhibit the growth of Lactobacillus acidophilus or Lactobacillus casei (34200).\n\nResearch on the use of tree turmeric alone is limited; typical dosing is unavailable. A specific combination product (Berberol, PharmExtracta) has been used at a dose providing tree turmeric extract 1176 mg and milk thistle extract 210 mg daily for 6-12 months (97624).\nStandardization & Formulation\nOne specific combination product containing tree turmeric and milk thistle extract (Berberol, PharmExtracta) is standardized to contain 85% berberine from tree turmeric and 60% to 80% silybin from milk thistle extract (95019, 96140, 96141, 96142, 97624, 101158). Similar products with monacolins and other ingredients have also been used (Berberol K, PharmExtracta; Zeta Colest, Erbozeta) (97625, 116928).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, tree turmeric might have additive effects when used with anticoagulant and antiplatelet drugs and increase the risk of bleeding.\nIn vitro and animal research suggest that berberine, a constituent of tree turmeric, can inhibit platelet aggregation (33660, 33694).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nTheoretically, tree turmeric, taken alone or in combination with milk thistle, might increase the risk of hypoglycemia in patients taking antidiabetes drugs.\nClinical research shows that taking a product containing tree turmeric and milk thistle extracts can lower blood glucose levels, glycated hemoglobin (HbA1c), and insulin resistance in patients with type 2 diabetes, including those on antidiabetic agents (95019, 96140, 96141). Additionally, clinical research suggests that berberine, a constituent of tree turmeric, can lower blood glucose levels (20579, 34247, 34265, 34282).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking tree turmeric along with antihypertensive drugs might have additive effects and increase the risk of hypotension.\nAnimal research suggests that berberine, a constituent of tree turmeric, can have hypotensive effects (33692, 34308). Also, a meta-analysis of clinical research suggests that taking berberine in combination with amlodipine (Norvasc) can lower systolic and diastolic blood pressure when compared with taking amlodipine alone (91956).\nless\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, use of tree turmeric along with CNS depressants might increase the risk of additive therapeutic and adverse effects.\nAnimal research suggests that berberine, a constituent of tree turmeric, can have sedative effects (13519, 33650, 33664, 33692).\nless\nCYCLOSPORINE (Neoral, Sandimmune)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nLIKELY\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nBerberine, a constituent of tree turmeric, can reduce metabolism of cyclosporine and increase serum levels.\nSome clinical evidence suggests that berberine inhibits cytochrome P450 3A4 (CYP3A4), which metabolizes cyclosporine (13524, 21112, 34239).\nless\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, tree turmeric might increase the levels and clinical effects of drugs metabolized by CYP2C9.\nPreliminary clinical evidence suggests that berberine, a constituent of tree turmeric, can inhibit CYP2C9 (34279).\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, tree turmeric might increase the levels and clinical effects of drugs metabolized by CYP2D6.\nIn vitro research and preliminary clinical evidence suggest that berberine, a constituent of tree turmeric, can inhibit CYP2D6 (21117, 34279, 34297).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nTheoretically, tree turmeric might increase the levels and clinical effects of drugs that are substrates of CYP3A4.\nIn vitro research and preliminary clinical evidence suggest that berberine, a constituent of tree turmeric, moderately inhibits CYP3A4 (13524, 21114, 34279, 34297).\nless\nDEXTROMETHORPHAN (Robitussin DM, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, tree turmeric might increase levels of dextromethorphan and potentially increase the risk of adverse effects including drowsiness, confusion, and irritability.\nPreliminary clinical research suggests that berberine, a constituent of tree turmeric, can inhibit cytochrome P450 2D6 (CYP2D6) activity and reduce the metabolism of dextromethorphan (34279).\nless\nMIDAZOLAM (Versed)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, tree turmeric might increase levels of midazolam and potentially increase the risk of adverse effects including sedation and respiratory depression.\nPreliminary clinical evidence suggests that berberine, a constituent of tree turmeric, can inhibit cytochrome P450 3A4 (CYP3A4) activity and reduce metabolism of midazolam (34279).\nless\nPENTOBARBITAL (Nembutal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, tree turmeric might increase the sedative effects of pentobarbital.\nAnimal research suggests that berberine, a constituent of tree turmeric, can prolong pentobarbital-induced sleeping time (13519).\nless\nTACROLIMUS (Prograf)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nLIKELY\nLevel of Evidence\nD (Anecdotal evidence)\nBerberine, a constituent of tree turmeric, can inhibit metabolism of tacrolimus and increase plasma levels.\nSome clinical evidence suggests that berberine inhibits cytochrome P450 3A4 (CYP3A4), which metabolizes tacrolimus (13524, 21114, 34279, 34297, 91954). In a 16-year-old patient with idiopathic nephrotic syndrome who was being treated with prednisone 40 mg/m2 and tacrolimus 6.5 mg twice daily, concomitant use of berberine, a constituent of tree turmeric, 200 mg three times daily increased plasma levels of tacrolimus from 8 to 22 ng/mL and increased serum creatinine levels from 0.7 to 1.2 mg/dL. Following a reduction of tacrolimus dosing to 3 mg daily, the blood concentration of tacrolimus decreased to 12 ng/mL and the serum concentration of creatinine decreased to 0.9 mg/dL (91954).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, berberine, a constituent of tree turmeric, might have antiplatelet effects.\nIn vitro and animal research suggests that berberine can inhibit platelet aggregation (33660, 33694). Theoretically, tree turmeric might have additive effects when used with other herbs and supplements that have anticoagulant and antiplatelet effects and might increase the risk of bleeding. See other products with anticoagulant activity here. See other products with antiplatelet activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nClinical research suggests that tree turmeric might have hypoglycemic effects.\nClinical research shows that a product containing tree turmeric and milk thistle extracts can lower blood glucose levels, glycated hemoglobin (HbA1c), and insulin resistance in patients with diabetes, including those on antidiabetic agents (95019, 96140, 96141, 96142). Theoretically, concomitant use of tree turmeric along with other herbs and supplements that decrease blood glucose levels might increase the risk of hypoglycemia. See other products with hypoglycemic activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, berberine, a constituent of tree turmeric, might have hypotensive effects.\nAnimal and clinical research suggest that berberine may lower blood pressure (33692, 34308, 91956). Theoretically, combining tree turmeric with other herbs and supplements with hypotensive effects might increase the risk of hypotension.\nless\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, berberine, a constituent of tree turmeric, might have sedative effects.\nAnimal research suggests that berberine can have sedative effects (13519, 33650, 33664, 33692). Theoretically, use of tree turmeric with other herbs and supplements with sedative properties might have additive therapeutic and adverse effects. See other products with sedative properties here.\nless\nPROBIOTICS\nTheoretically, berberine, a constituent of tree turmeric, might inhibit probiotic growth.\nIn vitro research shows that berberine can inhibit the growth of certain probiotic species, including Bifidobacterium longum and Bifidobacterium bifidum. Berberine does not appear to inhibit the growth of Lactobacillus acidophilus or Lactobacillus casei (34200). Theoretically, tree turmeric may inhibit the beneficial effects of probiotic supplements containing Bifidobacterium species.\nless",
            "Interactions with Conditions": "HYPERBILIRUBINEMIA\nBerberine, a constituent of tree turmeric, can cause kernicterus in newborns, particularly preterm neonates with hyperbilirubinemia (2589).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tree turmeric.",
            "Pharmacokinetics": "Absorption\nBerberine, a constituent of tree turmeric, appears to be a substrate of nuclear transporters such as P-glycoprotein and organic cation transporter. This might limit its oral bioavailability (13525, 96140). Evidence from animal research shows that the time to maximum blood concentration of berberine is 2.4 hours (34320).\nMetabolism\nBerberine appears to undergo phase I hepatic metabolism (13525). Three metabolites-atrorrhizine-3-sulfate, demethyleneberberine-2-sulfate, and thalifendine-10-sulfate have been observed in human urine after the use of berberine chloride (34212).\nExcretion\nBerberine is excreted through urine and feces (2591, 34314).",
            "Mechanism of Action": "General\nThe applicable parts of tree turmeric are the fruit, stems, leaves, wood, root, and root bark (96143). The primary active constituent of tree turmeric is berberine (13519).\nAnti-cancer effects\nPreliminary research suggests that the tree turmeric constituent berberine might have antitumor effects (13521).\nAnti-inflammatory effects\nPreliminary research suggests that berberine, a constituent of tree turmeric, blocks production of the proinflammatory cytokines interleukin-1 (IL1)-beta and tumor necrosis factor (TNF)-alpha by blocking nuclear factor-kappaB, the transcription factor responsible for regulation of cytokine production. Berberine has potential usefulness in treating alcoholic liver disease, which is associated with increased levels of IL1-beta and TNF-alpha (13522). Preliminary research also suggests that berberine selectively inhibits cyclooxygenase (COX)-2 expression (12488).\nAntidiabetic effects\nA meta-analysis including studies of patients with type 1 diabetes and dyslipidemic disorders shows that a combination of tree turmeric and milk thistle significantly decreases fasting blood glucose levels (105756). The validity of this analysis is limited by the heterogeneity of the included studies and patient populations.\nAntimicrobial effects\nBerberine, a constituent of tree turmeric, has antimicrobial effects including antibacterial, antifungal, and some antimycobacterial and antiprotozoal activity (7258, 7259). Berberine has activity against Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, Shigella boydii, Vibrio cholerae, Mycobacterium tuberculosis, Candida albicans, Candida tropicalis, Trichophyton mentagrophytes, Microsporum gypseum, Cryptococcus neoformans, Sporotrichum schenckii, Entamoeba histolytica, and Giardia lamblia (2530, 2587, 2588, 7258, 7259, 8012). Preliminary research suggests berberine might inhibit bacterial sortase, a protein responsible for anchoring gram-positive bacteria to cell membranes (13540).\nCardiovascular effects\nPreliminary research suggests that extracts of tree turmeric fruit have a dose-dependent positive inotropic effect with a negligible effect on heart rate (13518). A meta-analysis including studies of patients with type 1 and type 2 diabetes and dyslipidemic disorders shows that a combination of tree turmeric and milk thistle significantly decreases low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglyceride levels and increases high-density lipoprotein (HDL) cholesterol levels (105756). The validity of this analysis is limited by the heterogeneity of the included studies and patient populations.\nHepatoprotective effects\nPreliminary research suggests that berberine, a constituent of tree turmeric, might protect the liver from hepatotoxins (13519). Berberine has potential usefulness in treating alcoholic liver disease, which is associated with increased levels of IL1-beta and TNF-alpha (13522).\nHypoglycemic effects\nLaboratory research suggests that the berberine in tree turmeric lowers insulin levels by increasing the expression of the insulin receptor and insulin sensitivity. However, berberine is also thought to repair pancreatic islet cells, increasing insulin production. This is possibly due to the antioxidant effects of berberine (96140, 96142). Berberine also seems to decrease intestinal glucose absorption and increase glucose uptake from the blood (96141).\nHypolipidemic effects\nLaboratory research suggests that the berberine in tree turmeric increases the expression of the low-density lipoprotein (LDL) receptor, leading to a reduction in LDL cholesterol levels in the blood (96140). Also, berberine seems to downregulate a protein involved in the reduced efficacy of statins (96141)."
        }
    },
    "Trendione [FAST FACTS]": {
        "sections": {
            "Overview": "Trendione is marketed as a prohormone, or a hormone precursor. Usually, a segment of the prohormone is cleaved or altered to produce a biologically active hormone such as testosterone, estrogen, or a derivative (91094, 91095).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Warnings": "Prohormones which are intended to provide anabolic activity in the body meet the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469). Certain prohormones have also been prohibited by the National Collegiate Athletic Association (NCAA) (13163).",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Prohormones can be converted to active hormones in the body and cause adverse effects such as menstrual irregularities, infertility, hair loss, and acne. Prohormones have also been associated with hepatotoxicity and increased risk of cardiovascular disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing prohormones are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Prohormones can be converted to active hormones in the body and cause adverse effects such as menstrual irregularities, infertility, hair loss, and acne. Prohormones have also been associated with hepatotoxicity and increased risk of cardiovascular disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing prohormones are dangerous (91094). Avoid using.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using trendione for athletic performance, there is insufficient reliable information about the clinical effects of trendione for this purpose.\nExercise-induced muscle damage. Although there is interest in using trendione for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of trendione for this purpose.\nMuscle strength. Although there is interest in using trendione to increase muscle strength, there is insufficient reliable information about the clinical effects of trendione for this purpose.\nObesity. Although there is interest in using trendione for weight loss, there is insufficient reliable information about the clinical effects of trendione for this purpose.\nMore evidence is needed to rate trendione for these uses.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Tribulus": {
        "sections": {
            "Overview": "Tribulus is a small, annual plant which grows in temperate and tropical parts of the world, including southern Europe, China, Africa, south Asia, Mexico, and the southern United States (92023, 92033). Tribulus is most widely known for its use as an aphrodisiac in Chinese, Indian, and Greek traditional medicine (92022, 92025, 92027, 92031, 92033). Other traditional uses include gastrointestinal conditions and infections, respiratory tract infections, liver disease, skin conditions, and to stimulate abortion, appetite, and lactation.",
            "Safety": "POSSIBLY SAFE when tribulus is used orally and appropriately, short-term. Tribulus extract has been used with apparent safety at doses of 750-1500 mg daily for up to 90 days (7514, 13255, 92027, 97327, 97330, 97331, 97332). Powdered tribulus fruit has been used with apparent safety at a dose of 6 grams daily for up to 60 days (105245). There is insufficient reliable information available about the safety of tribulus extract when used for more than 90 days or in larger doses.\nLIKELY UNSAFE when the spine-covered fruit is used orally. There have been reports of bilateral pneumothorax and bronchial polyp after oral consumption of the spine-covered fruit (818).\nPREGNANCY: POSSIBLY UNSAFE when used orally. Animal research suggests that tribulus might adversely affect fetal development (12674); avoid using.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tribulus seems to be well tolerated.\nSerious Adverse Effects (Rare)\nOrally: Cases of liver and kidney injury, seizures, and chronic painful erection with impaired sexual function have been reported. Pneumothorax and bronchial polyp after consuming the spine-covered tribulus fruit have been reported.\nGastrointestinal\nOrally, tribulus can cause abdominal pain, cramping, nausea, vomiting, diarrhea, and constipation (92022, 92027). However, in one study, the rates of these gastrointestinal complaints were similar for patients taking tribulus and those receiving placebo (92022).\nless\nGenitourinary\nIn one case report, a patient taking two tribulus tablets (unknown dose) daily for 15 days presented to the local emergency department with a painful erection lasting 72 hours. The priapism was resolved with medical management; however, post-episode sexual function was impaired (92023).\nless\nHepatic\nIn one case report, a patient drinking tribulus water 2 liters daily for two days presented with lower limb weakness, seizures, hepatitis, and acute kidney injury. The patient's condition improved after hemodialysis and discontinuation of tribulus water (92069).\nless\nNeurologic/CNS\nOrally, tribulus has been reported to cause general excitation and insomnia. These symptoms were reversed upon discontinuation of the drug or decreasing the dose (78867). In one case report, a patient drinking tribulus water 2 liters daily for two days presented with lower limb weakness, seizures, hepatitis, and acute kidney injury. The patient's condition improved after hemodialysis and discontinuation of tribulus water (92069).\nless\nPulmonary/Respiratory\nIn one case report, a patient developed a bilateral pneumothorax after consuming the spine-covered fruit of tribulus (818). In another case report, a patient developed a polyp in the lobar bronchus of the right interior lobe due to the presence of a tribulus fruit spine (78852).\nless\nRenal\nIn one case report, a patient drinking tribulus water 2 liters daily for two days presented with lower limb weakness, seizures, hepatitis, and acute kidney injury. The patient's condition improved after hemodialysis and discontinuation of the tribulus water (92069). In another case report, a healthy male taking one tribulus tablet (unknown dose) daily for a few months for bodybuilding purposes developed hyperbilirubinemia followed by acute kidney failure 2-3 weeks later. The patient was managed with intravenous fluids and a low-salt, low-protein diet (92025).\nless\nOther\nIn one case report, gynecomastia was observed in a male weightlifter taking an herbal combination product containing tribulus. However, it is not clear if this adverse effect can be attributed to tribulus alone (78859).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nSexual dysfunction. Oral tribulus seems to improve sexual experience in females with hypoactive sexual desire disorder (HSDD) or sexual dysfunction. Some research also shows that oral tribulus improves sexual function in males.\nClinical research in premenopausal and postmenopausal patients with HSDD shows that taking tribulus 250 mg three times daily (Androsten, Herbarium) for 3 months improves overall satisfaction and lubrication, as well as pain, desire, sexual arousal, and ability to reach orgasm, when compared with placebo (92027, 97331, 97332). Other preliminary clinical research in females with HSDD shows that taking tribulus extract 7.5 mg daily for 4 weeks improves sexual desire, arousal, satisfaction, orgasm, pain, and lubrication when compared with placebo (92022). A nonblinded clinical study comparing tribulus dosing regimens shows that taking oral tribulus 280 mg, either once daily or in three divided daily doses, for 90 days results in similar improvements in sexual dysfunction, regardless of menopausal status. However, neither dosing schedule increases clitoral blood flow when compared with baseline (108551).\n\nTribulus has also been studied in males. One clinical study in males with erectile dysfunction, with or without HSDD, shows that taking tribulus (Tribestan, Sopharma AD) 500 mg three times daily for 3 months improves sexual desire and intercourse satisfaction when compared with placebo (97330).\nless\nPOSSIBLY INEFFECTIVE\nAthletic performance. Oral tribulus does not seem to improve athletic performance.\nSmall clinical studies in athletes show that taking tribulus orally, alone or in combination with other ingredients such as androstenedione, most often as 450-770 mg daily for 5-8 weeks, does not seem to enhance body composition or exercise performance when compared with placebo or a control group (7514, 13255, 92029, 108552).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAngina. It is unclear if oral tribulus is beneficial for angina.\nPreliminary clinical research shows that taking a tribulus extract orally might reduce symptoms of angina when compared with a control (3931).\nless\nAtopic dermatitis (eczema). Oral tribulus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nSome preliminary clinical research shows that taking tribulus orally in combination with 9 other herbs (Zemaphyte) daily for 8 weeks reduces redness and skin lesions in adults and children with nonexudative atopic dermatitis (12627, 12628). However, other research shows no effect (12630). It is unclear if these effects are due to tribulus, the other ingredients, or the combination.\nless\nBacterial vaginosis. Topical tribulus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with bacterial vaginosis shows that using a specific vaginal suppository (Forzajeh) containing tribulus, myrtle, fennel, and tamarind daily for 1 week is as effective as metronidazole vaginal suppository for improving vaginal discharge volume and odor, pelvic pain, cervical inflammation, and vaginal pH (100339). It is unclear if these effects are due to tribulus, the other ingredients, or the combination.\nless\nBenign prostatic hyperplasia (BPH). Oral tribulus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with BPH shows that taking a combination supplement (Prostalyn, East India Pharmaceutical Works Ltd.) containing tribulus 600 mg and curry leaf (Murraya koenigii) 600 mg twice daily for 12 weeks improves prostate symptoms when compared to baseline, with no difference when compared to tamsulosin 400 mcg daily. This supplement also seems to reduce prostate volume by around 2 mL (92033).\nless\nCancer. Although there is interest in using oral tribulus for cancer, there is insufficient reliable information about the clinical effects of tribulus for this condition.\nChronic fatigue syndrome (CFS). Although there is interest in using oral tribulus for CFS, there is insufficient reliable information about the clinical effects of tribulus for this condition.\nDiabetes. It is unclear if oral tribulus is beneficial for diabetes.\nPreliminary clinical research in females with type 2 diabetes who are taking oral hypoglycemic agents shows that taking tribulus extract powder 500 mg twice daily for 3 months modestly reduces fasting glucose and postprandial glucose levels, but not glycated hemoglobin, when compared with placebo. However, the validity of these findings is limited by the difference in diabetes severity between groups at baseline (97327).\nless\nErectile dysfunction (ED). It is unclear if oral tribulus is beneficial for ED. Research is conflicting.\nClinical research in patients with ED shows that taking tribulus (Tribestan, Sopharma AD) 500 mg three times daily for 3 months does not provide a clinically beneficial improvement in erectile function when compared with placebo (97330). Other clinical research shows that taking tribulus 400 mg twice daily for 30 days does not improve erectile function when compared with placebo (92031). However, one preliminary clinical study in patients with partial androgen deficiency shows that taking tribulus 250 mg three times daily for 3 months improves erectile function when compared to baseline (92028).\n\nTribulus has also been studied in combination with other ingredients. Preliminary clinical research shows that taking a combination supplement (Tradamix TX1000, Tradapharma Sagl) containing tribulus 450 mg, brown algae 300 mg, and chitosan 250 mg twice daily for 3 months improves sexual satisfaction, desire, ejaculation function, and sexual quality of life when compared with placebo in patients with mild-to-moderate ED (92030). It is unclear if these effects are due to tribulus, the other ingredients, or the combination.\nless\nExercise-induced muscle damage. It is unclear if oral tribulus is beneficial for exercise-induced muscle damage.\nClinical research in a small number of healthy, untrained males shows that taking tribulus 500 mg daily for 2 weeks prior to performing resistance exercise reduces markers of muscle damage, including creatine phosphokinase (CPK) and lactate dehydrogenase (LDH), but does not reduce levels of the inflammatory markers interleukin-6 (IL-6) or C-reactive protein (CRP), when compared with placebo (103236). However, another small clinical study in male CrossFit athletes shows that taking tribulus 770 mg capsules (Quamtrax Pharmaceuticals) daily for 42 days does not reduce CPK but does improve CRP and oxidant status when compared with placebo (111747). However, it is unclear whether any improvements are clinically significant. A very small crossover clinical study in trained male athletes shows that taking 20 mg/kg/day of tribulus in 3 divided doses 30 minutes before meals with 500 mL of water for 4 weeks does not reduce muscle soreness after intensive aerobic exercise when compared with placebo (111746).\nless\nGonorrhea. Although there is interest in using oral tribulus for gonorrhea, there is insufficient reliable information about the clinical effects of tribulus for this condition.\nHypercholesterolemia. Although there is interest in using oral tribulus for hypercholesterolemia, there is insufficient reliable information about the clinical effects of tribulus for this condition.\nHypertension. It is unclear if oral tribulus can lower blood pressure.\nIn patients with pre-hypertension, clinical research shows that taking powdered tribulus fruit 2 grams three times daily for 2 months reduces systolic and diastolic blood pressure by 6 and 5 mmHg, respectively, when compared with placebo (105245). It is unclear what effect Tribulus may have in patients with diagnosed hypertension.\nless\nKidney stones (nephrolithiasis). Although there is interest in using oral tribulus for kidney stones, there is insufficient reliable information about the clinical effects of tribulus for this purpose.\nMale infertility. It is unclear if oral tribulus is beneficial for male infertility; the available research is conflicting.\nCase series suggest that taking a specific tribulus product (Tribestan, Sopharma) 250 mg three times daily for 30 days improves ejaculate volume, sperm concentration, and sperm motility in patients with infertility due to oligoasthenozoospermia (78865), and improves libido and erections in patients with primary hypogonadism (78868). Conversely, a small clinical study in patients with oligozoospermia shows that taking tribulus granules 6 grams daily for 60 days does not improve sperm count when compared with placebo (92032). In patients with idiopathic infertility, taking tribulus 250 mg three times daily for 3 months does not increase sperm concentration, sperm motility, serum testosterone levels, or luteinizing hormone levels (97328). The difference in these findings might be due to the small study sizes, as well as the variable etiology of infertility.\nless\nMenopausal symptoms. Oral tribulus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research shows that taking a combination product containing tribulus 40 mg, ginger, saffron, and Ceylon cinnamon (Aphrodit, Goldaru Company) twice daily for 4 weeks improves mental and physical symptoms during menopause, but not genitourinary symptoms, when compared with placebo (97326). It is not clear if this effect is due to tribulus, the other ingredients, or the combination.\nless\nOsteoporosis. Although there is interest in using oral tribulus for osteoporosis, there is insufficient reliable information about the clinical effects of tribulus for this condition.\nPolycystic ovary syndrome (PCOS). Oral tribulus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne clinical study shows that taking tribulus extract (Tribulus forte, Mediherb, Integra Healthcare Ltd) 245 mg daily along with other ingredients and lifestyle modification during the follicular phase of the menstrual cycle for 3 months improves some symptoms of PCOS, including a 33% reduction in oligomenorrhea or amenorrhea and a 43-day reduction in the duration between menstrual cycles, when compared with lifestyle modification alone. Taking tribulus with other ingredients also improves quality of life by about 30% and reduces body mass index by 1 kg/m2 when compared with placebo. Although the conception rate increased 4-fold in patients taking the combination product, the live birth rate was similar to those taking placebo. (97216). It is unclear if these effects are due to tribulus, the other ingredients, or the combination.\nless\nPremature ejaculation. Oral tribulus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking a combination product containing tribulus, 5-HTP, winter savory, and chanca piedra (EiacuMev, Farmaceutica Mev) daily for 3 months improves time to ejaculation by 30 seconds and reduces symptoms related to premature ejaculation when compared to control (97016).\nless\nMore evidence is needed to rate tribulus for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTribulus extract has most often been used in doses of 750-1200 mg daily for 12 weeks. See Effectiveness section for condition-specific information.\nVaginal:Research is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tribulus.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTaking tribulus with antidiabetes drugs might increase the risk of hypoglycemia.\nClinical research shows that Tribulus can lower blood glucose levels in adults with type 2 diabetes who are taking antidiabetes medications (97327).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking tribulus with antihypertensive drugs might increase the risk of hypotension.\nAnimal research shows that tribulus can lower blood pressure by inhibiting angiotensin-converting enzyme (ACE) (12673). Tribulus has also demonstrated hypotensive effects in pre-hypertensive adults (105245).\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tribulus might increase the levels and clinical effects of lithium.\nTribulus is thought to have diuretic properties (12681). Due to these potential diuretic effects, tribulus might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTribulus might have hypoglycemic effects.\nClinical research shows that tribulus can lower blood glucose levels (97327). Theoretically, tribulus might have additive effects when used with other herbs and supplements that also lower glucose levels. See other products with hypoglycemic activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, tribulus might have hypotensive effects.\nAnimal and clinical research shows that tribulus can lower blood pressure (12673, 105245). Theoretically, combining tribulus with other herbs and supplements with hypotensive effects might increase the risk of hypotension.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, tribulus might interfere with blood glucose and blood pressure control during and after surgical procedures. Tell patients to discontinue tribulus at least 2 weeks before elective surgical procedures. Animal research shows that tribulus can lower blood glucose levels and blood pressure (12673, 12679).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tribulus.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tribulus.",
            "Mechanism of Action": "General\nThe applicable parts of tribulus are the leaf, fruit, and root. Tribulus contains two major alkaloid fractions, the beta-carboline indoleamines harmane and norharmane, flavonoids, and the soponins diosgenin and protodioscin (3929, 12673, 12675, 12676, 78856). Levels of protodioscin are not consistent but depend on soils in which tribulus is grown (78849). Phytochemical investigation of the aerial parts of tribulus of Bulgarian origin resulted in the isolation of furostanol saponin 1, also known as tribol (78858). Two steroid saponins, terrestrinins A and B, have also been isolated from tribulus (78857). Three other steroidal saponins were isolated from tribulus in a separate study (78850).\nAnthelmintic effects\nIn vitro research has found that tribulus extract might have anthelmintic activity (12680).\nAnti-diabetic effects\nPreliminary animal research suggests that tribulus lowers blood glucose (12679).\nAnticancer effects\nIn vitro research shows that a specific saponins isolated from tribulus is cytotoxic against a human malignant melanoma cell line (78850). In other in vitro research, saponins from tribulus promotes apoptosis in hepatoma cells (78860). A growth inhibitory effect, as well as morphology effect, on a human breast cancer cell line has also been observed with tribulus in vitro (78855). Spirostanol-based steroidal saponins from tribulus seem to exhibit remarkable activity against human malignant melanoma cell line, human oral epidermoid carcinoma, human breast ductal carcinoma, and human ovary carcinoma cells (78853). In vitro, tribulus regulates tyrosinase activity and melanocyte proliferation (78854).\nAntifungal effects\nIn vitro research shows that the spirostanol-based steroidal saponins from tribulus exhibit remarkable activity against the fungal organisms Candida albicans and Cryptococcus neoformans (78853).\nCardiovascular effects\nPreliminary clinical research suggests tribulus might have anti-anginal activity. It seems to dilate coronary arteries and improve coronary circulation (3931). It also may lower blood pressure by inhibiting angiotensin-converting enzyme (ACE) (12673). Extracts from the fruit and leaves seem to have a diuretic effects, which may explain the traditional use of tribulus for kidney stones and other urinary problems (12681). In vitro research shows that a water-soluble extract of tribulus has potent stimulant effects on isolated heart muscle in hypodynamic state (78847). It is thought that a glycoside fraction is present in the extract due to an increase in the force of myocardial contraction with a negative chronotropic effect. Other research shows that an alcohol extract of tribulus fruit has both muscarinic, nicotinic, and hypotensive activity (78864).\nHormonal effects\nSome preliminary clinical research suggests that tribulus can improve sexual dysfunction in males and females and erectile dysfunction in males (92022, 92027, 92028, 92030, 92033, 97330, 97331, 97332). These effects may be due to changes in hormone levels. Preliminary animal research has found that the protodioscin constituent of tribulus increases levels of testosterone, luteinizing hormone, dehydroepiandrosterone (DHEA), and dihydrotestosterone (12675, 12677, 92077). In animal research, protodioscin had no effect on the isolated corpus cavernosal strips from rabbits (78848, 78869). Steroid saponins extracted from tribulus stimulated sperm production and improved sperm viability in rats (78869).\n\nOne clinical study in adults with partial androgen deficiency suggests that taking tribulus 250 mg three times daily for 3 months significantly increases serum testosterone levels when compared to baseline, with no improvement in luteinizing hormone (92028). Other clinical research shows that taking tribulus daily for 3 months significantly increases free and bioavailable serum testosterone levels in premenopausal and postmenopausal patients with hypoactive sexual desire disorder (97331, 97332). Clinical research in premenopausal and postmenopausal adults suggests that taking tribulus 280 mg once daily for 90 days increases levels of free, total, and bioavailable testosterone when compared to the same dosage taken as three divided doses daily. Neither dosing regimen affected levels of prolactin, thyroid stimulating hormone, or sex hormone-binding globulin (108551). However, tribulus may not affect testosterone levels in healthy males. One clinical study in healthy young males shows that taking tribulus daily for 4 weeks has no effect on levels of serum testosterone, androstenedione, or luteinizing hormone (78862). Another small clinical study in male CrossFit athletes undergoing a 1-hour training session three times per week shows that taking tribulus 770 mg daily for 6 weeks has no effect on testosterone or cortisol, nor does it impact testosterone: cortisol ratios, when compared with placebo (108552).\nMusculoskeletal effects\nThere is interest in using tribulus to prevent bone loss after menopause. Research in rats with ovaries removed shows that taking tribulus extract daily for 28 days increases bone mineral density (BMD) when compared with control rats. This increase in BMD is thought to be caused by a tribulus-induced reduction in urinary calcium loss and increase in serum dehydroepiandrosterone (DHEA) levels (100338).\nNeurologic/CNS effects\nTribulus contains two major alkaloid fractions, the beta-carboline indoleamines harmane and norharmane (78856). Animal research shows that administration of synthetic harmane subcutaneously to sheep causes nervous effects, such as limb paresis. In addition, another tribulus extract exhibits significant analgesic activity in albino mice (78871)."
        }
    },
    "Trichopus Zeylanicus": {
        "sections": {
            "Overview": "Trichopus zeylanicus is a rare plant native to India. It is commonly called \"arogyapacha,\" which literally means \"a plant that gives health and vitality\" or \"healthy green\" (15887). The fruit has been used as a local food source. It has also been used as an aphrodisiac and adaptogen, and to improve stamina.",
            "Safety": "There is insufficient reliable information available about the safety of Trichopus zeylanicus.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nObesity. Although there has been interest in using oral Trichopus zeylanicus for weight loss, there is insufficient reliable information about the clinical effects of Trichopus zeylanicus for this purpose.\nPeptic ulcers. Although there has been interest in using oral Trichopus zeylanicus for peptic ulcers, there is insufficient reliable information about the clinical effects of Trichopus zeylanicus for this purpose.\nSexual dysfunction. Although there has been interest in using oral Trichopus zeylanicus for sexual dysfunction, there is insufficient reliable information about the clinical effects of Trichopus zeylanicus for this purpose.\nMore evidence is needed to rate Trichopus zeylanicus for these uses.\nless",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Trichopus zeylanicus.",
            "Interactions with Drugs": "IMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Trichopus zeylanicus might reduce the effects of immunosuppressants.\nAnimal research suggests that Trichopus zeylanicus might have immunostimulant effects (15885).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "General\nThe applicable parts of Trichopus zeylanicus are the fruit and leaf (15884).\nAdaptogenic effects\nA glycopeptidolipid fraction of Trichopus zeylanicus extract appears to reduce markers of physiological stress in animal models by reducing experimentally-induced inflammation, increasing antibody response-induced immunosuppression, and reducing gastric ulceration (15885). A Trichopus zeylanicus leaf extract also reduces antigen-stimulated mast cell degranulation (15886) and decreases induced fatigued in animal models (15888).\nAnti-inflammatory effects\nIn animal models, Trichopus zeylanicus leaf extract reduces levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-) in the liver and intestinal tract (115614).\nAnti-oxidant effects\nIn animal models,Trichopus zeylanicus leaf extract demonstrate protective effects against oxidative stress caused by ibuprofen toxicity (115614).\nGastrointestinal effects\nIn animal models, Trichopus zeylanicus leaf extracts reduce gastric pH and gastric acid output (15884).\nHepatoprotective effects\nIn animal models, Trichopus zeylanicus leaf extracts demonstrate protective effects against liver damage caused by acetaminophen or ibuprofen toxicity (15884, 115614).\nMetabolic effects\nIn animal models, Trichopus zeylanicus leaf extract decreases blood glucose levels and increases free fatty acid levels at rest. The extract increases blood glucose and decreases free fatty acids in animals after exercise, suggesting that it stimulates use of fatty acids during exercise (15887).\nSexual effects\nTrichopus zeylanicus has traditionally been used as an aphrodisiac. Animal research shows that administration of a leaf extract stimulates sexual behavior (15884)."
        }
    },
    "Tronadora": {
        "sections": {
            "Overview": "Tronadora is an ornamental shrub with large long leaves and yellow trumpet-like flowers. It is sometimes used for medicinal purposes in India and Latin America (96665, 96667).\n\nKEY HIGHLIGHTS\nUsed for diabetes and digestive disorders, but there is insufficient reliable information available to rate tronadora for any condition.\nInsufficient reliable information available about the safety or side effects.\nNo known major interactions.",
            "Safety": "There is insufficient reliable information available about the safety of tronadora.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information available about adverse effects of tronadora. Topically, tronadora might cause allergic dermatitis (96666).\nDermatologic\nTopically, tronadora might cause allergic dermatitis. In one case report, an Indian woman that regularly plucked tronadora flowers as part of her morning pooja ritual developed allergic dermatitis (96666).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. A small clinical trial in patients with type 2 diabetes shows that taking a combination of tronadora 100 mg and Guazuma ulmifolia 300 mg each before meals for 90 days modestly improves levels of fasting glucose and glycated hemoglobin when compared with taking placebo. Most patients were taking oral antidiabetic agents and or insulin (110886). It is unclear if any benefits are due to tronadora, Guazuma ulmifolia, or the combination.\nMore evidence is needed to rate tronadora for this use.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tronadora.",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, concomitant use of tronadora and antidiabetes drugs might increase the risk of hypoglycemia. Clinical research suggests that a combination of tronadora and Guazuma ulmifolia reduce levels of fasting glucose in patients with type 2 diabetes, including those already taking antidiabetes agents (110886). The effect of tronadora alone is unknown. Animal research is conflicting (13494, 13495, 13621, 110887, 110888).",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, tronadora might have hypoglycemic effects. Clinical research shows that taking tronadora in combination with other ingredients can decrease blood glucose levels in patients with type 2 diabetes (110886). Animal research is conflicting (13494, 13495, 13621, 110887, 110888). Although the effect of tronadora alone is unclear, theoretically tronadora might have additive effects with other herbs and supplements that decrease blood glucose levels. Some herbs and supplements with hypoglycemic potential include agaricus mushroom, devil's claw, fenugreek, guar gum, Panax ginseng, Siberian ginseng, and others.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "In mice, the acute LD50 of tronadora leaf extract was estimated at 5000 mg/kg. Subacute toxicity analysis over 28 days resulted in no adverse clinical or behavioral effects with doses of up to 500 mg/kg daily. However, there were some adverse effects on levels of liver enzymes, blood glucose, platelets, and white blood cell counts at the higher doses (101175).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of tronadora.",
            "Mechanism of Action": "General\nThe applicable parts of tronadora are the leaf and stem, and less frequently, the flower and root. Tronadora leaves contain alkaloids such as tecomine and tecostamine. Tronadora flower extracts contain tannins, saponins, phytosterols, triterpenes, coumarins, anthraquinones, flavonoids, phenols, and alkaloids (96663, 96665, 101175). The leaves have been shown to contain luteolin, apigenin, and chrysoeriol (110888).\nAnti-inflammatory effects\nAnimal research shows that tronadora flower alcoholic extracts have demonstrated anti-inflammatory effects (96665, 110887). Theoretically, these effects might be due to its flavonoid constituent's ability to reduce prostaglandin synthesis (96665).\nAntidiabetic effects\nTronadora has been used traditionally for diabetes; however, laboratory research on the effect of tronadora is conflicting. Some animal research suggests tronadora extracts result in a modest reduction in blood glucose. However, normal glucose levels were not achieved (110887, 110888). Other animal research suggests it has no effect on blood glucose (13494) or it causes an initial increase in blood glucose, followed by mild hypoglycemia. It also might decrease hepatic glycogen levels (13495, 13621). In vitro research suggests that tronadora leaf alcoholic extract has pancreatic lipase inhibitory activity. Inhibition of pancreatic lipase blocks digestion and therefore, the absorption and storage, of fats from the diet. Because increased fat mass contributes to insulin resistance, this activity of tronadora is theorized to help reduce fat mass and reduce insulin resistance (96667).\nAntimicrobial effects\nIn vitro, tronadora alcoholic and aqueous extracts have demonstrated antibacterial activity against E. coli and B. subtilis. The tronadora constituent tecomine also exhibits these antibacterial effects (96663).\nHypotensive effects\nAnimal research suggests tronadora might lower blood pressure (110888).\nLipid effects\nAnimal research suggests tronadora might lower plasma cholesterol and triglyceride levels (13494, 110888)."
        }
    },
    "Trypsin": {
        "sections": {
            "Overview": "Trypsin is a proteolytic enzyme naturally excreted by the pancreas to aid in digestion (511). Commercial trypsin is prepared from animal sources, such as porcine or bovine pancreas (92235).",
            "Safety": "POSSIBLY SAFE when used topically by healthcare professionals trained in wound debridement (506).\nThere is insufficient reliable information available about the safety of trypsin for its other uses. Although trypsin has been safely used in clinical research in doses of up to 288 mg orally daily in combination with other enzymes for up to 3 months, it is unclear if trypsin taken orally alone is safe (37193, 92235, 99473).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nTopically, trypsin can cause localized pain and transient burning (506). Orally, trypsin taken in combination with other enzymes can cause mild-to-moderate gastrointestinal symptom such as nausea, heartburn, and stomach pain (37193, 92235). It is not known if trypsin or other enzymes causes these adverse effects.\nDermatologic\nTopically, trypsin can cause localized pain and transient burning (506).\nless\nGastrointestinal\nOrally, trypsin taken in combination with other enzymes can cause mild-to-moderate gastrointestinal symptom such as nausea, heartburn, and stomach pain (37193, 92235). It is not known if trypsin or other enzymes causes these adverse effects.\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nColorectal cancer. A small clinical study in patients with colorectal cancer receiving chemotherapy shows that taking a specific combination supplement containing trypsin and other enzymes (Wobe-Mugos E) attenuates worsening quality of life, modestly increases relapse-free survival, and increases the number of patients surviving over 42 months (99474). The effects of trypsin alone are unclear.\nDiabetes. A small observational study in patients with a family history of type 1 diabetes found that taking a product containing trypsin 48 mg, bromelain 90 mg, and rutin 100 mg (Mucos Pharma) daily for 24 months is not associated with reduced incidence of type 1 diabetes at 8 years (99472). Further higher quality research is needed to draw a conclusion.\nExercise-induced muscle soreness. A small clinical study shows that taking a combination protease tablet containing papain 50 mg, trypsin 75 mg, bromelain 50 mg, amylase 10 mg, lipase 10 mg, lysosome 10 mg, and chymotrypsin 2 mg, four times in one day before downhill running can improve recovery of contractile muscle function and decrease muscle soreness compared to placebo (67838). The effects of trypsin alone are unclear.\nExercise-induced respiratory infections. A small clinical study in non-elite male runners shows that taking a combination product (Wobenzym Plus, Mucos Pharma) providing rutin 600-1200 mg, trypsin 288-576 mg, and bromelain 540-1080 mg daily for 3 weeks starting one week before a marathon, does not reduce the risk of a post-race upper respiratory tract infection when compared with placebo (96766). A limitation of this study is that it was not powered to detect a difference in exercise-induced infections between groups.\nMultiple sclerosis (MS). A preliminary clinical study in patients with relapsing-remitting MS shows that taking an enzyme combination containing trypsin 48 mg, bromelain 90 mg, and rutin 100 mg per tablet for at least 3 months does not affect disability progression, relapses or central nervous system lesions when compared with placebo (99468). The validity of these results are limited by the short duration of treatment, and the effects of trypsin alone are unclear.\nOsteoarthritis. Taking trypsin orally in combination with rutin and bromelain seems to be effective for treating osteoarthritis of the knee. Most clinical research in patients with knee osteoarthritis shows that taking the combination enzyme product (Wobenzym PS, formerly Phlogenzym, Mucos Pharma) at a dose providing up to 600 mg rutin, 288 mg trypsin, and 540 mg bromelain daily for 3-12 weeks, is as effective as diclofenac (Voltaren) 50 mg two to three times daily for relieving pain and improving knee function. This product also seems to reduce the need for rescue medication by 95% compared to placebo (6252, 92235, 99467, 99477). It is unclear if these improvements are due to trypsin, other ingredients, or the combination. Trypsin has not been studied for osteoarthritis as a single-ingredient product.\nPostoperative swelling. A small preliminary clinical study in patients undergoing surgery of the jaw shows that taking an enzyme combination of trypsin 96 mg, bromelain 180 mg, and rutin 200 mg twice daily for 5 days in addition to standard treatment reduces soft-tissue thickness (indicating the amount of swelling) at most of the nine assessed facial-points compared to control (99476). This study is limited by its small size and significant differences in swelling at pre-determined points during the first postoperative day. This suggests that factors in addition to enzyme therapy might have influenced the differences in results.\nRadiation dermatitis. There is conflicting evidence whether taking a combination supplement containing trypsin reduces adverse effects from radiation. Some low quality clinical research in cancer patients receiving radiation therapy suggests that a specific combination product (Wobe-Mugos E, Mucos Pharma), which contains trypsin 40 mg, and other enzymes might reduce adverse reactions at the site of radiation, such as skin deterioration, when compared to no additional treatment (67831, 99471). The results are these studies are limited by a lack of blinding and a lack placebo control. Evidence from another small, but higher quality clinical study shows that taking the same product beginning 3 days prior to radiation and continuing until the last day of radiation therapy does not reduce acute radiation-related complications such as skin deterioration when compared to placebo (67834).\nSprains. A preliminary clinical study in patients with a sprained ankle shows that taking a specific enzyme combination (Phlogenzym, Mucos Pharma) containing trypsin 48 mg, bromelain 90 mg, rutin 100 mg, or taking different combinations of the individual enzymes three times daily for 10 days is not more effective for relieving pain than placebo (99473). The effects of trypsin alone are unclear.\nWound healing. Some preliminary evidence suggests that applying trypsin topically in combination with chymotrypsin may be helpful for cleansing wounds of necrotic material and enhancing wound healing (715, 716). Other preliminary research suggests that applying trypsin topically in combination with castor oil and Peru balsam may improve wound healing, including the healing of infected wounds. However, as a debriding agent, trypsin seems to be no better than mechanical gauze (99573). In fact, the US Food and Drug Administration (FDA) determined in the 1970s that trypsin is ineffective as a debriding agent (95757).\nThere is insufficient reliable information available about the effectiveness of trypsin for these uses.",
            "Dosing & Administration": "Adult\nOral:\nExercise-induced muscle soreness: A combination protease tablet containing papain 50 mg, trypsin 75 mg, bromelain 50 mg, amylase 10 mg, lipase 10 mg, lysosome 10 mg, and chymotrypsin 2 mg, four times in one day has been used (67838).\n\nOsteoarthritis: A specific combination product (Wobenzym PS, formerly Phlogenzym, Mucos Pharma) containing up to a total of rutin 600 mg, trypsin 288 mg, and bromelain 540 mg, given as 2 tablets 3 times daily has been used in divided doses for up to 12 weeks on an empty stomach (6252, 92235, 99467, 99477).\n\nPostoperative swelling: An enzyme combination of trypsin 96 mg, bromelain 180 mg, and rutin 200 mg twice daily for 5 days has been used (99476).\n\nRadiation dermatitis: Three tablets of a specific combination product (Wobe-Mugos E, Mucos Pharma), containing papain 100 mg, trypsin 40 mg, and chymotrypsin 40 mg per tablet, 3-4 times daily have been used beginning 3-7 days before radiation therapy and continuing for 5 days or 9 weeks (67831, 99471).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of trypsin.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of trypsin.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of trypsin.",
            "Mechanism of Action": "General\nTrypsin is a proteolytic enzyme formed in the small intestines by the action of enteropeptidase on trypsinogen (511). Trypsin supplements are derived from fungi or bacterial sources, pancreas of livestock, or from plant sources (13).\nAnti-inflammatory effects\nTrypsin combined with bromelain prevents swelling in animal models (37200). In burn patients, taking a specific supplement (Chymoral Forte D.S.) containing trypsin and chymotrypsin, seems to reduce circulating inflammatory markers such as interleukin-6 and interleukin 1B compared to patients taking a multivitamin (99475).\nDermatological effects\nTrypsin is used to remove dead tissue that remains after trauma, infections such as decubitus ulcers, and surgical procedures. The removal of dead cells allows the growth of healthy tissues (13). Some topical preparations that are available contain balsam of Peru and castor oil to protect the skin and prevent premature epithelial destruction (13). Evidence from in vitro studies of necroses and purulent exudates (2648) and a human study (2649) shows streptokinase-streptodornase can have better proteolytic activity than trypsin alone.\nHematologic effects\nThere is interest in using trypsin and other enzymes for improving absorption of iron and reducing incidence of iron-deficiency anemia. Taking trypsin along with heme-iron might impact the absorption of iron. Clinical research shows that taking 100 mg trypsin increases absorption of heme iron as hemoglobin, but decreases the absorption of heme iron as hemin (a part of hemoglobin) (99469)."
        }
    },
    "Turkey Corn": {
        "sections": {
            "Overview": "Turkey corn is a plant native to the United States and Canada (106513). The dried tuber of turkey corn has been traditionally used for digestive complaints, menstrual disorders, urinary tract diseases, and skin rashes (18).",
            "Safety": "POSSIBLY UNSAFE when used orally. Theoretically, the constituent bicuculline, an antagonist of gamma-aminobutyric acid (GABA), could cause poisoning (18).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally (18); avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of turkey corn.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of turkey corn.",
            "Interactions with Drugs": "LITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, turkey corn might reduce excretion and increase levels of lithium due to potential diuretic effects.\nTurkey corn is thought to have diuretic properties (18). However, this has not been reported in humans.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with turkey corn.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of turkey corn.",
            "Mechanism of Action": "General\nThe applicable part of turkey corn is the dried tuber. It contains various isoquinoline alkaloids, including bicuculline, corlumine, protopine, cryptopine, and cularine (18).\nDiuretic effects\nTurkey corn is thought to have diuretic properties (18).\nGABAergic effects\nBicuculline, a constituent of turkey corn, is a centrally-acting, spasmogenic antagonist of gamma-aminobutyric acid (GABA) (18)."
        }
    },
    "Turkey Tail Mushroom": {
        "sections": {
            "Overview": "Turkey tail mushroom is a common mushroom that grows on the stumps and other decomposing wood of broad-leaved trees (91751, 94073, 102916). In traditional Chinese medicine it is used for enhancing immune function and removing toxins, as well as for cancer, hepatitis, and infections (94073, 94076). In current research, two constituents of turkey tail mushroom are commonly used in place of the whole mushroom. These are polysaccharide krestin (PSK) and polysaccharide peptide (PSP).",
            "Safety": "LIKELY SAFE when turkey tail mushroom is used orally and appropriately (5477). ...when polysaccharide krestin (PSK) and polysaccharide peptide (PSP) isolates of turkey tail mushroom are used orally and appropriately (1635, 1636, 1640, 1641, 1648, 1649, 1650, 1651, 1652, 1653, 1654) (1655, 1656, 1657, 1658, 1659, 1660, 1661, 1662, 70167, 70168, 70171, 70188, 70200, 94076).\nThere is insufficient reliable information available about the safety of turkey tail mushroom when used topically or intravaginally.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, turkey tail mushroom and its PSK component are generally well tolerated. There have been reports of gastrointestinal side effects, hematological abnormalities, liver dysfunction, and palpitations, but these are in patients who received PSK in addition to standard chemotherapy. It is not known if these are due to PSK, the chemotherapy, or both.\nCardiovascular\nPalpitations have occurred when PSK is taken with standard chemotherapy for cancer (1657). It is not clear if this is due to PSK, the chemotherapy, or both.\nless\nDermatologic\nPigmentation of the nails and erythema have occurred when PSK is taken with standard chemotherapy (1657, 1660, 70175, 94076). It is not clear if this is due to PSK, the chemotherapy, or both.\n\nIntravaginally, a specific gel (Papilocare, Procare Health) containing turkey tail mushroom with neem, carboxymethyl-beta-glucan, hyaluronic acid, gotu kola, aloe, and alpha-glucan oligosaccharide has been reported to cause vulvovaginal stinging, burning, itching, and candidiasis (108305, 111904). The specific role of turkey tail mushroom is unclear.\nless\nGastrointestinal\nNausea, vomiting, appetite loss, stomach discomfort, diarrhea, constipation, and gastric ulcer have occurred when PSK is taken with standard chemotherapy for cancer (1651, 1657, 70175, 70201, 94076). However, one study reported a decreased incidence of gastrointestinal side effects when PSK was taken with chemotherapy (70188, 70197).\nless\nHematologic\nLeukopenia, thrombocytopenia, and albuminuria have occurred when PSK is taken with standard chemotherapy (1651, 1657, 70175, 70201, 94076). It is not clear if this is due to PSK, the chemotherapy, or both.\nless\nHepatic\nElevated liver enzymes, liver function impairment, and hepatotoxicity have occurred when PSK is taken with standard chemotherapy (1651, 1657, 70175, 70201, 94076). It is not clear if this is due to PSK, the chemotherapy, or both.\nless\nMusculoskeletal\nMalaise and fatigue have occurred when PSK is taken with standard chemotherapy (1657, 1660, 70175, 94076). It is not clear if this is due to PSK, the chemotherapy, or both.\nless\nPulmonary/Respiratory\nCoughing has occurred when PSK is taken with standard chemotherapy (1657, 1660, 70175, 94076). It is not clear if this is due to PSK, the chemotherapy, or both.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCancer. Taking PSK, a constituent of turkey tail mushroom, as an adjunct to standard cancer therapy may improve response rates and survival in some patients with cancer. Very limited data suggests that whole turkey tail mushroom is not beneficial.\nThe PSK constituent of turkey tail mushroom has been used as an adjunct to standard cancer therapy in Japan for several decades, in doses ranging from 1 to 3.6 grams daily (94076). It has been used in a dose of 3 grams daily for 24-36 months for breast (1648, 1650, 1654, 1656), colorectal (1657, 1660, 70165, 70167, 70168, 70171, 70173, 70174, 70176, 70190)(94076), esophageal (1649), gastric (1640, 1651, 1652, 1657, 1658, 1659, 1660, 70161, 70170, 70175)(70179, 70181, 70183, 70186, 70189, 70191, 70194, 70198), hepatic (1655, 70188), and lung cancers (1653, 70180, 70184), as well as for leukemia (70200, 70206). It has also been used in a dose of 1 gram daily for up to 72 months for colorectal cancer (94076), 1 gram three times daily for 1 month for nasopharyngeal cancer (1661, 70195), and 2 grams/m2 per day in 3 divided doses, rotating in cycles with chemotherapy, for gastric cancer (1659, 70194, 70195).\n\nA meta-analysis of 13 clinical trials including over 2500 patients with esophageal, gastric, colon, rectal, breast, or nasopharyngeal cancer, shows that taking PSK in addition to conventional therapy reduces 5-year mortality by 9% when compared with conventional therapy alone. When individual cancer types are considered, the benefit of PSK is most evident in patients with breast, gastric, colon, or rectal cancer (94076). Another meta-analysis of 14 clinical trials shows that taking PSK, polysaccharide peptide (PSP), or turkey tail mushroom in combination with chemotherapy is associated with a 17% lower risk of mortality in some, but not all, types of cancer when compared with chemotherapy alone. However, overall there was no difference in relapse-free survival or total clinical efficacy, defined as complete responses plus partial responses (102915). The reliability and relevance of these meta-analyses is unclear since the trials looked at several different types of cancer, used varying doses and durations of therapy with different turkey tail mushroom extracts, and were all conducted in China or other Asian countries.\n\nResearch on the use of whole turkey tail mushroom rather than the constituent PSK for treating cancer is limited. A small clinical study in 15 patients with inoperable hepatocellular carcinoma shows that taking turkey tail mushroom 2.4 grams daily for 6-12 weeks does not improve time to progression, progression-free survival, overall survival, or quality of life when compared with placebo (96568). However, this study was likely underpowered to detect any differences.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCervical dysplasia. Intravaginal turkey tail mushroom has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA specific vaginal gel (Papilocare, Procare Health) containing turkey tail mushroom, neem, carboxymethyl-beta-glucan, hyaluronic acid, gotu kola, aloe, and alpha-glucan oligosaccharide has been examined in preliminary clinical and observational research in patients with human papillomavirus (HPV)-related cervical lesions. One clinical study shows that topical application for 6 months is associated with a normal Pap smear in 85% of patients, compared with 65% of those receiving only regular monitoring. Benefits were greatest in high-risk patients (108305). In patients over 40 years of age, treatment with this gel resulted in a normal Pap smear in 92% of patients, compared with 50% of those receiving only regular monitoring (111905). Both studies also showed improvements in cervical re-epithelization and HPV clearance (108305, 111905). Observational research has also been conducted. One observational study in patients with high-risk HPV infection has found that using this same product is associated with 4.8-, 2.3-, and 5.1-fold increased odds of HPV DNA clearance, remission at colposcopy, and remission with cytology at 6 months, respectively, when compared with untreated patients (108306). In another observational study, using this product for 6 or 12 months is associated with repair of cervical low-grade lesions and a normalized cytology and colposcopy in about 75% of patients. HPV clearance was achieved in 71.6% of patients (111904). Doses of gel administration have varied. The gel is usually applied once daily for 21 days, followed by 7 days with no treatment, and then alternate days for up to 2-12 months (108305, 108306, 111904, 111905). It is occasionally applied once daily for 21 days, followed by 7 days with no treatment, repeated for 3 months, and then alternated days for 3 months (108305).\nless\nChronic fatigue syndrome (CFS). Although there has been interest in using oral turkey tail mushroom for CFS, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nGenital herpes. Although there has been interest in using oral turkey tail mushroom for genital herpes, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nHepatitis. Although there has been interest in using oral turkey tail mushroom for hepatitis, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nMuscle strength. Although there has been interest in using oral turkey tail mushroom for muscle strength, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nTinea corporis. Although there has been interest in using oral turkey tail mushroom for tinea corporis, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nUpper respiratory tract infection (URTI). Although there has been interest in using oral turkey tail mushroom for URTI, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nUrinary tract infections (UTIs). Although there has been interest in using oral turkey tail mushroom for UTIs, there is insufficient reliable information about the clinical effects of turkey tail mushroom for this purpose.\nMore evidence is needed to rate turkey tail mushroom for these uses.",
            "Dosing & Administration": "Adult\nOral:\nThe PSK constituent of turkey tail mushroom is most commonly used in a dose of 3 grams daily for up to 36 months. Whole turkey tail mushroom has been used in a dose of 2.4 grams daily for up to 12 weeks. See Effectiveness section for condition-specific information.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere are two main polysaccharides isolated from turkey tail mushroom that are used medicinally. These are polysaccharide krestin (PSK) and polysaccharide peptide (PSP) (94075, 94076). Both are commercially available and used as health supplements (91751, 94075, 94076). In one clinical study, a water extract of the fruiting bodies of turkey tail mushroom contained 33.8% total polysaccharides (94073). In another study, PSP was composed of 90% polysaccharides and 10% peptides (94075).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking turkey tail mushroom with antidiabetes drugs might increase the risk of hypoglycemia.\nAnimal research suggests that turkey tail mushroom and a polysaccharide component can have hypoglycemic effects (108307, 111907).\nless\nCYCLOPHOSPHAMIDE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, the polysaccharide peptide (PSP) component of turkey tail mushroom might increase exposure to cyclophosphamide.\nSome animal research shows that the PSP component of turkey tail mushroom can increase the area under the concentration-time curve (AUC) of cyclophosphamide by 44% to 50% and the half-life by 34% to 43% (96569). This interaction could potentially increase the effects and adverse effects of cyclophosphamide. However, it is not known whether PSP affects the levels of the active metabolites of cyclophosphamide that are responsible for its clinical activity.\nless\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nINSIGNIFICANT\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, the polysaccharide peptide (PSP) component of turkey tail mushroom might inhibit CYP2C9.\nLaboratory research suggests that the PSP component of turkey tail mushroom dose-dependently inhibits CYP2C9 (94075). Theoretically, taking PSP with drugs metabolized by CYP2C9 might increase drug levels and the risk of adverse effects. However, this has not been reported in humans.\nless\nTAMOXIFEN (Nolvadex)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, the polysaccharide peptide (PSP) component of turkey tail mushroom might interfere with the absorption of tamoxifen.\nAnimal research suggests that PSP increases the time to reach maximum concentration of a single dose of tamoxifen by about 9.5 hours, or 228%. When repeated doses of tamoxifen were given, the time to reach maximum concentration was increased by about 5.6 hours, or 93%. However, PSP did not affect the maximum concentration or the area under the curve of tamoxifen (108308).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, turkey tail mushroom might have hypoglycemic effects.\nAnimal research suggests that turkey tail mushroom can have hypoglycemic effects (108307, 111907). Theoretically, turkey tail mushroom might have additive effects with herbs that decrease blood glucose levels. See other products with hypoglycemic activity here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, turkey tail mushroom might interfere with blood glucose control throughout surgery. Tell patients to discontinue turkey tail mushroom at least 2 weeks before elective surgical procedures. Animal research suggests that turkey tail mushroom can have hypoglycemic effects (108307, 111907).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with turkey tail mushroom.",
            "Pharmacokinetics": "Absorption\nAnimal studies with radio-labeled polysaccharide krestin (PSK), a constituent of turkey tail mushroom, show that it is partially decomposed to small molecules in the digestive tract (1642). Radio-labeled PSK is completely absorbed within 24 hours following oral administration in mice, and peak plasma levels of low molecular weight substances occur at 0.5-1 hours in rats and 1-2 hours in rabbits. Larger molecules such as PSK appear in the serum after 4-24 hours.\nDistribution\nIn mice, radio-labeled PSK or its metabolites have been detected in the digestive tract, bone marrow, salivary glands, thymus, adrenal gland, brain, liver, spleen, pancreas, and tumor tissue. The most prolonged activity is found in the liver and bone marrow (1642).\nExcretion\nIn animals, approximately 70% of radio-labeled PSK is excreted in expired air, 20% in feces, 10% in urine, and 0.8% in bile. Approximately 86% is excreted within 24 hours (70192).",
            "Mechanism of Action": "General\nThe applicable parts of turkey tail mushroom are the fruiting body and mycelium (5494). The turkey tail mushroom fruiting body contains triterpenoids (oleanolic acid, friedelin, glutinol, ursolic acid, corosolic acid, esculentic acid, lupeol, and betulinic acid), sterols (e.g., cerevisterol), polysaccharides, ribonucleotides (dihydrouridine, deoxyuridine), phenols (vanillic acid, viridoside, and benzoic acid derivatives), glycosides (ethylglucopyranoside, nigerose, and trehalose), and furans (e.g., methoxyfurfural) (102916).\n\nTurkey tail mushroom is used in two forms, either as the extract of the fruiting bodies or as biomass, which contains mycelia and primordia. The biomass may be more resistant to proteolytic enzymes and may have immune activities not present in the extract form (91751). Turkey tail mushroom biomass has secondary metabolites such as terpenes, steroids, and anthraquinones that are not found in turkey tail mushroom extract (91751). Turkey tail mushroom contains several polysaccharides, including polysaccharide peptide (PSP) and polysaccharide krestin (PSK), which are thought to be the active components of turkey tail and are used medicinally (1600, 1635, 1636, 1637, 1638, 1639, 1640, 1641, 1642, 1648, 1649, 1650, 5484, 5494, 94073). PSP is isolated from the COV-1 strain of turkey tail mushroom via water extraction and alcoholic precipitation. It is a Chinese product. PSK is isolated from the CM-101 strain via water extraction and salting out with ammonium sulfate. It is a Japanese product (91751, 94073, 94075, 94076). Differences in growing environments and strains lead to varying biological activities of turkey tail mushroom (94075).\nAnalgesic effects\nPreliminary research in animals suggests that turkey tail mushroom might have analgesic activity (1645, 1646).\nAnti-inflammatory effects\nIn vitro, triterpenoids and sterols from turkey tail mushroom fruiting bodies have been shown to inhibit nitric oxide, tumor necrosis factor-alpha, and interleukin-6, suggesting anti-inflammatory activity (102916).\nAntidiabetic effects\nAnimal research suggests that turkey tail mushroom may have antidiabetic effects. Extracellular polysaccharopeptides (ePSP) from turkey tail mushroom appear to regulate glucose metabolism through several pathways, including increasing glucose transporters in cell membranes and decreasing gluconeogenic enzymes, such as glucose-6-phosphatase in the liver, which help lower postprandial blood glucose levels. (116174).\n\nAdditionally, an animal model of diabetes suggests that turkey tail mushroom might be protective against pancreatic inflammation (108307). However, turkey tail polysaccharide does not inhibit alpha-amylase activity, indicating that this may not play a role in the antidiabetic effects of turkey tail mushroom (111907).\nAntifungal effects\nIn tumor-bearing mice, polysaccharide krestin (PSK) has a protective effect against experimentally-induced Candida albicans infection. This effect is possibly mediated by Th1 cell functions (70169).\nAntineoplastic effects\nThere is interest in using turkey tail mushroom, specifically polysaccharide peptide (PSP) or polysaccharide krestin (PSK), for antineoplastic effects. These polysaccharides have cytotoxic activity against various tumor cells in vitro (102915). PSK has been used in Japan as a biological response modifier in cancer chemotherapy regimens with varying results (1640, 1641, 1651, 1652, 1653, 1654, 1655, 1656, 1657, 1658)(1659, 1660, 1661, 1662, 94076). PSK has been found to inhibit tumor cell motility as well as chemotactic activity for macrophages (70203). PSK may prevent cancer metastasis by inhibiting tumor invasion and adhesion, reducing production of cell matrix-degrading enzymes, reducing tumor cell attachment to endothelial cells, suppressing tumor cell migration, inhibiting angiogenesis, and modulating cytokine production. PSK has also been found to stimulate the immune system and to activate the classical and alternative pathways of the complement cascade, which may further contribute to its antineoplastic effects (1642, 70204, 70205, 94073). In humans, PSK is considered to exert an immune-potentiating effect on T-lymphocytes (70196). Various animal and human trials show that markers of immunosuppression, including serum alpha-2 globulin levels, stimulation index, immunosuppressive acidic protein, sIL-2R, interleukin-10, alpha-1-antichymotrypsin, sialic acid, and killer T cells are lower in groups receiving PSK (1642, 1649, 70164, 70170, 70178, 70186, 70198). The immunologic effects of PSK in humans appears to be determined by the duration, not frequency, of PSK administration (1658). It therefore seems that PSK suppresses cancer metastasis at several different steps and that its mechanism of action includes direct action on the tumor cell as well as immunomodulation (1637, 70207). In humans, HLA alleles may be associated with resistance or susceptibility to lymph node metastasis, and HLA-A2 antigen may be a useful predictor of the response to PSK (70212).\n\nEarly evidence suggests that PSP may have activity against lung cancers, leukemia, hepatomas, and gastric cancers (1635, 96569). When given with cyclophosphamide, PSP seems to improve immune function by increasing white cell, natural killer cell, and antibody levels (10291). It also increases release of interleukins 1-beta, 2, and 6, and of tumor necrosis factor alpha (96569).\nAntioxidant effects\nAnimal research suggests that polysaccharide krestin (PSK) , a constituent of turkey tail mushroom, improves mRNA transcription to enhance glutathione peroxidase activity (70160). Other animal research suggests that turkey tail mushroom powder has antioxidant effects (108307).\nAntiviral effects\nLaboratory research suggests that polysaccharide peptide (PSP) , a constituent of turkey tail mushroom, has activity against the human immunodeficiency virus (HIV) via inhibition of reverse transcriptase and an enzyme involved with viral glycosylation (1643, 1644).\nHepatoprotective effects\nAnimal research suggests that polysaccharide peptide (PSP), a constituent of turkey tail mushroom, might protect against acetaminophen-induced hepatotoxicity (1647).\nVaginal effects\nPreliminary research shows that intravaginal application of a commercially available combination product containing beta- glucans, Azadirachta indica, aloe vera, and turkey tail mushroom (Palomacare, Procare Health), once daily at bedtime for 12 days in between periods, improves reepithelization of the cervical mucosa and overall vaginal health as measured by elasticity, fluid volume, pH, epithelial integrity, and moisture, when compared with baseline. Results also showed a nonsignificant improvement in vaginal microbiota which may protect against vaginal conditions such as human papilloma virus (HPV) infection (94074)."
        }
    },
    "Turmeric": {
        "sections": {
            "Overview": "Turmeric is a spice commonly used in Asian food that is derived from the root of the turmeric plant. The plant is a perennial herb and a member of the Zingiberaceae (ginger) family, and is cultivated in India and Southeast Asia (11140, 102350). It is used in traditional Chinese and Indian medicine, and in Indian religious ceremonies (11140). Curcumin is the yellow-colored primary active constituent derived from turmeric (102345). This turmeric constituent is commonly used to color foods and cosmetics (6002).",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using turmeric for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "LIKELY SAFE when used orally and appropriately, short-term. Turmeric products providing up to 8 grams of curcumin have been safely used for up to 2 months (10453, 11144, 11150, 17953, 79085, 89720, 89721, 89724, 89728, 101347)(81036, 101349, 107110, 107116, 107117, 107118, 107121, 109278, 109283, 114899) and products providing up to 1500 mg of curcumin daily have been safely used for up to 12 months (114898). Additionally, turmeric in doses up to 3 grams daily has been used with apparent safety for up to 3 months (102350, 104146, 104148, 113357, 114906). ...when used topically and appropriately (11148).\nPOSSIBLY SAFE when used as an enema, short-term. Turmeric extract in water has been used as a daily enema for up to 8 weeks (89729). ...when used topically as a mouthwash, short-term. A mouthwash containing 0.05% turmeric extract and 0.05% eugenol has been used safely twice daily for up to 21 days (89723).\nPREGNANCY: LIKELY SAFE when used orally in amounts commonly found in food.\nPREGNANCY: LIKELY UNSAFE when used orally in medicinal amounts; turmeric might stimulate the uterus and increase menstrual flow (12).\nLACTATION: LIKELY SAFE when used orally in amounts commonly found in food. There is insufficient reliable information available about the safety of using turmeric in medicinal amounts during lactation.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, turmeric is generally well tolerated.\nMost Common Adverse Effects\nOrally: Constipation, dyspepsia, diarrhea, distension, gastroesophageal reflux, nausea, and vomiting.\n\nTopically: Curcumin, a constituent of turmeric, can cause contact urticaria and pruritus.\nCardiovascular\nOrally, a higher dose of turmeric in combination with other ingredients has been linked to atrioventricular heart block in one case report. It is unclear if turmeric caused this adverse event or if other ingredients or a contaminant were the cause. The patient had taken a combination supplement containing turmeric 1500-2250 mg, black soybean 600-900 mg, mulberry leaves, garlic, and arrowroot each about 300-450 mg, twice daily for one month before experiencing atrioventricular heart block. Heart rhythm normalized three days after discontinuation of the product. Re-administration of the product resulted in the same adverse effect (17720).\nless\nDermatologic\nFollowing occupational and/or topical exposure, turmeric or its constituents curcumin, tetrahydrocurcumin, or turmeric oil, can cause allergic contact dermatitis (11146, 79270, 79470, 79934, 81410, 81195). Topically, curcumin can also cause rash or contact urticaria (79985, 97432, 112117). In one case, a 60-year-old female, with no prior reactivity to regular oral consumption of turmeric products, developed urticaria after topical application of turmeric massage oil (97432). A case of pruritus has been reported following topical application of curcumin ointment to the scalp for the treatment of melanoma (11148). Yellow discoloration of the skin has been reported rarely in clinical research (113356). Orally, curcumin may cause pruritus, but this appears to be relatively uncommon (81163, 97427, 104148, 114899). Pitting edema may also occur following oral intake of turmeric extract, but the frequency of this adverse event is less common with turmeric than with ibuprofen (89720). A combination of curcumin plus fluoxetine may cause photosensitivity (89728).\nless\nGastrointestinal\nOrally, turmeric can cause gastrointestinal adverse effects (107110, 107112, 112118), including constipation (81149, 81163, 96135, 113355), flatulence and yellow, hard stools (81106, 96135), nausea and vomiting (10453, 17952, 89720, 89728, 96127, 96131, 96135, 97430, 112117, 112118), diarrhea or loose stool (10453, 17952, 18204, 89720, 96135, 110223, 112117, 112118, 114898, 114899), dyspepsia (17952, 89720, 89721, 96161, 112118), gastritis (89728), distension and gastroesophageal reflux disease (18204, 89720), abdominal fullness and pain (81036, 89720, 96161, 97430, 114898, 114899), epigastric burning (81444), and tongue staining (89723).\nless\nHepatic\nOrally, turmeric has been associated with liver damage, including non-infectious hepatitis, cholestasis, and hepatocellular liver injury. There have been at least 70 reports of liver damage associated with taking turmeric supplements for at least 2 weeks and for up to 14 months. Most cases of liver damage resolved upon discontinuation of the turmeric supplement. Sometimes, turmeric was used concomitantly with other supplements and medications (99304, 102346, 103094, 103631, 103633, 103634, 107122, 109288, 110221). The Drug-Induced Liver Injury Network (DILIN) has identified 10 cases of liver injury which were considered to be either definitely, highly likely, or probably associated with turmeric; none of these cases were associated with the use of turmeric in combination with other potentially hepatotoxic supplements. Most patients (90%) presented with hepatocellular pattern of liver injury. The median age of these case reports was 56 years and 90% identified as White. In these case reports, the carrier frequency on HLAB*35:01 was 70%, which is higher than the carrier frequency found in the general population. Of the ten patients, 5 were hospitalized and 1 died from liver injury (109288).\n\nIt is not clear if concomitant use with other supplements or medications contributes to the risk for liver damage. Many case reports did not report turmeric formulation, dosing, or duration of use (99304, 103094, 103631, 103634, 109288). However, at least 10 cases involved high doses of curcumin (250-1812.5 mg daily) and the use of highly bioavailable formulations such as phytosomal curcumin and formulations containing piperine (102346, 103633, 107122, 109288, 110221).\nless\nNeurologic/CNS\nOrally, turmeric has been associated with headache and vertigo (81163, 114898).\nless\nPsychiatric\nOrally, the turmeric constituent curcumin or a combination of curcumin and fluoxetine can cause giddiness, although this event seems to be uncommon (81206, 89728).\nless\nRenal\nOrally, turmeric has been linked to one report of kidney failure, although the role of turmeric in this case is unclear. A 69-year-old male developed kidney failure related to calcium oxalate deposits in the renal tubules following supplementation with turmeric 2 grams daily for 2 years as an anti-inflammatory for pelvic pain. While turmeric is a source of dietary oxalates, pre-existing health conditions and/or chronic use of antibiotics may have contributed to the course of disease (113343).\nless\nOther\nThere is a single case report of death associated with intravenous use of turmeric. However, analysis of the treatment vial suggests that the vial contained only 0.023% of the amount of curcumin listed on the label. Also, the vial had been diluted in a solution of ungraded polyethylene glycol (PEG) 40 castor oil that was contaminated with 1.25% diethylene glycol. Therefore the cause of death is unknown but is unlikely to be related to the turmeric (96136).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAllergic rhinitis (hay fever). Oral turmeric seems to improve symptoms in people with allergic rhinitis.\nA large clinical study in people with allergic rhinitis shows that taking a specific curcumin product (Organika Health Products) 500 mg daily for 2 months reduces nasal symptoms, including sneezing, itching, runny nose, and congestion, when compared with placebo (96138).\nless\nDepression. Most research shows that oral curcumin, a constituent of turmeric, when used at doses of at least 1 gram daily for at least 6 weeks improves symptoms of depression when taken alone or in combination with antidepressant medications.\nCurcumin appears to be most beneficial for depression in middle aged patients compared to older patients, when taken for at least 6 weeks, and when used at a dose of at least 1 gram daily. In adults with major depressive disorder, a meta-analysis of data from 6 clinical studies, as well as individual studies not included in this analysis, show that taking curcumin 1 gram daily along with an antidepressant moderately improves depression symptoms when compared with placebo (96131, 96139). Another meta-analysis of 10 studies shows symptom reductions in patients with major depression when combined with conventional antidepressants, but not when used alone in patients with milder depressive symptoms. However, the quality of the evidence is low (104971). Additionally, a large clinical study in adults with mild-moderate symptoms of depression shows that taking curcumin 750 mg twice daily for 12 months modestly reduces depression symptoms when compared with placebo (114898).\n\nWhen used alone, one clinical study shows that curcumin 1 gram daily for 6 weeks may be similarly effective to fluoxetine 20 mg daily. Taking both products together seems to be more effective than either product alone, increasing the response rate from 65% to 78% (89728).\n\nGuidelines from The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce state that curcumin extract at doses of 500-1000 mg daily is provisionally recommended for monotherapy or adjunctive use in mild to moderate depression (110318).\nless\nDyspepsia. Oral turmeric may be modestly beneficial for some patients with dyspepsia. In patients with functional dyspepsia, small clinical studies show that oral curcumin, a constituent of turmeric, is similarly effective when compared with the proton-pump inhibitor omeprazole.\nClinical research shows that taking turmeric 500 mg four times daily for 7 days can relieve overall symptoms of dyspepsia in 64% more patients than taking placebo (11144). A small, unblinded clinical study in patients with a type of dyspepsia called postprandial distress syndrome shows that taking turmeric 250 mg or 500 mg orally three times daily after meals for 4 weeks is associated with reductions in symptom scores which are similar to those seen with simethicone 60 mg three times daily for 4 weeks. However, the recurrence rate upon stopping therapy was about 14% with simethicone, compared with 43% to 46% with turmeric (104963).\n\nIn patients with functional dyspepsia, taking the constituent curcumin appears similarly effective when compared with omeprazole, but might not provide further symptom reduction in those also taking famotidine or omeprazole (106063, 106801, 111599). One small clinical study in Iran shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg daily in addition to famotidine 40 mg daily for 30 days is no more effective for reducing overall symptoms of dyspepsia, such as abdominal pain, heartburn, bloating, and nausea, when compared with famotidine alone (106063). Another small clinical study in Thailand shows that taking curcumin 500 mg four times daily for 4 weeks is similarly effective for reducing dyspepsia severity and improving satisfaction when compared with an unspecified dose of omeprazole and more effective when compared with placebo (106801). Similarly, a moderate-size clinical study in Thailand shows that taking curcumin 500 mg four times daily for 4 weeks is similarly effective for reducing dyspepsia severity when compared with omeprazole 20 mg daily. However, taking curcumin and omeprazole in combination did not provide further symptom reduction (111599). The validity of these results is limited by the high rate of study dropouts.\nless\nHyperlipidemia. Research is conflicting on whether oral turmeric, curcumin, or curcuminoids can reduce serum lipids. Any improvement in lipids is likely to be small. Reasons for the conflicting findings may relate to turmeric formulation, duration of treatment, and/or the baseline cholesterol status of the included patients.\nResults from meta-analyses of clinical research show inconsistent and conflicting results. One large meta-analysis of over 50 clinical studies in healthy adults and those with a variety of conditions shows that supplementation with turmeric or curcumin 80-4000 mg daily for 4-24 weeks reduces total cholesterol by 4 mg/dL, low-density lipoprotein (LDL) cholesterol by 5 mg/dL, and triglycerides by 7 mg/dL and increases high-density lipoprotein (HDL) cholesterol by 2 mg/dL when compared with placebo (112119). Two other meta-analyses of 27 clinical studies agree that taking turmeric, curcumin, or curcuminoids moderately reduce triglyceride levels but suggest that turmeric does not improve total cholesterol when compared with placebo. However, the meta-analyses contradict one another on whether turmeric and its constituents reduce LDL cholesterol or increase HDL cholesterol. (96128, 96135). Additionally, a third meta-analysis of 10 clinical trials shows that taking up to 2400 mg daily of curcumin or curcuminoids, from turmeric or isolated sources, for up to 12 weeks, does not significantly improve triglycerides, LDL cholesterol, HDL cholesterol, or total cholesterol (110220).\nless\nNonalcoholic fatty liver disease (NAFLD). Oral curcumin, a constituent of turmeric, seems to attenuate fat deposition and improve some metabolic parameters in adults with NAFLD.\nClinical research shows that taking curcumin daily reduces NAFLD severity in 30% to 79% of patients, compared to 5% to 27.5% of patients receiving placebo. Curcumin also reduces the quantity of additional fat deposition in the liver to 0% to 4.5%, compared to 17.5% to 26% in those taking placebo. Most research shows that taking curcumin also reduces liver enzyme levels, body mass index (BMI), blood glucose levels, glycated hemoglobin (HbA1c), and total cholesterol when compared with placebo. Although some clinical research shows that taking curcumin improves levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, a meta-analysis of clinical research shows that these lipid levels are not improved in patients with NAFLD, specifically (97430, 97431, 100258, 102350, 106062, 107120, 109279, 111349, 114901). However, another meta-analysis of 14 small, heterogeneous clinical studies in adults with NAFLD, that included some of these studies, shows that taking various doses and forms of turmeric or curcumin modestly reduces liver enzyme levels, improves measures of insulin resistance, reduces waist circumference, and improves LDL, HDL, and triglyceride levels when compared with placebo (111348). A small clinical trial in patients with NAFLD given specific lifestyle recommendations shows that taking curcumin modestly reduces the frequency of metabolic syndrome and fatty liver but does not have beneficial effects on fatty liver-associated indices, adiposity, or the atherogenic index, when compared with placebo (109285). Findings for specific endpoints are mixed between individual studies and may depend on the dose and formulation of curcumin used or the duration of treatment.\n\nThese studies have used various doses and formulations. In one study, 500 mg of a dispersion formulation equivalent to 70 mg of curcumin daily for 8 weeks was used (97430). Also, 250 mg once daily or 500 mg twice daily of a specific phytosomal formulation (Meriva, Indena) containing curcumin and soy phosphatidylcholine in a 1:2 ratio and standardized to an overall curcuminoid content of 20% was taken for 8 weeks (97431, 106062). Another study used 1 gram of powdered turmeric rhizome taken three times daily with meals for 12 weeks (102350). One study used a curcumin-piperine complex (Curcumin C3 complex 500 mg plus Bioperine 5 mg) daily for 8 weeks (107120). One study used curcumin (Arjuna Natural Extract) 500 mg three times daily for 12 weeks (109285).\n\nDespite positive results with curcumin in several small clinical studies of patients with NAFLD, there is some concern that curcumin might cause hepatotoxicity in rare cases, especially when highly bioavailable formulations are used in high doses (103633). There is also evidence that the risk for hepatotoxicity with curcumin may be increased in individuals with the HLAB*35:01 allele (109288). Curcumin-induced hepatotoxicity has not been reported in clinical trials of patients with NAFLD, and its potential mechanism is unclear. However, patients seeking to take curcumin for NAFLD should be advised to monitor for symptoms of hepatotoxicity, including abdominal pain, dark urine, fatigue, jaundice, nausea, and pruritus.\nless\nOral mucositis. Oral curcumin or curcumin-containing mouthwash seem to reduce the development of severe oral mucositis, as well as reduce the severity and pain of oral mucositis, associated with cancer treatment.\nClinical research in patients receiving radiotherapy following recent radical surgery for oral cancer shows that taking turmeric (BCM-95, Arjuna Natural Pvt. Ltd., India) during radiotherapy reduces the incidence of severe oral mucositis to 25% or 20% in those taking turmeric 500 mg two or three times daily, respectively, compared with 65% in those taking placebo. The incidences of severe oral pain, dysphagia, and dermatitis were also reduced by at least 50% (105398). A small clinical study in patients receiving chemotherapy with or without head and neck radiotherapy shows that taking a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina) 80 mg twice daily for 7 weeks improves severity of oral mucositis at weeks 1, 4, and 7 and reduces pain at week 7 when compared with placebo. Effects were more pronounced in those with chemotherapy-induced oral mucositis than radiotherapy-induced oral mucositis (106800). In patients with head and neck cancer receiving radiotherapy, preliminary clinical research shows that swishing with 10 mL of turmeric solution (prepared by dissolving turmeric 400 mg in 80 mL of water) six times daily for 6 weeks delays mucositis and reduces the number of cases of intolerable mucositis by 49% when compared to swishing with 10 mL of povidone-iodine solution twice daily for 6 weeks (89726). Another small clinical study shows that swishing with 10 mL of nanoparticulate curcumin 0.1% mouthwash three times daily for 6 weeks is associated with a 50% lower risk of developing oral mucositis, and a delay of 2 weeks in the onset of mucositis, when compared with benzydamine 0.15% mouthwash (104969). A small clinical study in patients with mucositis due to head and neck radiotherapy shows that taking curcumin nanoparticles (SinaCurcumin, ExirNanoSina) 40 mg daily or using 10 mL of a curcumin 0.1% mouthwash three times daily for up to 21 days improves scores related to pain, burning, ulceration, and erythema when compared with placebo. Results with either oral or topical curcumin were similar (111350).\nless\nOsteoarthritis. Some oral turmeric extracts and combination products containing turmeric seem to improve certain symptoms of knee osteoarthritis. However, it is unclear how turmeric compares to the use of non-steroidal anti-inflammatory drugs (NSAIDs).\nSeveral meta-analyses of clinical studies show that turmeric extracts and/or curcuminoid products reduce knee pain and stiffness, improve physical function, and reduce the need for rescue medication when compared with placebo (104970, 106792, 109280, 110222). However, a reduced effect was noted in patients with increasing age or body mass index (104790). The studies evaluated in these meta-analyses are heterogeneous, of low- to moderate-quality, and utilized a variety of products and/or dosing strategies (104970, 106792, 109280, 110222). Small to moderate-sized clinical studies show that specific products (Meriva, Indena; Theracurmin, Theravalues Corp) containing curcumin 90-100 mg twice daily for up to 6 months, or specific turmeric extracts (Turmacin, Natural Remedies Pvt. Ltd.; Curcugen, DolCas Biotech, LLC) 500 mg twice daily for 6-12 weeks, reduce pain and analgesic use and improve functionality when compared with placebo (17953, 80988, 89721, 97424, 104148, 107118). A specific turmeric extract (CuraMed, EuroPharma USA) 1500 mg daily for 12 weeks improves functionality, but not pain, when compared with placebo (96127). Also, a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina), 40 mg twice daily for 6 weeks, improves pain, stiffness, and physical activity scores and reduces intake of rescue acetaminophen by about 60% when compared with placebo (102349). However, not all turmeric products seem to be effective for improving symptoms of osteoarthritis. One small clinical study shows that taking a specific turmeric extract (B-Turmactive, PLAMECA S.A.) 500 mg daily for one week does not reduce knee pain when compared with placebo (104147). Also, a meta-analysis of clinical research shows that benefits are limited to bio-optimized forms of curcuminoids, and benefits related to pure extracts are lacking (110222).\n\nTurmeric has also been compared with conventional treatments for knee osteoarthritis in small meta-analyses, a network meta-analysis, and individual clinical studies. However, the evidence is mixed as to whether turmeric is as effective or more effective than NSAIDs, such as ibuprofen 400 mg taken 2-3 times daily, diclofenac 25-100 mg daily, or chondroprotective drugs (17952, 89720, 89722, 106792, 109280, 110222, 113607). A network meta-analysis comparing 6 interventions in adults with knee osteoarthritis suggests that curcumin monotherapy, curcumin with chondroprotective agents, or curcumin with NSAIDs improves scores related to pain, function, and stiffness while reducing the need for rescue medication and the incidence of adverse events (113607). Individual studies are heterogenous with respect to comparator medication and dosing schedule. Doses included a non-commercial turmeric extract 500 mg 3-4 times daily for 4-6 weeks (17952, 89720) or turmeric extract 500 mg twice daily for 3 months (89722).\n\nTopical turmeric has also been evaluated. One clinical study shows that applying curcumin topically as a 5% ointment in Vaseline twice daily for 6 weeks reduces pain associated with knee osteoarthritis by a mean of about 11 on a 100-point visual analog scale when compared with placebo (104964). Another clinical study in patients with knee osteoarthritis shows that applying curcumin in a self-nano-emulsifying polyethylene glycol organogel 1.5 grams to the knee twice daily for 8 weeks reduces pain, stiffness, and difficulty with physical function scores by 72%, 62%, and 46%, respectively, when compared to baseline, with improvements superior to placebo for all outcomes (113357).\n\nResearch also shows that taking specific combination products containing turmeric and other ingredients can improve pain and functionality in patients with osteoarthritis. These combination products have combined turmeric with chondroitin sulfate and glucosamine hydrochloride (CartiJoint Forte, Fidia Farmaceutici SpA); boswellic acid (Curamin, EuroPharma USA; Rhulief); Boswellia serrata (Rhulief); ashwagandha, Boswellia serrata, and zinc (Articulin-F, Eisen Pharmaceutical Co. Pvt. Ltd.); devil's claw and bromelain (AINAT, Laboratoire de Rhumatologie Applique); Boswellia serrata, guggul, and valerian (Phytoproflex, OPTM Healthcare); Boswellia serrata and terminalia (LI73014F2, Laila Nutraceuticals); ashwagandha, Boswellia serrata, and ginger (Artrex, Mendar); or extracts of ginger rhizome, devil's claw tuber, Boswellia serrata resin, and celery seed (Tregocel, Max Biocare) (19276, 51950, 81466, 89717, 89719, 96127, 97419, 97421, 97428, 106078)(109280).\nless\nPruritus. Oral turmeric has been evaluated for the management of pruritus of various etiologies, with promising results.\nClinical research in patients with kidney failure shows that taking turmeric 500 mg orally three times daily for 8 weeks decreases symptoms of uremic pruritus by 1.9-fold when compared with placebo (89724). Also, a small clinical study in patients with sulfur mustard-induced chronic pruritus shows that taking a specific combination product (C3 Complex, Sami Labs LTD) containing curcumin 1 gram plus extract from black pepper or long pepper (Bioperine) daily for 4 weeks reduces pruritus severity and improves quality of life when compared with placebo (81120, 81176).\nless\nPOSSIBLY INEFFECTIVE\nAlzheimer disease. Neither oral turmeric nor its constituent curcumin appears to improve cognitive function or attenuate cognitive decline in adults with this condition.\nA small clinical trial shows that taking the turmeric constituent, curcumin, 1-4 grams daily for 6 months does not improve mental state examination scores when compared with placebo (17096). Furthermore, a meta-analysis of this study and another small clinical study in patients with Alzheimer disease shows that the turmeric group experienced greater cognitive decline when compared with placebo (100261). While this research is limited by small study sizes and heterogeneous patient populations, the current evidence does not support the use of turmeric in patients with this condition.\nless\nPeptic ulcers. Oral turmeric does not seem to improve the healing of peptic or gastric ulcers when compared with placebo or liquid antacids.\nSome clinical research shows that taking turmeric 2 grams three times daily for 8 weeks does not improve the healing of peptic ulcers when compared with placebo in Vietnamese patients (81444). Also, taking powdered turmeric rhizome 250 mg four times daily for 6 weeks seems to be less effective than a liquid aluminum-magnesium-hydroxide antacid for promoting gastric ulcer healing (81284).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. Although there has been interest in using topical turmeric for acne, there is insufficient reliable information about the clinical effects of turmeric for this purpose.\nAge-related cognitive decline. Some small clinical studies suggest that oral curcumin, a constituent of turmeric, may modestly improve cognition in elderly patients experiencing cognitive decline.\nA meta-analysis of three small clinical trials shows that curcumin modestly improves cognition in the elderly (100261). One of these clinical trials shows that taking a specific brand of curcumin (Theracurmin, Theravalues Corp.) 90 mg twice daily for 18 months improves long-term memory and attention when compared with placebo in middle-aged and older adults with or without mild cognitive impairment (96161).\nless\nAmenorrhea. Although there has been interest in using oral turmeric for amenorrhea, there is insufficient reliable information about the clinical effects of turmeric for this purpose.\nAnkylosing spondylitis. Although there has been interest in using oral turmeric for ankylosing spondylitis, there is insufficient reliable information about the clinical effects of turmeric for this purpose.\nAnxiety. Some clinical research show that oral curcumin reduces symptoms of anxiety.\nA meta-analysis of 8 mostly low-quality clinical studies in adults with anxiety symptoms or an anxiety disorder diagnosis shows that taking curcumin 500-1000 mg daily for up to 12 weeks modestly reduces symptoms of anxiety when compared with placebo (114902). The validity of the meta-analysis is limited by the heterogeneity of the included studies, including differences in the patient populations, form and doses curcumin, treatment durations, and types of anxiety scales used. Additionally, all studies were conducted in either Iran or Australia which may limit generalizability of results to other populations.\nless\nAromatase inhibitor-induced arthralgia. It is unclear if oral curcumin, a constituent of turmeric, is beneficial for aromatase inhibitor-induced arthralgia.\nA small clinical trial in patients experiencing aromatase inhibitor-induced arthralgia shows that taking curcuminoids as a nanoemulsion (Curcumin C3 Complex, Sabinsa Corporation) 200 mg daily for 3 months does not improve grip strength or joint symptoms when compared with placebo (113345). However, this study may have been underpowered to detect a difference between groups.\nless\nAsthma. Some small clinical studies suggest that oral turmeric, as an adjunct to conventional asthma treatment, does not improve lung function or symptoms in adults and children with asthma.\nOne small clinical study in adults with mild to moderate asthma shows that adjuvant therapy with turmeric as curcumin 500 mg twice daily for 30 days does not improve lung function based on FEV1, or improve symptoms such as dyspnea, wheezing, cough, or tightness, when compared to standard treatment alone (99349). A small clinical trial in children 7-18 years of age with moderate to severe asthma shows that adding turmeric 500-1000 mg (containing 20-40 mg curcuminoids) daily for 6 months to standard therapy does not improve overall asthma symptoms when compared with placebo and standard therapy, although it may decrease the frequency of nighttime awakenings and the use of rescue inhalers (99348). Due to their small sizes and high drop-out rates, these studies may have been underpowered to detect a difference between groups.\nless\nAthletic performance. It is unclear if oral curcumin, a constituent of turmeric, is beneficial for athletic performance.\nPreliminary clinical research in middle-aged male long-distance runners shows that taking a turmeric extract providing 2 grams of curcumin 95% and piperine 5% daily for 6 weeks does not improve aerobic capacity when compared with placebo (109286).\nless\nBenign prostatic hyperplasia (BPH). It is unclear if oral curcumin, a constituent of turmeric, is beneficial in BPH.\nA clinical study in patients with BPH shows that taking curcumin 2250 mg once daily along with tamsulosin and finasteride for 6 months improves lower urinary tract symptoms related to storage, but not overall symptoms or symptoms related to voiding, by about 35%, compared with 25% in those receiving tamsulosin and finasteride alone. Periprostatic fat thickness, quality of life, and erectile function also were improved (106799).\nless\nBeta-thalassemia. It is unclear if oral turmeric is beneficial for iron overload in patients with beta-thalassemia.\nA small clinical study in patients with beta-thalassemia major and iron overload shows that taking turmeric extract containing curcumin 500 mg twice daily for 12 weeks modestly reduces non-transferrin bound iron (NTBI) by 0.6 micromol/L, but not hemoglobin, transferrin saturation, total iron binding capacity, ferritin, or hepcidin, when compared with placebo (99306). Another small clinical study in adult males with beta-thalassemia intermedia and iron overload shows that taking a higher dose of curcumin 500 mg three times daily for 12 weeks modestly reduces serum iron and ferritin turmeric levels and transferrin saturation when compared with placebo (108871).\nless\nBruises. Although there has been interest in using topical turmeric to alleviate bruising, there is insufficient reliable information about the clinical effects of turmeric for this purpose.\nCachexia. It is unclear if oral curcumin, a constituent of turmeric, is beneficial for cancer cachexia.\nA small clinical trial in patients with cancer anorexia-cachexia syndrome shows that taking curcumin 800 mg twice daily for 8 weeks does not reduce weight loss or improve body composition or handgrip strength when compared with placebo (109283).\nless\nCanker sores. Some preliminary research suggests that topical curcumin, a constituent of turmeric, is beneficial for minor canker sores.\nPreliminary clinical research in young adults with minor canker sores shows that applying a 2% curcumin oral gel for 6 months reduces ulcer size, pain, and recurrence rate and increases healing rate similarly to 0.1% triamcinolone oral paste (104962). The validity of the study is limited by a lack of investigator blinding and the lack of an intention to treat analysis. Another small clinical study shows that applying a 1% curcumin nanomicelle gel (SinaCurcumin Pharmaceuticals) on lesions three times daily for one week is modestly more effective than applying a 2% curcumin gel for reducing pain and ulcer size (109282). The validity of this finding is limited by the lack of a non-curcumin comparator group.\nless\nCarpal tunnel syndrome. Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear. It is unclear if topical curcumin, a constituent of turmeric, is beneficial for carpal tunnel syndrome.\nA moderate-sized clinical study in adults with mild to moderate carpal tunnel syndrome shows that taking a combination product containing turmeric, alpha-lipoic acid, acetyl-L-carnitine, phosphatidylserine, and vitamins C, E, B1, B2, B6, and B12 twice daily for 60 days reduces symptom severity and pain but does not improve measures of hand and wrist function when compared with control (111702). The validity of these effects is limited by a lack of blinding. The study may also be inadequately powered to detect a difference between groups. Additionally, it is unclear if the effects are due to turmeric, other ingredients, or the combination.\n\nTopical turmeric has also been investigated. A small clinical study in patients with mild to moderate carpal tunnel syndrome shows that applying a 1% curcuminoid gel (Sinanomin) to the wrists twice daily for 8 weeks modestly decreases symptom severity and improves function when compared with a placebo gel. However, there was no change in electrodiagnostic testing of the injury. All patients also used a night splint (113356).\nless\nChemotherapy-induced acral erythema. It is unclear if oral or topical turmeric reduces the risk for acral erythema from capecitabine.\nA small clinical trial in adults with cancer shows that taking turmeric 4 grams daily for 6 weeks starting at the beginning of treatment with capecitabine does not reduce the incidence of acral erythema overall; however, it does seem to reduce acral erythema grade 2 or higher when compared with expected incidence rates (99309).\n\nTopical turmeric has also been evaluated. A clinical study in patients with colorectal, gastric, pancreatic, or breast cancer receiving capecitabine shows that applying a specific ointment (Alpha) standardized to contain curcumin extract 0.5% and henna extract 10% to the soles and palms twice daily, beginning on day 1 of chemotherapy and continued for 4 cycles, does not prevent acral erythema or improve World Health Organization severity scores when compared with placebo. A post-hoc analysis suggests that there may have been a trend toward delayed onset and progression; however, this study was not structured to assess these outcomes (108874).\nless\nChemotherapy-induced diarrhea. It is unclear if oral curcumin reduces symptoms of chemotherapy-induced diarrhea.\nA small clinical study in patients with various forms of cancer receiving standard chemotherapy for that cancer type shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg twice daily for 9 weeks does not reduce symptoms of diarrhea when compared with placebo (107111).\nless\nChemotherapy-induced nausea and vomiting (CINV). It is unclear if oral curcumin reduces CINV.\nA small clinical study in patients with various forms of cancer receiving standard chemotherapy for that cancer type shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg twice daily for 9 weeks modestly reduces symptoms of nausea, but not vomiting, in the second and third months after the start of treatment when compared with placebo (107111).\nless\nChemotherapy-induced peripheral neuropathy. It is unclear if oral curcumin reduces symptoms of chemotherapy-induced peripheral neuropathy.\nA small clinical study in patients with various forms of cancer receiving standard chemotherapy for that cancer type shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg twice daily for 9 weeks modestly reduces symptoms of chemotherapy-induced peripheral neuropathy over a three-month period when compared with placebo (107111).\nless\nChronic kidney disease (CKD). It is unclear if oral turmeric is beneficial for CKD.\nA meta-analysis of four small clinical trials in patients with CKD related to diabetic nephropathy or lupus nephritis shows that taking curcumin or turmeric for 0.5-4 months moderately reduces proteinuria when compared with placebo (109276). Also, a small clinical trial in children and young adults ages 6-25 years with vascular dysfunction related to autosomal dominant polycystic disease (PKD) shows that curcumin powder 25 mg/kg daily for 12 months does not improve vascular function or kidney function when compared with placebo (107117).\nless\nColorectal adenoma. It is unclear if oral turmeric is beneficial for managing colorectal adenoma.\nPreliminary clinical research in adults with familial adenomatous polyposis shows that taking curcumin 1500 mg twice daily for 12 months does not reduce the quantity or size of lower intestinal adenomatous polyps when compared with placebo (97427). A very small clinical trial in patients with familial adenomatous polyposis shows that taking 8 capsules daily of a turmeric extract, in a formulation also containing pepper fruit, spirulina, seaweed, and ginger root, for 6 months does not affect total polyp number or burden when compared with placebo. However, both number and burden were modestly reduced in the left colon. Each capsule provided curcuminoids 123.65 mg and turmerones 26.79 mg (110223).\nless\nColorectal cancer. It is unclear if oral turmeric is beneficial for the prevention or treatment of colorectal cancer.\nA small clinical trial in patients undergoing chemotherapy following colorectal cancer surgery shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg daily for 8 weeks modestly improves some measures of quality of life when compared with placebo (107109). In addition, a small clinical study in people at high risk for colorectal cancer, such as those who smoke, shows that taking the turmeric constituent, curcumin, 4 grams daily for 30 days can reduce the number of precancerous rectal aberrant crypt foci (18204). It is not clear if this results in a reduced risk for colorectal cancer.\nless\nCoronary artery bypass graft (CABG) surgery. One small study suggests that oral turmeric may reduce the risk for myocardial infarction after CABG surgery.\nPreliminary clinical research shows that taking the turmeric constituent, curcuminoids, 4 grams daily in four divided doses, beginning 3 days prior to surgery and continuing for 5 days post-surgery, decreases the relative risk of myocardial infarction following CABG by approximately 56% when compared with placebo (81143).\nless\nCoronavirus disease 2019 (COVID-19). It is unclear if oral turmeric or its constituent, curcumin, is beneficial for reducing symptoms of COVID-19.\nSmall studies have evaluated curcumin as an adjunctive therapy in adults hospitalized with confirmed COVID-19. Patients in these studies also received treatments such as antimicrobials, anti-inflammatory medications, anticoagulants, antiretrovirals, and immunosuppressants (104966, 105393, 107119). One study shows that adding curcumin reduces the duration of shortness of breath by 6-9 days when compared with patients who received other treatments in combination with probiotics. However, there were no differences in the duration of other symptoms, including fever, cough, or sore throat. Subgroup analyses suggest that taking curcumin may improve oxygenation and reduce the need for supplemental oxygen or ventilation (105393). Another study shows that adding curcumin modestly reduces the time to resolution of COVID-19 symptoms, the length of supplemental oxygen use, and the likelihood for deterioration in the patients' condition when compared with patients who received other treatments alone (104966). A third study shows some benefit of curcumin on fever and cough when compared with baseline; however, it is unclear if any changes were significant when compared with placebo (107119). Doses of curcumin used in these studies include curcumin 525 mg with piperine 2.5 mg (C3 Complex, SamiDirect) twice daily, starting at admission and continuing for 14 days (105393), or a specific nanocurcumin product (SinaCurcumin, ExirNanoSina) 80 mg twice daily for 2 weeks or 240 mg daily in divided doses for 7 days (104966, 107119). Limitations of these studies include the small number of patients with severe symptoms, the large number of outcomes evaluated, the inconsistencies in other treatments used, the lack of clarity related to presentation of some results, and, in most cases, a lack of blinding.\n\nTurmeric has also been evaluated in adults in the outpatient setting with suspected or confirmed mild to moderate COVID-19. One small clinical study shows that taking curcumin (SinaCurcumin, ExirNanoSina) 80 mg twice daily for 14 days in addition to other COVID-19 treatments (mainly hydroxychloroquine and azithromycin) reduces the duration of cough, chills, myalgia, and smell and taste disturbance, but not dyspnea, fever, sore throat, or others, by 1-2 days when compared with placebo with other treatments (106802). The validity of this study is limited by the lack of confirmatory diagnosis at baseline and lack of consistency with other treatments, as well as the unclear reporting of symptom duration in relation to the initiation of treatment. Another small clinical study in outpatients confirmed to have COVID-19 shows that taking curcumin 1000 mg plus piperine 10 mg (Sami Labs Limited) daily for 14 days modestly improves weakness, but not cough, pain, headache, difficulty breathing, or biochemical indices, when compared with placebo (109278). However, a clinical study in adults with confirmed asymptomatic or mild COVID-19 shows that taking curcumin (curcuRouge, TheraBioPharma) 360 mg twice daily for 7 days within 5 days of COVID-19 diagnosis does not reduce the risk of fever or oxygen saturation below 96% when compared with placebo (114905).\n\nSome research has also examined the effect of turmeric as part of a polyherbal combination. Clinical research in patients hospitalized for moderate COVID-19 symptoms shows that using an Ayurvedic formulation 1776 mg twice daily containing turmeric, ashwagandha, ginger, and Boswellia serrata (BV-4051) for 14 days modestly reduces the duration of illness and reduces the severity of fever, cough, and smell and taste dysfunction when compared to placebo. There was no beneficial effect on other symptoms, including nasal congestion, breathing difficulty, headache, and gastrointestinal symptoms. More than half of the patients were also treated with remdesivir which did not impact the majority of these findings (109899).\nless\nCrohn disease. It is unclear if oral turmeric is beneficial for improving symptoms of active Crohn disease.\nSome clinical research shows that taking the turmeric constituent, curcumin, 1.08 grams daily for one month, then 1.44 grams daily for one month, can reduce bowel movements, diarrhea, and abdominal pain when compared to baseline in patients with Crohn disease (79730). The validity of these findings is limited by the lack of a comparator group.\nless\nDenture stomatitis. Topical turmeric may be beneficial for treating denture stomatitis.\nA small clinical study in patients with denture stomatitis shows that applying topical curcumin gel (Curenext, Abbott Laboratories) three times daily for 2 weeks resolves denture stomatitis lesions similarly to clotrimazole ointment (106797).\nless\nDiabetes. Lower quality clinical studies suggest that oral curcumin, a constituent of turmeric, may modestly improve glycemic control in patients with diabetes.\nA meta-analysis of small clinical trials in patients with diabetic kidney disease shows that curcumin reduces levels of fasting glucose by approximately 8.3 mg/dL when compared with placebo. Curcumin was used in doses of 66.3-1670 mg daily for 2-6 months (107114). Preliminary clinical research included in the analysis shows that taking a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina) 80 mg daily for 12 weeks reduces fasting blood glucose by about 20 mg/dL (104149). Other meta-analyses of low- to moderate-quality clinical studies in patients with a variety of conditions including type 2 diabetes show that taking turmeric extract, curcumin, or curcuminoids for 4-36 weeks improves glycated hemoglobin (HbA1c) by 0.4-0.7% and reduces fasting glucose by approximately 13 mg/dL when compared with placebo or conventional treatment (106806, 108877, 113604). The validity of these findings is limited by the heterogeneity of the included studies and broad curcuminoid doses ranging from 46-1500 mg daily. Conversely, other meta-analyses in patients with type 2 diabetes show that curcumin does not reduce HbA1c or insulin levels when compared with placebo (104965, 108877, 113604).\nless\nDiabetic foot ulcers. It is unclear if oral curcumin is beneficial in patients with diabetic foot ulcers.\nPreliminary clinical research in patients with grade 3 diabetic foot ulcers shows that taking nanocurcumin 80 mg orally daily for 12 weeks does not improve glycated hemoglobin (HbA1c) or change the rate of ulcer healing when compared with placebo. Taking turmeric did result in modest decreases in fasting blood glucose, insulin levels, and insulin resistance (104972).\nless\nDiabetic nephropathy. It is unclear if oral curcumin is beneficial in patients with diabetic nephropathy.\nMeta-analyses of two to four small clinical trials in patients with diabetic kidney disease show that curcumin modestly improves serum levels of creatinine, total cholesterol, and fasting glucose, and reduces systolic blood pressure by 4 mmHg, when compared with placebo. However, there was no effect on diastolic blood pressure, proteinuria, or serum levels of other plasma lipids or blood urea nitrogen. Curcumin was used in doses of 66.3-1670 mg daily for 2-6 months (107114). One small study included in this analysis, which evaluated patients receiving hemodialysis, shows that taking a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina) 80 mg daily for 12 weeks reduces fasting blood glucose by about 20 mg/dL when compared with placebo (104149).\nless\nDry eye. Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA clinical study in adults with dry eye disease shows that taking a combination supplement containing curcumin extract that provides 200 mg curcuminoids plus lutein, vitamin D3, and zeaxanthin daily for 8 weeks improves tear production and overall patient-reported symptoms (e.g., burning or sore eyes, blurred vision, difficulty reading) when compared with placebo (116214). However, the clinical significance is unclear, and the use of artificial tears did not differ between groups. It is unclear if these benefits are due to turmeric, other ingredients, or the combination.\nless\nDysmenorrhea. Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA clinical study in university students aged 18 to 24 in Iran with mild to severe primary dysmenorrhea and premenstrual syndrome (PMS) shows that taking a specific combination product containing curcumin 500 mg plus extract from black pepper 5 mg (C3 Complex, Sami Labs) daily, starting 7 days prior to menstruation and continuing for 3 days after menstruation for 3 consecutive menstrual cycles, does not improve the severity of symptoms when compared with placebo (106805). Conversely, a small clinical study in adults with moderately painful dysmenorrhea shows that taking a single dose of a combination product containing turmeric, Boswellia serrata, and sesame (Rhuleave-K, Arjuna Natural Private Ltd.) 1000 mg at the start of menstruation relieves menstrual cramp pain and reduces pain intensity for up to 6 hours when compared with placebo (112806). However, it is unclear if these effects are due to turmeric, other ingredients, or the combinations.\nless\nEndometriosis. It is unclear if oral turmeric is beneficial for reducing pain due to endometriosis.\nA small clinical study in adults with endometriosis shows that taking the turmeric constituent, curcumin, 500 mg twice daily for 8 weeks does not affect pain associated with endometriosis or quality of life when compared with placebo (113603).\nless\nErythema. Although there has been interest in using topical turmeric for reducing erythema, there is insufficient reliable information about the clinical effects of turmeric for this purpose.\nExercise-induced muscle damage. It is unclear if oral curcumin, a constituent of turmeric, is beneficial for reducing muscle damage from exercise.\nA meta-analysis of 12 small, lower-quality clinical studies in adults shows that taking curcumin 150-500 mg as a single dose before or after exercise or 180-5000 mg daily for up to 56 days reduces markers of muscle damage (i.e. serum creatine kinase levels) when compared with placebo. Curcumin seems most beneficial for this effect in untrained adults and when administered as a single dose. Additionally, a meta-analysis of 3 of these clinical studies shows that curcumin improves range of motion (114897). The interpretation of these findings is limited by significant heterogeneity.\nless\nExercise-induced muscle soreness. It is unclear if oral turmeric or its constituent, curcumin, is beneficial for reducing muscle soreness from exercise.\nA meta-analysis of 12 small, lower-quality clinical studies in trained and untrained adults shows that taking curcumin 150-500 mg as a single dose before or after exercise or 180-5000 mg daily for up to 56 days time reduces muscle soreness when compared with placebo. Subgroup analysis indicated that the largest effect size is observed at 96 hours post-exercise with progressively smaller effect sizes at earlier time points (114897). The interpretation of these findings is limited by significant heterogeneity.\n\nTurmeric has also been examined in combination with other ingredients. Clinical research in healthy active adults with moderate to severe exercise-induced muscle pain shows that taking a single, 1000-mg dose of turmeric and Boswellia serrata extracts in black sesame oil (Rhuleave-K; Arjuna Natural Private Ltd.) improves pain relief when compared with placebo, with maximal benefits within about 3 hours. The number of people needed to treat to obtain pain relief of at least 50% over a 6-hour period was 1.1 (109277).\nless\nGingivitis. Small clinical studies suggest that oral turmeric and turmeric mouthwash may reduce the severity of gingivitis. Turmeric mouthwash appears to be similarly effective to chlorhexidine mouthwash.\nA meta-analysis of generally preliminary clinical research shows that rinsing with a mouthwash containing curcumin for 3-4 weeks is as effective as rinsing with chlorhexidine for reducing the severity of gingivitis or plaque (106059). Mouthwashes in these studies contained 0.05% to 20% curcumin and were usually used twice daily for 3-4 weeks (81127, 89723, 106059). One mouthwash contained 0.05% turmeric extract and 0.005% eugenol (89723). Another small clinical trial shows that taking a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina) 80 mg daily by mouth after breakfast for 4 weeks reduces the severity of gingivitis and gingival bleeding, but not plaque, when compared with placebo in patients with gingivitis and mild periodontitis (104146).\nless\nGout. Although there is interest in using oral turmeric for gout, there is insufficient reliable information about the clinical effects of turmeric for this condition.\nGulf war syndrome. It is unclear if oral curcumin is beneficial in patients with Gulf war syndrome.\nA small preliminary clinical trial in patients with Gulf war syndrome shows that taking curcumin (Meriva, Indena, S.p.A.) 500 mg twice daily for 30 days reduces overall symptoms, including pain, fatigue, gastrointestinal distress, and others, by 19% when compared with baseline. Taking a higher dose of 2000 mg twice daily for an additional 30 days appears to be no more effective than the lower dose (105395).\nless\nHearing loss. It is unclear if oral turmeric is beneficial for treating hearing loss.\nA small clinical study in adults with mild to moderate hearing impairment shows that taking curcumin 500 mg daily for 12 weeks improves some measures of auditory function, such as auditory brain stem response threshold, when compared with placebo (114906).\nless\nHelicobacter pylori. Small clinical studies suggest that oral turmeric is not beneficial for eradicating H. pylori when used alone or in combination with standard triple therapy or famotidine.\nOne small clinical study in patients with H. pylori gastritis shows that taking turmeric 2.1 grams daily for 4 weeks is less effective for eradicating H. pylori than taking an omeprazole-based triple regimen for one week (80957). Another small study in adults with peptic ulcers shows that taking a specific curcumin product (C3 Complex, Sami Labs LTD) 500 mg daily for 7 days, in conjunction with standard triple therapy, does not improve H. pylori eradication rates when compared with standard triple therapy alone. The addition of curcumin increased the resolution of dyspepsia symptoms by an additional 21%, but the clinical significance of this outcome is unclear (97420). In patients with dyspepsia, most of whom tested positive for fecal H. pylori antigen, clinical research shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg daily in addition to famotidine 40 mg daily for 30 days is no more effective for reducing fecal H. pylori antigen levels than taking famotidine alone (106063).\nless\nHypertension. It is unclear if oral curcumin is beneficial in patients with hypertension.\nA meta-analysis of approximately 30 clinical studies in healthy adults or patients with a variety of conditions shows that taking turmeric, curcumin, curcuminoids, or nano-curcumin for 4 to 24 weeks reduces systolic blood pressure by about 2 mmHg and diastolic blood pressure by about 0.8 mmHg when compared with placebo (113602). However, these blood pressure reductions may not be clinically meaningful. In addition, most of the included studies were small and utilized heterogeneous dosing regimens.\nless\nImpaired glucose tolerance (prediabetes). Oral turmeric may modestly improve glucose control in some patients with prediabetes.\nIn overweight or obese individuals with prediabetes, clinical research shows that taking a turmeric extract (BCM95 or Cucugreen; M/s Arjuna Natural Pvt Ltd.) 500 mg daily, providing 95% curcuminoids and at least 65% curcumin, for 90 days, either alone or in combination with zinc 30 mg as zinc gluconate, results in a small reduction in fasting glucose and glycated hemoglobin (HbA1c) when compared with placebo. There was also a small benefit in insulin sensitivity (105391). Other preliminary clinical research in adults with prediabetes shows that taking 500 mg of a combination of turmeric extract and Indian gooseberry extract in a 1:2 ratio along with phosphatidylcholine (EmbliQur) twice daily for 6 months modestly reduces fasting glucose and improves insulin resistance, when compared with placebo. However, changes in most other endpoints were not significantly different from placebo. Each 500 mg capsule contained turmeric extracts 29.86% and turmeric oil 1.27% (113355).\n\nThe effect of turmeric on progression to type 2 diabetes in patients with prediabetes has also been investigated. Preliminary clinical research shows that taking a turmeric extract containing curcumin 750 mg twice daily for 9 months reduces the percentage of patients with prediabetes who develop type 2 diabetes when compared with placebo (81163).\nless\nIrritable bowel syndrome (IBS). It is unclear if oral turmeric is beneficial for improving symptoms of IBS.\nPreliminary clinical research in otherwise healthy adults with IBS shows that taking a turmeric extract (Cynara Turmeric, Lichtwer Pharma) 72-144 mg daily for 8 weeks reduces IBS symptoms by about 40% to 60% when compared to baseline (79565). The validity of this finding is limited by the lack of a comparator group. Taking a combination product (CU-FEO, Alfa Wasserman S.p.A.) containing curcumin 42 mg and fennel essential oil 25 mg per capsule twice daily for 60 days improves overall ratings of abdominal pain, abdominal distention, and quality of life by 24% when compared with placebo (97422). It is unclear if these effects are due to turmeric, fennel, or the combination. Observational research suggests that adding a supplement (Enterofytol PLUS) providing curcumin 42 mg and berberine 200 mg twice daily for 2 months to conventional IBS treatment is associated with improvements in symptoms, such as abdominal discomfort, distension, and stool status, by up to 48% when compared with conventional treatment alone. Use of the supplement was also associated with a 64% reduced need for conventional treatments (113354).\nless\nJoint pain. Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research shows that taking capsules of a specific combination product (Instaflex Joint Support, Direct Digital) containing glucosamine sulfate 1500 mg, methylsulfonylmethane 500 mg, white willow bark extract 250 mg, ginger root concentrate 50 mg, Boswellia extract 125 mg, turmeric root extract 50 mg, cayenne 40 m H.U. 50 mg, and hyaluronic acid 4 mg in three divided doses daily for 8 weeks reduces joint pain severity by 37% compared to only 16% with placebo. However, it does not improve joint stiffness or function when compared with placebo (89560). It is unclear if these effects are due to turmeric, other ingredients, or the combination.\nless\nJuvenile idiopathic arthritis (JIA). Although there is interest in using oral turmeric for JIA, there is insufficient reliable information about the clinical effects of turmeric for this condition.\nKnee pain. It is unclear if oral turmeric is beneficial for knee pain.\nClinical research in individuals with knee pain not related to existing arthritis shows that taking turmeric extract (TurmXTRA 60N; Inventia Healthcare Ltd. and Laila Nutraceuticals) 250 mg, providing 60% curcuminoids, once daily for 90 days modestly reduces pain associated with walking 80 meters when compared with placebo. The time taken to walk 80 meters and to climb nine steps was reduced by 4-5 seconds (105396).\nless\nLichen planus. Evidence is conflicting on whether turmeric is beneficial for lichen planus.\nA meta-analysis of several small, heterogeneous, mostly low-quality clinical and observational studies in adults with oral lichen planus shows that oral or topical curcumin with or without corticosteroids for 2-12 weeks does not improve erythema, lesion size, or pain when compared with control (113605). Similarly, a network meta-analysis of small clinical trials in patients with oral lichen planus shows that applying topical turmeric gel does not improve symptoms, clinical resolution, clinical scores, or reduce pain when compared with other available interventions (111640).\n\nHowever, small individual clinical studies have shown some benefit in using turmeric orally or topically for lichen planus. A small clinical study shows that taking a specific turmeric extract (Curcumin C3 Complex, Sabinsa Corporation) containing curcuminoids 6000 mg daily in three divided doses for 12 days can reduce erythema and ulceration associated with lichen planus when compared with placebo (81109). Another small clinical study shows that taking a nanocurcumin product (SinaCurcumin, ExirNanoSina) 80 mg orally once daily for 1 month reduces oral lichen planus lesion size, pain, and burning similarly to prednisolone 10 mg taken orally once daily for 1 month (104961). Additionally, a small clinical study shows that applying turmeric twice daily for 4 months reduces burning, pain, and lesion size when compared to baseline. Turmeric reduces these outcomes similarly to topical ashwagandha or aloe vera (115931).\nless\nMetabolic syndrome. It is unclear if oral turmeric is beneficial for metabolic syndrome.\nResearch is conflicting on how turmeric, curcumin, and other formulations affect various measures of metabolic syndrome. Some clinical research and a meta-analysis of 13 clinical studies in patients with metabolic syndrome show that taking turmeric or curcumin decreases low-density lipoprotein (LDL) cholesterol, waist circumference by 2 cm, fasting blood glucose by 9 mg/dL, and diastolic blood pressure by 3 mmHg and increases high-density lipoprotein (HDL) cholesterol by 5 mg/dL when compared with placebo. However, other research shows that turmeric or curcumin have no effect on body weight, lipids, blood pressure, or blood glucose when compared with placebo (98999, 99311, 105400, 109284, 111347, 112118). The validity of these effects is limited by high heterogeneity within the included studies and incomplete information about randomization and blinding.\n\nStudies have used turmeric, curcumin, and curcumin extract 80-2400 mg, in divided doses, daily for 4-12 weeks, nano-curcumin 80 mg daily for 12 weeks, or calebin A (CurCousin, Sabinsa), which is a constituent of turmeric, 25 mg twice daily for 3 months (98999, 99311, 105400, 109284, 111347, 112118). Also, taking crude or phosphorylated curcuminoids 1 gram daily for 6 weeks does not improve sleep or reduce weight in these patients (105397).\nless\nMigraine headache. It is unclear if oral curcumin is beneficial for migraine headache.\nA small clinical trial in females with regular migraines shows that taking curcumin 500 mg twice daily for 8 weeks reduces the severity and duration, but not the frequency, of migraine headaches when compared with placebo. In individuals taking curcumin, the duration of headache per month was reduced by approximately 10.3 hours from baseline (107116).\nless\nMyocardial infarction (MI). It is unclear if oral curcumin is beneficial for reducing myocardial injury following a MI.\nClinical research in patients with an acute MI shows that taking curcuminoids 500 mg plus piperine (Bioperine) 5 mg daily (Sami Labs) for 8 weeks does not improve ejection fraction, serum levels of cardiac troponin 1, blood pressure, levels of fasting blood glucose, or kidney function parameters when compared to placebo. However, there were some modest benefits on levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, glycated hemoglobin, and certain liver enzymes such as aspartate aminotransferase (AST) and alkaline phosphatase (ALP) (107115). The validity of this study is limited by its short duration and relatively small sample size.\nless\nObesity. Oral turmeric might modestly improve weight loss, although any effect is unlikely to be clinically significant.\nMultiple meta-analyses of small, mostly low-quality clinical studies in adults with a variety of comorbid conditions show that taking various forms and doses of turmeric or curcumin results in an average weight loss of about 0.6-1 kg, a decrease in body mass index (BMI) of about 0.2-0.5 kg/m2, and a decrease in waist circumference of about 1.3 cm when compared with control (102345, 111351, 111352). A sub-analysis of dose and duration shows that a reduction in waist circumference only occurs with curcumin daily doses above 1000 mg, and duration of treatment longer than 8 weeks (102345).\nless\nOral submucous fibrosis. Small studies suggest that topical or oral curcumin might be beneficial for oral submucous fibrosis. However, the research is heterogenous with respect to outcomes, comparators, and the turmeric preparations, doses, and routes of administration utilized.\nA meta-analysis of 3 small clinical trials shows that turmeric modestly improves mouth opening when compared with control. In addition, a systematic review of 11 studies shows that turmeric improves overall symptoms, including mouth opening, tongue protrusion, burning sensation, and cheek flexibility. However, studies were small with short duration and used variable dosing strategies. Most trials have studied oral turmeric 300-400 mg, either alone or with black pepper 100 mg or piperine 5 mg, for 3-6 months. Less commonly, turmeric was provided in lozenge form (105399). Also, a network meta-analysis suggests that the turmeric constituent curcumin with or without piperine is most the effective for reducing tongue protrusion when compared indirectly with various medical and antioxidant therapies; however, this analysis suggests that curcumin does not rank among the most effective interventions for improving mouth opening, burning sensation, or cheek flexibility (113514).\n\nOther preliminary clinical research shows that taking a specific oral product containing curcumin 300 mg and piperine 5 mg (Turmix tablets, Sanat Products), three times daily for 12 weeks, improves mouth opening, burning sensation, and tongue protrusion when compared with baseline, but not when compared with an antioxidant product containing alpha-lipoic acid, beta-carotene, copper, lycopene, selenium, and zinc. Mouth opening is further improved by concurrent use of a mouthwash (Turmix mouthwash, Sanat Products), containing 0.1% w/v turmeric extract (standardized to 95% curcumin), with thymol, eucalyptol, clove oil, mentha oil, and tea tree oil, twice daily for 12 weeks (102347). A small clinical study shows that applying topical curcumin gel (Curenext, Abbott Laboratories) 5 mg daily in 3-4 divided doses for 6 weeks, in combination with oral physical therapy, improves mouth opening similarly to using an aloe vera gel in combination with oral physical therapy. However, decreases in burning sensation are greater with aloe gel than curcumin gel (104967). It is not clear whether the gels, oral physical therapy, or the combination of both is responsible for the outcome. Finally, clinical research shows that applying a paste providing turmeric and holy basil 10 grams each, mixed in 10 mL of honey, to the oral mucosa 4 times daily for 3 months modestly improves mouth opening, tongue protrusion, and burning sensation and reduces the presence of fibrous bands when compared with taking a vitamin B supplement. There was no effect on the shape of the uvula (113325).\nless\nPain (acute). Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with acute musculoskeletal pain shows that taking a specific combination product containing turmeric and Boswellia serrata extracts in black sesame oil (Rhuleave-K; Arjuna Natural Private Ltd.) 1000 mg daily for 7 days is as effective as acetaminophen 1000 mg daily for pain relief, onset of pain relief, and onset of maximal pain relief (109287). This study is limited by its lack of blinding and placebo control. Additionally, the dose of acetaminophen used in this study is below the standard recommended daily dose.\nless\nPeriodontitis. There is limited evidence on the oral or topical use of turmeric or its constituent curcumin in patients with periodontitis.\nA meta-analysis of heterogenous clinical studies in patients with chronic periodontitis suggests that use of local delivery gel products, usually turmeric 2% or a specific product containing curcumin (Curenext), modestly reduces pocket depth when compared with routine products, such as chlorhexidine. However, limited research suggests that curcumin products do not affect plaque or gingivitis measures, and curcumin irrigation does not affect pocket depth based on limited research (107108). A small preliminary clinical study in patients with severe chronic periodontitis shows that placing curcumin gel 2 mg on one side of the mouth along with scaling and root planing (SRP) reduces plaque and probing pocket depth, but not gingival index, when compared with SRP alone (101339).\n\nThe use of oral curcumin has also been investigated. A small clinical trial in patients with gingivitis and mild periodontitis shows that taking a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina) 80 mg daily after breakfast for 4 weeks reduces the severity of gingivitis and gingival bleeding, but not plaque, when compared with placebo (104146).\nless\nPhysical performance. It is unclear if oral turmeric may be beneficial for improving physical performance in older adults.\nA very small clinical study in moderately functioning, sedentary adults over age 65 with low-grade chronic inflammation shows that that taking a specific turmeric extract (Curcumin C3 Complex, Sabinsa Corporation) 500 mg twice daily for 12 weeks does not improve measures of physical function, walking speed, or muscle strength when compared with placebo (111357). However, this study may have been inadequately powered to detect any possible differences between groups.\nless\nPolycystic ovary syndrome (PCOS). Small clinical studies suggest that oral curcumin may improve some metabolic parameters in patients with PCOS, but these improvements may not be considered clinically significant.\nClinical research in patients with PCOS shows that taking curcumin 500 mg one to three times daily for 6-12 weeks improves some metabolic parameters (104968, 105394, 106795). Conversely, a small clinical study in patients aged 18 to 45 with PCOS in Iran shows that taking curcumin 1000 mg daily for 12 weeks modestly reduces fasting glucose but does not improve other metabolic parameters when compared with placebo. Taking curcumin also did not improve testosterone levels or hirsutism scores (111355). Meta-analyses show that taking curcumin modestly decreases body mass index (BMI) and improves measures of glycemic control, including fasting glucose and insulin resistance, and levels of total cholesterol when compared with placebo or metformin alone. However, effects on high-density lipoprotein (HDL) cholesterol levels were mixed and there was no effect on low-density lipoprotein (LDL) cholesterol or triglyceride levels (105394, 106795, 110219). Other preliminary clinical research shows that taking curcumin decreases plasma dehydroepiandrosterone and fasting plasma glucose levels when compared with placebo (104968).\n\nCurcumin has also been evaluated in combination therapy. Some clinical research in adults with PCOS also shows that taking nano-curcumin (SinaCurcumin, ExirNanoSina) 80-240 mg daily for 3 months in combination with metformin 1500 mg daily modestly improves some metabolic parameters including fasting insulin, insulin resistance, as well as HDL, LDL, total cholesterol, and triglycerides when compared with metformin alone or placebo alone (106060, 116944). Furthermore, combination therapy with metformin also showed slight improvements in fasting blood glucose and body weight when compared with placebo (116944). Clinical research in patients with PCOS shows that taking curcumin 500 mg one to three times daily for 6-12 weeks improves some metabolic parameters (104968, 105394, 106795). Conversely, a small clinical study in patients aged 18 to 45 with PCOS in Iran shows that taking curcumin 1000 mg daily for 12 weeks modestly reduces fasting glucose but does not improve other metabolic parameters when compared with placebo. Taking curcumin also did not improve testosterone levels or hirsutism scores (111355). Meta-analyses show that taking curcumin modestly decreases body mass index (BMI) and improves measures of glycemic control, including fasting glucose and insulin resistance, and levels of total cholesterol when compared with placebo or metformin alone. However, effects on high-density lipoprotein (HDL) cholesterol levels were mixed and there was no effect on low-density lipoprotein (LDL) cholesterol or triglyceride levels (105394, 106795, 110219). Other preliminary clinical research shows that taking curcumin decreases plasma dehydroepiandrosterone and fasting plasma glucose levels when compared with placebo (104968).\nless\nPostoperative pain. Small clinical studies suggest that oral curcumin, a constituent of turmeric, may modestly reduce pain in various postoperative recovery settings.\nOne small clinical study in patients undergoing laparoscopic cholecystectomy shows that taking curcumin 2 grams daily reduces postoperative pain, fatigue, and the need for analgesics by the second postoperative week when compared with placebo (81099). In patients undergoing surgery for inguinal hernia and/or hydrocele, taking curcumin 1.2 grams daily for 5 days reduces inflammation and tenderness by the sixth postoperative day when compared with placebo (81206). Curcumin was taken in 3-4 divided doses daily in these studies. Finally, taking a single dose of curcumin 200 mg after surgical removal of impacted third molars modestly reduces acute postoperative pain when compared with taking mefenamic acid 500 mg (99305).\nless\nPremenstrual syndrome (PMS). It is unclear if oral turmeric may be beneficial for improving symptoms of PMS.\nSome preliminary clinical research in patients with PMS shows that taking curcumin 100 mg twice daily, starting 7 days prior to menstruation and continuing for 3 days after menstruation, improves physical, behavioral, and mood symptoms, as well as overall severity of symptoms, when compared with placebo (97433). Conversely, in university students aged 18 to 24 in Iran with mild to severe PMS and primary dysmenorrhea, a clinical study shows that taking a specific combination product containing curcumin 500 mg plus extract from black pepper 5 mg (C3 Complex, Sami Labs) daily, starting 7 days prior to menstruation and continuing for 3 days after menstruation for 3 consecutive menstrual cycles, does not improve the severity of symptoms when compared with placebo (106805).\nless\nProstate cancer. It is unclear if oral turmeric is beneficial for the prevention or treatment of prostate cancer.\nOne small clinical study shows that taking curcumin 1.8 grams orally three times daily for 7 days, starting 4 days prior to docetaxel and prednisone treatment and continuing for up to 6 cycles, reduces PSA levels by at least half in 59% of patients when compared to baseline. Also, all patients with measurable lesions showed at least stable disease after treatment, and 40% of patients showed partial response when compared with baseline (96132). It is unclear if the addition of turmeric is beneficial when compared with docetaxel and prednisone alone. In contrast, an additional small clinical trial shows that taking curcumin 6 grams daily for 7 days every 3 weeks, starting four days before docetaxel, does not improve PSA levels or progression-free or overall survival when compared with docetaxel alone (105392).\nless\nPsoriasis. Evidence is limited to one small study of topical use in patients with scalp psoriasis.\nPreliminary clinical research in adults with scalp psoriasis shows that applying a tonic of turmeric to the scalp twice daily for 9 weeks modestly improves overall symptoms and quality of life when compared with a placebo tonic (97429).\nless\nQuality of life. Some preliminary clinical research suggests that oral curcumin might improve quality of life in patients with various chronic conditions.\nSmall or low-quality clinical trials in various patient populations show that taking curcumin improves at least some measures of quality of life when compared with placebo. Research has been conducted in patients with cancer, sulfur mustard-induced chronic pruritus, benign prostatic hyperplasia (BPH), or irritable bowel syndrome (IBS). Studies have evaluated curcumin 2250 mg once daily for 6 months, a specific combination product (C3 Complex, Sami Labs LTD) containing curcumin 500-1000 mg plus piperine (Bioperine) daily for 4-9 weeks, or a combination product (CU-FEO, Alfa Wasserman S.p.A.) containing curcumin 42 mg and fennel essential oil 25 mg per capsule twice daily for 60 days (81120, 81176, 97422, 106799, 107109, 107111). Also, in patients with scalp psoriasis, applying a tonic of turmeric to the scalp twice daily for 9 weeks modestly improves quality of life when compared with a placebo tonic (97429).\nless\nRadiation dermatitis. It is unclear if oral or topical turmeric is beneficial for reducing the severity of radiation dermatitis.\nA meta-analysis of 4 clinical studies in patients with breast cancer shows that taking curcumin 500-2000 mg three times daily for 3-7 weeks or applying curcumin gel 500 mg three times daily for 7 weeks reduces the radiation dermatitis severity score by about 0.5 points (on a 4-point scale) when compared with placebo or other control (111354). The validity of this analysis is limited by the heterogeneity of the included studies. However, a small clinical study in patients with breast cancer shows that taking nanocurcumin 80 mg twice daily during and for up to 2 weeks after treatment does not reduce skin reaction severity overall, but does modestly reduce pain, when compared with taking placebo. Also, there was a small reduction in skin reaction severity near the end of the study. All patients also used aloe vera leaf as part of the hospital protocol (109281). Another small preliminary clinical study in head and neck cancer patients shows that a specific cream (Vicco turmeric cream, Vicco Laboratories) containing turmeric and sandalwood oil, applied 5 times daily during radiation therapy, seems to reduce frequency and severity of radiation dermatitis when compared with baby oil (99307).\nless\nRadiation proctopathy. It is unclear if oral turmeric is beneficial for preventing proctitis or cystitis in patients receiving radiotherapy for prostate cancer.\nA small clinical study in patients with prostate cancer shows that taking a specific nanocurcumin product (SinaCurcumin, ExirNanoSina) 120 mg daily, for 3 days before and also during a course of radiotherapy, does not reduce the occurrence of proctitis or cystitis when compared with placebo (100259). This study may have been underpowered to detect small treatment effects.\nless\nRespiratory tract infections. Although there is interest in using oral turmeric for various respiratory tract infections, including bronchitis and the common cold, it has not been clinically evaluated.\nRheumatoid arthritis (RA). Small clinical studies suggest that oral curcumin, a constituent of turmeric, may modestly improve some symptoms of RA.\nMeta-analyses of small clinical trials in patients with RA show that taking curcumin alone or with other treatments modestly reduces overall RA symptoms, pain, and markers of inflammation when compared with control groups, including placebo or other treatments. However, some research shows that there is no beneficial effect on tender or swollen joint count from the limited available clinical research (109280, 111358), while other research shows that there is a benefit (112117). Clinical studies have evaluated curcumin 120-1200 mg daily for 2 weeks to 3 months (11149, 18205, 96129). The validity of these findings is limited by the small size of the studies, and in some cases, the lack of a comparator group.\nless\nSarcopenia. Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in elderly patients with sarcopenia shows that taking a specific slow-release product containing turmeric, protein, carbohydrate, and fiber (Cureit, Aurea Biolabs), 500 mg orally daily for 3 months, increases handgrip strength by about 1% and distance walked before feeling tired by about 6% when compared with placebo. It also increases weightlifting capacity by about 6% from baseline, compared with a 5% decrease from baseline in those taking placebo (104973). It is unclear whether these small changes are clinically meaningful.\nless\nSchizophrenia. Although there is interest in using oral turmeric for improving cognitive function in patients with schizophrenia, there is insufficient reliable information about the clinical effects of turmeric for this use.\nSepsis. It is unclear if oral curcumin, a constituent of turmeric, is beneficial in patients with sepsis.\nA small clinical trial in patients admitted to the intensive care unit (ICU) with sepsis shows that a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina), 80 mg dissolved in water and administered via gastric tube following lavage twice daily for 10 days does not affect length of ICU stay, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, blood pressure, or heart rate when compared with placebo (108873).\nless\nSmoking cessation. Oral turmeric has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized clinical study in adults with a history of smoking 5 or more cigarettes daily for at least 3 years shows that taking a specific combination product containing turmeric 50 mg, ashwagandha, Indian gooseberry, tribulus, bacopa, Albizia lebbeck, licorice, clove, ginger, cowhage, and holy basil (Smotect, Smotect India) daily for 3 months reduces the number of cigarettes smoked by approximately 3 per day when compared with placebo. This product also reduces levels of alveolar carbon monoxide and carboxyhemoglobin but does not improve lung capacity (112115). However, only data from patients who completed treatment were analyzed, which limits the validity of this study. It is unclear if these effects are due to turmeric, other ingredients, or the combination. A moderate-sized clinical study in adults with a history of smoking 5 or more cigarettes daily for at least 3 years shows that taking a specific combination product containing turmeric 100 mg, ashwagandha, Indian gooseberry, tribulus, bacopa, Albizia lebbeck, licorice, clove, ginger, cowhage, and holy basil (Smotect, Smotect India) twice daily for 3 months reduces the number of cigarettes smoked by approximately 3 per day when compared with placebo. This product also reduces levels of alveolar carbon monoxide and carboxyhemoglobin but does not improve lung capacity (112115). However, only data from patients who completed treatment were analyzed, which limits the validity of this study. It is unclear if these effects are due to turmeric, other ingredients, or the combination.\nless\nStress. It is unclear if oral turmeric is beneficial for reducing occupational stress in healthy adults.\nA small clinical trial in healthy adults with occupational stress-related anxiety and fatigue shows that taking a specific type of turmeric (CurQfen, Akay Flavours and Aromatics Pvt Ltd.) that contains fenugreek dietary fiber for improved bioavailability at a dose of 500 mg twice daily for 30 days reduces stress and fatigue and improves quality of life when compared with placebo, and also when compared with a standard curcumin supplement with lower bioavailability (99308).\nless\nStroke. It is unclear if oral turmeric is beneficial for stroke.\nA small clinical study conducted in Iran in adults with a recent ischemic stroke shows that taking curcumin 500 mg and piperine, a pepper constituent, 5 mg (Sami Lans, India) daily for 12 weeks reduces carotid intima-media thickness, triglycerides, total cholesterol, and systolic and diastolic blood pressure, but does not improve low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or quality-of-life indicators when compared with placebo (113601). The validity of this study is limited by the lack of statistical adjustment for multiple comparisons which can lead studies to erroneously show differences between treatment groups.\nless\nSystemic lupus erythematosus (SLE). There is limited evidence on the oral use of turmeric in adults with lupus nephritis.\nPreliminary clinical research in adults with lupus nephritis shows that taking turmeric 1.5 grams daily in three divided doses for 3 months reduces systolic blood pressure and improves kidney function when compared to baseline (81104). The validity of this finding is limited by the lack of a comparator group.\nless\nTuberculosis. It is unclear if oral turmeric is beneficial in patients receiving treatment for tuberculosis.\nA small clinical study in adults receiving antituberculosis treatment shows that taking a formulation containing turmeric 0.5 grams and Tinospora cordifolia 0.5 grams twice daily for 4 months can reduce levels of Mycobacterium tuberculosis in the sputum and improve lesion healing when compared with antituberculosis treatment alone. Also, liver toxicity associated with the antituberculosis treatment seems to be reduced when administered with this formulation (80424). It is unclear if these effects are due to turmeric, Tinospora cordifolia, or the combination.\nless\nUlcerative colitis. It is unclear if oral or rectal turmeric, or its constituent, curcumin, is beneficial in adults with ulcerative colitis.\nAlthough two small clinical studies in adults with ulcerative colitis show that taking oral turmeric extract 2-3 grams daily for 1-6 months improves the rate of remission and reduces relapse rate (79966, 97423), a meta-analysis of these studies and one additional clinical study shows that turmeric does not improve remission rates when compared with placebo (99000). A specific product (Cur-Cure, Bara Herbs Inc) was used in some of these studies. Reasons for the conflicting findings are unclear, but may be due to small patient populations, concerns about blinding, and the inclusion of patients who were also taking immunomodulating drugs. It may also be due to differences in how a study measures remission. A meta-analysis of small clinical studies in patients with mild to moderate ulcerative colitis shows that adding oral curcumin 0.5-3 grams daily to standard treatment for 1-6 months may improve clinical remission rates, but not endoscopic remission rates, when compared with placebo (108872). However, the validity of this finding is limited by the small number of studies that evaluated endoscopic remission.\n\nA small clinical study shows that administering an enema form of turmeric extract (NCB-02, Himalaya Drug Company) as 20 mL, containing turmeric extract 140 mg, daily for 8 weeks increases response rate from 50% to about 93% and increases remission rate from about 31% to 71% when compared with placebo in patients with active ulcerative colitis. However, patients using the turmeric extract enema for shorter durations did not improve when compared with placebo (89729). Turmeric has also been investigated in combination with the Mediterranean diet. A small clinical trial shows that taking curcumin (VeNatura Curcumin Supplement) 800 mg twice daily while following the Mediterranean diet for 8 weeks is no more effective for improving ulcerative colitis symptom severity than following the Mediterranean diet without supplemental curcumin (113339).\nless\nUveitis. It is unclear if oral curcumin is beneficial for uveitis.\nObservational research in patients with acute non-infectious uveitic macular edema shows that taking a specific hydrophilic curcumin product (Cucrcuwin, Diabec, Alfa Intes) 60 mg twice daily for 6 months, in conjunction with standard corticosteroid treatment, and then alone for an additional 6 months, modestly improves best corrected visual acuity, but not macular thickness or intraocular pressure, when compared with standard treatment alone for 6 months (107110).\nless\nWound healing. Although there is interest in using topical turmeric for wound healing, there is insufficient reliable information about the clinical effects of turmeric for this condition.\nChemotherapy-induced constipation. It is unclear if oral curcumin reduces symptoms of chemotherapy-induced constipation.\nA small clinical study in patients with various forms of cancer receiving standard chemotherapy for that cancer type shows that taking curcuminoids (C3 Complex, Sami Labs) 500 mg with piperine (Bioperine) 5 mg twice daily for 9 weeks does not reduce symptoms of constipation when compared with placebo (107111).\nless\nMore evidence is needed to rate turmeric for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTurmeric extract has most often been used in doses of 1.5 grams daily for up to 3 months. Turmeric extract has also been used in doses of up to 6 grams daily for a shorter duration of up to 12 days. See Effectiveness section for condition-specific information.\n\nTurmeric extract is typically standardized to curcuminoid content, with concentrations ranging from 75% to nearly 100% (81109, 89719, 89720, 89721, 89728, 89729, 97426, 99311). Many commercial products also contain piperine, an active constituent of pepper, to improve turmeric bioavailability. This ingredient may or may not be listed on the label (97426).\nTopical:\nTurmeric has been used in various topical formulations, including as a mouthwash, gel, cream, and tonic. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nAn evaluation of randomly selected turmeric products available in the United States found that turmeric root products contain 2.5-fold higher concentrations of lead than turmeric-derived curcuminoid extracts (97426).\n\nA specific turmeric extract (NCB-02, Himalaya Drug Company), which has been used in an enema, is standardized to 72% curcumin, 18.08% demethoxycurcumin, and 9.42% bisdemethoxycurcumin (89729).\n\nA specific turmeric extract (Acumin, Aurea Biolabs Ltd) based on a natural turmeric matrix contains 50% curcuminoids by weight (96129).\n\nAnother turmeric extract (C3 complex, Sami Labs LTD), which has been used orally, is standardized to 95% curcuminoids comprised of 70-80% curcumin, 15-25% demethoxycurcumin, and 2.5-6.5% bisdemethoxycurcumin (81109).\n\nA specific turmeric extract (Meriva, Indena), marketed as a phytosomal formulation, is standardized to contain 20% curcuminoids (providing 75% curcumin) complexed with soy phosphatidylcholine in a 1:2 weight ratio (17953, 80988, 97431, 106062).\n\nAnother specific turmeric extract (BCM-95, Arjuna Natural Extracts) has been standardized to contain 86% to 91% total curcuminoids and 7% to 8% turmeric oils (89719, 89728, 96127, 96130, 105398). This extract is used in two products used in clinical research (Curamin and CuraMed). CuraMed contains 552-578 mg of BCM-95 providing 500 mg curcuminoids, 376 mg of curcumin, 124 mg demethoxycurcumin and bisdemethoxycurcumin, and 49-52 mg volatile oil. Curamin contains 350 mg BCM-95, as well as 150 mg boswellia extract, 75% boswellic acids and 10% 3-O-acetyl-11-keto-boswellic acid (AKBA) (96127). This extract has also been used in another product (Biocurcumax) (96130).\n\nA specific turmeric extract containing curcumin-galactomannoside complex (CurQfen, standardized to contain not less than 35% of curcuminoids) 500 mg has been used (99308, 106804).\n\nFinally, a specific turmeric rhizome extract (Turmacin, Natural Remedies Pvt. Ltd.) is standardized to contain 12.6% polysaccharides (89721).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nALKYLATING AGENTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTurmeric has antioxidant effects. Theoretically, this may reduce the activity of chemotherapy drugs that generate free radicals. However, research is conflicting.\nIn vitro research suggests that curcumin, a constituent of turmeric, inhibits mechlorethamine-induced apoptosis of breast cancer cells by up to 70%. Also, animal research shows that curcumin inhibits cyclophosphamide-induced tumor regression (96126). However, some in vitro research shows that curcumin does not affect the apoptosis capacity of etoposide. Also, other laboratory research suggests that curcumin might augment the cytotoxic effects of alkylating agents. Reasons for the discrepancies may relate to the dose of curcumin and the specific chemotherapeutic agent. Lower doses of curcumin might have antioxidant effects while higher doses might have pro-oxidant effects (96125). More evidence is needed to determine what effect, if any, turmeric might have on alkylating agents.\nless\nAMLODIPINE (Norvasc)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTaking turmeric with amlodipine may increase levels of amlodipine.\nAnimal research shows that giving amlodipine 1 mg/kg as a single dose following the use of turmeric extract 200 mg/kg daily for 2 weeks increases the maximum concentration and area under the curve by 53% and 56%, respectively, when compared with amlodipine alone (107113). Additional animal research shows that taking amlodipine 1 mg/kg with a curcumin 2 mg/kg pretreatment for 10 days increases the maximum concentration and area under the curve by about 2-fold when compared with amlodipine alone (103099).\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTurmeric may have antiplatelet effects and may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs. However, research is conflicting.\nCurcumin, a constituent of turmeric, has demonstrated antiplatelet effects in vitro (11143, 81204, 81271). Furthermore, two case reports have found that taking turmeric along with warfarin or fluindione was associated with an increased international normalized ratio (INR) (89718, 100906). However, one clinical study in healthy volunteers shows that taking curcumin 500 mg daily for 3 weeks, alone or with aspirin 100 mg, does not increase antiplatelet effects or bleeding risk (96137). It is possible that the dose of turmeric used in this study was too low to produce a notable effect.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, taking turmeric with antidiabetes drugs might increase the risk of hypoglycemia.\nAnimal research and case reports suggest that curcumin, a turmeric constituent, can reduce blood glucose levels in patients with diabetes (79692, 79984, 80155, 80313, 80315, 80476, 80553, 81048, 81219). Furthermore, clinical research in adults with type 2 diabetes shows that taking curcumin 475 mg daily for 10 days prior to taking glyburide 5 mg decreased postprandial glucose levels for up to 24 hours when compared with glyburide alone, despite the lack of a significant pharmacokinetic interaction (96133). Other clinical studies in patients with diabetes show that taking curcumin daily can reduce blood glucose levels when compared with placebo (104149, 114898, 114900).\nless\nANTITUMOR ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTurmeric has antioxidant effects. Theoretically, this may reduce the activity of chemotherapy drugs that generate free radicals. However, research is conflicting.\nIn vitro and animal research shows that curcumin, a constituent of turmeric, inhibits doxorubicin-induced apoptosis of breast cancer cells by up to 65% (96126). However, curcumin does not seem to affect the apoptosis capacity of daunorubicin. In fact, some research shows that curcumin might augment the cytotoxic effects of antitumor antibiotics, increasing their effectiveness. Reasons for the discrepancies may relate to the dose of curcumin and the chemotherapeutic agent. Lower doses of curcumin might have antioxidant effects while higher doses might have pro-oxidant effects (96125). More evidence is needed to determine what effects, if any, antioxidants such as turmeric have on antitumor antibiotics.\nless\nCYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase or decrease levels of drugs metabolized by CYP1A1. However, research is conflicting.\nMost in vitro and animal research suggests that the turmeric constituent, curcumin, INHIBITS CYP1A1, primarily in the liver (15823, 21495, 80876, 81411). However, some evidence from in vitro research suggests that curcumin may INDUCE CYP1A1 in the intestines (21500).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase levels of drugs metabolized by CYP1A2. However, research is conflicting.\nIn vitro and animal research show that the turmeric constituent, curcumin, inhibits CYP1A2 (15823, 21497, 81304). However, other in vitro research suggests that curcumin does not significantly affect CYP1A2 (22000).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTurmeric might increase or decrease levels of drugs metabolized by CYP3A4.\nIn vitro and animal research show that turmeric and its constituents curcumin and curcuminoids inhibit CYP3A4 (21497, 21498, 21499). Also, 8 case reports from the World Health Organization (WHO) adverse drug reaction database describe increased toxicity in patients taking turmeric and cancer medications that are CYP3A4 substrates, including everolimus, ruxolitinib, ibrutinib, and palbociclib, and bortezomib (111644). In another case report, a transplant patient presented with acute nephrotoxicity and elevated tacrolimus levels after consuming turmeric powder at a dose of 15 or more spoonfuls daily for ten days prior. It was thought that turmeric increased levels of tacrolimus due to CYP3A4 inhibition (93544).\n\nConversely, other in vitro research suggests that turmeric induces CYP3A4 activity, leading to reduced levels of CYP3A4 substrates (111404). An animal model suggests that induction of CYP3A4 occurs after daily curcumin use for 1 week (116945). However, the induction of CYP3A4 by turmeric has not been reported in humans.\nless\nDOCETAXEL (Taxotere)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase blood levels of oral docetaxel.\nAnimal research suggests that the turmeric constituent, curcumin, enhances the oral bioavailability of docetaxel (80999). However, the significance of this interaction is unclear, as this drug is typically administered intravenously in clinical settings.\nless\nESTROGENS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, large amounts of turmeric might interfere with hormone replacement therapy through competition for estrogen receptors.\nIn vitro research shows that curcumin, a constituent of turmeric, displaces the binding of estrogen to its receptors (21486).\nless\nGLYBURIDE (Diabeta, others)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, taking turmeric and glyburide in combination might increase the risk of hypoglycemia.\nClinical research shows that taking curcumin 475 mg daily for 10 days prior to taking glyburide 5 mg increases blood levels of glyburide by 12% at 2 hours after the dose in patients with type 2 diabetes. While maximal blood concentrations of glyburide were not affected, turmeric modestly decreased postprandial glucose levels for up to 24 hours when compared to glyburide alone, possibly due to the hypoglycemic effect of turmeric demonstrated in animal research (96133).\nless\nHEPATOTOXIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, turmeric might increase the risk of liver damage when taken with hepatotoxic drugs.\nThere is concern that turmeric might cause hepatotoxicity, especially when highly bioavailable formulations are used in high doses (103633, 107122, 109288, 110221).\nless\nLOSARTAN (Cozaar)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase the effects of losartan.\nResearch in hypertensive rats shows that taking turmeric can increase the hypotensive effects of losartan (110897).\nless\nMETHOTREXATE (Trexall, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, turmeric might have additive effects when used with hepatotoxic drugs such as methotrexate.\nIn one case report, a 39-year-old female taking methotrexate, turmeric, and linseed oil developed hepatotoxicity (111644).\nless\nNORFLOXACIN (Noroxin)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase the effects and adverse effects of norfloxacin.\nAnimal research shows that taking curcumin, a turmeric constituent, can increase blood levels of orally administered norfloxacin (80863).\nless\nORGANIC ANION-TRANSPORTING POLYPEPTIDE SUBSTRATES (OATP)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase blood levels of OATP4C1 substrates.\nIn vitro research shows that the turmeric constituent curcumin competitively inhibits OATP4C1 transport. This transporter is expressed in the kidney and facilitates the renal excretion of certain drugs (113337). Theoretically, taking turmeric might decrease renal excretion of OATP substrates.\nless\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase the absorption of P-glycoprotein substrates.\nIn vitro and animal research shows that curcuminoids and other constituents found in turmeric can inhibit P-glycoprotein expression and activity (21472, 21473, 21474, 21475, 21476, 21477, 21478, 21479, 21480)(21482, 21484, 111644).\nless\nPACLITAXEL (Abraxane, Onxol)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might alter blood levels of paclitaxel, although any effect may not be clinically relevant.\nClinical research in adults with breast cancer receiving intravenous paclitaxel suggests that taking turmeric may modestly alter paclitaxel pharmacokinetics. Patients received paclitaxel on day 1, followed by either no treatment or turmeric 2 grams daily from days 2-22. Pharmacokinetic modeling suggests that turmeric reduces the maximum concentration and area under the curve of paclitaxel by 12.1% and 7.7%, respectively. However, these changes are not likely to be considered clinically relevant (108876). Conversely, animal research suggests that curcumin, a constituent of turmeric, enhances the oral bioavailability of paclitaxel (22005). However, the significance of this interaction is unclear, as this drug is typically administered intravenously in clinical settings.\nless\nSULFASALAZINE (Azulfidine)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTurmeric might increase the effects and adverse effects of sulfasalazine.\nClinical research shows that taking the turmeric constituent, curcumin, can increase blood levels of sulfasalazine by 3.2-fold (81131).\nless\nTACROLIMUS (Prograf)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTurmeric might increase the effects and adverse effects of tacrolimus.\nIn one case report, a transplant patient presented with acute nephrotoxicity and elevated tacrolimus levels of 29 ng/mL. The patient previously had tacrolimus levels within the therapeutic range at 9.7 ng/mL. Ten days prior to presenting at the emergency room the patient started consumption of turmeric powder at a dose of 15 or more spoonfuls daily. It was thought that turmeric increased levels of tacrolimus due to cytochrome P450 3A4 (CYP3A4) inhibition (93544). In vitro and animal research show that turmeric and its constituent curcumin inhibit CYP3A4 (21497, 21498, 21499).\nless\nTALINOLOL\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTurmeric may reduce the absorption of talinolol in some situations.\nClinical research shows that taking curcumin for 6 days decreases the bioavailability of talinolol when taken together on the seventh day (80079). The clinical significance of this effect is unclear.\nless\nTAMOXIFEN (Nolvadex)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, turmeric might reduce the levels and clinical effects of tamoxifen.\nIn a small clinical trial in patients with breast cancer taking tamoxifen 20-30 mg daily, adding curcumin 1200 mg plus piperine 10 mg three times daily reduces the 24-hour area under the curve of tamoxifen and the active metabolite endoxifen by 12.8% and 12.4%, respectively, as well as the maximum concentrations of tamoxifen, when compared with tamoxifen alone. However, in the absence of piperine, the area under the curve for endoxifen and the maximum concentration of tamoxifen were not significantly reduced. Effects were most pronounced in patients who were extensive cytochrome P450 (CYP) 2D6 metabolizers (107123).\nless\nTOPOISOMERASE I INHIBITORS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTurmeric has antioxidant effects. There is some concern that this may reduce the activity of chemotherapy drugs that generate free radicals. However, research is conflicting.\nIn vitro research shows that curcumin, a constituent of turmeric, inhibits camptothecin-induced apoptosis of breast cancer cells by up to 71% (96126). However, other in vitro research shows that curcumin augments the cytotoxic effects of camptothecin. Reasons for the discrepancies may relate to the dose of curcumin and the chemotherapeutic agents. Lower doses of curcumin might have antioxidant effects while higher doses might have pro-oxidant effects (96125). More evidence is needed to determine what effect, if any, turmeric might have.\nless\nTRAMADOL (Ultram)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, turmeric might increase or decrease levels of tramadol.\nAnimal research suggests that a single dose of curcumin, a constituent of turmeric, may increase tramadol's maximum concentration (Cmax) by inhibiting metabolism, while continued daily use for 7 days may reduce the area under the curve (AUC) due to the induction of drug-metabolizing enzymes such as cytochrome P450 3A4 (CYP3A4) (116945). However, this interaction has not been reported in humans.\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTurmeric might increase the risk of bleeding with warfarin.\nOne case of increased international normalized ratio (INR) has been reported for a patient taking warfarin who began taking turmeric. Prior to taking turmeric, the patient had stable INR measurements. Within a few weeks of starting turmeric supplementation, the patient's INR increased to 10 (100906). Additionally, curcumin, the active constituent in turmeric, has demonstrated antiplatelet effects in vitro (11143, 81204, 81271), which may produce additive effects when taken with warfarin.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, turmeric might have antiplatelet effects.\nTaking turmeric with other products that increase the risk of bleeding might have additive effects (11143, 81204, 81217, 81271). In vitro and animal research shows that turmeric might affect platelet aggregation. See other products with anticoagulant activity here.\nless\nHEPATOTOXIC HERBS AND SUPPLEMENTS\nTheoretically, large doses of turmeric might increase the risk for hepatotoxicity.\nTaking turmeric with other products that might cause liver damage could potentially increase the risk for liver damage, especially when highly bioavailable formulations are used in high doses (103633, 107122, 109288, 110221, 111644). See other products with hepatotoxic potential here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, turmeric might have hypoglycemic effects.\nTaking turmeric with other products with hypoglycemic potential might increase the risk of hypoglycemia. The turmeric constituent, curcumin, might reduce blood glucose levels in patients with diabetes (79692, 79984, 80313, 80315, 80476, 80553, 81219, 80155, 81048, 96133, 104149, 114898, 114900). See other products with hypoglycemic potential here.\nless\nIRON\nThere is some concern that turmeric or curcumin supplements may decrease the absorption of iron; however, this interaction may not be clinically relevant.\nIn vitro and animal research suggests that turmeric and its constituent, curcumin, may bind with iron and prevent its absorption (21467, 21468, 21469, 21470). However, this does not appear to occur in humans when turmeric is used at levels commonly found in the diet (21471). This effect also has not been observed in a clinical trial in healthy patients receiving supplementation with both curcumin and ferrous sulfate (106798).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBILE DUCT OBSTRUCTION AND GALLSTONES\nTurmeric can cause gallbladder contractions (11145). Use with caution in patients with gallstones or gallbladder disease.\nless\nBLEEDING DISORDERS\nTurmeric has been reported to have antiplatelet effects (11143, 81204, 81217, 81271). Theoretically, taking turmeric might increase the risk of bleeding and bruising in individuals with bleeding disorders.\nless\nHORMONE SENSITIVE CANCERS/CONDITIONS\nTurmeric might have mild estrogenic effects, which could theoretically exacerbate hormone-sensitive conditions. However, research is conflicting. Some in vitro evidence suggests that curcumin, a constituent of turmeric, competitively inhibits the binding of 3H-estradiol or beta-galactosidase with the estrogen receptor (21486, 26203, 26204). Other in vitro research suggests that curcumin might have beneficial anticancer effects against hormone-sensitive cancers (26205, 26206).\nless\nINFERTILITY\nTheoretically, turmeric might have antifertility effects; until more is known, use with caution in patients trying to conceive. In vitro and animal research suggests that oral curcumin can reduce fertility, decrease sperm motility and density, cause degenerative changes in the seminiferous tubules, and reduce production of testosterone in adult Leydig cells (79404, 80650, 80944, 81069).\nless\nLIVER DISEASE\nTheoretically, turmeric might have hepatotoxic effects; especially when highly bioavailable formulations are used in high doses. Until more is known, avoid use in patients with cholestasis or hepatitis (103633). There have been at least 70 reports of liver damage associated with the use of turmeric supplements (99304, 102346, 103094, 103631, 103633, 103634, 107122, 109288, 110221, 111644).\nless\nPERIOPERATIVE\nTurmeric has antiplatelet and hypoglycemic effects, which might cause excessive bleeding or interfere with blood glucose control if used perioperatively (11143, 81204, 81217, 81271, 106793). Tell patients to discontinue turmeric at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with turmeric.",
            "Pharmacokinetics": "Absorption\nIn humans, the oral bioavailability of curcumin is very low (10453, 18204, 79562, 80364). The average peak serum concentrations after taking curcumin 4 grams, 6 grams, and 8 grams were 0.51 mcM, 0.63 mcM, and 1.77 mcM, respectively (79085).\n\nCurcumin absorption appears to increase when taken with food (17096) or piperine (the active ingredient in black or white pepper) (81400, 104965), or when taken in a capsule (81136), in a liposomal formulation (80922, 102345, 104965), in a nanoparticle powder (102345, 102349, 113345), in a phospholipid complex (102345), as part of a novel turmeric matrix system (96129), or as a water-dispersible turmeric extract (106064). Despite suggestions that bromelain may enhance turmeric absorption, there is no supportive evidence.\n\nSpecific oral formulations of turmeric have demonstrated increased absorption. Absorption of curcumin from BCM-95 (Biocurcumax) is 5- to 7-fold higher than plain curcumin; elevated levels last over 8 hours with BCM-95, compared to 4-5 hours with plain curcumin (81460). Theracurmin, a nanoparticle water-dispersible formulation, produces a 27-fold higher area under the curve than plain curcumin powder, with a half-life of 13 hours (81092, 97424). When taken daily for 18 months, random blood levels of curcumin ranged between 3-67.3 ng/mL (96161). TurmXtra 60N, a water-dispersible turmeric extract containing 60% curcuminoids, results in increased curcumin absorption when compared to a standard extract. Taking TurmXtra at a dose providing curcumin at 10% of the levels of a standard extract results in similar peak and mean plasma levels of total curcuminoids and approximately doubles peak levels of total curcumin (106064).\n\nTopically, curcumin is detected in the deeper layers of skin, as well as in hair follicles, after application of a water microemulsion of turmeric (80094).\nMetabolism\nCurcumin undergoes significant metabolism in the liver and intestines, contributing to low oral bioavailability (102349). In humans, curcumin is present in the plasma as glucuronide and sulfate conjugates (10453, 18204, 79522, 80364). The half-lives of these conjugates are 6-24 hours (18204).\nExcretion\nIn humans, curcumin is present in the feces following consumption of an extract (10453). In some studies, curcumin was undetectable in the urine following oral intake (79085); however, other studies detected curcumin and its conjugates in the urine (79522, 79598, 79630, 80506).",
            "Mechanism of Action": "General\nThe applicable part of turmeric is the rhizome or roots. Turmeric's major active constituents are the curcuminoids (80713, 80809), which include the polyphenol curcumin (diferuloylmethane) (80405, 80434, 80599, 80642, 80691, 102345), demethoxycurcumin (80405, 80434, 80599, 80642, 80691), bisdemethoxycurcumin (80405, 80434, 80599, 80642, 80691), calebin, and other diarylheptanoids (79809). Turmeric rhizomes or roots also contain tumerin, tumerones (78963, 79338, 79465, 79924, 80125, 102350) and turmeronols (102350), and sesquiterpenes (79124, 79924, 80095, 80125, 80454). Other constituents of turmeric include minerals such as iron and potassium (79427, 80521); fatty acids, such as oleic acid, linoleic acid, and linolenic acid (49742); and the polysaccharides ukonans A-D (79468, 79587, 81186).\nAnalgesic effects\nOrally, turmeric and its constituent curcumin have been shown to reduce pain, particularly the late phase of pain, in animal models (80451, 80511). Although the exact mechanism of action is not clear, some evidence from in vitro research suggests that curcumin can inhibit transient receptor potential vanilloid 1 (TRPV1)-mediated pain hypersensitivity (80898).\nAnti-allergy effects\nHuman research suggests that treatment with curcumin decreases the production of inflammatory cytokines and prostaglandins from monocytes and neutrophils (96138).\nAnti-Alzheimer effects\nThere is preliminary evidence that curcumin might have activity in Alzheimer disease. In middle-aged and elderly adults, taking curcumin prevents measures of amyloid and/or tau accumulation in the amygdala and hypothalamus (96161). In animal models, curcumin caused disaggregation of amyloid beta, and decreased brain amyloid, plaque, and oxidized protein levels (17096, 79074, 79941, 80080, 80534). In vitro evidence suggests that curcumin reduces beta-amyloid production by inhibiting the upregulation of beta-site APP-cleaving enzyme-1 (BACE-1), which is the rate-limiting enzyme for beta-amyloid production (80368, 80409). Other in vitro research suggests that curcuminoids increase the clearance of amyloid beta from mononuclear cells and enhance the uptake of amyloid beta by macrophages from patients with Alzheimer disease (79941, 80144, 80520). In addition to reducing the production and increasing the clearance of amyloid beta, in vitro and animal research also suggest that curcuminoids from turmeric protect against impairment by, or toxicity of, amyloid protein (79023, 79096, 79179, 80913, 81030).\n\nEvidence from animal research also suggests that curcuminoids have acetylcholinesterase (AChE) inhibitory activities (80469, 80971).\nAnti-arthritic effects\nIn human research, some research has found that curcumin inhibits levels of inflammatory markers associated with arthritis, including C-reactive protein, rheumatoid factor, tumor necrosis factor (TNF)-alpha, and/or the erythrocyte sedimentation rate (96129, 110222). It also has antioxidant effects (110222) and may inhibit interleukin 1-beta (IL-1-beta) stimulated inflammatory and catabolic mediators, including prostaglandin E2, IL-6, IL-8, and nitric oxide (102349, 110222). Animal models suggest that turmeric extract reduces arthritis-associated joint inflammation by inhibiting NF-kB activation (79961). Curcumin also seems to suppress the production of matrix metalloproteinases, which are involved in cartilage degradation (79010, 80787, 102349). It also has a protective effect against degradation and the catabolic function of IL-1-beta, lipopolysaccharides, and tumor necrosis factor-alpha in chondrocytes and cartilage (102349). Curcumin also stimulates matrix regeneration by restoring synthesis of collagen type II and glycosaminoglycan (102349). In vitro evidence suggests that turmeric rhizome extract inhibits the growth and promotes apoptosis in synovial fibroblasts, which are generally characterized by hyperplasia in patients with rheumatoid arthritis (80153). Also, in vitro evidence suggests that curcumin inhibits the cytokine macrophage migration inhibitory factor (MIF), which is involved in rheumatoid arthritis pathogenesis (70963).\nAnti-gingivitis effects\nPreliminary clinical research suggests that turmeric-containing mouthwashes may help reduce gingivitis severity in patients with this condition (81127, 89723). Potential mechanisms of action may include a reduction of the inflammatory cell infiltrate and increased collagen content and fibroblastic cell numbers (81062), inhibition of tumor necrosis factor-alpha and interleukin-1beta gene expression induced by a specific periodontopathic bacterium (80466), and inhibition of nicotine-induced ERK expression, which is involved in periodontal disease (79576).\nAnti-inflammatory effects\nCurcumin seems to have anti-inflammatory activity, possibly by inhibiting cyclooxygenase-2 (COX-2), prostaglandins, leukotrienes, and other cytokines involved in pro-inflammatory signaling pathways (11138, 11139, 11140, 12482, 18205, 79251, 79661, 80480, 81203, 96139)(102347, 107116). Curcumin also seems to inhibit inflammatory enzymes such as collagenase, elastase, and hyaluronidase (79251). Additionally, clinical research in mixed populations, including healthy adults as well as patients with a variety of comorbidities or autoimmune disorders, shows that turmeric or curcumin reduces the inflammatory markers interleukin (IL)-6, C-reactive protein (CRP), high-sensitivity (hs)-CRP, and erythrocyte sedimentation rate (ESR). However, the effect of turmeric or curcumin on IL-1 beta or tumor necrosis factor (TNF)-alpha is inconsistent (100260, 106793, 106794, 106795, 106804, 107109, 107116, 107119, 108873, 108875)(110218, 110219, 111353, 114898, 114899, 114900, 114903). Other research in humans has found no effect of curcumin on these or other inflammatory mediators (105396, 107109, 107117, 107119).\nAnti-lithogenic effects\nIn humans, curcumin can induce gallbladder contractions (11145, 78882). Theoretically, this may prevent gallstone production, as shown in animal models (79339, 81094).\nAnticancer effects\nTurmeric exhibits chemopreventive and growth inhibitory activity against several tumor cell lines (79042, 79580, 79689, 81110, 81209, 81273, 81331, 81349, 81350, 81440). It seems to induce apoptosis in cancer cells, possibly by upregulating p53 expression, and may inhibit angiogenesis (11141, 11142, 12482, 81065). Curcumin might reduce activity of procarcinogenic eicosanoids, such as prostaglandin-E2 and 5-hydroxyeicosatetraenoic acid (5-HETE), via inhibition of cyclooxygenases and 5-lipoxygenase (18204, 80504, 80834, 80917). Preliminary evidence suggests curcumin can also reduce precancerous rectal aberrant crypt foci (18204, 81294). Some laboratory evidence suggests that curcumin can inhibit the cellular pathways leading to tumor metastasis, invasion, and angiogenesis (96132).\n\nTurmeric may also reduce the carcinogenic effect of other drugs or chemicals. In animal models, benzo(a)pyrene-related CYP1A1 and CYP1A2 induction is normalized by a 1% turmeric diet, suggesting that turmeric might inhibit activation of carcinogens that are metabolized by CYP enzymes (15823, 15824). The turmeric diet also appears to increase glutathione S-transferase (GST) activity in some tissues (15823).\nAntidepressant effects\nIn humans, the antidepressant effects of curcumin were related to decreased levels of inflammatory cytokines and increased levels of serotonin and brain-derived neurotrophic factor (BDNF). Decreased cortisol levels also suggest the role of the hypothalamic pituitary adrenal axis in the anti-depressant effects of curcumin (96139, 114898). Evidence from in vitro and animal research suggests that the antidepressant effects of turmeric extract stem from its ability to inhibit monoamine oxidase (MAO) A and possibly MAO B, which leads to increased levels of serotonin, dopamine, and noradrenaline (79192, 79652, 79707, 80432). The turmeric constituent curcumin also appears to increase adenylyl cyclase activity and cyclic adenosine monophosphate (cAMP) concentration, which has been associated with antidepressant effects (80607).\nAntidiabetic effects\nEvidence from animal and clinical research suggests that turmeric and its constituents reduce levels of glucose and HbA1c (79114, 79591, 79692, 79970, 79984, 80785, 114898, 114900) and elevate plasma insulin levels (80785, 81048), which may improve blood glucose control in diabetics.\n\nEvidence from animal models suggests that turmeric may reduce diabetic neuropathic pain by inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) (79842). In addition to reducing diabetic neuropathic pain, turmeric may also prevent the development of diabetes-associated neuronal damage. Animal models suggest that turmeric may reduce neuronal damage associated with diabetes by reducing the expression of cerebellar proteins associated with cholinergic and insulin receptor activity, as well as glucose transport (80810). Curcuminoids from turmeric also appear to reduce diabetes-associated neuronal injury via antioxidant effects (80493).\n\nAnimal models suggest that curcumin may protect against the development of diabetic nephropathy by decreasing dephosphorylation and increasing acetylation of histone H3 and attenuating the increased expression of HSP-27 and MAP kinase p38 in the diabetic kidney (80249). Curcumin may also prevent diabetes-associated kidney dysfunction by inhibiting the histone acetyltransferase p300 and nuclear factor-kappaB (NF-kB) (80594, 80742).\n\nAnimal models suggest that curcumin may help prevent the development of diabetic retinopathy by inhibiting diabetes-induced increases in interleukin-1beta, vascular endothelial growth factor (VEGF), and NF-kB levels in the retina (80071, 80147).\n\nA meta-analysis of clinical studies in patients with type 2 diabetes, migraine, metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), or kidney failure shows that nanocurcumin supplementation improves fasting blood glucose levels, but not glycated hemoglobin (HbA1c), regardless of baseline fasting blood glucose levels, trial duration, or body weight. Fasting insulin levels and insulin resistance also are improved (106793).\nAntimicrobial effects\nTurmeric or its curcuminoid constituents seem to have activity against some bacteria, including Eschericia coli, Yersinia enterocolitica, Staphylococcus aureus, Bacillus subtilis, Bacillus cereus, Helicobacter pylori, Mycobacterium tuberculosis, and Neisseria gonorrhoeae (36131, 39892, 43458, 51912, 80183, 80481, 80569, 80798). Some in vitro evidence suggests that the antibacterial action of curcumin against E. coli results from curcumin's inhibition of enoyl-ACP reductase from E. coli (80871). Other in vitro evidence suggests that curcumin inhibits the bacterial cell proliferation of Bacillus subtilis by inhibiting the assembly of FtsZ (80192). Additional in vitro evidence shows that turmeric constituents inhibit sortase A from Staphylococcus aureus cells, which prevents these cells from adhering to fibronectin; this may reduce S. aureus invasion of endothelial cells (79742). Other in vitro research shows that curcumin inhibits Ikappa B kinase-alpha and -beta and NF-kappaB-inducing kinase in Neisseria gonorrhoeae cells, which prevents the bacteria from adhering to mucosal epithelial cells (79637).\n\nTurmeric also appears to have activity against human immunodeficiency virus (HIV) (11140, 79359), hepatitis C (80886), hepatitis B (79694, 80644), herpes simplex (78899, 80244), and Epstein-Barr (79116, 81376) viruses. Also, animal models show that curcumin may have activity against the protozoan Leishmania amazonensis (11140, 79309), Toxoplasma gondii (80570), Schistosomiasis mansoni (80586), Giardia lamblia (79865), and Plasmodium (79980, 80619, 81011). In vitro evidence suggests that curcumin has antiparasitic activity against Cryptosporidium parvum (80706).\nAntioxidant effects\nPreliminary research suggests that turmeric and its constituent curcumin might have antioxidant effects (11140, 11147). Both turmeric and its constituents have been found to scavenge free radicals and phenolic oxidants and decrease levels of reactive oxygen species (39885, 49430, 71907, 79090, 79204, 80370, 102347). Curcumin has been shown to increase levels of glutathione, superoxide dismutase (SOD), and other antioxidant enzymes in vitro and in animal research (80306, 80370, 80891, 81055, 81070). However, results of research in humans is mixed regarding the effect of turmeric or curcumin on levels of SOD or total antioxidant capacity, and some research shows that it reduces levels of malondialdehyde (MDA), a marker of oxidation (100260, 106804, 109286, 111353, 114898, 114899, 114903). In one study, plasma vitamin E increased after 6 months of treatment with 1-4 grams/day of curcumin, possibly indicating that antioxidant effects of curcumin were sparing vitamin E (17096).\nAntishiga toxin effects\nIn vitro evidence suggests that curcumin can reduce cell death associated with shiga toxin (stx)1 by enhancing expression of heat shock protein 70 (HSP70) (79028) or blocking the binding of stx to cells (79903). Theoretically, this may contribute to the antidiarrheal effects of curcumin.\nAntithrombotic effects\nCurcumin might have antithrombotic effects. Preliminary research suggests it might inhibit platelet-activating factor and arachidonic acid platelet aggregation, possibly by interfering with thromboxane synthesis (11143, 46897, 81217) or by blocking TNF-alpha-induced expression of thrombomodulin and endothelial protein C receptor (79578).\nCardiovascular effects\nIn human research, curcuminoids decrease the risk of myocardial infarction following coronary artery bypass grafting (81143). Laboratory evidence suggests that turmeric may protect against myocardial infarction by reducing inflammatory cytokines and extracellular matrix proteases (79382, 79588, 79607, 80371, 80653, 80802). Other cardiovascular effects induced by turmeric in laboratory research include blood pressure reduction (79673, 107113), vasorelaxation (79544, 79645, 80075, 81078), antithrombosis (78888, 79701), lipid level lowering (80325, 80640), and endothelial function improvement (80371, 80662).. Meta-analyses show that curcumin increases flow-mediated dilation, but not other measures of endothelial function (102348, 114903). Clinical studies show that turmeric or curcumin reduce some measures of arterial stiffness, including pulse wave velocity (101340, 114900, 114903). In atherosclerotic animal models, curcumin reduced atherosclerotic lesions (79150, 80325), improved left ventricular function (79382, 80802, 80924), and reversed cardiac hypertrophy (80724). Inhibition of migration and proliferation of vascular smooth muscle cells (VSMC), and promotion of cell differentiation, have also been reported in animal and in vitro research (79073, 79325, 79426, 79729, 81419).\n\nThere is also interest in using turmeric to reduce cardiovascular risk. A meta-analysis of clinical studies in patients with type 2 diabetes, migraine, metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), or kidney failure shows that nanocurcumin supplementation improves levels of triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterol among those with elevated baseline levels and obesity. High-density lipoprotein (HDL) cholesterol is also improved, regardless of baseline levels or trial duration, particularly in those with metabolic syndrome or obesity and those who are overweight. Systolic blood pressure, but not diastolic blood pressure, is also improved, particularly in those with elevated baseline systolic blood pressure, with trial duration less than 12 weeks, and in those with metabolic syndrome (106793).\nFertility effects\nEvidence from in vitro and animal research suggests that curcumin can decrease sperm motility and density; cause degenerative changes in the seminiferous tubules; reduce luteinizing hormone (LH)-stimulated production of testosterone in adult Leydig cells; and reduce fertility when administered orally (79335, 79404, 80650, 80944, 81069). These effects are attributed to the inhibition of Leydig cell function or the hypothalamus-pituitary axis (79404). However, some evidence suggests that curcumin has positive effects on fertility. Laboratory research suggests that curcumin protects against the death of follicular cells and improves oocyte maturation in immune ovarian failure (81031). It also protects against ischemia-reperfusion induced injury of the testicles (80259).\nGastrointestinal effects\nIn both human and animal research, turmeric or its constituents increased bowel motility (80494, 81075). In animal research, curcumin improved activity of digestive enzymes (49538). In animal research, turmeric and its constituent curcumin reduced the incidence of gastrointestinal ulcers and increased intestinal wall mucus and nonprotein sulfhydryl content (80042, 80560, 81187). Evidence from animal models also suggests that turmeric and its constituent curcumin reduce injury related to inflammatory colitis (79199, 79247, 79267, 79891).\nHematologic effects\nClinical research in patients admitted to the intensive care unit with sepsis shows that administering a specific nanoparticle formulation of curcumin (SinaCurcumin, ExirNanoSina) 80 mg twice daily for 10 days decreases white blood cell, lymphocyte, and neutrophil counts, all of which were elevated at baseline, when compared with placebo. Curcumin also reduced platelet counts when compared with placebo, although these levels remained in the normal range throughout the study (108873).\nHepatoprotective effects\nTurmeric is traditionally used for liver health and for the treatment of jaundice and hepatitis. In animal models, turmeric constituents have been shown to attenuate induced liver damage and fibrosis (78957, 79322, 79439, 80416, 80699, 80705, 80831, 80846, 80857, 80923). Potential mechanisms of action include beneficial effects on levels and activity of inflammatory cytokines or matrix metalloproteases (79551, 79915, 80055, 80216, 80416, 80699, 80831, 80846, 80942). While most animal research shows that turmeric is hepatoprotective, some toxicity studies in animals suggests that turmeric extracts can increase liver enzymes and liver weight, especially when given in high doses for longer durations. Rarely, turmeric has been linked to cases of acute non-infectious cholestatic hepatitis, and most often these cases are related to the use of highly bioavailable formulations at high doses (103633). There is also evidence that the risk for hepatotoxicity with turmeric may be increased in individuals with the HLAB*35:01 allele (109288). However, the mechanism of turmeric-induced hepatotoxicity is unclear.\nHypolipidemic effects\nClinical research suggests turmeric reduces levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (78995, 89725, 114900). Curcumin and other constituents of turmeric also decrease levels of oxidized LDL (81268, 81306). Animal research suggests that turmeric may lower cholesterol by stimulating the conversion of cholesterol to bile acids by increasing the activity of hepatic cholesterol-7 alpha hydroxylase (80225, 81086, 81338, 81445). Other animal research suggests that turmeric decreases levels of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), which limits the formation of cholesterol in the body (81086). In vitro evidence suggests that the turmeric constituent curcumin upregulates the expression of LDL receptors on the surface of mouse macrophage and human hepatoma cells, which increases cholesterol uptake by these cells (79782, 79873, 80415).\nImmunomodulatory effects\nPreliminary research suggests that turmeric and curcumin might have immunostimulatory effects (11140, 11147).\nIron chelating effects\nHuman research in adults with beta-thalassemia intermedia shows that taking curcumin 500 mg three times daily for 3 months in addition to the iron chelator deferasirox and standard treatment downregulates mRNA expression of growth differentiating factor 15 (GDF-15), which may in turn reduce suppression of hepcidin levels. Elevated hepcidin promotes internalization and degradation of the transmembrane iron exporter ferroportin, thereby inhibiting the release of iron from enterocytes, hepatocytes, and macrophages into the plasma, resulting in iron-chelating effects (113606).\nMusculoskeletal effects\nA small clinical study in healthy young adult females with moderate physical activity levels shows that taking curcumin 500 mg daily for 8 weeks decreases muscle damage, as measured by lactate dehydrogenase, and improves maximum oxygen update (VO2 max) when compared with placebo (106804).\nRadioprotective effects\nPreliminary clinical and animal research suggests that turmeric or its constituent curcumin can decrease radiation-induced mucositis (79436, 89726). Potential mechanisms of action may involve a reduction in chromosomal aberrations, chromosomal fragments, and DNA strand breaks (78880, 79140, 79435, 80376, 81265, 81435). The protective effects may also be related to the antioxidant effects of turmeric (78877, 80955).\nRenal protective effects\nIn animal models, turmeric or curcumin prevented renal injury and reduced inflammation induced by ischemia/reperfusion or by agents such acetaminophen or cyclosporine (79663, 79725, 79798, 80579, 80622, 80624, 80857, 80948, 81413). Also, curcumin has been shown to inhibit the accumulation of collagen IV and fibronectin in the glomeruli of animals with nephritis (79488).\nRespiratory effects\nTurmeric is commonly used for bronchitis and respiratory infections. Although there is inadequate human research investigating curcumin for this purpose, laboratory research has been conducted in both animals and in vitro models. Curcumin has been found to prevent fibrosis following induced lung injury (78982, 79295, 79889, 80118, 80912). Curcumin also appears to inhibit lung inflammation (80806, 80909), airway hyperreactivity (79284, 80956), and pulmonary emphysema (80548). Potential mechanisms of action included the inhibition of inflammatory cytokines (78982, 79133, 79295, 79555, 80045, 80212), reduced neutrophil levels (80548), antioxidant effects (78982, 79295, 79539, 79552, 79555, 80203, 80909, 80956), effects on NF-kappa B cell signaling (79555), protection of the anti-inflammatory protein histone deacetylase-2 (80322), and decreased nitric oxide synthase activity (78982, 80417, 80956).\nSkin effects\nIn human research, taking curcumin was found to reduce pruritus severity (81120, 81176, 89724). Also, topical curcumin was of benefit in patients with skin lesions due to cancer (11148). Topical curcumin is commonly used for various skin conditions. Potential benefits of turmeric have been shown in animal models of skin damage, such as chronic ultraviolet B (UVB)-irradiated skin damage (80716). Benefits have included prevention of skin thickness increase and prevention of reduction in skin elasticity and the formation of wrinkles (80716). The inhibition of NF-kappaB may play a role in curcumin-induced beneficial effects in keratinocytes (79154). Would healing may also be improved. In animal research, topical curcumin increased cellular proliferation and collagen synthesis and crosslinking at the wound site, resulting in faster healing and increased tensile strength (79884). In the wound bed, curcumin resulted in alterations of TGF-beta and increased levels of inducible nitric oxide synthase (79213).\nWeight loss effects\nCurcumin may have a beneficial effect in obesity through downregulation of Janus kinase, which is thought to have a role in the pathogenesis of obesity, and inhibition of an enzyme that activates cortisol in adipocytes, playing a role in central obesity. Curcumin may also inhibit adipocyte differentiation through suppression of peroxisome proliferator activated receptor gamma (PPAR-gamma), and enhance monophosphate activated protein kinase and lipolysis (102345)."
        }
    },
    "Turpentine Oil": {
        "sections": {
            "Overview": "Turpentine oil is obtained by the distillation of the oleoresin, or gum turpentine, of longleaf pine and other Pinus species. Terpin hydrate is a semi-synthetic derivative of turpentine (6).\n\nTurpentine oil is used as a fragrance additive in some over-the-counter medicated chest rubs, including Vicks VapoRub. Although original formulations of these products produced in the early 1900s listed turpentine oil as an active ingredient, it is now only included as an inactive additive ingredient.",
            "Safety": "POSSIBLY SAFE when applied topically in small quantities, short term (2).\nPOSSIBLY UNSAFE when applied topically in large quantities or to large areas of skin (2). Turpentine oil can be absorbed through the skin and cause poisoning, including kidney damage (98851).\nLIKELY UNSAFE when used orally for medicinal purposes. Turpentine oil 2 mL/kg is considered toxic, with 120-180 mL being potentially lethal in adults (17).\nThere is insufficient reliable information available about the safety of turpentine oil when inhaled.\nCHILDREN: LIKELY UNSAFE when used orally. As little as 15 mL of turpentine oil is potentially lethal in children (17). There is insufficient reliable information available about the safety of turpentine oil applied topically or inhaled as vapors in children.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally. In addition to its toxic effects, turpentine oil might be an abortifacient (19). There is insufficient reliable information available about the safety of turpentine oil applied topically or inhaled as vapors during pregnancy and lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, turpentine oil is generally regarded as unsafe. Turpentine oil can cause headache, insomnia, coughing, pulmonary aspiration, vomiting, hematuria, albuminuria, urinary tract inflammation, coma, and death (6, 17).\n\nBy inhalation, turpentine oil can cause respiratory tract inflammation, increased airway resistance, and discomfort of the throat and airways (17).\n\nTopically, turpentine oil seems to be well tolerated when used in small amounts and appropriately. Topical use can cause skin irritation, contact allergies, and hypersensitivity in some people (6, 98859). Topical application of large quantities of turpentine oil can result in systemic absorption (98851), which has been reported to cause systemic poisoning (2).\nDermatologic\nTopically, turpentine oil can cause skin irritation, contact allergies, and hypersensitivity in some people (6, 98859).\nless\nGastrointestinal\nOrally, turpentine oil can cause vomiting (6, 17).\nless\nGenitourinary\nOrally, turpentine oil can cause hematuria, albuminuria, and/or urinary tract inflammation (6, 17). Topically, applying large quantities of turpentine oil to the skin can cause symptoms of turpentine oil poisoning, including kidney damage (2).\nless\nNeurologic/CNS\nOrally, turpentine oil can cause headache, insomnia, and in more severe cases, coma and/or death. (6, 17). Topically, applying large quantities of turpentine oil to the skin can cause symptoms of turpentine oil poisoning, including central nervous system damage (2).\nless\nPulmonary/Respiratory\nOrally, turpentine oil can cause coughing. It has also been reported to cause pulmonary aspiration leading to hemorrhagic pulmonary edema (6, 17). As inhalation therapy, turpentine oil can cause discomfort of the throat and airways, mild respiratory tract inflammation, and increased airway resistance (17, 98857). Turpentine oil can also exacerbate bronchial spasms in people with asthma and whooping cough (7).\n\nIn one case report, an 18-month-old male developed lung parenchymal damage with formation of multiple abscess cavities and lung necrosis after accidental turpentine oil inhalation and aspiration (98858). In another case report, a 67-year-old female developed acute eosinophilic pneumonia after reported inhalation of turpentine oil over the course of a few minutes. Although the clinicians did not perform allergy testing or a challenge test, other causes, including medications, supplements, and household exposures, were ruled out with a structured questionnaire. The patient responded well to steroid therapy and did not sustain permanent lung damage (104204).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nWound healing. Preliminary clinical research in adults with skin abscesses shows that applying a specific topical ointment (ilon, Abszess Salbe) containing turpentine oil 7.2%, larch turpentine 5.4% and eucalyptus oil 1.2%, and other ingredients, once daily for 10 days moderately improves patient-reported symptoms scores when compared with placebo. In addition, approximately 45% more patients met complete healing criteria in the treated group (112200). It is unclear if this effect is due to turpentine oil, other ingredients, or the combination.\nMore evidence is needed to rate turpentine oil for these uses.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of turpentine oil.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nINSIGNIFICANT\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nThere is some concern that turpentine oil can inhibit CYP1A2 enzyme activity by up to 90% via induction of inflammation and subsequent downregulation of CYP activity. However, animal research suggests that turpentine oil does not affect the metabolism of phenacetin, a CYP1A2 substrate, despite inducing inflammation (94059).\nSome medications metabolized by CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, tizanidine (Zanaflex), zileuton (Zyflo), zolmitriptan (Zomig), and others.\nless\nTOPICAL DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nSome in vitro research shows that alpha-pinene, the major constituent of turpentine oil, does not increase the absorption of chlorpromazine or haloperidol when applied topically (98856). However, animal research shows that turpentine oil increases the absorption of ibuprofen when applied topically (98854). Theoretically, applying turpentine oil to the skin along with other medications might increase the effects and side effects of these medications.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of turpentine oil.",
            "Pharmacokinetics": "Absorption\nTurpentine oil is systemically absorbed after oral, topical, and inhaled administration. In human studies, 60% to 70% of inhaled turpentine oil is absorbed in the lungs (98853, 98857). In laboratory studies of human epidermis, topical exposure to turpentine oil for up to 1 hour results in the absorption of 49% of the alpha-pinene constituent and 24% of the beta-pinene constituent (98851).\nMetabolism\nTurpentine oil undergoes oxidation to various metabolites, including myrtenol, verbenol, and myrtenic acid (98852).\nExcretion\nApproximately 78% of the turpentine oil present in the body is eliminated via exhalation from the lungs, which can produce a characteristic aromatic breath odor. Approximately 22% of the turpentine oil in the body is excreted renally, with renal elimination of metabolites peaking at about 1.6 hours after administration (98852).",
            "Mechanism of Action": "General\nTurpentine oil is obtained by distillation of the oleoresin of longleaf pine or other pine species (6). It is composed of a mixture of terpenes and terpenoids, with an approximate composition of 59% to 85% alpha-pinene, 3% to 24% beta-pinene, 4% to 15% camphene, 5% to 15% limonene, and small amounts of delta-3-carene and terpinolenes. The exact composition is dependent upon the species of pine, the geographic location, and the time of harvest. R-alpha-pinene, which is found in higher concentrations in American pine than in European pine, has a stronger irritant effect than S-alpha-pinene (98855).\nCNS effects\nTurpentine oil is a central nervous system depressant and therefore, a pulmonary aspiration hazard.\nDermatologic effects\nWhen applied topically, turpentine oil is irritating and exhibits rubefacient and counterirritant effects (6, 11). R-alpha-pinene exhibits a stronger irritant effect than S-alpha-pinene. Turpentine oil derived from American pine contains higher quantities of R-alpha-pinene when compared with European pine (98855).\nRespiratory effects\nWhen inhaled, turpentine oil can have a decongestant effect, possibly by stimulating the cold receptors, which results in reflex vasoconstriction (7)."
        }
    },
    "Turtlehead": {
        "sections": {
            "Overview": "Turtlehead is a flowering herb that grows in the northeastern United States and Canada. It has traditionally been used as a cathartic and tonic (18).",
            "Safety": "There is insufficient reliable information available about the safety of turtlehead.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of turtlehead.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of turtlehead.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with turtlehead.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of turtlehead.",
            "Mechanism of Action": "General\nThe applicable parts of turtle head are the above ground parts and root. Turtle head contains iridoide monoterpenes including catalpol and a bitter-tasting resin (18)."
        }
    },
    "Tylophora": {
        "sections": {
            "Overview": "Tylophora is a climbing perennial plant native to parts of tropical Asia, including India, Sri Lanka, Thailand, and Malaysia (29116). It has been naturalized to Africa. The name Tylophora comes from 'tylos' meaning knot and 'phoros' meaning bearing (29114).",
            "Safety": "There is insufficient reliable information available about the safety of Tylophora.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Tylophora might cause nausea, vomiting, change in taste, and mouth soreness (29118, 29119, 29120, 29121, 29122).\nGastrointestinal\nOrally, Tylophora leaf has been reported to cause nausea in up to 10.8% of patients, vomiting in up to 16.6% of patients, mild upper abdominal pain in up to 5.6% of patients, and soreness of the mouth or loss of taste in up to 1.4% of patients in clinical research (29118, 29119, 29120, 29121, 29122).\nless\nNeurologic/CNS\nOrally, Tylophora has been reported to cause giddiness or drowsiness in clinical research (29119).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. There is contradictory evidence about the effectiveness of Tylophora for asthma. Preliminary clinical research suggests that placing Tylophora extract containing total alkaloids 0.5 mg in 0.5 grams glucose on the tongue and then swallowing, followed by a 1-2 hour bed rest without food daily for 6 days, or taking Tylophora extract 40 mg daily for 6 days, appears to improve symptoms of asthma (29118, 29122). At the end of the first week, up to 57% of patients in the Tylophora groups were improved compared with 23.5% to 31.6% of patients in the placebo groups. This improvement in the Tylophora group continued to last until at least the end of an 8-week follow-up period. Similarly, taking a single Tylophora leaf daily for 6 days increases the number of patients reporting moderate to complete relief of symptoms compared to taking a spinach leaf. Approximately 11% to 28% of patients treated with spinach leaf reported improvement compared to 50% to 62% of patients treated with Tylophora leaf (29120). Taking Tylophora leaf powder 350 mg daily for 7 days also appears to improve asthmatic symptoms when compared to placebo (29117).\nHowever, not all research shows positive results. Some preliminary clinical research suggests that taking Tylophora 400 mg daily and spinach leaves 160 mg daily for 6 days does not improve symptoms of asthma or lung function when compared with a placebo (29119).\nless\nMore evidence is needed to rate Tylophora for this use.",
            "Dosing & Administration": "Adult\nOral:\nAsthma: Tylophora leaf powder 350-400 mg daily for 6-7 days (29117, 29119), one Tylophora leaf daily for up to 12 days (29120, 29121), Tylophora extract 40 mg daily for 6 days (29122), or Tylophora extract containing total alkaloids 0.5 mg daily for 6 days has been used (29118).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Tylophora.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "In animal research, the oral median lethal dose of purified Tylophora alkaloids suspended in peanut oil was 35.32 mg/kg (29123). At single doses of 12-100 mg/kg, inactivity, respiratory distress, salivation, nasal discharge, and diarrhea occurred (29123). In a short-term toxicity study, Tylophora extract 1.25-2.5 mg/kg daily produced no signs of poisoning or death (29123). At 5 mg/kg daily, signs of poisoning and death occurred in two rats. Fatality occurred in all animals at doses of 10 mg/kg daily after 7 days (29123).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Tylophora.",
            "Mechanism of Action": "General\nThe applicable parts of Tylophora are the leaves and the stem (29132). Major constituents of Tylophora include tylophorine, tylophorininine, desmethyltylophorine, desmethyltylophorinine, and kaempferol. Constituents in the roots include tylophorinidine and gamma fararine. Leaves contain D-septicine, D-iso-tylocrebrine, alpha- and beta-amyrine, beta-sitosterols, stigmasterol, and campesterols. Aerial parts contain skimmianine, ceryl alcohol, wax, resin, caoutchouc, tannin, glucose, calcium salts, and potassium salts (29116, 29126).\nAnti-cancer effects\nThere is interest in Tylophora for its antitumor effects. Preliminary research in animal models suggests that the stem and leaf extracts of Tylophora have anti-cancer effects against lymphoid leukemia and lymphocytic leukemia (29132). Other preliminary research shows that the Tylophora constituent tylophorine inhibits vascular endothelial growth factor (VEGF) angiogenesis processes of umbilical cells in vitro, which suggests that it might also inhibit angiogenesis and growth of tumor cells. Furthermore, tylophorine was shown to reduce tumor growth in mice models (98735).\nAnti-histamine effects\nIn animal research, intraperitoneally administered Tylophora extract was found to have direct bronchodilator and membrane stabilizing properties, as well as immunosuppressive effects (29131). In animal research, tylophorine, a constituent of Tylophora, inhibited systemic anaphylaxis, Schultz-Dale's reaction, and immunocytoadherence (29124). Tylophorine also inhibited mast cell degranulation and the associated release of histamine when induced by diazoxide. Proposed mechanisms of action include inhibition of mast cell degranulation due to an elevation in intracellular cAMP.\nEndocrine activity\nIn humans with asthma, Tylophora increased urinary 17-ketosteroids and decreased absolute eosinophil count (29130). Theoretically, this may be due to an indirect effect of Tylophora on the adrenal gland, causing release of adreno-corticoid hormones. In animal research, Tylophora antagonized the dexamethasone/hypophysectomy-induced suppression of the pituitary, suggesting a direct stimulation of the adrenal cortex (29125).\nImmune system effects\nIn animal research, Tylophora was found to depress cell-mediated immunity (29129). In humans, Tylophora may stimulate phagocytosis and concurrently inhibit humoral immunity (29119, 29122)."
        }
    },
    "Tyramine": {
        "sections": {
            "Overview": "Tyramine is a chemical that occurs naturally in humans, animals, and various foods. Foods containing high levels of tyramine include air-dried or cured sausage, aged cheese, some types of soy sauce, fermented or stored tofu, sauerkraut, yeast extract, and fermented beverages, including wine and beer. However, modern methods of fermentation generally produce lower levels of tyramine than historical methods (15649, 15701, 15702, 30868, 100191, 101010). Tyramine is sometimes included in dietary supplements (100198). Some products claim that tyramine comes from Acacia rigidula, which contains small amounts of tyramine in its leaves and twigs (21078).",
            "Safety": "POSSIBLY SAFE when used in amounts commonly found in foods. The European Food Safety Authority (EFSA) states that consuming meals containing up to 600 mg of tyramine is not expected to cause adverse health effects in healthy individuals (101206).\nPOSSIBLY UNSAFE when consumed in amounts exceeding 600 mg per meal. The safety of tyramine has not been well studied. However, tyramine can cause vasoconstriction and hypertension (100189). The EFSA states that meals containing more than 600 mg tyramine may carry an increased risk for these adverse health effects (101206).\nThere is insufficient reliable information available about the safety of tyramine supplements.\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tyramine that occurs naturally in foods seems to be generally well tolerated when consumed in quantities of no more than 600 mg per meal. Higher quantities might increase the risk for adverse effects.\nCardiovascular\nOrally and intravenously, unspecified doses of tyramine have increased systolic, but not diastolic, blood pressure. Intravenous tyramine is not used clinically but is commonly used to examine safety and interaction outcomes (100189, 100190, 101013, 101014). A single dose of oral tyramine 400 mg has been reported to cause heart palpitations and elevations in systolic blood pressure in healthy volunteers (105519). In one case series, consuming foods thought to contain tyramine, including cheese, was associated with hypertension. However, tyramine levels of the implicated foods were not determined (101018).\n\nIn a previously healthy, 39-year-old male, chronic use of a multi-ingredient sports supplement was associated with the development of a thrombus, angina, and acute myocardial infarction. The product claimed to contain synephrine 40 mg, caffeine 400 mg, and unspecified amounts of octopamine and tyramine, in addition to various other products such as St. John's Wort. It is not clear if these effects were due to tyramine, the other ingredients, the patient's concomitant dehydration, or a combination of these factors (100091).\nless\nNeurologic/CNS\nOrally, a single dose of tyramine 400 mg has been reported to cause dry mouth, restlessness, dizziness, and headache in healthy volunteers (105519). In a case series, consuming foods thought to contain tyramine, including cheese, was associated with headache, dizziness, memory dysfunction, blurred vision, numbness, and tingling. However, tyramine levels of the implicated foods were not determined (101018).\nless\nPsychiatric\nIn a case series, consuming foods thought to contain tyramine, including cheese, was associated with panic attacks with palpitations. However, tyramine levels of the implicated foods were not determined (101018).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there has been interest in using oral tyramine for athletic performance, there is insufficient reliable information about the clinical effects of tyramine for this purpose.\nObesity. Although there has been interest in using oral tyramine for obesity, there is insufficient reliable information about the clinical effects of tyramine for this purpose.\nMore evidence is needed to rate tyramine for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\n\nMany foods and drinks contain tyramine, including air-dried or cured sausage, aged cheese, some types of soy sauce, fermented or stored tofu, sauerkraut, yeast extract, wine, and beer (15649, 15701, 15702, 30868, 100191, 101017). Taking tyramine along with tyramine-containing foods and drinks might increase the risk of hypertensive crisis.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of tyramine.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nALCOHOL\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of alcohol and tyramine might increase the risk of adverse effects from tyramine.\nIn vitro research suggests that alcohol may potentiate the toxic effects of biogenic amines, including tyramine, possibly by decreasing their breakdown (100195, 100196).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nLIKELY\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTyramine may increase the risk of hypertension and reduce the effects of antihypertensive drugs.\nIn humans, oral and intravenous tyramine increases systolic blood pressure (100188, 100189, 100190, 101013, 101014).\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nLIKELY\nLevel of Evidence\nB (Nonrandomized clinical trial)\nConcomitant use of tyramine with MAOIs may increase the risk of serious adverse effects from tyramine.\nTyramine is metabolized by monoamine oxidase. Concurrent use of MAOIs with tyramine can lead to elevated levels of tyramine in the body. This can increase the effects of tyramine, which has been reported to cause hypertension, headache, and hypertensive crisis in numerous cases (100189, 100192, 101010). Sensitivity to tyramine can increase up to 10-fold to 100-fold in people using an MAOI (100189, 101010). The European Food Safety Authority states that meals containing more than 50 mg of tyramine might present a risk to patients that are using third generation MAOI medications. Meals containing more than 6 mg of tyramine are likely to present a risk to patients who are taking classic MAOI medications (101206).\nless\nSTIMULANT DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking tyramine with stimulant drugs might increase the risk of adverse cardiovascular effects.\nTyramine is thought to have stimulant effects (94386, 100198).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH STIMULANT PROPERTIES\nTheoretically, tyramine might have additive effects with supplements that have stimulant properties.\nTyramine is thought to have stimulant effects (94386, 100198). Theoretically, taking tyramine with herbs and supplements with stimulant properties might increase the risk of adverse cardiovascular effects. See other products with stimulant effects here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHYPERTENSION\nTyramine increases systolic blood pressure (100188, 100189, 100190, 101013, 101014). Taking tyramine might exacerbate high blood pressure.\nless\nMIGRAINES\nIn humans with migraines, intravenous tyramine induced a migraine in 50% to 75% of patients within 24 hours (101015). Theoretically, taking tyramine could initiate a migraine.\nless\nPERIOPERATIVE\nTyramine increases systolic blood pressure (100188, 100189, 100190, 101013, 101014). Theoretically, taking tyramine might interfere with surgical procedures by increasing blood pressure. Tell patients to discontinue using tyramine at least 2 weeks before elective surgical procedures.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tyramine.",
            "Pharmacokinetics": "Absorption\nAfter oral intake, tyramine is absorbed rapidly, reaching peak levels in under an hour (100189, 105519). However, the overall bioavailability of oral tyramine is low (105519). The absorption of tyramine is greatest under fasting conditions. Food reduces its absorption and bioavailability, and increases the time to peak levels by a median of 0.5 hours (100189).\nMetabolism\nTyramine is metabolized in various ways. Monoamine oxidase (MAO) metabolizes tyramine to 4-hydroxyphenylacetaldehyde, which is further metabolized to 4-hydroxyphenylacetic acid (4-HPPA) (105519). Metabolism of tyramine by MAO takes place in the intestines and the liver, before reaching the general circulation, as well as in platelets (100189, 101010, 101018, 105519). Tyramine is also metabolized to dopamine by cytochrome P450 2D6 (CYP2D6) enzymes (105519) and to octopamine by dopamine-beta-hydroxylase (101015). Tyramine can also be sulfo-conjugated to tyramine-o-sulfate (101012). Tyramine is a substrate of organic cation transporter 1 (OTC1), which is believed to facilitate the metabolism and elimination of tyramine (105519).\n\nIn theory, individuals with genetic polymorphisms for enzymes that metabolize tyramine may have altered exposure to tyramine. However, clinical research in healthy adults with CYP2D6, MAO, and OTC1 polymorphisms has not demonstrated a difference in the pharmacokinetics or relevant clinical effects of tyramine, such as heart rate or blood pressure, after a single oral dose of 400 mg (105519).\nExcretion\nTyramine and its metabolites, including tyramine-o-sulfate and 4-HPPA, are excreted in urine (100194, 101012, 105519). In fasted conditions, the elimination half-life of tyramine was 0.5 hours. The elimination half-life increased to as much as 3 hours when taken with a meal (100189).",
            "Mechanism of Action": "General\nTyramine is a chemical derived from the amino acid tyrosine. It is considered a trace amine, a type of biogenic amine (100098, 100194). Although tyramine can be made naturally in the body from tyrosine, it is also produced in foods during the degradation of proteins by microbes, including during spoilage or during fermentation with tyramine-producing starter cultures (100191, 100195, 100196, 101010).\nCardiovascular effects\nIn clinical research, tyramine has been shown to increase systolic, but not diastolic, blood pressure (100188, 100189, 100190, 101013, 101014, 105519). In healthy individuals, tyramine infusion has been shown to increase plasma noradrenaline, resulting in biochemical changes suggesting a more hypercoagulable state, as well as decreases in blood flow and vascular conductance (100193).\n\nTyramine is primarily metabolized by monoamine oxidase (MAO). If MAO is inhibited, typically by the use of an MAO inhibitor (MAOI), this can increase the absorption and circulating levels of tyramine, resulting in increased release of norepinephrine from peripheral adrenergic neurons (100189, 100192, 101010).\nNeurological effects\nTrace amine-specific receptors exist for tyramine and other trace amines. These receptors seem to signal intracellular functions and help tyramine play a role in the fine-tuning of neurotransmission (100098, 100194). After being actively transported across the sympathetic nerve membrane, tyramine indirectly stimulates the nerves by elevating synaptic levels of norepinephrine. However, it has only a small effect, if any, on plasma levels of norepinephrine. In this way, tyramine mimics the effects of sympathetic adrenergic nerve stimulation This mechanism of action is thought to at least partially explain the elevating effect of tyramine on blood pressure and cardiac output, as well as the inhibiting effects on insulin production by the pancreas (100188, 100189, 100190).\n\nTyramine causes migraines in some individuals. The mechanism of action is possibly related to the inhibition of tyramine breakdown, by inhibiting monoamine oxidase or other enzymes, an increase in the production of tyramine, and/or the metabolism of tyramine to octopamine. Both tyramine and octopamine can displace other monoamine neurotransmitters and trigger the release of norepinephrine from sympathetic nerve terminals (11996, 30868, 100098, 101010, 101012). In patients with migraine, especially those with migraine with aura, platelet levels of octopamine are elevated, while tyramine levels are not altered. However, normal tyramine levels are so low that any changes might be difficult to measure (100098). In patients with cluster headaches, elevated platelet levels of octopamine are accompanied by increased levels of platelet and plasma tyramine (11996).\nWeight loss effects\nTyramine is marketed in products as a stimulant and is included in some weight loss products (100198). However, in vitro, tyramine appears to be metabolized quickly in adipose cells and does not stimulate lipolysis. It might even have weak antilipolytic effects, although this is unlikely to be clinically relevant (100194)."
        }
    },
    "Tyrosine": {
        "sections": {
            "Overview": "Tyrosine is a nonessential amino acid synthesized in the body from the essential amino acid, phenylalanine (7212). In the diet, it is found in beans, nuts, seeds, dairy, meats, fish, eggs, and some grains (7217). Since dietary needs of tyrosine are dependent on phenylalanine intake, tyrosine is an essential amino acid for individuals with phenylketonuria (PKU). These individuals are unable to consume phenylalanine in the diet (7212).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Tyrosine has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts, short-term. Tyrosine has been used safely in doses up to 150 mg/kg daily for up to 3 months (7210, 7211, 7215). ...when used topically and appropriately (6155).\nPREGNANCY AND LACTATION: There is insufficient reliable information available about the safety of tyrosine during pregnancy and lactation when used in medicinal amounts. Some pharmacokinetic research shows that taking a single dose of tyrosine 2-10 grams orally can modestly increase levels of free tyrosine in breast milk. However, total levels are not affected, and levels remain within the range found in infant formulas. Therefore, it is not clear if the increase in free tyrosine is a concern (91467).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, tyrosine seems to be well tolerated. No serious adverse effects have been documented; however, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Fatigue, headache, heartburn, and nausea.\nGastrointestinal\nOrally, tyrosine can cause nausea and heartburn when taken at a dose of 150 mg/kg (7211). Taking tyrosine 4 grams daily in combination with 5-hydroxytryptophan 800 mg and carbidopa 100 mg can cause diarrhea, nausea, and vomiting. These effects can be mitigated by lowering the dosage (918).\nless\nMusculoskeletal\nOrally, larger doses of tyrosine (150 mg/kg) can cause arthralgia, but this is uncommon (7211).\nless\nNeurologic/CNS\nOrally, larger doses of tyrosine (150 mg/kg) can cause headache and fatigue (7211). Taking a combination of tyrosine 4 grams, 5-hydroxytryptophan 800 mg, and carbidopa 100 mg can cause drowsiness and agitation. These effects can be mitigated by lowering the dosage (918).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nEFFECTIVE\nPhenylketonuria (PKU). Oral tyrosine as a component of medical foods is recommended in people with PKU, a disorder in which phenylalanine cannot be endogenously metabolized into tyrosine.\nTyrosine is used as a component of medical foods for people with phenylketonuria (PKU) (7212, 7213, 7232). Current guidelines recommend that people with PKU maintain a diet low in phenylalanine and incorporate tyrosine as a component of medical foods to maintain normal blood levels of tyrosine (95108). Supplementation with additional tyrosine is recommended only for patients with consistently low blood levels of tyrosine despite using tyrosine-containing medical foods (95108). Routine supplementation with free tyrosine is not recommended for most patients because it can produce wide variations in tyrosine plasma concentrations and side effects (7212, 95108). Tyrosine intake does not improve neuropsychological measures in patients with PKU (81503, 91471, 95108).\nless\nPOSSIBLY EFFECTIVE\nCognitive function. Oral tyrosine might improve cognitive function, particularly in patients exposed to stressors such as excessive cold, noise, or sleep deprivation.\nMost research suggests that taking tyrosine orally improves cognitive function, particularly under stressful conditions. Small clinical studies in healthy adults show that taking tyrosine 100-300 mg/kg in the setting of exposure to stressors such as excessive cold, noise, or sleep deprivation improves cognitive performance measures, such as executive function and short-term memory, when compared with placebo (7215, 81472, 81476, 81484, 81501). Other small clinical studies in healthy patients show that taking tyrosine 2 grams may improve response time without detracting from performance and could improve some measures of cognitive response to conflict when compared with placebo (101082, 111248). Some of these small studies may be inadequately powered to detect an effect on some cognitive function tests.\n\nTyrosine has also been evaluated in combination with other ingredients for this purpose. A small clinical study in healthy adults with fatigue shows that taking tyrosine, serine, alanine, glutamate, and aspartate daily for 4 weeks improves measures of cognitive function including attention, spatial cognition, orientation, motivation, and time management when compared with placebo (111249). It is unclear if these effects are due to tyrosine, other ingredients, or the combination.\nless\nMemory. Taking tyrosine orally seems to improve memory in patients exposed to stressors such as cold or those having to complete multiple tasks at once.\nSmall clinical studies in healthy adults show that taking tyrosine 150-300 mg/kg prior to acute exposure to stress that is cold-induced, noise-induced, or induced by multi-tasking improves memory performance when compared with placebo (81469, 81477, 81499, 81501). However, tyrosine 150 mg/kg does not seem to improve memory in less stressful situations such as performing one simple task or testing when not exposed to cold (81469, 81499).\nless\nPOSSIBLY INEFFECTIVE\nAthletic performance. Oral tyrosine does not improve athletic performance when taken prior to exercise.\nClinical studies show that taking tyrosine orally prior to participating in treadmill or cycling exercises conducted at temperate temperatures or in the heat does not improve strength, endurance, or performance when compared with placebo (81471, 81474, 81504, 91470, 104403). Another very small clinical study in healthy males shows that taking a multi-ingredient pre-workout supplement containing L-tyrosine, beta-alanine, L-citrulline maleate, arginine alpha-ketoglutarate, L-taurine, and caffeine does not increase bench press strength endurance when compared with equivalent amounts of anhydrous caffeine (111250).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlcohol use disorder. Oral tyrosine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with alcohol use disorder shows that taking a combination of tyrosine 900 mg, D,L-phenylalanine 1.5 grams, L-glutamine 300 mg, and L-tryptophan 400 mg daily along with a multivitamin supplement reduces withdrawal symptoms and decreases stress when compared with placebo (81552). It is unclear if these effects are due to tyrosine, other ingredients, or the combination.\nless\nAttention deficit-hyperactivity disorder (ADHD). It is unclear if oral tyrosine is beneficial for improving ADHD symptoms.\nA very small clinical study shows that taking tyrosine does not improve symptoms of ADHD in children when compared with baseline (7209). Furthermore, another very small clinical trial in adults with ADHD shows that taking tyrosine daily for 8 weeks does not improve inattention when compared with baseline. Some patients might have transient symptom improvement after 2 weeks, but seem to acquire tolerance by 6 weeks (7210). The validity of these findings is limited by the small study size and lack of control groups.\nless\nCocaine dependence. Oral tyrosine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical trial in patients with cocaine dependence shows that taking L-tyrosine 1 gram in the morning and L-tryptophan 1 gram in the evening for 14 days does not reduce drug cravings or withdrawal symptoms when compared with placebo (81480).\nless\nDementia. Oral tyrosine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA very small clinical study in patients with severe Alzheimer disease or multi-infarct dementia shows that taking a combination of tyrosine 4 grams, 5-HTP 800 mg, and carbidopa 100 mg orally daily does not improve clinical or psychological parameters in most patients when compared with baseline (918). The validity of this finding is limited by the small study size and a lack of control group.\nless\nDepression. It is unclear if oral tyrosine is beneficial for improving major depressive disorder.\nA small clinical study in patients with major depression shows that taking L-tyrosine 100 mg/kg daily for 4 weeks does not improve depressive symptoms when compared with placebo (7208).\nless\nErectile dysfunction (ED). Although there is interest in using oral tyrosine for ED, there is insufficient reliable information about the clinical effects of tyrosine for this condition.\nFatigue. Oral tyrosine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in healthy adults with fatigue shows that taking tyrosine, serine, alanine, glutamate, and aspartate daily for 4 weeks does not improve subjective or objective measures of fatigue when compared with placebo (111249).\nless\nHypertension. It is unclear if oral tyrosine is beneficial for reducing hypertension of mild severity.\nA very small clinical study in patients with mild essential hypertension shows that taking oral tyrosine 2.5 grams three times daily with meals for 2 weeks does not affect systolic or diastolic blood pressure when compared with control (81487).\nless\nMitochondrial myopathies. Although there is interest in using oral tyrosine for nemaline myopathy, a type of mitochondrial myopathy, there is insufficient reliable information about the clinical effects of tyrosine for this condition.\nNarcolepsy. It is unclear if oral tyrosine is beneficial for improving narcolepsy symptoms.\nA small clinical study in patients with narcolepsy shows that taking capsules containing tyrosine 3 grams orally three times daily for 4 weeks might reduce feelings of tiredness or drowsiness when compared with placebo, but the overall effect is not clinically significant. Tyrosine also does not seem to improve sudden muscle weakness, sleep paralysis, night-time sleep, sleep latency, or speed and attention after waking when compared with placebo (81482).\nless\nObesity. Oral tyrosine has only been evaluated for in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in overweight or obese patients shows that taking a supplement containing tyrosine 1.2 grams, cayenne 450 mg, green tea 1.5 grams, caffeine 150 mg, and calcium carbonate 3.89 grams daily for 8 weeks slightly reduces body fat mass by 0.9 kg when compared with placebo (81475). It is not clear if any potential benefit is due to tyrosine, other ingredients, or the combination.\nless\nOpioid withdrawal. Oral tyrosine has only been evaluated for heroin withdrawal in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in Chinese males undergoing detoxification for heroin addiction shows that taking a combination of tyrosine 50 mg/kg, 5-HTP 200 mg, phosphatidylcholine 1200 mg, and L-glutamine 50 mg/kg daily for 6 days can reduce insomnia and withdrawal symptoms and improve mood when compared with placebo (88178). It is not clear if this effect is due to tyrosine, other ingredients, or the combination.\nless\nParkinson disease. Although there is interest in using oral tyrosine for Parkinson disease, there is insufficient reliable information about the clinical effects of tyrosine for this condition.\nPremenstrual syndrome (PMS). Although there is interest in using oral tyrosine for PMS, there is insufficient reliable information about the clinical effects of tyrosine for this condition.\nSchizophrenia. It is unclear if oral tyrosine is beneficial for improving schizophrenia symptoms.\nA very small clinical study in patients with schizophrenia shows that taking L-tyrosine 10 grams daily in four divided doses along with molindone 150 mg daily for 3 weeks does not improve symptoms of schizophrenia when compared with taking molindone alone (81554).\nless\nSleep deprivation. It is unclear if oral tyrosine is beneficial for improving alertness in sleep deprived adults.\nA small clinical study shows that taking tyrosine 150 mg/kg after the loss of a night's sleep seems to delay performance decline in psychomotor tests by about 3 hours when compared with placebo (7215). Another small clinical study in sleep-deprived patients shows that taking tyrosine 150 mg/kg improves memory, reasoning, and vigilance when compared with placebo at 5.5 hours after ingestion, but not at 1.5 hours. Tyrosine was less effective than taking amphetamine, phentermine, or caffeine (81472).\nless\nStress. Although there is interest in using oral tyrosine for stress, there is insufficient reliable information about the clinical effects of tyrosine for this condition.\nWrinkled skin. Topical tyrosine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small study in patients with photodamaged skin shows that applying a topical preparation containing 10% vitamin C, acetyl tyrosine, zinc sulfate, sodium hyaluronate, and bioflavonoids (High Potency Serum, Cellex-C International Inc.) for 3 months to the face seems to improve fine and coarse wrinkling, yellowing and sallowness, roughness, and skin tone when compared with placebo (6155). It is unclear if the benefits are due to tyrosine, other ingredients, or the combination.\nless\nMore evidence is needed to rate the effectiveness of tyrosine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTyrosine has most commonly been used in doses of 100-300 mg/kg daily (81476, 81484, 81501, 101082). See Effectiveness section for condition-specific information.\nTopical:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization and formulation of tyrosine.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nLEVODOPA\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tyrosine might decrease the effectiveness of levodopa.\nTyrosine and levodopa compete for absorption in the proximal duodenum by the large neutral amino acid (LNAA) transport system (2719). Advise patients to separate doses of tyrosine and levodopa by at least 2 hours.\nless\nTHYROID HORMONE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, tyrosine might have additive effects with thyroid hormone medications.\nTyrosine is a precursor to thyroxine and might increase levels of thyroid hormones (7212).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "THYROID DISORDERS\nTheoretically, tyrosine, a precursor for thyroxine, might boost thyroid hormone levels. This might exacerbate hyperthyroidism and Graves' disease, or alter the treatment of hypothyroidism (7212). Tell patients with thyroid disorders not to take tyrosine supplements.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with tyrosine.",
            "Pharmacokinetics": "Absorption\nTyrosine levels are increased in the blood in a dose-dependent manner following oral use (81502, 91467, 91470, 98221). For a given dose, plasma levels appear to be higher in adults over 60 years of age than in younger adults, possibly due to lower first-pass metabolism in the liver (98221). Peak plasma levels of tyrosine generally occur within 1.5-3 hours after oral intake, although the time to maximum plasma concentration may be as long as 6 hours in some patients (91467).\nDistribution\nTyrosine is classified as a large neutral amino acid (LNAA) and is transported across the blood brain barrier by the LNAA transporter. Tyrosine competes with other LNAAs, such as tryptophan, to get into the brain (7217).\nMetabolism\nIn the brain, tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-dopa), dopamine, norepinephrine, and then epinephrine. The rate limiting enzyme is tyrosine hydroxylase (81470). In healthy humans, an acute intake of tyrosine increases plasma levels of norepinephrine, epinephrine, and dopamine (81495). Adults over 60 years of age have higher plasma levels of tyrosine than younger individuals taking the same dose. This may cause negative feedback inhibition of tyrosine hydroxylase activity, blunting the dopamine response compared with younger adults (98221).\nExcretion\nIntake of tyrosine increases urinary levels of norepinephrine, epinephrine, dopamine, 3-methoxy-4-hydroxyphenylglycol, vanillylmandelic acid, and homovanillic acid in men (81523).",
            "Mechanism of Action": "General\nTyrosine is a nonessential amino acid that the body synthesizes from phenylalanine. For people with phenylketonuria (PKU) who cannot synthesize tyrosine from phenylalanine, tyrosine is an essential amino acid (7212). Tyrosine can also be obtained from dietary proteins in dairy products, meats, fish, eggs, nuts, beans, oats, and wheat. When dietary intake of tyrosine is inadequate, phenylalanine is converted to tyrosine (7217). Dietary needs of tyrosine are dependent on phenylalanine intake. When phenylalanine intake is adequate (about 9 mg/kg daily), dietary tyrosine intake should be about 7 mg/kg daily (7214). Inadequate tyrosine intake is rare in developed nations. Tyrosine is incorporated into all proteins.\nAnti-stress effects\nTyrosine is a precursor of thyroxine and melanin (7212); it is also a precursor for the synthesis of catecholamines, norepinephrine, epinephrine, and dopamine (7215, 7217). There is interest in tyrosine for preventing the negative effects related to stress. Some scientists think that the brain may not be able to synthesize enough tyrosine from phenylalanine under stressful conditions (7217). Catecholamines like epinephrine, norepinephrine, and dopamine that are synthesized from tyrosine can become depleted during stress (81488). There is speculation that increasing the availability of tyrosine to the brain allows increased catecholamine synthesis, and avoidance of the negative effects of stress, such as the physical expression of fear (91466, 91468, 104402). There is some evidence in animals and humans that supplemental tyrosine might improve performance, memory, and learning, under extreme environmental conditions, intense exercise, psychological stress (7215, 7217, 81476, 81484, 81501, 91470).\nAntidepressant effects\nTyrosine may play a role in depression. Tyrosine is a precursor for the synthesis of catecholamines, norepinephrine, epinephrine, and dopamine (7215, 7217). Low levels of norepinephrine may play a role in depression and dopamine may play a role in the function of antidepressant agents (81470). In healthy humans, an acute intake of tyrosine increases plasma levels of norepinephrine, epinephrine, and dopamine (81495). In human research, drinking an amino acid beverage lacking in the catecholamine precursors tyrosine and phenylalanine resulted in reduced the response of the brain to incentives; however, there were no functional changes in behavior (91465).\nCognitive effects\nThere is interest in using tyrosine for enhancing cognitive function. It is theorized that tyrosine enhances cognitive function by acting as a precursor for the synthesis of the neurotransmitters norepinephrine and dopamine (111249)."
        }
    }
}